0001558370-22-003208.txt : 20220310 0001558370-22-003208.hdr.sgml : 20220310 20220310063845 ACCESSION NUMBER: 0001558370-22-003208 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 112 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220310 DATE AS OF CHANGE: 20220310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immuneering Corp CENTRAL INDEX KEY: 0001790340 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40675 FILM NUMBER: 22727336 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET, SECOND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-500-8080 MAIL ADDRESS: STREET 1: 245 MAIN STREET, SECOND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 10-K 1 imrx-20211231x10k.htm 10-K
2.463.441361267749501291361267749501292.463.440001790340--12-312021FYfalseImmuneering Corp36192920049501292632019900063786324959330263201994950129000048247000001790340us-gaap:CommonClassAMember2021-08-030001790340imrx:SeriesBConvertiblePreferredStockTrancheTwoMember2021-05-310001790340imrx:SeriesBConvertiblePreferredStockTrancheTwoMember2021-03-310001790340imrx:SeriesBConvertiblePreferredStocksTrancheOneMember2020-12-310001790340imrx:SeriesConvertiblePreferredStockMember2019-09-200001790340imrx:SeriesConvertiblePreferredStockMember2020-01-310001790340imrx:SeriesConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-12-310001790340imrx:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-12-310001790340us-gaap:PreferredStockMember2020-12-310001790340imrx:SeriesConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-310001790340us-gaap:PreferredStockMember2019-12-310001790340us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2021-12-310001790340us-gaap:DomesticCountryMemberus-gaap:ResearchMember2021-12-310001790340us-gaap:PreferredStockMember2021-01-012021-12-310001790340us-gaap:CommonClassAMemberus-gaap:IPOMember2021-08-032021-08-030001790340us-gaap:CommonClassAMember2021-08-032021-08-030001790340imrx:SeriesConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-01-012021-12-3100017903402021-07-232021-07-230001790340us-gaap:RetainedEarningsMember2021-12-310001790340us-gaap:AdditionalPaidInCapitalMember2021-12-310001790340us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001790340us-gaap:RetainedEarningsMember2020-12-310001790340us-gaap:AdditionalPaidInCapitalMember2020-12-310001790340us-gaap:RetainedEarningsMember2019-12-310001790340us-gaap:AdditionalPaidInCapitalMember2019-12-310001790340us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001790340us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-12-310001790340us-gaap:CommonClassAMemberus-gaap:CommonStockMember2019-12-310001790340srt:MaximumMemberimrx:TwoThousandTwentyOneIncentiveAwardPlanMemberus-gaap:CommonClassAMember2021-07-232021-07-230001790340srt:MaximumMemberimrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2021-07-232021-07-230001790340imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2021-01-012021-12-310001790340srt:MinimumMember2021-01-012021-12-310001790340srt:MaximumMember2021-01-012021-12-310001790340srt:MinimumMember2020-01-012020-12-310001790340srt:MaximumMember2020-01-012020-12-310001790340us-gaap:ResearchAndDevelopmentExpenseMemberimrx:BioArkiveIncMember2021-01-012021-12-310001790340us-gaap:ResearchAndDevelopmentExpenseMemberimrx:BioArkiveIncMember2020-01-012020-12-310001790340srt:MinimumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2021-01-012021-12-310001790340srt:MaximumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2021-01-012021-12-310001790340us-gaap:FurnitureAndFixturesMember2021-01-012021-12-310001790340us-gaap:ComputerEquipmentMember2021-01-012021-12-310001790340imrx:LabEquipmentMember2021-01-012021-12-310001790340us-gaap:LeaseholdImprovementsMember2021-12-310001790340us-gaap:FurnitureAndFixturesMember2021-12-310001790340us-gaap:ComputerEquipmentMember2021-12-310001790340imrx:LabEquipmentMember2021-12-310001790340us-gaap:FurnitureAndFixturesMember2020-12-310001790340us-gaap:ComputerEquipmentMember2020-12-310001790340srt:MinimumMemberimrx:SeriesConvertiblePreferredStockMember2021-01-012021-12-310001790340imrx:SeriesBConvertiblePreferredStockMember2021-01-012021-12-310001790340imrx:SeriesConvertiblePreferredStockMember2020-01-012020-12-310001790340imrx:SeriesBConvertiblePreferredStockMember2020-01-012020-12-310001790340us-gaap:IPOMember2021-08-032021-08-030001790340srt:MinimumMember2021-12-310001790340imrx:SeriesBConvertiblePreferredStockTrancheTwoMember2021-04-012021-05-310001790340imrx:SeriesBConvertiblePreferredStocksTrancheOneMember2020-12-012020-12-310001790340imrx:SeriesConvertiblePreferredStockMember2020-01-012020-01-310001790340imrx:SeriesConvertiblePreferredStockMember2019-01-012019-12-310001790340us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001790340us-gaap:StateAndLocalJurisdictionMember2021-12-310001790340us-gaap:DomesticCountryMember2021-12-310001790340us-gaap:RetainedEarningsMember2021-01-012021-12-310001790340us-gaap:RetainedEarningsMember2020-01-012020-12-310001790340imrx:OfficeLeaseInSanDiegoCalifornia2020Member2020-10-310001790340imrx:StorageSpaceInSomervilleMassachusettsMember2021-12-310001790340imrx:OfficeSpaceInCambridgeMassachusettsNewYorkMember2021-12-310001790340imrx:OfficeLeaseInSanDiegoCalifornia2020Member2021-12-310001790340imrx:StockIncentivePlan2015Member2021-12-310001790340us-gaap:AccountsPayableAndAccruedLiabilitiesMemberimrx:BioArkiveIncMember2020-12-310001790340imrx:BioArkiveIncMember2017-01-012017-12-310001790340imrx:SeriesConvertiblePreferredStockMember2019-09-202019-09-2000017903402021-08-030001790340imrx:CustomerTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001790340imrx:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001790340imrx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001790340imrx:CustomerFiveMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001790340imrx:CustomerTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001790340imrx:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001790340imrx:CustomerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001790340imrx:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001790340imrx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001790340imrx:CustomerFourMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001790340imrx:CustomerFourMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001790340imrx:CustomerFiveMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001790340us-gaap:CommonClassAMemberus-gaap:IPOMember2021-08-030001790340us-gaap:CommonClassBMember2021-12-310001790340us-gaap:CommonClassAMember2021-12-310001790340us-gaap:CommonClassBMemberus-gaap:IPOMember2021-08-030001790340us-gaap:CommonClassBMember2020-12-310001790340us-gaap:CommonClassAMember2020-12-310001790340srt:MaximumMemberimrx:StockIncentivePlan2015Member2021-12-310001790340us-gaap:EmployeeStockOptionMember2021-12-310001790340imrx:TwoThousandTwentyOneIncentiveAwardPlanMember2021-12-310001790340srt:MaximumMemberimrx:TwoThousandTwentyOneIncentiveAwardPlanMember2021-07-230001790340imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2021-07-230001790340us-gaap:WarrantMember2020-12-310001790340us-gaap:EmployeeStockOptionMember2020-12-310001790340imrx:SeriesConvertiblePreferredStockMember2020-12-3100017903402019-12-310001790340us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001790340us-gaap:WarrantMember2020-01-012020-12-310001790340us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001790340imrx:SeriesConvertiblePreferredStockMember2020-01-012020-12-310001790340imrx:SeriesBConvertiblePreferredStockMember2020-01-012020-12-310001790340us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001790340us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001790340us-gaap:CostOfSalesMember2021-01-012021-12-310001790340imrx:StockIncentivePlan2015Member2021-01-012021-12-310001790340us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001790340us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001790340us-gaap:CostOfSalesMember2020-01-012020-12-310001790340imrx:StockIncentivePlan2015Member2020-01-012020-12-310001790340us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001790340imrx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-12-310001790340imrx:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-12-310001790340imrx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-12-310001790340imrx:CustomerFourMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-12-310001790340imrx:CustomerFiveMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-12-3100017903402019-01-012019-12-3100017903402021-06-012021-06-300001790340imrx:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-01-012021-12-310001790340imrx:SeriesConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-310001790340imrx:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-310001790340us-gaap:PreferredStockMember2020-01-012020-12-310001790340srt:MinimumMemberimrx:SeriesConvertiblePreferredStockMember2021-12-310001790340imrx:SeriesConvertiblePreferredStockMember2019-09-300001790340imrx:SeriesConvertiblePreferredStockMember2019-12-310001790340imrx:SeriesConvertiblePreferredStockMember2021-12-310001790340imrx:SeriesBConvertiblePreferredStockMember2021-01-012021-03-310001790340us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2020-03-272020-03-270001790340us-gaap:DomesticCountryMemberus-gaap:ResearchMember2020-03-272020-03-270001790340us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001790340us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-01-012021-12-310001790340imrx:SeriesConvertiblePreferredStockMember2019-12-312019-12-310001790340imrx:SeriesBConvertiblePreferredStockMember2021-12-310001790340srt:MaximumMemberimrx:TwoThousandTwentyOneIncentiveAwardPlanMember2021-07-232021-07-230001790340imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2021-07-232021-07-230001790340us-gaap:IPOMember2021-08-030001790340us-gaap:CommonClassBMember2021-01-012021-12-310001790340us-gaap:CommonClassAMember2021-01-012021-12-310001790340us-gaap:CommonClassBMember2020-01-012020-12-310001790340us-gaap:CommonClassAMember2020-01-012020-12-310001790340imrx:SeriesBConvertiblePreferredStockMember2020-12-310001790340imrx:BioArkiveIncMember2021-12-310001790340us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340imrx:GovernmentSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340imrx:GovernmentSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:FairValueMeasurementsRecurringMember2021-12-310001790340us-gaap:USTreasurySecuritiesMember2021-12-310001790340imrx:GovernmentSecuritiesMember2021-12-310001790340us-gaap:CommercialPaperMember2021-12-3100017903402020-01-012020-12-310001790340imrx:BioArkiveIncMember2021-12-222021-12-220001790340imrx:BioArkiveIncMember2021-12-220001790340imrx:BioArkiveIncMemberimrx:LeaseTerminationOnMarch312024Member2021-12-310001790340imrx:BioArkiveIncMemberimrx:LeaseTerminationOnDecember312022Member2021-12-310001790340imrx:BioArkiveIncMemberimrx:LeaseTerminationOnApril302032Member2021-12-3100017903402021-12-3100017903402020-12-3100017903402022-03-0300017903402021-06-300001790340us-gaap:CommonClassBMember2022-03-030001790340us-gaap:CommonClassAMember2022-03-0300017903402021-01-012021-12-31imrx:segmentxbrli:sharesiso4217:USDutr:sqftxbrli:pureimrx:Dimrx:agreementimrx:trancheimrx:Voteiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from                      to

Commission File Number: 001-40675

Immuneering Corporation

(Exact name of registrant as specified in its charter)

Delaware

26-1976972

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

245 Main St.

Second Floor

Cambridge, MA

02142

(Address of Principal Executive Offices)

(Zip Code)

(617) 500-8080

(Registrant’s telephone number)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading symbol

    

Name of Exchange on which registered

Class A common Stock, par value $0.001 per share

IMRX

The Nasdaq Global Market

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes      No  

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes      No  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes      No  

As of June 30, 2021, the last day of the registrant’s most recently completed second fiscal quarter, the registrant’s Class A common stock was not publicly traded. The registrant's Class A common stock, began trading on the Nasdaq Global Market on July 30, 2021. As of March 3, 2022, the aggregate market value of the registrant’s voting and non-voting common stock held by non-affiliates of the registrant was approximately $136.9 million (based upon the closing sale price of the Class A common stock on that date on the Nasdaq Global Market).

As of March 3, 2022, the registrant had 26,377,299 shares of Class A common stock, $0.001 par value per share, issued and outstanding and 0 shares of Class B common stock, $0.001 par value per share, issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Definitive Proxy Statement relating to the registrant’s 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the end of the registrant’s fiscal year ended December 31, 2021 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.

TABLE OF CONTENTS

    

    

Page

PART I

Item 1.

Business

7

Item 1A.

Risk Factors

55

Item 1B.

Unresolved Staff Comments

116

Item 2.

Properties

116

Item 3.

Legal Proceedings

116

Item 4.

Mine Safety Disclosures

116

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

116

Item 6.

[Reserved]

117

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

117

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

129

Item 8.

Financial Statements and Supplementary Data

130

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

157

Item 9A.

Controls and Procedures

157

Item 9B.

Other Information

157

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

157

PART III

Item 10.

Directors, Executive Officers and Corporate Governance

158

Item 11.

Executive Compensation

158

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

158

Item 13.

Certain Relationships and Related Transactions, and Director Independence

158

Item 14.

Principal Accounting Fees and Services

158

PART IV

Item 15.

Exhibits, Financial Statement Schedules

158

Item 16.

Form 10-K Summary

160

2

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including without limitation statements regarding our plans to develop, manufacture and commercialize our product candidates, the timing or outcome of our ongoing or planned clinical trials for IMM-1-104, any of our other pipeline product candidates and any future product candidates, the clinical utility of our product candidates, the filing with, and approval by, regulatory authorities of our product candidates, the sufficiency of funds to operate the business of the Company, the ongoing impact of the pandemic related to COVID-19 and its variants on our business and operations, including manufacturing, research and development, clinical trials and employees, our cash needs and availability including our revenue streams, and the plans and objectives of management for future operations, are forward-looking statements.

The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those projected in the forward-looking statements, including, but not limited to, those described in the sections of this Annual Report on Form 10-K entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. These risks and uncertainties include, but are not limited to:

our limited operating history;
our history of operating losses;
risks related to the pandemic related to COVID-19 and its variants;
our ability to raise the substantial additional capital that will be required to finance our operations;
the difficulty of obtaining regulatory approval for any of our current or future product candidates;
our ability to file INDs (as defined below) or IND amendments or comparable documents in foreign jurisdictions in order to commence clinical trials on the timelines we expect;
our limited experience in designing clinical trials;
the risk of substantial delays in completing, if at all, the development and commercialization of our current or future product candidates;
risks related to adverse events, toxicities or other undesirable side effects caused by our current or future product candidates;
the risk of delays or difficulties in the enrollment and/or maintenance of patients in clinical trials;
our substantial reliance on the successful development of our current and future product candidates, as well as our platform, including our proprietary technologies such as DCT and Fluency;
risks related to competition in our industry;
the market opportunity for our product candidates, if approved;
risks related to manufacturing;

3

risks related to our reliance on third parties;
risks related to our intellectual property; and
other important risk factors that could affect the outcome of the events set forth in these statements and that could affect our operating results and financial condition are described in the “Risk Factors” section of this Annual Report on Form 10-K.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Unless otherwise stated or the context requires otherwise, references to “Immuneering,” the “Company,” “we,” “us,” and “our,” refer to Immuneering Corporation and its subsidiaries.

4

Risk Factors Summary

We are subject to numerous risks and uncertainties, including those further described below in Part I Item IA. “Risk Factors” in this Annual Report on Form 10-K, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following are principal factors that may offset our competitive strengths or have a negative effect on our business strategy, which could materially adversely affect our business, financial conditions, results of operations, future growth prospects, or cause a decline in the price of our common stock:

We have a limited operating history, have not completed any clinical trials and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.
We have incurred significant net losses for the past several years and we expect to continue to incur significant net losses for the foreseeable future and may never attain profitability.
We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.
The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, or to obtain regulatory approval to treat the indications we seek to treat with our product candidates, we will be unable to generate product revenue or the level of planned product revenue and our business will be substantially harmed.
We may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.
Our current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
We are early in our development efforts. Our business is substantially dependent on the successful development of our current and future product candidates. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval to treat the indications we seek to treat with our product candidates, and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.
We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems. Any failure of these or other elements of our platform will materially harm our business.
Our long-term prospects depend in part upon discovering, developing and commercializing product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.
Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our DCT platform to build a pipeline of product candidates with commercial value.
We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.

5

We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities could be negatively impacted.
The COVID-19 pandemic and potential future pandemics could continue to adversely impact our business, including our anticipated clinical trials and their timelines, supply chain and business development activities.
We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations, or CROs, to conduct certain aspects of our preclinical studies, and in the future, our clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
We contract with third parties for the manufacturing of our product candidates for preclinical studies, and expect to continue to do so for clinical trials and ultimately, for commercialization of any approved product candidate. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.
If we are unable to obtain and maintain patent and other intellectual property protection for our product candidates and technologies or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be impaired, and we may not be able to compete effectively in our market.

6

PART I

Item 1. Business

We aim to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using our translational bioinformatics platform. We have more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, our disease-agnostic discovery platform enables us to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry. Our lead product candidate IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR to modulate the signaling dynamics of the MAPK pathway.  Specifically, it is designed to use deep cyclic inhibition to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, moderate level of signaling sufficient to spare healthy cells.  IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutant tumors, guided by our proprietary, human-aligned 3D tumor modeling platform combined with translational bioinformatics and expertise in translational planning. In addition to IMM-1-104, we have six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.

We plan to submit an Investigational New Drug application (an “IND”) to the Food and Drug Administration (“FDA”) for IMM-1-104 in the third quarter of 2022. In addition, we anticipate filing an IND for IMM-6-415, our MEK-io candidate, in 2023, and plan to file an additional IND for another oncology program in 2024.

Overview

Our platform is enabled by our ability to efficiently analyze high-throughput molecular-level biochemical assays, including transcriptomics, genomics and/or proteomics, collectively referred to as Omics data. These different types of biochemical assays each provide us with unique information about the molecular mechanisms of disease biology and drug response. Since our inception, we have partnered with industry- leading pharmaceutical and biotechnology companies to perform a variety of analyses that utilize our expertise in translational bioinformatics. Examples publicly disclosed by our partners include our analyses of ibrutinib, ipilimumab, daratumumab, glatiramer acetate and pridopidine.

In early 2018, we began applying our proprietary platform and approach to internally develop our wholly owned pipeline of orally administered small molecule drug programs. Our approach played a critical role in determining the most important characteristics for and creation of IMM-1-104. Specifically, our platform enables us to:

leverage insights from human data to identify disease transcriptional profiles we aim to counteract;
identify novel biology, specifically evaluating new ways to drug an existing target by utilizing our proprietary Disease Cancelling Technology, or DCT, and analyze mechanisms of existing drugs;
generate novel chemistry that overcomes MAPK-feedback loops to achieve optimal signaling dynamics; and
profile IMM-1-104 in a large number of 3D models using our own translational planning to identify the types of cancer most likely to be sensitive to the product candidate.

Our current oncology programs target mutations of the RAS/RAF/MEK/ERK, or MAPK, and the PI3K/AKT/mTOR, or mTOR, pathways. The MAPK and mTOR signaling pathways run parallel to each other, and in over half of all cancers, one or both of these pathways are inappropriately activated (as depicted below). Existing drugs targeting these pathways are limited by toxicity, resistance and/or are narrowly focused on subpopulations with specific mutations. The MAPK and mTOR pathways function to drive cell proliferation, differentiation, survival and a variety of other cellular functions that are critical for the formation of tumors.

7

Fundamental Cancer Signaling Cellular Pathways: MAPK and mTOR

Graphic

Each of the programs in our oncology pipeline is designed to cause cyclical disruption of abnormal activation of the MAPK and mTOR signaling pathways while limiting drug-related toxicity. Traditional drug approaches have been designed to sustain pathway inhibition, which can cause on-target drug-related toxicity and limit clinical durability as a result of drug holidays or treatment discontinuation. Based on insights derived from our translational bioinformatics platform, our differentiated approach is to design drugs with short half-lives that provide enhanced mechanistic control of the target of interest and break tumor addiction, which is the tumor’s ability to indefinitely self-replicate, metastasize and evade the host’s immune system, among other capabilities, through deep cyclic disruption of these pathways (i.e., signaling dynamics). By cyclically disrupting these core oncogenic signaling pathways in cancer cells, we believe we can create novel therapeutics that maximize therapeutic activity in broad patient populations while providing an improved tolerability profile (as depicted below). We believe we are pioneers in this unique approach of leveraging signaling dynamics against tumor addiction.

Signaling Dynamics: Traditional Sustained Inhibition Versus Our Cyclic Approach

Graphical user interface, diagram

Description automatically generated with medium confidence

8

Our Wholly Owned Pipeline

Our oncology programs target clinically validated pathways, but we seek to improve patient outcomes across a wide range of addressable solid tumor types through our differentiated programs. In addition to our oncology pipeline, we are also leveraging our platform to build a neuroscience pipeline initially focusing on Alzheimer’s disease, or AD. Our current pipeline of product candidates and discovery programs is depicted below.  

Chart, funnel chart

Description automatically generated

Dual-MEK Program

Our dual mitogen-activated protein kinase kinase, or MEK, product candidate, IMM-1-104, is designed to be a highly selective inhibitor of mitogen-activated protein kinase kinase kinase, or ERK, activation (i.e., phosphorylation), prevent MAPK pathway reactivation and have a short plasma half-life that reduces sustained pathway inhibition (as depicted below). Unlike MEK inhibitors approved by the U.S. Food and Drug Administration, or the FDA, IMM-1-104 is designed to prevent RAF-mediated activation of MEK by engagement of the RAF activation loop on MEK, such as CRAF-bypass, and further disrupt the kinase suppressor of RAS 1 and 2, or KSR. Additionally, with a short plasma half-life, IMM-1-104 can achieve deep cyclic inhibition of the MAPK pathway. We believe this innovative method of pathway inhibition normalizes cancer cell signaling dynamics and prevents further damage to normal healthy cells. Collectively, we believe these qualities differentiate IMM-1-104 from known MEK inhibitors by potentially enabling IMM-1-104 to avoid drug resistance while improving tolerability.

9

Dual-MEK Inhibition Prevents Activation of MEK and Downstream Activation of ERK

Graphic

In preclinical studies, we observed that IMM-1-104 inhibited MEK and ERK across a wide range of human and murine solid tumor models, including those with activating mutations in KRAS, NRAS, HRAS and BRAF. In addition, in head-to-head preclinical studies, we evaluated IMM-1-104 in murine-based KRAS, NRAS, and BRAF mutant solid tumor models representing lung, colon, pancreas and skin cancer, and observed tumor stasis or regression with insignificant body weight loss, or BWL, when compared to certain current FDA- approved MEK and BRAF inhibitors. Given the data observed in these preclinical studies, we believe that IMM-1-104 has the potential to deliver clinical benefit as monotherapy and, in the future, may potentially be administered in select drug combinations for patients with RAS and/or RAF mutant solid tumors who currently have limited treatment options.

IMM-1-104 is currently undergoing Investigational New Drug, or IND, enabling studies. We plan to submit an IND for IMM-1-104 to the FDA in the third quarter of 2022. We intend to enroll our first patient in our first-in-human Phase 1 clinical trial of IMM-1-104 in the fourth quarter of 2022 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors, if our IND for IMM-1-104 is accepted.

MEK-Immuno-Oncology

Our MEK-immuno-oncology, or MEK-io, program is focused on developing innovative allosteric MEK inhibitors to be administered in combination with select immune modulators (e.g., checkpoint inhibitors) for the treatment of “cold” solid tumors, which are immunologically inaccessible. Our investigational MEK-io program inhibitors were designed to target MEK in a way that disrupts the MAPK pathway at ERK and to also reduce baseline MEK activation. We designed these inhibitors with unique pharmacokinetic, or PK, and pharmacodynamic, or PD, profiles that may enhance cycle inhibition time of MEK and ERK to optimize the patient’s immune response and promote maximal antitumor responses when administered in combination with select immune modulators. We recently selected a development candidate, IMM-6-415, for the MEK-io program, and initiated IND-enabling studies in the first quarter of 2022.

We observed an initial in vivo proof-of-concept for our MEK-io program, from a related analogue compound to IMM-6-415, in a widely utilized syngeneic murine model. We evaluated this analogue compound as monotherapy and in combination with a checkpoint inhibitor and compared to vehicle to observe tumor growth inhibition in tumor-bearing BALB/C mice. Neither treatment alone altered tumor growth as compared to vehicle. However, when we administered our analogue MEK-io program inhibitor in combination with the checkpoint inhibitor, we observed greater than 50% tumor growth inhibition after two weeks of dosing as compared to vehicle treated mice.

10

IMM-6-415 may enhance responses to checkpoint inhibitors in tumors that have been responsive to these class of agents. We observed single agent activity in the Colon-26 syngenetic colorectal tumor model and are evaluating IMM-6-415 as monotherapy or in combination with checkpoint inhibitors in CT26 and MC-38 syngeneic models. We plan to submit  an IND for IMM-6-415 to the FDA in 2023.

Additional Oncology Discovery Research Programs

We are leveraging our platform to continue expanding our oncology pipeline by targeting the MAPK and mTOR pathways in novel ways. We have five additional programs in various stages of drug discovery focused on targeting these pathways through novel pharmacological approaches. We expect to file an IND for at least one of these programs in 2024.

Neuroscience Programs

AD is the most common form of dementia and one in three adults over the age of 65 succumb to AD-related dementia or another form of dementia. We believe there are specific subgroups of AD that can be stratified through gene expression and brain pathology. To identify AD subgroups, we have leveraged our platform to employ a patient-centric, data-driven approach. AD is a neurodegenerative disorder of uncertain cause and pathogenesis characterized by memory impairment and further cognitive decline that can ultimately affect the patient’s behavior, speech, visuospatial orientation and motor system. AD is a complex multifactorial disease driven by genetic and environmental causes that affects older adults and is one of the leading sources of morbidity and mortality in the aging population. The estimated total healthcare costs for the treatment of AD were approximately $305 billion in 2020, with the cost expected to increase to more than $1 trillion by 2050.

Our neuroscience programs are in the early stages of drug discovery, and we are evaluating undisclosed targets to pursue a unique approach to treating AD. Our focus is to slow the progression of AD by developing targeted therapies for distinct biological mechanisms that we have identified in specific AD subgroups. Our platform and expertise in neurology and neuroscience have allowed us to determine biological differences in AD patients to help develop novel product candidates that may potentially address the significant unmet needs of this underserved patient population.

Our Team

We were founded in 2008 by our Chief Executive Officer and President, Benjamin J. Zeskind, Ph.D., and the Chairman of our board of directors, Robert J. Carpenter, with the goal of leveraging translational bioinformatics to generate insights into the mechanisms that cause certain patients to respond to specific medicines across multiple therapeutic areas. Our multi-disciplinary team brings together experts across translational bioinformatics, preclinical and clinical development in both oncology and neuroscience and includes individuals with extensive experience at some of the leading pharmaceutical companies, including Johnson & Johnson, AstraZeneca, Merck and Incyte.

Our History

Our company is built on more than a decade of experience in translational bioinformatics. Since our founding in 2008, we have utilized this experience to generate insights into the mechanisms that cause certain patients to respond to specific medicines across therapeutic areas by analyzing Omics data. Our computational biology services business has helped us to better understand how translational bioinformatics can contribute to each stage of drug development, from early drug discovery to clinical development and through commercialization. However, we recognized the limitations of applying translational bioinformatics in isolation to specific stages of the drug development process and realized that bioinformatics could be even more helpful if applied continuously throughout the drug development process. Over time, we have developed a proprietary technology platform to facilitate that process and, in early 2018, we began applying the extensive insights from and capabilities of our platform and approach to create a wholly owned pipeline of drug programs, initially focusing on oncology.

11

Our Strategy

Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases. Our platform allows us to leverage human biological data to generate insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views. We are developing novel product candidates that aim to optimize both safety and efficacy for diseases with suboptimal treatment options. To achieve our mission, we are executing a near-term strategy with the following key elements:

Advance IMM-1-104 into Clinical Development. We believe that IMM-1-104 has the potential to treat broad populations of solid tumor patients, specifically those with inappropriate activation of the MAPK pathway. IMM-1-104 has been specifically designed to overcome MAPK-feedback loops and, combined with its intentionally short half-life, could have the potential to provide broader therapeutic activity and an improved tolerability profile relative to known MEK inhibitors. We believe IMM-1-104 has the potential to target patients with a wide spectrum of mutations in KRAS and NRAS, as well as other mutations that activate the MAPK pathway. IMM-1-104 is currently in IND-enabling studies, and we expect to submit an IND in the third quarter of 2022.
Advance IMM-6-415 through IND-Enabling studies. We recently commenced IND-enabling studies for IMM-6-415 and plan to submit an IND in 2023. IMM-6-415 is a dual-MEK inhibitor that has drug-like properties optimized for immune modulation, and may enhance and/or expand clinical responses to checkpoint inhibitors in tumors that have proved historically challenging to immune modulating therapies. In addition, we may target patient populations with RAS and RAF mutations who have observed low rates of clinical responses to checkpoint inhibitors.
Progress Our Pipeline of Additional MAPK and mTOR Pathway Programs to IND-Enabling Studies. Other key programs in our oncology pipeline also leverage our knowledge of the MAPK and mTOR pathways, translational bioinformatics and signaling dynamics. For example, we are advancing programs which modulate the formation of RAS dimers to kill RAS-driven tumors while sparing healthy cells. We are also applying our platform to other relevant pathways and have initiated a program targeting PI3Kα in the mTOR pathway. We intend to develop other programs for the mTOR pathway, as well as other oncogenic pathways. We anticipate submitting an IND for at least one of these programs in 2024.
Utilize Our Platform to Advance Our Neuroscience Programs. In addition to our extensive oncology pipeline, we have built a neuroscience pipeline initially focused on AD, which leverages key components of our platform. We have identified subgroups of AD with distinct molecular drivers and have identified unique undisclosed targets for these specific subgroups. Currently, we are developing investigational small molecules to inhibit these undisclosed targets, which we intend to continue advancing towards IND-enabling studies.
Continue to Grow and Advance Our Platform. We have built a biopharmaceutical company that fully integrates bioinformatics across all aspects of drug discovery and development. We currently utilize our bioinformatics platform for our drug discovery efforts in oncology and neuroscience, and as we advance our product candidates into and through the clinic, we plan to utilize data and insights from our bioinformatics platform to not only guide future clinical development but to also provide key learnings back to our earlier stage programs. Lastly, we continue to iterate on our existing technology and processes, and develop new technologies for our platform, all aimed at creating the most efficient process for the development of product candidates that we believe have the potential to optimize both safety and efficacy in broad patient populations with high unmet medical needs.

Our Bioinformatics Approach

Leveraging our history in translational bioinformatics, we have built a biopharmaceutical company that incorporates our expertise into every step of our process to discover and develop novel product candidates. Our goal is to meaningfully improve patient outcomes as compared to drugs developed through traditional drug discovery approaches. Our integrated approach has already yielded programs that have exhibited preclinical tumor growth inhibition against a broad range of clinically challenging solid tumors, which are advancing towards the clinic. Our Dual-MEK and MEK-io drug programs are currently in IND-enabling studies, while the rest of our programs are in earlier stage preclinical studies. We have

12

expanded our team of experts, including drug discovery and clinical development experts, to develop a pipeline of product candidates by leveraging our translational bioinformatics expertise (as depicted below).

Our Bioinformatics Expertise Leveraged Through All Stages of Drug Discovery and Development

Diagram

Description automatically generated

Cancer Overview

Cancer is the second most common cause of death worldwide with approximately 10 million deaths annually and an incidence of approximately 19.3 million new cases in 2020. Cancer is defined as a collection of diseases in which abnormal cells divide uncontrollably and can invade nearby tissues. The uncontrollable division of abnormal cells typically results in a malignant tumor (i.e., cancerous) or benign tumor (i.e., non-cancerous). There are two main categories of cancer: hematologic (i.e., blood) cancers and solid tumor cancers. Hematologic cancers are cancers of the blood cells, and include leukemia, lymphoma and multiple myeloma. Solid tumor cancers are cancers of any of the body’s other organs or tissue, including the pancreas, skin, lung and colon. Core tumor capabilities seen in cancer patients include the ability to indefinitely self-replicate, develop new blood vessels (i.e., angiogenesis), evade cell death (i.e., apoptosis), sustain self-sufficient growth, invade other tissues (i.e., metastasis), alter signaling pathways, evade immune system responses and modify metabolism. Tumor survival is dependent on certain of these capabilities (i.e., tumor addiction).

MAPK and mTOR Pathways

In all cells, signaling pathways govern how cells regulate themselves as well as direct activities in relation to other cells in the body. Two of the most commonly altered signaling pathways in cancer are the MAPK and mTOR pathways. MAPK and mTOR are both oncogenic signaling pathways that run parallel to each other. RAS is a family of related oncogenes found upstream in each pathway that codes for four highly related protein isoforms, HRAS, NRAS, KRAS4A and KRAS4B. In over half of all cancers, one or both of these pathways are inappropriately activated, often through mutations in the key members of the pathway, including RAS, RAF and PI3Kα. When RAS is switched “on” through the activation of the membrane-bound receptor tyrosine kinase, or RTK, the MAPK and mTOR pathways function to drive cell proliferation, differentiation, survival and a variety of other cellular functions that are critical for the formation of tumors. In addition, the membrane-bound RTKs can separately activate the mTOR pathway without the assistance of RAS.

13

Through widespread adaptation of molecular profiling, we now recognize that up to one in two cancer patients harbor tumors which are inappropriately activated through the MAPK pathway, and an additional one in three display alterations that impact the mTOR pathway. Many of these patients display tumors with activation mutations in RAS or RAF, which lie upstream of MEK and ERK. Because inappropriate activation of the MAPK and/or mTOR pathways supports many of the core tumor capabilities described above, efforts to create new therapeutics to target these pathways has been a high priority in cancer drug research. However, therapeutics that target the MAPK and mTOR pathways have not lived up to the expectations of effectively disrupting these pathways with high patient tolerability. Nearly all targeted therapeutics against the MAPK and mTOR pathways have been designed for sustained pathway suppression, which has resulted in on-target drug-related toxicity that limits clinical durability and potential drug-drug combinations. Furthermore, sustained irreversible covalent inhibition of these pathways may lead to treatment resistance, as highlighted in a recently published study in the New England Journal of Medicine. The study focused on patients treated with adagrasib, an irreversible covalent inhibitor of KRASG12C, and reported that 45% of patients (17 patients out of 38) in the study receiving adagrasib monotherapy developed resistance. Of these patients, many resistance mechanisms were observed involving non-G12C variations in KRAS, variations in NRAS or BRAF, or other resistance mechanisms related to the MAPK and mTOR pathways. A second study published in Nature (November 10, 2021) evaluated 43 patients treated with sotorasib, an irreversible covalent inhibitor of KRASG12C, and reported 27 patients with multiple treatment-emergent resistance alterations. Of these, 15 patients reported resistance mechanisms involving RAS/RAF mutations.

Developing novel therapeutics to effectively and safely target these pathways may provide clinical benefit in large patient populations with significant unmet needs. In addition, although these two pathways represent two of the most active areas in cancer drug discovery and development, targeted therapeutics that more effectively and safely normalize, but not ablate, ERK and mTOR signaling may uncouple drug activity and tolerability, while optimizing both. Our oncology pipeline is designed to non-chronically disrupt molecular pathways that enable tumor addiction while limiting drug-related toxicity of normal healthy cells that also rely, to a lesser degree, on these pathways.

Our Programs Target Aggressive Solid Tumors That Display High RAS/RAF Mutations

Graphic

Our Differentiated Approach to Tackling Some the Most Challenging Cancers

We are leveraging our platform to target the MAPK and/or mTOR pathway. Our differentiated approach is to design drugs with short half-lives that provide enhanced mechanistic control of the target of interest and break tumor addiction through deep cyclic disruption of these pathways (i.e., signaling dynamics). We believe we are pioneers in this approach of leveraging signaling dynamics against tumor addiction, and our insights derived from our translational bioinformatics platform supports our belief that this approach may result in novel therapies targeting these pathways. Traditional drug approaches have been designed to sustain pathway inhibition, which leads to on-target drug-related toxicity and becomes

14

limiting for clinical durability as a result of drug holidays or treatment discontinuation. The mutational activation and/or overexpression of the signaling components that activate the MAPK pathway are well-known, and MEK has been previously validated as a therapeutic target. We believe our programs, as compared to FDA-approved treatments targeting the MAPK pathway, have the potential to be differentiated by their unique target engagement and PK and PD profiles. For example, our lead product candidate, IMM-1-104, is designed to inhibit ERK, prevent MAPK- pathway reactivation and have a short plasma half-life that reduces sustained pathway inhibition compared to other drugs targeting the same mechanistic pathway. By cyclically disrupting these core oncogenic signaling pathways in cancer cells, we believe we can create novel therapeutics in oncology that maximize therapeutic activity in broad patient populations while providing an improved tolerability profile as compared to other FDA-approved treatments for cancers caused by MAPK pathway activation.

Our Oncology Pipeline

Our current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Our Dual-MEK product candidate, IMM-1-104, and our MEK-io product candidate, IMM-6-415 are currently being evaluated in IND-enabling studies and are complemented by multiple earlier- stage programs that also target the MAPK and mTOR pathways. The following table summarizes our oncology pipeline:

Chart, funnel chart

Description automatically generated

Overview of Our Lead Program: Dual-MEK

Background of MEK Inhibitors

Activating mutations of RAS and/or RAF in the MAPK pathway are observed in approximately 30% of all cancer patients, and inappropriate activation of this pathway is observed in up to 50% of all tumors and represents one of the most highly utilized signaling pathways in oncologic drug discovery. In aggressive solid tumors of the pancreas, skin, lungs and colon, mutations in RAS and/or RAF are even more common. For example, approximately 40% of lung cancers and approximately 90% of pancreatic cancers are due to RAS and/or RAF mutations. To date, FDA-approved MEK inhibitors have been ineffective at treating RAS mutant tumors when compared to BRAF mutant tumors because of a well-known mechanism of resistance, CRAF- mediated MEK activation, or the CRAF-bypass. In addition, a well-known limitation of current FDA- approved MEK inhibitors are their high rates of serious drug-related adverse events, most often in over 50% of  treated patients, which results in drug intolerability.  The longer half-life of  these drugs (e.g., up to 2 to 4 days), or

15

moderate half-life (e.g., 3 to 6 hours) with increased dosing frequency, contributes to high rates of adverse events because these drugs systemically circulate for an extended period of time destroying healthy normal cells, which also rely on the pathway for survival. Our goal in developing IMM-1-104 is to address these shortcomings to potentially provide patients with better outcomes, improved tolerability, durability and expand drug-drug combination opportunities (as depicted below).

IMM-1-104: Designed to be a Highly Differentiated Dual-MEK Inhibitor

Diagram

Description automatically generated

Our Solution: IMM-1-104

We have leveraged our platform to develop our lead product candidate, IMM-1-104, which is designed to be a highly selective dual-MEK inhibitor that promotes additional scaffold-related disruption of KSR. We are developing IMM-1-104 to treat patients with cancer, including pancreatic, melanoma, colorectal and non-small cell lung cancer, or NSCLC, caused by mutations of RAS and/or RAF. In order to overcome MAPK-feedback and CRAF-mediated MEK activation, a well-known limitation of current FDA-approved MEK inhibitors, we developed IMM-1-104 to allosterically inhibit MEK by targeting the site lying adjacent to the binding pocket of adenosine triphosphate, or ATP, which results in downstream inhibition of ERK. In addition, unlike FDA-approved MEK inhibitors, IMM-1-104 is designed to prevent RAF-mediated activation of MEK by unique engagement of MEK that further disrupts KSR. We believe the bypass of these drug resistance mechanisms will provide for better patient outcomes by enhancing therapeutic activity throughout the course of treatment. By reducing steady state drug trough levels, we also designed IMM-1-104 to limit or reduce high rates of serious drug-related adverse events that are observed in current FDA-approved MEK inhibitors (e.g., ranging from 45% to 69%), most often given in combination with a RAF inhibitor, which contribute to discontinuation rates of up to 10% to 15%.

With a goal of improving the tolerability profile of our MEK inhibitor, we designed IMM-1-104 to have a short plasma half-life, resulting in a near-zero steady state drug trough concentration that enables deep cyclic inhibition of the MAPK pathway. We believe this method of drug cadence-driven pathway inhibition has the potential to normalize cancer cell signaling dynamics and prevent further damage to normal healthy cells. Collectively, we believe these qualities may differentiate IMM-1-104 from known MEK inhibitors by potentially allowing IMM-1-104 to avoid drug resistance while improving tolerability due to its dual allosteric inhibition of MEK, KSR disruption and short plasma half-life.

16

Preclinical Studies Overview: IMM-1-104

In multiple preclinical studies, we observed that IMM-1-104 inhibited activated MEK (i.e., pMEK) and activated ERK (i.e., pERK) across a wide range of murine and humanized 3D solid tumor models, including those with activating mutations in KRAS, NRAS, HRAS and BRAF. In addition, in head-to-head preclinical studies, we evaluated IMM-1-104 in murine-based KRAS, NRAS, and BRAF mutant solid tumor models representing lung (i.e., A549), colon (i.e., Colon-26), pancreas (i.e., MIA PaCa-2) and skin cancer (i.e., A375 and SK-MEL-2), and observed tumor stasis or regression with insignificant BWL when compared to current FDA-approved MEK inhibitors, including selumetinib, binimetinib, encorafenib and AMG-510 (now known as sotorasib). Given the data observed in our previously conducted preclinical studies, we believe that IMM-1-104 has the potential to deliver clinical benefit as monotherapy and, in the future, may potentially be administered in select drug combinations for patients with RAS and/or RAF mutant solid tumors who currently have limited treatment options.

Preclinical Studies: Maximum Tolerated Dose and Therapeutic Effect

In our early maximum tolerated dose, or MTD, studies, we observed that oral administration of IMM-1-104 twice a day of up to 150 mg/kg/dose was well-tolerated in mice. In other preclinical studies, we observed that the maximum therapeutic effect of IMM-1-104 was reached when administered orally twice a day between 100 and 150 mg/kg/dose. These dosing studies provided the basis of IMM-1-104’s dosing schedule in subsequent preclinical studies.

Preclinical Studies: Pharmacogenomics

In a pharmacogenomics study utilizing a colorectal KRASG12D tumor model in BALB/c mice, we evaluated downstream ERK inhibition of the MAPK pathway after IMM-1-104 treatment. We orally administered vehicle, selumetinib and IMM-1-104 twice a day at 100 mg/kg/dose, then harvested the tumors after 18 days of chronic treatment at 2 and 12 hours following the last drug dose to evaluate RNAseq changes. The tumors were collected across distinct BALB/c mice and RNAseq changes were evaluated using statistical analysis software. Consistent with IMM-1-104’s designed short plasma half-life, we observed deep, cyclic inhibition of most of the top genes in the ERK transcriptome, as noted by the differences of the dark and light blue bars, which we believe may improve tolerability by allowing healthy normal cells to regenerate before the next dose is administered. For example, Erg1 and Spry4 were both downregulated over 16-fold at 2 hours after receiving the first dose on day 18 of the study, and at 12 hours after the first dose, which was prior to the second dose, both genes were approaching their baseline state when compared to vehicle treated tumors (as depicted below). In contrast to IMM-1-104, we did not observe deep cyclic inhibition by selumetinib, but rather observed sustained MAPK pathway suppression versus vehicle groups between the two timepoints on day 18 (as depicted below). The top 20 genes were a subset of a 52-gene signature for ERK signaling.

17

Head-to-Head Comparison of IMM-1-104 Against Selumetinib Using a Colon-26 Syngeneic Tumor Model: Deep Cyclic Inhibition of the ERK Transcriptome

Graphic

* Adjusted p-value < 0.05, for each treatment versus vehicle (n = 3-4 independent tumors per group)

Preclinical Studies: Resistance to CRAF-bypass

We evaluated IMM-1-104 head-to-head against four FDA-approved MEK inhibitors for CRAF-bypass resistance in a KRAS mutant NSCLC tumor model. We exposed the tumor cells with 100 nM of each drug for 2 hours and evaluated MEK and ERK activation levels. We observed that IMM-1-104 was able to reduce overall activity of the MAPK pathway at ERK and pathway reactivation at MEK through a decrease in MEK and ERK activation, resulting in CRAF-bypass resistance. In contrast, we observed that all four FDA- approved MEK inhibitors displayed an increase in activated MEK, resulting in CRAF-bypass (as depicted below).

18

Head-to-Head Comparison of IMM-1-104 against Four FDA-Approved MEK Inhibitors Using a A549 Xenograft Tumor Model: Prevented Downstream Activation of ERK (↓ pERK) and Inhibited Activation of MEK (↓ pMEK)

Graphic

Preclinical Studies: Tumor Regression and Body Weight Loss

We evaluated IMM-1-104 head-to-head against binimetinib and selumetinib in an aggressive murine colorectal tumor model (i.e., Colon-26), which expresses mutant KRASG12D. We observed that IMM-1-104 demonstrated greater tumor growth inhibition, where notably 5 of 8 mice experienced tumor regression during the first 10 days of dosing, as well as greater tolerability, evidenced by changes in BWL. In addition, we observed that IMM-1-104 had overall better durability of antitumor response as compared to the two FDA- approved MEK inhibitors, as demonstrated by significantly lower tumor volume, or TV, progression. This study demonstrated that IMM-1-104 as compared to binimetinib and selumetinib provided greater tumor inhibition, lower BWL and lower TV progression (as depicted below).

19

Head-to-Head Comparison of IMM-1-104 Against Binimetinib and Selumetinib Using a Colon-26 Syngeneic Tumor Model: Body Weight Loss and Tumor Volume

Graphical user interface

Description automatically generated

After observing the results of the Colon-26 tumor study, we completed two follow-up in vivo studies, where we evaluated IMM-1-104 head-to-head against binimetinib or encorafenib, a BRAF inhibitor, as monotherapy plus the combination of binimetinib with encorafenib in BALB/c mice tumor models with RAS and RAF mutations. It should be noted that when encorafenib is used to treat KRAS mutant tumors that are wild type for BRAF, it can paradoxically activate the MAPK pathway and antagonize the effects of binimetinib. In addition, the drug doses and schedules used for binimetinib and encorafenib in these studies were consistent with what was provided in their NDAs to the FDA.

We evaluated IMM-1-104 head-to-head against binimetinib monotherapy and in combination with encorafenib in the KRASG12S human NSCLC tumor model (i.e., A549). When comparing IMM-1-104 to binimetinib monotherapy, we observed that IMM-1-104 had greater tumor growth inhibition (as depicted below). The observations of IMM-1-104 head-to-head against binimetinib alone and in combination with encorafenib, which was not considered relevant for a KRAS mutant, RAF wild-type tumor model, has been included in the figure below for comparison purposes.

20

Head-to-Head Comparison of IMM-1-104 Against Binimetinib +/- Encorafenib Using a A549 Xenograft Tumor Model: Tumor Volume

Chart

Description automatically generated

We also evaluated IMM-1-104 head-to-head against binimetinib and encorafenib monotherapy and the combination of binimetinib with encorafenib in a BRAFV600E human melanoma tumor model. It should be noted that the administered combination of binimetinib and encorafenib for BRAF mutant melanoma, such as BRAFV600E/K, is an FDA-approved combination. As expected, when comparing IMM-1-104 alone to binimetinib in combination with encorafenib, we observed that the combination therapy had greater tumor growth inhibition (as depicted below). However, when we compared IMM-1-104 to binimetinib monotherapy, we observed that IMM-1-104 had greater tumor growth inhibition (as depicted below). We believe the greater single agent MEK inhibitor activity provides an opportunity to expand IMM-1-104 into drug-drug combinations with other MAPK pathway inhibitors, such as encorafenib, to treat RAF mutant cancers, such as BRAFV600E/K, among other MAPK pathway mutations.

21

Head-to-Head Comparison of IMM-1-104 Against Binimetinib +/- Encorafenib Using a A375 Xenograft Tumor Model: Tumor Volume

Chart

Description automatically generated

In a further in vivo study based on humanized 3D tumor model data, we evaluated IMM-1-104 head-to-head against AMG-510 (sotorasib) and gemcitabine alone, and IMM-1-104 in combination with AMG-510, for 21 days in the KRASG12C mutant tumor model (i.e., MIA PaCa-2). In a previous study conducted by a third-party, AMG-510 demonstrated sensitivity to this pancreatic tumor model. Comparing IMM-1-104 alone, against AMG-510 and in combination with AMG-510, we observed tumor regressions with insignificant BWL (i.e., within 3% of baseline), which we believe indicates activity, durability and tolerability of IMM-1-104 against a KRASG12C mutant pancreatic cancer model (as depicted below).

22

Head-to-Head Comparison of IMM-1-104 +/- AMG-510 (sotorasib) and Gemcitabine Using a MIA PaCa-2 Xenograft Tumor Model: Tumor Volume

Graphical user interface, chart

Description automatically generated

In an in vivo study based on humanized 3D tumor model data, we evaluated IMM-1-104 monotherapy as compared to binimetinib for 21 days in the NRASQ61R mutant tumor model (i.e., SK-MEL-2). We observed better tumor growth inhibition relative to binimetinib (as depicted below).

23

Head-to-Head Comparison of IMM-1-104 Against Binimetinib Using a SK-MEL-2 Xenograft Tumor Model: Tumor Volume

Chart, line chart

Description automatically generated

In a further in vivo study based on humanized 3D tumor model data, we evaluated IMM-1-104 monotherapy as compared to vehicle for 21 days in the NRASQ61R mutant tumor model (i.e., SK-MEL-2). We observed midcycle tumor regressions in mice treated with IMM-1-104, which we believe indicates activity and durability of IMM-1-104 against an NRASQ61R mutant melanoma cancer model (as depicted below).

24

Evaluation of IMM-1-104 as Compared to Vehicle Using a SK-MEL-2 Xenograft Tumor Model: Tumor Volume

Chart, line chart

Description automatically generated

Preclinical Studies: 3D Tumor Growth Models

3D tumor growth models mimic the tumor microenvironment, or TME, more closely than 2D models, and we believe the 3D model more accurately reflects human tumor biology and complexity when evaluating pharmacological data of MAPK pathway inhibition in vivo.  We have established and evaluated over 60 humanized 3D tumor models that display mutations in the RAS isoforms, amongst other altered MAPK pathway targets, including BRAF, CRAF, NF1 and ERK, to evaluate their sensitivities to IMM-1-104. In general, we observed that tumor models with KRAS or NRAS mutations and certain molecular profiles were most sensitive to IMM-1-104, followed closely by tumor models with BRAF mutations. For example, the IC50 of IMM-1-104 ranged from 68.7 nM in NRASQ61K to 214.7 nM in NRASG12D, whereas the IC50 of IMM-1-104 ranged from 814.7 nM to greater than 10,000 nM in BRAFV600E and certain RAS mutants, respectively. More specifically, our 3D tumor modeling data suggested that KRAS mutant pancreatic cancer and NRAS mutant melanoma may be particularly sensitive to single agent IMM-1-104.

To further examine the translational opportunity in KRAS mutant pancreatic cancer and NRAS mutant melanoma, we evaluated several of these cancer mutations utilizing real-world data through a pan-cancer registry, the Genomics Evidence Neoplasia Information Exchange, or GENIE. The total number of patients in the analysis are depicted below in blue and the percentage of patients with a known mutation in KRAS or NRAS are shown as a percentage of the total patients (depicted below in black). Biomarker sensitive profiles (depicted below in green) and biomarker resistant profiles (depicted below in red) are projected subsets of patients with mutated KRAS or NRAS that may be sensitive or resistant to IMM-1-104. We observed that the overwhelming majority of pancreatic cancers associated with KRAS mutations (i.e., 92%) and melanoma associated with NRAS mutations (i.e., 73%) are found to harbor a biomarker profile that may be sensitive to IMM-1-104 (as depicted below).

25

Translational Profiling for KRAS Mutant Pancreatic Cancer and NRAS Mutant Melanoma Utilizing a Pan-Cancer Registry, GENIE

Chart

Description automatically generated with low confidence

A picture containing diagram

Description automatically generated

Clinical Development Overview: IMM-1-104

IMM-1-104 is currently undergoing IND-enabling studies. We plan to submit an IND for IMM-1-104 to the FDA in the third quarter of 2022. We continue to expand our preclinical pharmacology models, including research to further understand sensitivity and resistance biomarkers related to IMM-1-104. We have conducted 28-day good laboratory

26

practices, or GLP, orally dosed safety and toxicology studies in rats and dogs prior to initiating our Phase 1 clinical trial of IMM-1-104. We intend to enroll the first patient in our first-in-human Phase 1 clinical trial of IMM-1-104 in the fourth quarter of 2022 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors if our IND for IMM-1-104 is accepted. The Phase 1 clinical trial of IMM-1-104 is being designed to primarily evaluate its safety and tolerability, and to also identify dose-limiting toxicities.

Our clinical development plan for IMM-1-104 will initially focus on indications selected by our translational data. Additional indications will be based on future preclinical studies and clinical trial outcomes. Our goal is to further expand the development of IMM-1-104 in indications, including a broad range of RAS and/or RAF mutant tumors. In addition, we plan to evaluate IMM-1-104 in combination with FDA-approved MAPK and adjacent pathway inhibitors to treat certain cancers in the future.

MEK-io Program

We are developing innovative investigational allosteric MEK inhibitors to be administered in combination with select immune modulators (e.g., checkpoint inhibitors) for the treatment of “cold” solid tumors. Our investigational MEK-io program inhibitors are designed to target MEK in a way that disrupts the MAPK pathway at ERK and to also reduce baseline MEK activation. We are designing these inhibitors with unique PK and PD profiles that may enhance cycle inhibition time of MEK and ERK to optimize the patient’s immune response and promote maximal antitumor responses when administered in combination with select immune modulators. KRAS mutant tumors impact approximately 15% of patients globally and include cold or “non-inflamed” tumors. Cold tumors are immunologically inaccessible, meaning the patient’s immune system cannot provide an appropriate antitumor response because the lack of T-cell infiltration in the tumor, which is required for the immune system (i.e., T-cells) to find, target and attack the tumor. Checkpoint inhibitors work by helping to reactivate and enhance the patient’s immune system by allowing T-cells to better provide an appropriate antitumor response. If a cold tumor were to become “hot” or “inflamed,” this would create an inflammatory process enabling T-cells to infiltrate the tumor and allow them to recognize and attack the tumor (i.e., an antitumor response). We believe our investigational MEK-io program inhibitors have the potential to turn a cold tumor hot, and when administered in combination with a checkpoint inhibitor, could provide an innovative approach to treat patients with cold solid tumors by providing MEK/ERK inhibition and optimizing antitumor response, which would not typically be seen in these patients.

We observed an initial in vivo proof-of-concept for our MEK-io program, with a related analogue to our MEK-io product candidate IMM-6-415, in a widely utilized syngeneic murine model. We evaluated it as monotherapy and in combination with a checkpoint inhibitor as compared to vehicle to observe tumor growth inhibition in tumor-bearing BALB/C mice. Neither treatment alone altered tumor growth as compared to vehicle. However, when we administered in combination with the checkpoint inhibitor, we observed greater than 50% tumor growth inhibition (TGI) after two weeks of dosing as compared to vehicle treated mice.

Our MEK-io product candidate, IMM-6-415, is currently in IND-enabling studies. IMM-6-415 may enhance responses to checkpoint inhibitors in tumors that have been poorly responsive to these class of agents. We observed dose-dependent, tumor growth inhibition by IMM-6-415 in a syngeneic Colon-26 animal model following oral administration of the drug to identify maximum tolerated dose in a once per day, or QD,  schedule (TGI after 8 days at 175 mg/kg = 46%) or twice per day, or BID, schedule (TGI after 8 days at 150 mg/kg = 74%). Current preclinical studies are evaluating IMM-6-415 as monotherapy or in combination with checkpoint inhibitors in CT26 and MC-38 syngeneic models. We plan to submit an IND for IMM-6-415 to the FDA in 2023.

Trifecta-MEK Program

We are developing novel product candidates that are designed to uniquely engage MEK and inhibit the upstream activation events of MEK and the downstream activation events of ERK in MEK itself, for the treatment of solid tumors. We believe the inhibition of upstream and downstream activation events of MEK and ERK bypass MAPK pathway reactivation events (i.e., drug resistance). Our investigational Trifecta- MEK program inhibitors are designed to be differentiated from IMM-1-104 and IMM-6-415 due to their potential mechanism of target engagement, novel allosteric inhibition of MEK and KSR disruption, along with a unique PK approach. The potential dosing intervals, potency and mechanisms of target engagement of our investigational Trifecta-MEK program inhibitors may broaden the application of these inhibitors to

27

metabolically diverse RAS and RAF mutant tumors. We are designing our investigational Trifecta-MEK program inhibitors to be administered as monotherapy to provide potentially better alternatives to combination therapies inhibiting MEK and RAF in BRAF mutant tumors.

We have evaluated one of our investigational Trifecta-MEK program inhibitors head-to-head against binimetinib and encorafenib in a cell-based potency study to observe comparisons in the reduction of activated MEK and ERK in KRASG12S and BRAFV600E mutant tumor models.  In the KRAS mutant tumor model, our investigational Trifecta-MEK program inhibitor provided greater inhibition of activated MEK and ERK as compared to binimetinib and encorafenib (as depicted below). In the BRAF mutant tumor model, our investigational Trifecta-MEK program inhibitor displayed greater inhibition of activated MEK and ERK as compared to binimetinib, and greater activated ERK inhibition as compared to encorafenib (as depicted below). Our Trifecta-MEK program is currently in the drug discovery stage of development.

Head-to-Head Comparison of One of Our Investigational Trifecta-MEK Program Inhibitors Against Encorafenib and Binimetinib Using A549 and A375 Xenograft Tumor Models

Graphic

KRAS4B Program

We are developing investigational mutation agnostic KRAS4B inhibitors that are designed to bind to a unique, undisclosed site on KRAS4B for the treatment of solid tumors. We believe our investigational KRAS4B inhibitors have the potential to disrupt RAS nanocluster biology and prevent MAPK signaling in patients with KRAS mutant tumors, which represent approximately 15% of all cancer patients. Although drugs in this class have begun targeting RAS mutations, such as

28

KRASG12C, we believe a majority of KRAS mutations, which we are designing our KRAS4B inhibitors to target, will remain unaddressed.

In an in vitro tumor model, we observed a half maximal tumor inhibitor concentration, or IC50, of 1 μM for one of our investigational KRAS4B inhibitors. A low IC50 value means that a drug is effective at low concentrations and may provide lower systemic toxicity when administered to the patient because of the low concentration required to generate therapeutic activity. Based on this tumor model, we believe our investigational KRAS inhibitors may achieve KRAS4B inhibition when administered at low concentrations, providing a potentially improved tolerability profile as compared to other FDA-approved MAPK pathway inhibitors. Our KRAS4B program is currently in the drug discovery stage of development.

RAS Induction Program

We are developing investigational RAS inducers that are designed to hyperactivate the MAPK pathway to potentially induce tumor cell death. Our RAS inducers are designed to be agnostic to known activating mutations of any oncogene of the MAPK pathway, providing the potential clinical opportunity to effectively treat any patient with an activated MAPK pathway, which represents over 50% of all cancer patients globally. A study by Leung et al (Mol Can Res 2019) supports this novel pharmacological approach by demonstrating that the hyperactivation of the MAPK pathway in tumor cells that express mutant RAS or RAF are intolerant to further increases in activity at the level of ERK and induce tumor cell death. This approach was further validated by clinical observations of secondary tumor reductions in some patients when targeted agents that inhibit the MAPK pathway were discontinued.

In an in vitro KRAS mutant tumor model, we observed cell-based induction of the MAPK pathway at activated ERK of 844% when administering 30 μM of one of our RAS inducers. Additional in vivo modeling is required to validate this pharmacologic strategy, but we believe that, if successful, short pulsatile target induction will be critical. Our RAS induction, or RASi, program is currently in the drug discovery stage of development.

Covalent-MEK Program

We are developing investigational irreversible allosteric inhibitors of MEK by attacking one of three critical amino acids lying adjacent to the binding pocket. We believe the covalent, or irreversible inhibition, fully disrupts MEK enzymatic activity completely avoiding any potential drug resistance from MAPK pathway reactivation events. Covalent-MEK’s novel pharmacological approach provides scaled attenuation of the MAPK pathway disruption that is anchored to the half-life of MEK itself, which has been reported to be approximately 12 to 14 hours.

Our Covalent-MEK program is in the drug discovery stage of development and builds on our dynamic portfolio of novel and mechanistically distinct MEK inhibitors.

PI3K-alpha Program

We are developing investigational allosteric PI3Kα inhibitors designed to target PI3Kα agnostically in common mutations and further disrupt upstream activation events of the mTOR pathway. Similar to IMM- 1-104, we intend to design our PI3Kα inhibitors with a short plasma half-life to potentially normalize tumor signaling dynamics while retaining healthy normal cells. While still in the early drug discovery stage of development, we envision our PI3K-alpha program will be able to address significant unmet clinical needs in certain subsets of cancer, as well as reaching a broader patient population in combination with one or more of our MEK or RAS drug programs, where the mTOR pathway may synergistically work in tandem with MAPK pathway inhibition.

Our Neuroscience Programs

In addition to our extensive oncology pipeline, we are also leveraging our platform to build a neuroscience pipeline initially focusing on AD. Our neuroscience programs are in the early stages of drug discovery, and we are evaluating undisclosed targets to pursue a unique approach to treating AD. We believe by treating AD- related neuroinflammation, rather than treating amyloid beta protein, or β-amyloid, and hyperphosphorylated tau deposition in the brain, we may be able to slow the progression of AD. We believe our platform and expertise in neurology and neuroscience has allowed us to determine

29

biological differences in AD patients to help develop novel product candidates that have the potential to address the significant unmet needs of this underserved patient population.

Alzheimer’s Disease Overview

AD is a neurodegenerative disorder of uncertain cause and pathogenesis and is the most common form of dementia. AD is characterized by memory impairment and further cognitive decline that can ultimately affect the patient’s behavior, speech, visuospatial orientation and motor system. AD is a complex multifactorial disease driven by genetic and environmental causes that affects older adults and is one of the leading sources of morbidity and mortality in the aging population. Established risk factors for AD include age, family history of dementia, rare dominantly inherited mutations in genes that impact β-amyloid in the brain (as described below) and apolipoprotein E epsilon 4 allele (as described below). The disease is most often categorized into three different groups: early-onset AD, late-onset AD and familial AD. Late-onset AD, also referred to as sporadic AD, is the most common form of the disease representing approximately 90% of the patients, and is classified in patients who present with symptoms at older ages (i.e., ≥ 65 years), while early-onset AD is classified in patients who present with symptoms at younger ages (i.e., < 65 years). Familial AD is an inherited form of AD (i.e., genetic) and patients with early-onset AD most often have some inherited form of the disease. In contrast, sporadic AD most often involves common and rare genetic risk factors, as well as environmental factors.

Available data supports a worldwide prevalence of AD of approximately 35 million people, or approximately 6 million people in the United States. The prevalence of AD is known to increase exponentially with age, essentially doubling every 5 years after the age of 65. Diagnosis of AD is typically only considered after symptoms manifest and while the diagnosis of AD can be based on clinical criteria or detection of certain biomarkers, such as β-amyloid and tau, a postmortem histopathologic examination is required to confirm the diagnosis. Recent emerging evidence supports that neurological changes may occur years before patients start to experience early clinical manifestations of AD, which is most often memory impairment.

Limitations of Current Targeted Therapies for Alzheimer’s Disease

Since 2003, only two new treatments for AD have been approved by the FDA, representing a significant unmet medical need. Despite clinical trials of numerous agents over a wide range of mechanisms, there are currently only six FDA-approved treatments for AD, and none of these treatments has been shown to do anything more than briefly and modestly improve AD symptoms, ultimately failing to prevent or slow disease progression. Patients may develop AD irrespective of β amyloid deposition. Without a disease-modifying treatment that targets the underlying cause of AD, many AD patients require daily supportive care from their families or other caregivers.

Pathogenesis of Alzheimer’s Disease

While the pathogenesis of AD remains unclear, the genetic basis for early-onset and familial AD is understood most clearly. Most AD patients appear to have an overproduction and/or decreased clearance of β-amyloid, which is neurotoxic. This explanation of AD is otherwise known as the “amyloid hypothesis.” β-amyloid is produced by the cleavage of a protein translated from the amyloid precursor protein gene, or APP, and cleaved by α-secretase, β-secretase, and γ-secretase. Presenilin is a sub-component of γ-secretase and is partially responsible for cleaving APP. Mutations in presenilin 1 gene, or PSEN1, or presenilin 2, or PSEN2, and APP result in overproduction of β-amyloid and are known to cause familial AD in greater than 95% of patients. In addition, the pathogenesis of AD is believed to involve a second protein, tau.

Tau plays a role in stabilizing the biological mechanisms required for facilitating neuronal activity and communication. In patients suffering from AD, observations have shown that tau accumulates and causes neurotoxicity as a result of its hyperphosphorylation. In addition, transmission of pathologic forms of tau between neurons has been proposed to account for the spread of AD in the brain.

There are several other important and potentially overlapping pathways that are considered to be involved in AD. For example, the strongest association of sporadic AD involves human apolipoprotein E gene, or APOE. APOE is involved in multiple cellular processes, including cholesterol transport and immune regulation, amongst others. APOE is known to

30

have three alleles, including epsilon 4, or APOE4. Carriers of one APOE4 are two to three times more likely to develop AD as compared to noncarriers, and those with two APOE4 are at approximately 8 to 12 times more likely to develop AD. Despite APOE4’s strong link to sporadic AD, some carriers of APOE4 never develop any cognitive decline. Unlike familial and early-onset AD, the genetic basis for sporadic AD is complex and poorly understood, and often involves environmental factors.

Pathology of Alzheimer’s Disease

The hallmark neuropathologic changes of AD are diffuse and neuritic plaques, marked by extracellular β-amyloid deposition and neurofibrillary tangles, comprised of the intracellular accumulation of hyperphosphorylated tau (as depicted below). The pathology of AD is characterized by the widespread death of neurons in the brain and follows a destructive trajectory starting at the hippocampus, which is responsible for learning and memory. As AD progresses, the pathology gradually spreads to other important regions of the brain further causing cognitive decline. Among AD patients, the levels of brain atrophy vary and the underlying cause of this is unknown.

Healthy Brain Compared to an AD Patient’s Brain with β-Amyloid and Tau Deposition

Graphic

Heterogeneity Among Alzheimer’s Disease Patients

A growing body of evidence suggests that AD is a heterogeneous group of diseases, which may partially explain the lack of consistent clinical data, including clinical trials. The cardinal symptoms of AD are cognitive impairment, including memory impairment, loss of executive function, impaired judgement and problem solving, behavioral and psychological problems, and visuospatial impairment. While nearly all AD patients struggle with cognitive decline, there is no prescribed pattern or progression of symptoms. For example, some AD patients have significant β-amyloid and hyperphosphorylated tau deposition, but experience little or no cognitive impairment.

The pattern of memory impairment in patients suffering from AD is distinctive. Memory of events occurring at a particular time and place is often profoundly affected in these patients. These memory deficits develop insidiously and progress slowly over time, evolving to include deficits of semantic memory (i.e., general knowledge accumulated throughout life) and immediate recall. Impairments of procedural memory (i.e., how to perform certain actions and skills) appear only in the late stages of AD. In addition, behavioral and psychologic symptoms become more common in the middle to late course of the disease. These can begin with relatively subtle symptoms including apathy, social disengagement and irritability. However, emergence of behavioral disturbances such as agitation, aggression, wandering and psychosis are seen as well. Approximately 11% of AD patients suffer from some form of psychosis and at least 75% of AD patients deal with agitation, aggression and wandering. Although the signs and symptoms of AD are understood, the underlying cause of the disease, including progression of certain aspects of the disease, still remain unknown and provide an opportunity

31

for the development of disease-modifying treatments that would address significant unmet needs in the underserved AD patient population.

Our Approach to Alzheimer’s Disease

We believe there are specific subgroups of AD that can be stratified through gene expression and brain pathology. To identify AD subgroups, we have leveraged our platform to employ a patient-centric, data-driven approach through:

Patient Data. Categorizing and quality controlling postmortem patient data available from multiple public repositories.
Patient Stratification. Using a combination of different types of data, such as brain pathology and gene expression, to stratify patients into certain groups.
Our Expertise. Leveraging our computational biology expertise to develop machine learning algorithms to detect patterns across biological data and find subgroups based on distinct patterns.

Our approach to stratify AD patients based off specific subgroups and discover therapies that may benefit these patients is depicted in the image below.

AD Patient Subgroup Stratification and Application of Our Drug Discovery Platform

Graphic

We believe our platform and expertise in neurology and neuroscience has allowed us to determine biological differences in AD patients to help develop novel product candidates that have the potential to address the significant unmet needs of this underserved patient population. Through postmortem patient data, we have determined multiple subgroups of AD with varying degrees of neuropathology and cognitive deficiencies, differences in brain gene expression irrespective of β-amyloid or tau deposition, and inclusion or lack of high levels of gene expression resulting in neuroinflammation of the brain. We categorize the subgroup of patients with high levels of gene expression resulting in neuroinflammation of the brain as “Type I AD.”

Through our next-generation approach for AD drug discovery (as depicted above), we have been able to develop a streamlined strategy for identifying novel product candidates by utilizing the following elements of our platform:

Novel Biology. Leveraging DCT to identify robust novel targets using gene expression signatures from each AD subgroup. Characterizing mechanisms of action in central nervous system, or CNS, cell types for target assessment.
Novel Chemistry. Employing our Fluency technology to accelerate the identification of small molecules that selectively bind to a target of interest.

32

Proprietary Translational Planning. Utilizing the AD subgroup data that we have generated to select ideal preclinical models to improve clinical translation, including AD subgroup-specific induced pluripotent stem cell, or iPSC, lines, and defined existing and novel biomarkers specific to these patients.

By leveraging our data-driven discoveries, we believe we have a unique advantage to develop a targeted strategy for patient selection and to increase response rates by treating the underlying biology of the AD subgroups.

Our Neuroscience Pipeline

Our current neuroscience programs are dedicated to providing treatments for patients classified in a specific AD subgroup for which there are significant unmet needs and underserved patient populations. Our neuroscience programs are currently in the early stages of drug discovery and we are focused on advancing these programs into lead optimization. The following table summarizes our neuroscience pipeline:

Table

Description automatically generated

Our Neuroscience Programs—Rationale for Treating Neuroinflammation

We believe treating neuroinflammation in Type I AD patients will slow the progression of the disease. Previous academic studies have shown that neuroinflammation is a possible cause of AD pathology. In addition, other studies have determined that neuroinflammation is an early AD event that precedes β-amyloid and/or tau deposition in AD patients, and is necessary for AD patients to progress from mild cognitive symptoms to more severe cognitive impairment leading to diagnosis of AD. In a meta-analysis review of peripheral inflammatory markers in AD, an academic group reviewed 175 studies that enrolled over 26,000 patients and observed that AD patients have elevated inflammatory markers, including IL-1β and IL-6. In another study, IL-1β was associated with a faster rate of decline on executive functioning in older adults and IL-6 was associated with a faster decline of verbal memory. These observations are in agreement with our studies that identified subgroups of AD patients with elevated levels of neuroinflammatory gene expression. Collectively, through our own research and publicly available literature, we believe that treating neuroinflammation earlier in Type I AD patients may be able to slow the progression of the disease in these patients.

Our Solution: IMM-ALL-01

We are developing investigational small molecule inhibitors against an undisclosed target, or AO.01, for our IMM-ALL-01 program, which is currently in early stages of discovery. We believe that inhibition of AO.01 will decrease AD-related neuroinflammation by reducing the activation of microglia. Microglia are innate immune cells that have been observed to significantly increase AD-related neuroinflammation. Our preclinical studies in cultured microglia have demonstrated that 50 μM treatment with our AO.01 inhibitors decrease the release of IL-6 (as depicted in figure B below), an inflammatory marker that drives AD-related neuroinflammation, while promoting anti-inflammatory IL-10 expression (as depicted in figure A below).

33

In Vitro Observation of AO.01 Inhibitors Decreasing the Release of IL-6 and Promoting IL-10 Expression

Graphic

DCT revealed AO.01 as a target involved in AD-related neuroinflammatory mechanisms dysregulated in the brains of Type I AD patients. Through our bioinformatics analysis of independent study data, we observed that gene expression of AO.01 is significantly increased in activated microglia. In our in vitro studies, knockdown of AO.01 gene expression suppressed the neuroinflammatory behavior of primary microglia. Our RNAseq analysis of our internal microglia experiment confirmed reduced expression of neuroinflammatory pathway genes after AO.01 knockdown. Based on these studies, we observed that knockdown of AO.01 directly correlates with a decrease in neuroinflammatory markers. We further observed that knockdown of AO.01 gene expression decreased neuronal hyperphosphorylated tau deposition in a tau cell model. We believe this suggests that AO.01 inhibition may block multiple independent AD-related neuroinflammatory pathways by inhibiting and/or suppressing the release of neuroinflammatory markers, including IL-6, and decreasing tau deposition.

We plan to improve the in vitro potency of our AO.01 inhibitors by focusing on a resolved catalytic pocket of AO.01 to further reduce the proinflammatory activity of microglia. While our preliminary studies demonstrate high cell permeability for our current AO.01 inhibitors, we plan to focus on optimizing blood brain barrier penetrance during lead optimization to provide desirable activity in the brain. Our goal is to increase translatability by exploring the effect of our AO.01 inhibitors on inflammation in human microglia derived from acquired iPSC lines of Type I AD patients.

Our Solution: IMM-ALL-03

We are developing investigational small molecule inhibitors against an undisclosed target, or AO.03, for our IMM-ALL-03 program, which is currently in the early stages of discovery. We leveraged Fluency to identify and rank initial hits against the AO.03 protein and screened a subset of hits with drug-like properties through a cell-free assay. The screening assays confirmed several Fluency hits from different chemical classes to AO.03, and subsequent modification of our AO.03 hits significantly improved inhibition of AO.03’s activity (as depicted in figure A below). Our preclinical studies in activated microglia have demonstrated that 10 and 50 μM treatment with our AO.03 inhibitors decrease the release of IL-6 (as depicted in figure B below). In addition, in our preliminary studies, we have observed high cell permeability for our current AO.03 inhibitors. We plan to optimize blood brain barrier penetrance during lead optimization to provide desirable activity in the brain.

34

Fluency Platform Identifies Small Molecules Designed to Inhibit AO.03 and In Vitro Observation of AO.03 Inhibitors Decreasing the Release of IL-6

Graphic

Biological Relevance of AO.03

Through our platform, we have discovered that AO.03 is a target that is involved in aberrant inflammatory pathways in Type I AD pathogenesis, and that reduced AO.03 gene expression corrects the expression of genes related to Type I AD biology. In our in vitro studies, we observed that stimulation of microglia into a proinflammatory state triggered significant increases in AO.03 gene expression, whereas reduction of AO.03 gene expression had a causative effect in converting microglial behavior from a proinflammatory state to an anti-inflammatory state. Similar to AO.01, we also observed that lower AO.03 gene expression blocked neuronal tau deposition in a tau cell model, including phosphorylation of tau at a protein site called Threonine 181, or p181 (as depicted below). Based upon literature, there is strong evidence that p181 phosphorylation occurs early in AD progression and is positively correlated to the age of onset, suggesting early prevention of p181 phosphorylation may significantly delay AD symptoms. While in vitro analysis of stimulated microglia after AO.03 and AO.01 knockdown revealed non-identical, overlapping changes in cytokine release, RNAseq analyses have revealed that the targeted pathways of AO.03 and AO.01 are different. Concretely, reduction of AO.01 gene expression reduced expression of signaling genes for oxidation phosphorylation and the pentose phosphate pathway, whereas reduction of AO.03 gene caused a reduction of genes widely known to be involved in neuroinflammatory pathways in AD, including the IL-6 and toll-like receptor signaling pathways (as depicted below). We believe this represents unique opportunities for regulating several neuroinflammatory pathways in Type I AD patients.

35

The Biological Effect of Reducing AO.03 Gene Expression on Inflammation and Tau Deposition, and Pathway Analysis of AO.01 versus AO.03

A picture containing bar chart

Description automatically generated

Our Platform

Consistent with our approach of weaving bioinformatics and computational biology into every stage of the drug development process, we have developed a proprietary disease-agnostic platform that allows us to leverage human biological data to generate insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views. We are developing novel product candidates that aim to optimize both safety and efficacy for diseases with high unmet medical needs and suboptimal treatment options. Key elements of our platform include:

Insights from Human Data. Compare distinct groups of individuals who differ in a certain aspect of disease or response to a particular therapy, or identify new patient subsets.
Novel Biology. Identify novel targets and new ways to drug existing targets using DCT and/or our insights into mechanisms of response.
Novel Chemistry. Rapidly identify small molecules that selectively bind to a target of interest using our proprietary Fluency technology, and/or engineer PK to achieve optimal signaling dynamics.
Proprietary Translational Planning. Use humanized preclinical models and bioinformatics to prioritize indications and identify sensitive subpopulations.

Underlying each of these elements is our rigorous quality control and ability to analyze complex biological datasets. We are one of the few biopharmaceutical companies that has been involved in defining best practices for robustly analyzing bioinformatics data, as evidenced by co-authorship on journal articles together with regulators as well as writing invited reviews to educate the scientific community on this topic. This attention to rigorous quality control pervades all of our analyses, and we believe this enables us to extract meaningful information from a variety of databases of human data, including GENIE and The Cancer Genome Atlas Program, or TCGA.

Our platform is not limited to a single aspect or pathology; rather, it is disease-agnostic, which we believe enables us to identify, develop and evaluate product candidates across multiple disease areas simultaneously, with our initial focus in

36

oncology and neuroscience. While we currently have an emphasis on transcriptomic data, our platform is not limited to a single data type and thus we believe it will be able to evolve as new datasets emerge. Our platform enabled the initiation, discovery and development of our lead product candidate, IMM-1-104, and has led us to identify additional product candidates with novel compositions of matter by leveraging our platform and drug discovery process. Moreover, our platform has been applied extensively in successful partnerships with large pharmaceutical and biotechnology companies, and through our internal drug discovery and development.

Insights from Human Data

Our analyses often begin by comparing existing transcriptomic data from two groups of patients (e.g. from those whose tumors have metastasized versus those whose tumors have not) to help elucidate the biological mechanisms underlying a particular aspect of disease which we seek to counteract. As another example, we may analyze existing data from patients with differences in response to an existing therapy, in order to better understand what is happening in responders versus non-responders. We may also analyze existing data from patients with a disease to identify novel subsets of patients. Our platform has enabled us to conduct multiple projects that involve stratifying patients into novel subsets. We associate transcriptomic profiles with each subset, which can then be directly inputted into DCT to identify novel targets specific to a given patient subset.

Novel Biology

Disease Cancelling Technology

We have developed DCT to identify targets that reverse a disease signal across multiple relevant genes with the potential to yield product candidates with differentiated mechanisms that are less likely to be discovered by traditional drug discovery methods. Additional biologic context is derived from quantifying the extent to which different time points, concentrations and perturbations (e.g., inhibition and overexpression) may cancel a disease signal more effectively than existing drug targets. DCT ranks target perturbations by the extent to which they generate signals that counteract disease-associated gene expression changes observed in patient data. Thus, we believe DCT enables hypothesis-free, data-driven identification of novel targets and new ways to drug existing targets.

DCT leverages gene expression data derived from human patient samples to identify targets that may rescue abnormal gene expression and restore pathway homeostasis. In addition, DCT identifies biology relevant to attenuating a disease by quantifying the similarity of genome-wide signatures of specific aspects of the disease to signatures of target induced gene expression changes using a mathematical similarity metric. Uniquely, DCT quantifies the per-gene contribution to overall disease amplification or cancellation. An example of a typical analysis begins by running DCT to identify an unwanted, disease-specific gene expression pattern. The ideal input to DCT is focused on a specific aspect of a disease, such as tumors that have metastasized versus those that have not, rather than comparing diseased versus healthy states. DCT identifies target candidates by screening a disease differential expression signature and comparing it to thousands of target gene expression signatures.

DCT is able to rapidly compare disease state signatures against vast numbers of target signatures. DCT ranks signatures resulting from the modulation of specific targets by the extent to which they oppose disease signatures (as depicted below). Unlike some algorithms or artificial intelligence, or AI, approaches, the results originating from DCT are designed to be interpretable from a computational and biological perspective. This platform uses gene expression from patient datasets and does not rely on literature. Together with the target, DCT provides a specific list of testable genes associated with the target of interest, relevant drug concentrations and temporal dynamic information driving the result. Thus, we believe DCT can identify new targets and readily detect dynamic relevant biology relating to modulating a target in a better way.

A summary workflow for DCT’s novel target identification can be described as follows:

Carefully curated and quality controlled human transcriptomic data representing a specific aspect of disease, or Input 1, is input and vectorized for processing (as depicted below).

37

A carefully curated and quality controlled library of gene expression signals associated with perturbing specific targets at specific time points and concentrations, or Input 2, is input and vectorized for processing (as depicted below). This library can potentially include clustered regularly interspaced short palindromic repeats, or CRISPR, RNA interference, tool compounds, screening library compounds and existing drugs.
The strength of disease signal cancellation is measured between Input 1 and every target signature in Input 2.

Disease Cancelling Technology Summary Workflow for Target Identification

Graphic

A second filtration step selects target candidates for which multiple biological pathways are restored in the proper direction compared to the disease signal. DCT includes a method to compute a per pathway contribution to disease canceling in terms of percent contribution to overall disease reversal for cases when a specific pathway is particularly relevant. DCT is designed to have many capabilities in addition to identifying novel targets or novel ways to drug existing targets. To enable rapid translation to experimental validation, DCT can suggest ideal concentrations, temporal dynamics and marker genes to monitor. DCT is also capable of predicting target combinations for a given disease or an ideal target for combination with an existing therapy. For expanded utility, DCT has a graphical user interface that enables our biologists to interact with, sort, modify, query and run results along with producing visualizations of results.

38

We believe DCT has several advantages over other target identification technologies. The platform uses patient data as a starting point, rather than artificial 2D in vitro models. For example, our neuroscience program uses gene expression data from AD patient subsets as an input to DCT. We have presented data at American Association for Cancer Research and other conferences demonstrating how cell lines fail to capture the heterogeneity of patient tumors, and our discovery team’s experience in the 3D tumor modeling field has also highlighted the limitations of 2D in vitro data. Moreover, working closely with several FDA-approved drugs, we have found that transcriptomic data was most frequently and dynamically linked to drug activity. Thus, our core insights are derived from transcriptomic data (RNA), while some of our competitor’s platforms may focus on sequencing data (DNA), imaging data from phenotypic screens and/or literature. DCT is focused on identifying novel targets or novel ways to modulate existing targets, with the goal of generating novel therapeutics with improved clinical activity. We have not in-licensed external drugs and we do not focus on “drug repurposing” activities. Our pipeline is composed of programs with potentially novel pharmacological effects.

Biological Mechanisms of Response

We also identify novel biology by applying translational bioinformatics to analyze the biological mechanisms of response of existing therapies. This may include comparing the transcriptional profiles induced by a drug at different timepoints in order to highlight biological feedback loops that we then seek to counteract.

Novel Chemistry

Fluency

We developed Fluency, an easy-to-use AI-based tool, to allow for the rapid screening of large compound libraries for potential binders to a protein target of interest. Fluency can be run with any compound library, including libraries containing millions of compounds. It identifies the most attractive drug candidates within a library by making ranked predictions of binding affinity for all compounds. It also makes predictions about the target binding location for all compounds, which allows us to filter the library for drug candidates that are the most likely to affect a specific region of interest on the desired target. Fluency accelerates our drug development process by allowing us to go from millions of potential compounds down to what Fluency selects as the best hundred drug candidates within a single work day. This allows us to quickly advance only those select candidates to medicinal chemistry and experimental validation (as depicted below), increasing our capital efficiency. Knowledge of the 3D structure of the protein target of interest is not required, which expands the applicability of Fluency to include targets with poorly defined or non-existent 3D structures.

Fluency Accelerates Our Drug Discovery

Graphic

To illustrate both the ease of use, as well as the power of Fluency to identify promising drug candidates, we constructed a test screen of Tukysa® (tucatinib), a recently FDA-approved drug for the treatment of advanced breast cancer in combination with trastuzumab and capecitabine. Tukysa® is a tyrosine kinase inhibitor of human epidermal growth factor

39

receptor 2, or HER2 (also referred to as ERBB2). We created a test compound library by placing Tukysa® in a diverse chemical library of 17.8 million drug-like molecules and evaluated whether or not Fluency could identify it as a promising drug candidate against ERBB2 (depicted in the first panel below). The binding models within Fluency were trained against millions of carefully quality controlled, publicly available binding affinity measurements for compounds against thousands of proteins. However, because Fluency did not see Tukysa® or other molecules highly similar to Tukysa® during training, it did not know whether or not it was a promising candidate before the test screen was run. In our test screens, we input the protein of interest into Fluency, then select a library to screen, and optionally enter the region of interest within the protein (depicted in the second panel below). In the test screen for Tukysa®, we screened the test library against all amino acids within ERBB2.

Fluency Test Screen Input Example

Graphic

Fluency rapidly screened approximately 17.8 million compounds in less than 7 hours and identified Tukysa® as the best binder to ERBB2 along with a number of other potential candidates (as depicted below). Fluency’s location prediction for this compound points towards the kinase domain of ERBB2 which contains the binding site. Referring back to our drug discovery flow chart depicted above, Tukysa® would have been amongst the hundreds of compounds to go on to medicinal chemistry and experimental validation if we were searching for general ERBB2 binders or if we were searching for potential binders specific to the kinase domain.

Fluency Test Screen Output Example

Graphic

Fluency has been used to screen for potential drug candidates within our early-stage oncology and neuroscience programs. We have a dedicated team of AI experts who continue to evolve Fluency and are embedded in our end-to-end preclinical drug development processes. We continue to seek new ways to apply our AI expertise to develop novel product candidates and potentially improve the lives of patients.

40

Signaling Dynamics (PK-Driven)

Transcriptomic data has proven critical to these analyses because it provides an understanding of the extent to which specific genes are expressed at any given time, capturing temporal changes in pathway activation. Signaling networks differ between cell types, and we leverage this to modulate targets in such a way that certain cell types will be more impacted than others. Our platform enables us to assess the signaling dynamics of product candidates, which we believe allows us to optimize the chemistry of our product candidate programs to achieve broad therapeutic activity against diseased cells while sparing healthy normal cells. Modulation of these signaling networks impacts cell fate decisions in many cell types, including cancerous cells. Our computational biology expertise enables us to analyze transcriptomic data that closely reflects spatiotemporal dynamics of biological signaling networks.

Proprietary Translational Planning

Humanized Models. In oncology, we are deeply experienced in advanced, humanized 3D-based tumor growth models, which based on peer reviewed research by members of our team and others, more accurately predict drug response in animal models, and we believe in patients, compared to standard models. Unlike in vitro approaches, the 3D tumor growth models reflect the complexity of tumor biology given their alignment with the TME. Thus, we believe our deep expertise in 3D tumor models enables us to more accurately stratify patients likely to benefit from our potential product candidates. In neuroscience, we similarly seek to use human iPSC based models that more faithfully represent the biology of a heterogeneous patient population than more traditional cell lines.

Prioritize Indications and Identify Sensitive Subpopulations. We are able to leverage bioinformatics to analyze genomic data from large patient databases to identify specific indications where the majority of patients have characteristics that align with our more reflective humanized models, and identify biological mechanisms and biomarkers that enable us to identify subpopulations that are more likely to be sensitive based on their similarity to our translational approaches.

Our Platform and its Role in the IMM-1-104 Program

Our platform played a key role in creating the most important characteristics of our lead product candidate, IMM-1-104. In the early stages of the program, insights from human data were used to identify transcriptional profiles we aimed to counteract. DCT and our analysis of mechanisms of existing drugs led us to identify what we believe to be novel biology, specifically new ways to drug an existing target, to highlight the goal of counteracting a biologic feedback loop. Novel chemistry was generated to counteract the feedback loop, and the PK was tuned to generate optimal signaling dynamics (deep but cyclic interruptions of the pathway) as confirmed for translational profiling. Our proprietary translational planning has involved profiling IMM-1-104 in a large number of 3D models to identify the types of cancer (and biomarkers of subsets when needed) that we believe will have the highest probability of success in the clinic. Together, these insights enabled us to demonstrate in an in vitro model that a drug with feedback loop resistance combined with a short half-life was able to move toward in vivo improvements in key efficacy metrics and tolerability through modulation of tumor cell signaling dynamics.

Early in the program, we utilized human data to generate translational profiles specific to cancer patients experiencing cachexia, which causes extreme weight loss and muscle wasting. DCT was then utilized to identify targets and intervention time points, otherwise known as biological perturbations, that could counteract cachexia. Among the highest ranked perturbations were multiple MEK, inhibitors, but only the gene expression profiles induced by these MEK inhibitors at early time points (i.e., at 3 and 6 hours) were ranked highly for cancelling the disease-associated signals according to our technology. In contrast, the gene expression signals induced by MEK inhibitors at a later time point (i.e., at 24 hours) amplified or mimicked the transcriptomic signatures associated with diseases. These findings pointed to the importance of a feedback loop in the MAPK pathway called the CRAF-bypass, which may lead to resistance of MEK inhibition, and highlighted the critical importance of designing IMM-1-104 to potentially counteract the CRAF-bypass.

We next applied our platform’s ability to characterize mechanisms of response by generating transcriptomic (RNA sequencing) data evaluating the impact of a recently approved MEK inhibitor, selumetinib, relative to vehicle in KRASG12D tumor-bearing BALB/c mice, which are inbred, albino and immunodeficient mice ordinarily used in research models for cancer therapy. The BALB/c mice were orally administered 100 mg/kg of selumetinib twice a day for 18 days. Notably,

41

when we examined a set of genes known to be downstream of ERK and activated by the MAPK pathway, we saw reduced downregulation of the pathway following selumetinib treatment. There was very little difference between the degree of MAPK pathway downregulation at the 2 hour time point and the 12 hour time point, demonstrating that the inhibition achieved by a typical MEK inhibitor with a non-zero drug trough was both static and limiting in a chronic setting. This focused us on the need to develop IMM-1-104 with novel chemistry, specifically a short half-life to achieve deep cyclic inhibition. Through the medicinal chemistry process, we were able to conduct similar analyses to assess the impact of varying PK profiles on signaling dynamics, and when we conducted the same analysis with IMM-1-104 in the model referenced above, we observed much stronger downregulation at the 2 hour time point followed by a return to baseline at the 12 hour time point. These observed results confirm that we achieved the desired signaling dynamics of cycles of deep inhibition and release of the MAPK pathway.

We are utilizing our platform’s proprietary translational planning capabilities by evaluating IMM-1-104 in a large panel of 3D tumor models, and then applying our ability to robustly analyze challenging datasets to assess genomic data from publicly available cancer patient databases to prioritize indications for IMM-1-104 and identify biomarkers of response, when needed. We believe this analysis will enable us to identify substantial translational opportunities for additional indications.

Our Platform and Our Early-Stage Oncology Pipeline

We utilize Fluency, the novel chemistry element of our platform, to rapidly identify small molecule hits for a targeted region of a protein for many of the earlier stage programs in our oncology pipeline. Fluency is being utilized to accelerate the advancement of our RAS and PI3K-alpha programs. In addition, these earlier stage programs also utilize our platform’s ability to generate novel biology by characterizing mechanisms of response to address these targets in new ways. In the case of our RAS modulators, this involves targeting the process of RAS dimerization. Finally, we are also leveraging novel chemistry in the form of PK changes with the goal of achieving optimal signaling dynamics and deep cyclic inhibition to maximize therapeutic activity in broad populations while improving tolerability. We plan to evaluate each of our programs in humanized 3D models and leverage bioinformatics to prioritize indications and identify sensitive patient subgroups.

Our Platform and Our Neuroscience Programs

Our neuroscience programs began with our platform’s ability to identify insights from human data, specifically by methodically analyzing challenging datasets by assessing the robustness of various publicly available AD datasets. Given the lack of disease-modifying therapies and AD patient heterogeneity, robust analysis of data is a motivating factor to drive our success in this space. We applied our platform’s capability to stratify patients into previously undiscovered subsets, identifying new subpopulations of AD patients with strikingly different molecular biology and distinct gene expression profiles. We then applied our platform’s ability to identify novel biology by leveraging DCT to identify and rank novel targets for specific subsets of AD patients. Two of these undisclosed AD targets, AO.01 and AO.03, have been identified in vitro and have gone on to become the focus of our two lead neuroscience programs, IMM-ALL-01 and IMM-ALL-03, respectively. Once those targets had been identified and experimentally confirmed, we utilized Fluency to rapidly identify small molecules that are designed to selectively bind to the targets, and such selective binding has since been observed in vitro. We also leveraged our platform’s capabilities for characterizing mechanisms of response to assess the biological impact of those hits, and we are preparing for proprietary translational planning by using iPSC models to confirm the differences in response we expect to see in specific AD patient subgroups.

Competition

The pharmaceutical and biotechnology industries are characterized by rapid advancement of novel technologies, significant competition and a strong defense of intellectual property rights. While we believe that our proprietary platform and scientific expertise provides us with competitive advantages, we face competition from multiple sources, including larger and better-funded pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key factors that would affect our ability to effectively compete with other therapeutics include safety, efficacy, ease of administration, pricing, brand recognition and availability of reimbursement and coverage by third party payors.

42

Our Oncology and Neuroscience Programs

The current FDA-approved treatment options that target MAPK pathway cancers are either MEK inhibitors limited by their high rates of serious drug-related adverse events that result in drug intolerability and drug resistance through MAPK-feedback loops, or KRAS inhibitors limited to patients with specific KRAS mutations. We expect that our oncology programs targeting the MAPK pathway may compete with current FDA-approved therapies or clinical programs targeting KRAS mutant tumors that are being advanced by certain pharmaceutical and biotechnology companies.

There are currently only five FDA-approved treatments for AD, and these treatments are widely considered to only briefly and modestly improve AD symptoms, ultimately failing to prevent or slow disease progression.

We expect that our neuroscience programs that are initially focused on treating neuroinflammation in AD may compete with products or programs being advanced by certain pharmaceutical and biotechnology companies.

Intellectual Property

Our ability to obtain and maintain intellectual property protection for our products and technology is fundamental to the long-term success of our business. We rely on a combination of intellectual property protection strategies, including patents, trademarks, copyrights, trade secrets, license agreements, confidentiality policies and procedures, non-disclosure agreements, invention assignment agreements and technical measures designed to protect the intellectual property and confidential information and data used in our business.

As of March 3, 2022, we have: one issued U.S. patent; two pending U.S. patent applications; one U.S. provisional application; and one Patent Cooperation Treaty, or PCT, application that has not entered national stage. These patents and patent applications relate to subject matter, including: our lead product candidate, IMM-1-104, our MEK-io candidate, IMM-6-415, our DCT, and Fluency. Excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable; our owned issued U.S. patent and any patents that may issue from our owned pending U.S. patent applications are expected to expire in February, 2039; and any patents that may issue from our owned pending foreign patent applications or PCT applications are expected to expire in January, 2041.

With respect to IMM-1-104, as of March 3, 2022, we have one pending U.S. provisional application and one pending PCT application. The pending U.S. provisional application is directed to, among other things, combination claims with respect to IMM-1-104. This U.S. provisional application would need to be converted to a non-provisional application by January 6, 2023. Any patent that may issue, based upon this provisional U.S. application is expected to expire in January, 2043, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.The pending PCT application has not yet entered the national stage; its pending claims are directed to compounds, pharmaceutical compositions, and methods of use. Any patent that may issue, based upon this pending PCT application related to IMM-1-104, is expected to expire in January, 2041, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.

With respect to IMM-6-415, as of March 3, 2022, we have one pending provisional U.S. application; this application would need to be converted to a non-provisional application by January 6, 2023.  Any patent that may issue, based upon this provisional U.S. application related to IMM-6-415, is expected to expire in January, 2043, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.

With respect to our DCT, as of March 3, 2022, we have one issued U.S. patent and one pending U.S. patent application. The issued claims of this U.S. patent and the pending claims of this U.S. patent application are directed to methods (processes) and systems. Our issued U.S. patent related to our DCT and any patent that may issue from our pending patent application related to our DCT are expected to expire in February, 2039, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.

43

With respect to Fluency, as of March 3, 2022, we have one pending U.S. patent application. The pending claims of this U.S. patent application are directed to methods (processes) and systems. Any patent that may issue from our pending patent application related to Fluency is expected to expire in February, 2039, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.

The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. In the United States, a patent’s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. We cannot be sure that our pending patent applications that we have filed or may file in the future will result in issued patents, and we can give no assurance that any patents that have issued or might issue in the future will protect our current or future products, will provide us with any competitive advantage, and will not be challenged, invalidated, or circumvented.

In the United States, the patent term of a patent that claims an FDA-approved drug or biologic may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time that the drug or biologic is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug or biologic may be extended. Similar provisions are available in the EU and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug or biologic. In the future, if any drug candidates that we may develop receive FDA approval, we expect to apply for patent term extensions where applicable on patents covering those drugs. We plan to seek patent term extensions to any of our future issued patents in any jurisdiction where these are available. However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether these extensions should be granted, and if granted, the length of these extensions.

We intend to pursue additional intellectual property protection to the extent we believe it would be beneficial and cost-effective. Our ability to stop third parties from making, using or commercializing any of our patented inventions will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. With respect to our intellectual property, we cannot provide any assurance that any of our current or future patent applications will result in the issuance of patents in any particular jurisdiction, or that any of our current or future issued patents will effectively protect any of our products or technology from infringement or prevent others from commercializing infringing products or technology.

In addition to our reliance on patent protection for our inventions, products, and technologies, we also seek to protect our brand through the procurement of trademark rights. As of March 3, 2022, we have certain trademark registrations and pending applications for trademark registration, for the marks DISEASE CANCELLING and IMMUNEERING in the United States and/or certain foreign jurisdictions. Furthermore, we rely on trade secrets, know-how, unpatented technology and other proprietary information, to strengthen our competitive position. We have determined that certain technologies, including some of our software, are better protected as trade secrets. To mitigate the possibility of trade secret misappropriation, we enter into non-disclosure and confidentiality agreements with parties who have access to our trade secrets, such as our employees, consultants, advisors and other third parties. We also enter into invention assignment agreements with our employees and consultants that obligate them to assign to us any inventions they have developed while working for us. We generally control access to our proprietary and confidential information through the use of internal and external controls that are subject to periodic review. Although we take steps to protect our proprietary information and trade secrets, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. As a result, we may not be able to meaningfully protect our trade secrets. For further discussion of the risks relating to intellectual property, see the section titled “Risk Factors—Risks Related to Our Intellectual Property.”

44

Government Regulation

Among others, the FDA, U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare and Medicaid Services and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the preclinical and clinical development, manufacture, marketing and distribution of drugs such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, record keeping, approval, sales, commercialization, marketing, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates. Any drug candidates that we develop must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in those foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the European Union, or EU, are addressed in a centralized way, but country-specific regulation remains essential in many respects.

U.S. Drug Development Process

In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. The process required by the FDA before a drug may be marketed in the United States generally involves the following:

completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA’s good laboratory practice requirements and other applicable regulations;
submission to the FDA of an IND which must become effective before human clinical trials may begin;
approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;
performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use;
submission to the FDA of a New Drug Application, or NDA, after completion of all pivotal trials;
payment of user fees associated with an NDA;
a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review;
satisfactory completion of an FDA advisory committee review, if applicable;
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCPs;
potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA; and
FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.

Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The

45

central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. Some preclinical testing may continue even after the IND is submitted. The IND also includes results of animal and in vitro studies assessing the toxicology, PK, pharmacology, and PD characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting, under certain timelines, of ongoing clinical studies and clinical study results to public registries, specifically the clinicaltrials.gov website managed by the National Institutes of Health.

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, dose tolerance and dosing schedule and to identify possible adverse side effects and safety risks.
Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.

Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the approved indication. In certain instances, such as with accelerated approval drugs, the FDA may mandate the performance of Phase 4 trials as a condition of approval of an NDA.

46

The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.

A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval. Specifically, the FDA has promulgated regulations governing the acceptance of foreign clinical trials not conducted under an IND, establishing that such studies will be accepted as support for an IND or application for marketing approval if the study was conducted in accordance with GCP, including review and approval by an independent ethics committee, or IEC, and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an on-site inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA’s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. If a marketing application is based solely on foreign clinical data, the FDA requires that the foreign data be applicable to the U.S. population and U.S. medical practice; the studies must have been performed by clinical investigators of recognized competence; and the FDA must be able to validate the data through an on-site inspection or other appropriate means, if the FDA deems such an inspection to be necessary.

During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points are generally prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor to obtain the FDA’s feedback on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.

Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.

U.S. Review and Approval Process

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of

47

alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product application also includes a non-orphan indication.

The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product’s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of “filing” of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a “filing” decision after it the application is submitted. The FDA conducts a preliminary review of all  NDAs  within the first  60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.

The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs.

After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.

If regulatory approval of a product is granted, such approval will be granted for particular indications and may contain limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.

The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the

48

product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin.

Orphan Drug Designation and Exclusivity

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare  disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity (i.e., greater safety, greater efficacy, or a major contribution to patient care) or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.

Expedited Development and Review Programs

The FDA has a number of programs intended to expedite the development or review of products that meet certain criteria. Sponsors may request that FDA allow the use of one or more of these programs. For example, product candidates are eligible for fast track designation if they are intended to treat a serious or life- threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the review team during product development, and the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.

Any product candidate submitted to the FDA for approval, including a product candidate with a fast track designation or breakthrough therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. An NDA for a product candidate is eligible for priority

49

review if it has the potential to provide significant improvement in treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.

In addition, a product candidate may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. The FDA may withdraw accelerated approval if, among other things, the confirmatory study fails to verify clinical benefit; the applicant fails to perform required confirmatory studies with due diligence; postmarketing use demonstrates that postmarketing restrictions are inadequate to assure safe use; the applicant fails to adhere to agreed-upon postmarketing restrictions; promotional materials are false or misleading; or, other evidence demonstrates that the product is not shown to be safe or effective under its conditions of use. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.

Fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

Post-approval Requirements

Drug products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their  establishments  with  the  FDA  and  certain  state  agencies,  and  are  subject  to  periodic  unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.

The  FDA  may  withdraw  approval  if  compliance  with  regulatory  requirements  and  standards  is  not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
fines, warning letters, or untitled letters;
clinical holds on clinical studies;

50

refusal  of  the  FDA to  approve  pending  applications  or supplements  to approved  applications,  or suspension or revocation of product approvals;
product seizure or detention, or refusal to permit the import or export of products;
consent  decrees,  corporate  integrity  agreements,  debarment  or  exclusion  from  federal  healthcare programs;
mandated  modification  of  promotional  materials  and  labeling  and  the  issuance  of  corrective information;
the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or
injunctions or the imposition of civil or criminal penalties.

The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product’s FDA-approved labelling.

Marketing Exclusivity

Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDAm or an NDA submitted under Section 505(b)(2), or (505(b)(2) NDA), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity  provides  for  an  additional  six  months  of  marketing  exclusivity  attached  to  another  period  of exclusivity if a sponsor conducts

51

clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials.

Other Healthcare Laws

Pharmaceutical companies like us are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business.  Such regulation may constrain the financial arrangements and relationships through which we research, develop, and ultimately, sell, market and distribute any products for which we obtain marketing approval. Such laws include, without limitation, federal and state anti-kickback, fraud and abuse, and false claims laws, such as the federal Anti-Kickback Statute and the federal Civil False Claims Act, as well as federal and state data privacy and security laws and regulations, and transparency laws and regulations addressing drug pricing and payments and other transfers of value made by pharmaceutical manufacturers to physicians and other healthcare providers, such as the federal Physician Payment Sunshine Act. Violations of any of such laws or any other governmental regulations that apply may result in significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations to resolve allegations of noncompliance, exclusion from participation in federal and state healthcare programs, such as Medicare and Medicaid, and imprisonment.

Coverage and Reimbursement

Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.

Moreover, as a condition of participating in, and having products covered under, certain federal healthcare programs, such as Medicare and Medicaid, we may become subject to federal laws and regulations that require pharmaceutical manufacturers to calculate and report certain price reporting metrics to the government, such as Medicaid Average Manufacturer Price, or AMP, and Best Price, Medicare Average Sales Price, the 340B Ceiling Price, and Non-Federal Average Manufacturer Price reported to the Department of Veteran Affairs, and with respect to Medicaid, pay statutory rebates on utilization of manufacturers’ products by Medicaid beneficiaries.  Compliance with such laws and regulations will require significant resources and may have a material adverse effect on our revenues.  

Healthcare Reform

In the United States, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended, collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA:

 

 

 

increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price;

 

 

required collection of rebates for drugs paid by Medicaid managed care organizations;

52

expanded beneficiary eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability;

expanded the types of entities eligible for the 340B Drug Pricing Program;

 

 

required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70 percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D;

 

 

imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell “branded prescription drugs” and biologic agents apportioned among these entities according to their market share in certain federal government programs;

established the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services (“CMS”) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;

created the Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and

required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to licensed practitioners.

Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA.  On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court’s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace.  The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare.

Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 unless additional action is taken by Congress.  In addition, the American Taxpayer Relief Act of 2021, effective January 1, 2024, would eliminate the statutory cap on rebate amounts owed by drug manufacturers under the Medicaid Drug Rebate Program, or MDRP, which is currently capped at 100% of the AMP for a covered outpatient drug. In the future, there may be additional challenges and/or amendments to the ACA.

Moreover, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It also possible that governmental action will be taken in response to the COVID-19 pandemic.

We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could impact the amounts that federal and state governments and other third-party payors will pay for healthcare products and services.

53

Data Privacy and Security

Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. For example, the GDPR imposes strict requirements for processing the personal data of individuals within the European Economic Area, or the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to €20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Further, from January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.

Human Capital

As of December 31, 2021 we had 64 full-time employees, 54 of whom are dedicated to research and development. 31 of our employees hold doctorate degrees (i.e., Ph.D. or M.D.). None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.

We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off.

We believe that much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and focus on extending our diversity and inclusion initiatives across our entire workforce.

Our Corporate Information

We were incorporated under the laws of the state of Delaware in February 2008. Our principal executive offices are located at 245 Main Street, Second Floor, Cambridge, MA 02142 and our telephone number is (617) 500-8080.

Our corporate website address is www.immuneering.com. The information contained in, or accessible through, our website is not incorporated by reference into this Annual Report and you should not consider information on our website to be a part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.

Where you can find more information

We are subject to the information requirements of the Securities Exchange Act of 1934, as amended. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically, such as ourselves, with the SEC at http://www.sec.gov.

54

Item 1A. Risk Factors

Our future operating results could differ materially from the results described in this Annual Report on Form 10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. In these circumstances, the market price of our Class A common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See “Forward Looking Statements” for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.

Risks Related to Our Financial Condition and Capital Requirements

We have a limited operating history in developing pharmaceutical products, have not completed any clinical trials and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.

Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a biopharmaceutical company with a limited operating history in developing pharmaceutical products which makes it difficult to evaluate our business and prospects in future product development. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources and efforts to providing computational biology services to pharmaceutical and biotechnology companies, organizing and staffing our company, business planning, executing partnerships, raising capital, discovering, identifying and developing potential product candidates, securing related intellectual property rights and undertaking research and preclinical studies of our product candidates, including the anticipated Phase 1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. We have not yet demonstrated our ability to successfully initiate any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability to develop new pharmaceutical products than it could be if we had a longer operating history.

In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by biopharmaceutical companies developing products in rapidly evolving fields. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer.

We have incurred significant net losses for the past several years and we expect to continue to incur significant net losses for the foreseeable future and may never obtain profitability.

We have incurred net losses in each reporting period for the past several years, have not generated any revenue from product sales to date and have financed our operations principally through our computational biology services to pharmaceutical and biotechnology companies, the issuance of convertible debt and the sale of our convertible preferred stock and Class A common stock. We have incurred net losses of approximately $33.5 million and $17 million for the years ended December 31, 2021 and 2020 respectively. As of December 31, 2021, we had an accumulated deficit of approximately $59.3 million. Our losses have resulted principally from expenses incurred in research and development of our product candidates, from management and administrative costs and other expenses that we have incurred while building our business infrastructure. Our lead product candidate, IMM-1-104, is undergoing IND-enabling studies and we expect to submit an IND to the FDA in the third quarter of 2022. Subject to the FDA’s allowing us to proceed with clinical studies under an IND, we intend to enroll the first patient in a Phase 1 clinical trial of IMM-1-104 in the fourth quarter of 2022 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors, if our IND for IMM-1-104 is

55

accepted. Our other product candidates are in earlier stages of drug development. As a result, we expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses as we discover, develop and market additional potential product candidates.

We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we:

• advance the development of our lead product candidate, IMM-1-104, and our other product candidates, including IMM-6-415, through preclinical and clinical development, and, if approved by the FDA or other comparable foreign regulatory authorities, commercialization;

• incur manufacturing costs for our product candidates;

• seek regulatory approvals for any of our product candidates that successfully complete clinical trials;

• increase our research and development activities to identify and develop new product candidates;

• hire additional personnel;

• expand our operational, financial and management systems;

• invest in measures to protect and expand our intellectual property;

• establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize;

• expand our manufacturing and develop our commercialization efforts; and

• operate as a public company.

The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and our ability to achieve and maintain profitability.

We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we initiate and conduct clinical trials of, and seek marketing approval for our current and any future product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or other comparable foreign regulatory authorities to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related

56

to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. We also expect to incur additional costs associated with operating as a public company. Accordingly, it is likely that we will need to obtain substantial additional funding in order to maintain our continuing operations in the future.

As of December 31, 2021, we had approximately $150.2 million in cash and cash equivalents and marketable securities. Based on our current business plans, we believe that our existing cash and cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditures requirements into the third quarter of 2024. Our estimate as to how long we expect our existing cash and cash equivalents and marketable securities to be able to continue to fund our operating expenses and capital expenditures requirements is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.

Our future funding requirements will depend on many factors, including, but not limited to:

• the initiation, progress, timeline, cost and results of our clinical trials for our product candidates;

• the initiation, progress, timeline, cost and results of additional research and preclinical studies related to pipeline development and other research programs we initiate in the future;

• the cost and timing of manufacturing activities as we advance our product candidates through preclinical and clinical development, and commercialization;

• the potential expansion of our current development programs to seek new indications;

• the negative impact of the COVID-19 pandemic or future pandemics on our business;

• the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;

• the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights, in-licensed or otherwise;

• the effect of competing technological and market developments;

• the payment of licensing fees, potential royalty payments and potential milestone payments;

• the cost of general operating expenses;

• the cost and timing of completion of commercial-scale manufacturing activities;

• the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and

• the cost of operating as a public company.

Advancing the development of our product candidates will require a significant amount of capital. Our existing cash and cash equivalents will not be sufficient to fund all of the activities that are necessary to complete the development of our product candidates.

57

We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Additionally, the impact of the pandemic related to COVID-19 and its variants on the capital markets may affect the availability, amount and type of financing available to us in the future. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.

We may seek additional capital through a variety of means, including through public or private equity offering, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

Our ability to use our net operating losses and other tax attributes may be limited.

As of December 31, 2021, we had approximately $56.5 million of federal and $51.3 million of state net operating loss carryforwards, or NOLs, available to offset future taxable income. Under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change,” generally defined as a greater than 50% change by value in its equity ownership over a three-year period is subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes such as research tax credits to offset future taxable income. We have not performed an analysis to determine whether our past issuances of stock and other changes in our stock ownership may have resulted in other ownership changes. If it is determined that we have in the past experienced other ownership changes, or if we undergo one or more ownership changes as a result of future transactions in our stock, which may be outside our control, then our ability to utilize NOLs and other pre-change tax attributes could be further limited by Sections 382 and 383 of the Code, and certain of our NOLs and other pre-change tax attributes may expire unused. As a result, if or when we earn net taxable income, our ability to use our pre-change NOLs or other tax attributes to offset such taxable income or otherwise reduce any liability for income taxes may be subject to limitations, which could adversely affect our future cash flows.

Risks Related to Development, Regulatory Approval and Commercialization

The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, or to obtain regulatory approval to treat the indications we seek to treat with our product candidates, we will be unable to generate product revenue or the level of planned product revenue and our business will be substantially harmed.

We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical

58

development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:

•the FDA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;

• the FDA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;

• the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;

• the FDA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

• the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, or other submission or to obtain regulatory approval in the United States or elsewhere;

• we may be unable to demonstrate to the FDA or other comparable foreign regulatory authorities that a product candidate’s risk-benefit ratio for its proposed indication is acceptable;

• the FDA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

• the approval policies or regulations of the FDA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.

In addition, even if we obtain approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS. Regulatory authorities may not approve the price we intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business.

59

We may not be able to submit INDs or IND amendments or comparable documents in foreign jurisdictions to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.

While we plan to submit INDs or comparable documents for our potential product candidates, we may not be able to submit such INDs or comparable documents on the timeline we expect. For example, due to supply chain constraints and the impact of follow-on effects due to such constraints, we have had to move our planned submission of the IND for IMM-1-104 to the FDA from the first quarter of 2022 to the third quarter of 2022. We may also experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND or comparable document will result in the FDA or other comparable foreign regulatory authorities allowing further clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all.

Our company has limited experience in designing clinical trials and may experience delays or unexpected difficulties in obtaining regulatory approval for our current and future product candidates.

We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our planned clinical trials or any future clinical trials will be successful. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval for any product candidates. If the FDA does not approve any of our planned NDAs, it may require that we conduct additional costly clinical trials, preclinical studies or manufacturing validation studies before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA or other application that we submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA or other application that we submit. If any of these outcomes occur, we may be forced to abandon the development of our product candidates, which would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions.

We may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

Before obtaining marketing approval from the FDA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials.

In addition, we are substantially dependent on preclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties’ services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase, perhaps substantially.

60

We do not know whether our future clinical trials will begin on time or enroll patients on time, or whether our future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:

• the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;

• obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;

• any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

• obtaining approval from one or more institutional review boards, or IRBs;

 

•IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;

•delays in enrollment due to travel or quarantine policies, or other factors related to COVID-19 and its variants, other pandemics or other events outside our control;

•changes to clinical trial protocol;

•clinical sites deviating from trial protocol or dropping out of a trial;

•manufacturing sufficient quantities of product candidates or obtaining sufficient quantities of combination therapies for use in clinical trials;

•subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;

•subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;

•lack of adequate funding to continue the clinical trial;

•subjects experiencing severe or unexpected drug-related adverse effects;

•occurrence of serious adverse events in trials of the same class of agents conducted by other companies;

•selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;

•a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;

•any changes to our manufacturing process that may be necessary or desired;

61

•third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;

•third-party contractors not performing data collection or analysis in a timely or accurate manner; or

•third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.

For instance, due to supply chain constraints and the impact of follow-on effects due to such constraints, we have had to move our previously announced planned enrollment of the first patient in our first-in-human Phase 1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors in the fourth quarter of 2022 from the first half of 2022 as previously expected, assuming our IND for IMM-1-104 is accepted.  In addition, the ongoing pandemic related to COVID-19 and its variants and the measures taken by the governmental authorities could disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for our product candidates for use in our research and clinical trials, delay, limit or prevent our employees and CROs from continuing research and development activities, impede the ability of patients to enroll or continue in clinical trials, or impede testing, monitoring, data collection and analysis or other related activities, any of which could delay our clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.

Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.

Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:

• be delayed in obtaining marketing approval, if at all;

• obtain approval for indications or patient populations that are not as broad as intended or desired;

• obtain approval with labeling that includes significant use or distribution restrictions or safety warnings

• be subject to additional post-marketing testing requirements;

• be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;

62

• have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified REMS;

• be subject to the addition of labeling statements, such as warnings or contraindications;

• be sued; or

• experience damage to our reputation.

Our development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. Any delay in, or termination of, our clinical trials will delay the submission of an NDA to the FDA or similar applications with comparable foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product revenue. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation or the effectiveness or safety of our product candidate. The FDA has substantial discretion in the review and approval process and may disagree that our data support the claims we propose.

Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.

If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.

In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.

The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.

Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for their intended uses. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies and early-stage clinical trials does not mean that future clinical trials will be successful. We do not know whether any of our product candidates will perform in current or future clinical trials as they have performed in preclinical studies. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA or other

63

comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials.

In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidate. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.

We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business.

Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit applications seeking approval of our product candidates. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates.

Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose interim, preliminary or top-line data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Top-line and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.

From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between top-line, preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the trading price of our Class A common stock.

64

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, results of operations, prospects or financial condition. Moreover, such disclosure could adversely affect the trading price of our Class A common stock.

Our current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.

As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with the use of our product candidates. Results of our preclinical studies and clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with approved or other investigational products we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.

Patients in our clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials. Some of our product candidates may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients’ illnesses.

If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.

65

Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and costlier than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone or with collaborators. Other potentially significant negative consequences include that:

• we may be forced to suspend marketing of that product, or be forced to or decide to remove the product form the marketplace;

• regulatory authorities may withdraw or change their approvals of that product in one or more countries;

• regulatory authorities may require additional warnings on the label or limit access of that product to selective

specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;

• we may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies;

• we may be required to change the way the product is administered;

• we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or to be sued and held liable for harm caused to subjects or patients; and

• the product may become less competitive, and our reputation may suffer.

Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.

If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial’s conclusion as required by the FDA or other comparable foreign regulatory authorities. Additionally, our clinical trials will compete with other clinical trials for product candidates that focusing on the same therapeutic targets (e.g., evaluating patients harboring RAS mutant tumors) as our current and potential future product candidates, which may further limit enrollment of eligible patients or may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.

Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors’ product candidates. Patient enrollment for any of our clinical trials may be affected by other factors, including:

• size and nature of the patient population;

66

• severity of the disease under investigation;

• availability and efficacy of approved drugs for the disease under investigation;

• patient eligibility criteria for the trial in question as defined in the protocol;

• perceived risks and benefits of the product candidate under study;

• clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;

• efforts to facilitate timely enrollment in clinical trials;

• patient referral practices of physicians;

• the ability to monitor patients adequately during and after treatment;

• proximity and availability of clinical trial sites for prospective patients;

• continued enrollment of prospective patients by clinical trial sites;

• the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials; and

• delays or difficulties in enrollment and completion of studies due to the pandemic related to COVID-19 and its variants or any future pandemic.

Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.

Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.

Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:

• the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;

• the timing of market introduction of the product candidate as well as competitive products;

• the clinical indications for which the product candidate is approved;

• restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor products;

• the potential and perceived advantages of product candidates over alternative treatments;

67

• the cost of treatment in relation to alternative treatments;

• the availability of coverage and adequate reimbursement, as well as pricing, by third-party payors, including government authorities;

• the availability of the approved product candidate for use as a combination therapy;

• relative convenience and ease of administration;

• the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

• the effectiveness of sales and marketing efforts;

• unfavorable publicity relating to our products or product candidates or similar approved products or product candidates in development by third parties; and

• the approval of other new therapies for the same indications.

If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted.

We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.

Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.

We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable, and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can and often changes during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA policy during the period of drug development, clinical trials and FDA regulatory review.

Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing and seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving a NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.

68

We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.

 

Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our DCT platform to build a pipeline of product candidates with commercial value.

A key element of our strategy is to use and expand our DCT platform to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of various cancers. Although our research and development efforts to date have resulted in our discovery and preclinical development of IMM-1-104, it and other product candidates may not be safe or effective for the indications for which we study them in clinical trials, and we may not be able to develop any other product candidates. Our DCT platform is evolving and may not reach a state at which building a pipeline of product candidates is possible.

We have not commenced clinical trials for any product candidates developed with our DCT platform. The scientific research that forms the basis of our efforts to develop product candidates with our platforms is still ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our DCT platform is both preliminary and limited. As a result, we are exposed to a number of unforeseen risks and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates. For example, we have not tested any of the product candidates being developed using our DCT platform in humans, and our current data is limited to animal models and preclinical cell lines, the results of which may not translate into humans. As a result, it is possible that safety events or concerns could negatively affect the development of our product candidates, including adversely affecting patient enrollment among the patient populations that we intend to treat.

Given the novelty of our technologies, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of comparable experiences, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory agencies may lack experience in evaluating the safety and efficacy of our product candidates developed using our platforms, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted or approved by the FDA and comparable foreign regulatory authorities. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.

Additionally, a key element of our strategy is to use and expand our platforms to build a pipeline of product candidates and progress those product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have been focused on identifying a pipeline of product candidates directed at various disease types, we may not be able to develop product candidates that are safe and effective. Even if we are successful in building our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be approvable or marketable products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop, get approval for and begin to commercialize any product candidates, we will face difficulty in obtaining product revenue in future periods, which could result in significant harm to our financial position and adversely affect our share price.

69

Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future, which likely would result in significant harm to our financial position and adversely affect our stock price.

We may develop our current and future product candidates in combination with other therapies, which exposes us to additional risks.

We may also develop certain product candidates as biologic/drug combination products. Additional time may be required to obtain regulatory approval for our product candidates if they are combination products. Our product candidates that may be biologic/drug combination products will require coordination within the FDA and other comparable foreign regulatory authorities for review of their biologic and drug components. Although the FDA and other comparable foreign regulatory authorities have systems in place for the review and approval of combination products, we may experience delays in the development and commercialization of our product candidates that may be combination products due to regulatory timing constraints and uncertainties in the product development and approval process.

In addition, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.

We also may choose to evaluate our current product candidates or any other future product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell our product candidates we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.

If the FDA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy.

If we successfully develop our product candidates, we may seek approval from the FDA through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we initially contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.

We may in the future seek an accelerated approval for one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate

70

endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. If such post-approval studies fail to confirm the drug’s clinical benefit, the FDA may withdraw its approval of the drug.

Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success than our product candidates. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms and product candidates for specific indications may not yield any commercially viable products.

Risks Related to Our Business

We are early in our development efforts. Our business is substantially dependent on the successful development of our current and future product candidates. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval to treat the indications we seek to treat with our product candidates, and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.

We are early in our development efforts and we have not yet completed our IND-enabling studies for our lead product candidate, IMM-1-104. Our other product candidates are in earlier stages of drug development. We have invested substantially all of our efforts and financial resources in the identification of targets and preclinical development of small molecules targeting the MAPK and mTOR pathways in cancer therapy and small molecules targeting central nervous system disorders, including AD.

The success of our business, including our ability to finance our company and generate revenue from products in the future, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of the product candidates we develop, which may never occur. Our current product candidates,

71

and any future product candidates we develop, will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other markets, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts before we generate any revenues from product sales.

The success of our current and future product candidates will depend on several factors, including the following:

• the successful and timely completion of additional preclinical studies;

• the successful initiation, patient enrollment and completion of our anticipated clinical trials on a timely basis, including any delays arising out of the pandemic related to COVID-19 and its variants or any future pandemic;

• maintaining and establishing relationships with CROs and clinical sites for clinical development, both in the United States and internationally;

• the frequency and severity of adverse events in the clinical trials;

• the efficacy, safety and tolerability profiles that are satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval;

• the timely receipt of marketing approvals from applicable regulatory authorities;

•the extent of any required post-marketing approval commitments to applicable regulatory authorities;

• the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development;

• the maintenance of existing, or the establishment of new, scaled production arrangements with third-party manufacturers to obtain finished products that are appropriate for commercial sale of our product candidates, if approved;

• obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;

• the protection of our rights in our intellectual property portfolio;

• the successful launch of commercial sales following any marketing approval;

• a continued acceptable safety profile following any marketing approval;

• commercial acceptance by patients, the medical community and third-party payors; and

• our ability to compete with other therapies.

We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for IMM-1-104, or any other product candidate we develop, we may not be able to continue our operations.

72

We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems. Any failure of these or other elements of our platform will materially harm our business.

We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems, for significant elements of our drug discovery process, bioinformatics and computational biology software systems, database of information relating to our product candidates and their role in the targeted disease process, amongst others. Although we invest substantially in the backup/restore, high-availability architecture, monitoring and reporting, documentation and preventive security controls of our systems and proprietary technologies, these elements of our platform are still vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious or inadvertent human acts, and natural disasters. Our information technology systems and proprietary technologies are potentially also vulnerable to physical or electronic break-ins, employee errors, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology systems and proprietary technologies, failures or significant downtime of these systems could prevent us from conducting research and development activities for our current and future product candidates, and ultimately delay our drug discovery process. Any failure of our information technology systems and proprietary technologies will materially harm our business.

Our long-term prospects depend in part upon discovering, developing and commercializing product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.

Our future results of operations are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates beyond those we currently have in preclinical studies and early stage development. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical studies or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.

The success of the product candidates we have or may develop will depend on many factors, including the following:

• the success of our research methodology in identifying potential indications or product candidates;

• generating sufficient data to support the initiation or continuation of clinical trials;

• obtaining regulatory permission to initiate clinical trials;

• contracting with the necessary parties to conduct clinical trials;

• successful enrollment of patients in, and the completion of, clinical trials on a timely basis;

• the timely manufacture of sufficient quantities of the product candidate for use in clinical trials;

• adverse events in the clinical trials; and

• any potential interruptions or delays resulting from factors related to the pandemic related to COVID-19 and its variants or any future pandemic.

Even if we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this “Risk Factors” section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our other product candidates.

73

We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.

We have never commercialized a product candidate, and we currently have no sales force, marketing or distribution capabilities. We will have to develop our own sales, marketing and supply organization or outsource these activities to a third party to commercialize our products. If we decide to license our product candidate to others, we may need to rely on the marketing assistance and guidance of those collaborators.

Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenues from them or be able to reach or sustain profitability.

We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.

The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our products may need to compete with off-label drugs used by physicians to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our products.

In particular, there is intense competition in the fields of oncology we are pursuing. We have competitors both in the United States and internationally, including major multinational biopharmaceutical companies, established biotechnology companies, specialty biopharmaceutical companies, emerging and start-up companies, universities and other research institutions. For example, our product candidates and programs for oncology and neuroscience will compete with products or programs being advanced by certain pharmaceutical and biotechnology companies. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates.

We have chosen to initially address well-validated biochemical targets, and therefore expect to face competition from existing products and products in development for each of our product candidates. There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Many of these current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities and experience than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from

74

the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do.

Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.

If the market opportunity for any product candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.

We intend to initially focus our product candidate development on treatments for various oncology indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we develop could be significantly diminished and have an adverse material impact on our business.

We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate.

We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our product candidates. We believe our approach of treating conditions or diseases through neuroregeneration is novel and, as a result, the process for, and the outcome of, FDA approval is especially uncertain. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.

Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.

The COVID-19 pandemic and potential future pandemics could continue to adversely impact our business, including our anticipated clinical trials, supply chain and business development activities.

In December 2019, SARS-CoV-2, a novel strain of coronavirus, was first reported in Wuhan, China and has since become a global pandemic. The President of the United States declared the COVID-19 pandemic a national emergency and many states and municipalities in the United States have announced aggressive actions to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing “shelter-in-place” orders which direct individuals to shelter at their places of residence (subject to limited exceptions). We may experience limitations on

75

employee resources in the future, including because of sickness of employees or their families. The effects of government actions and our own policies and those of third parties to reduce the spread of COVID-19 and its variants may negatively impact productivity and slow down or delay our future clinical trials, preclinical studies and research and development activities, and may cause disruptions to our supply chain and impair our ability to execute our business development strategy. In the event that government authorities were to enhance current restrictions, our employees who currently are not telecommuting may no longer be able to access our facilities, and our operations may be further limited or curtailed.

As COVID-19 and its variants continues to spread, we may experience ongoing disruptions that could severely impact our business, preclinical studies and clinical trials, including:

• interruption or delays in our operations, which may impact our ability to conduct and produce preclinical results required for submission of an IND;

• delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;

• delays or difficulties in enrolling patients in our clinical trials;

• delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;

• delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; 

• changes in local regulations as part of a response to the pandemic related to COVID-19 and its variants which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;

• diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;

• interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;

• interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;

• risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and

• refusal of the FDA to accept data from clinical trials in affected geographies.

These and other disruptions in our operations and the global economy could negatively impact our business, results of operations and financial condition.   For example, due to supply chain constraints and the impact of follow-on effects due to such constraints, we had to move the timing of our recently announced plans to submit an IND for IMM-1-104 to the FDA, which are now expected to be in the third quarter of 2022, as well as the timing of our enrollment of the first patient in our first-in-human Phase 1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors in the fourth quarter of 2022, assuming our IND for IMM-1-104 is accepted.

Our future clinical trials may be affected by the pandemic related to COVID-19 and its variants or any future pandemic. For example, some clinical trial sites have slowed down or stopped further enrollment of new patients in clinical trials, denied access to site monitors and otherwise curtailed certain operations. Similarly, our ability to recruit and retain

76

principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and its variants, may be adversely impacted. Our planned clinical trials may also be impacted by interruptions or delays in the operations of the FDA and comparable foreign regulatory agencies. We and our CROs will act in accordance with the guidance issued by the FDA in our future clinical trials to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic related to COVID-19 and its variants. This may have unforeseen effects on the enrollment, progress and completion of these trials and the findings. These events could delay our clinical trials, increase the cost of completing our clinical trials and negatively impact the integrity, reliability or robustness of the data from our clinical trials.

In addition, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 and its variants or other infectious diseases could impact personnel at third-party manufacturing facilities upon which we may rely in the future, or the availability or cost of materials, which could disrupt the supply chain for our product candidates. To the extent our future suppliers and service providers are unable to comply with their obligations under our future agreements with them or they are otherwise unable to deliver or are delayed in delivering goods and services to us due to the pandemic related to COVID-19 and its variants, our future ability to continue meeting clinical supply demand for our product candidates or otherwise advancing development of our product candidates may become impaired.

The spread of COVID-19 and its variants and actions taken to reduce its spread may also materially affect us economically. While the potential economic impact brought by, and the duration of, the pandemic related to COVID-19 and its variants may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other biopharmaceutical companies have been highly volatile as a result of the pandemic related to COVID-19 and its variants. As a result, we may face difficulties raising capital through sales of our Class A common stock or such sales may be on unfavorable terms. COVID-19 and its variants and actions taken to reduce their spread continue to rapidly evolve. The extent to which COVID-19 and its variants may impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the pandemic related to COVID-19 and its variants adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section, such as those relating to the timing and results of our clinical trials and our financing needs

We may fail to adequately meet the requirements under our computational biology service contracts to pharmaceutical and biotechnology companies, which may harm our reputation, possibly resulting in related losses.

Over a decade ago, we began to offer computational biology services to pharmaceutical and biotechnology companies. We have deprioritized this business and plan to gradually wind down our computational biology services to pharmaceutical and biotechnology companies in the future. However, we are currently servicing several companies and in doing so, we must:

• accurately assess and meet the customer’s needs;

• ensure our computational biology services meet industry standards and practices for performance of similar services;

• retain the proper personnel to fulfill these service contracts; and

• compete effectively with other computational biology service providers performing similar services.

If we fail to adequately meet the requirements under our computational biology service contracts to our typical high standards, our reputation, growth opportunities and prospects could be adversely affected, possibly resulting in related losses. In addition, as is typical for contracts of this nature, there are inherent legal risks and potential liabilities associated with our work under each of our past, present and future contracts.

77

Risks Relating to Our Dependence on Third Parties

We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies, and in the future, our clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and to monitor and manage data for our ongoing preclinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We, our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.

Further, there is no guarantee that any such CROs, investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. These risks are heightened as a result of the efforts of government agencies and the CROs themselves to limit the spread of COVID-19 and its variants, including quarantines and shelter-in-place orders. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely.

Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.

If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.

78

We rely on, and in the future may rely on, third-party datasets and collaborations with third parties to inform patient selection, drug target identification and other bioinformatic and computational biology analyses for our existing product candidates and any future product candidates and for the supply of biomarker companion diagnostics.

We are using bioinformatics, including data analytics, biostatistics and computational biology, throughout our drug discovery and development process, including to identify new target and biomarker opportunities. As part of this approach, we interrogate public and proprietary datasets, including, but not limited to, human tumor genetic information and specific cancer-target dependency networks. We rely on these datasets and data analytics for multiple analyses, including identifying or validating some of our biomarker-target relationships and access to these databases may not continue to be available publicly or through a proprietary subscription on acceptable terms. Our past, present and future use of such datasets could also create potential liabilities for us if the data provided to us contains inherent errors, inaccuracies or artifacts, or if we improperly analyze, handle, store or utilize the data.

Many of our product candidates also rely on the availability and use of commercially available tumor diagnostics panels or data on the prevalence of our target patient population to inform the patient selection and drug target identification for our product candidates. In cases where such biomarker diagnostic is not already commercially available, we expect to establish strategic collaborations for the clinical supply and development of companion diagnostics. If these diagnostics are not able to be developed, or if commercial tumor profiling panels are not able to be updated to include additional tumor-associated genes, or if clinical oncologists do not incorporate molecular or genetic sequencing into their clinical practice, we may not be successful in developing our existing product candidates or any future product candidates.

If we decide to establish new collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.

Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.

We may face significant competition in seeking appropriate collaborators and the related negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.

In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.

If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or

79

commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.

We may enter into collaborations in the future with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.

We may seek third-party collaborators in the future for the development and commercialization of one or more of our product candidates. Our likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.

We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators’ abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates could pose numerous risks to us, including the following:

• collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;

• collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;

• collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;

• collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

• a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;

• collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings;

• disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;

• collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;

• collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all; and

80

• if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.

Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse and compliance laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, submission of false claims, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting/rebating, marketing and promotion, consulting, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.

Risks Related to Manufacturing

The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.

Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.

81

We contract with third parties for the manufacture of our product candidates for preclinical studies, and expect to continue to do so for clinical trials and ultimately, for commercialization of any approved product candidate. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements. Furthermore, the raw materials for our product candidates may be sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials.

We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

• the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;

• the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;

• the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;

• the breach by the third-party contractors of our agreements with them;

• the failure of third-party contractors to comply with applicable regulatory requirements;

• the failure of the third party to manufacture our product candidates according to our specifications;

• the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;

• clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and

• the misappropriation of our proprietary information, including our trade secrets and know-how.

We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would

82

significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.

In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the impact of the pandemic related to COVID-19 and its variants, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to or voluntarily change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively affect our ability to develop product candidates in a timely manner or within budget.

Our or a third-party’s failure to execute on our manufacturing requirements, do so on commercially reasonable terms and timelines and comply with cGMP requirements could adversely affect our business in a number of ways, including:

• inability to meet our product specifications and quality requirements consistently;

• inability to initiate or continue clinical trials of our product candidates under development;

• delays in submitting regulatory applications, or receiving marketing approvals, for our product candidates, if at all;

• inability to commercialize any product candidates that receive marketing approval on a timely basis;

loss of the cooperation of future collaborators;

• subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; 

• requirements to cease development or to recall batches of our product candidates;

• in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates; and

• our future profit margins.

83

Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.

As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.

Risks Related to Legal and Regulatory Compliance Matters

Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and government price reporting, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.

Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include, among others, the following:

• the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;

• the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties laws, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per claim penalties per false claim or statement. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;

• the federal Criminal Statute on False Statements Relating to Healthcare Matters, which makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services;

• the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from participation in federal

84

healthcare programs to provide items or services reimbursable by a federal healthcare program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment;

• the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

• the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare and Medicaid Services, or CMS, information regarding payments and other transfers of value to physicians (as defined by statute), certain other healthcare providers starting in 2022 and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually;

• analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require biotechnology companies to comply with the biotechnology industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and

• some state laws require biotechnology companies to report information to state agencies and/or commercial purchasers on the pricing of certain drug products that exceed a certain level as identified in the relevant statute. Some of these laws and regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations.

Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices, including our arrangements with physicians, some of whom have ownership interests in us, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.

The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to

85

collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.

As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. For instance, in the U.S., most healthcare providers, including research institutions from which we may obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended. We are not currently acting as a covered entity or business associate under HIPAA and thus are not subject to its requirements. However, any person may be prosecuted under HIPAA’s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA’s requirements for disclosure of individually identifiable health information.

We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the European Union General Data Protection Regulation, or the GDPR, governs certain collection and other processing activities involving personal data about individuals in the EEA. Among other things, the GDPR imposes requirements regarding the security of personal data, the rights of data subjects to access and delete personal data, requires having lawful bases on which personal data can be processed, includes requirements relating to the consent of individuals to whom the personal data relates, requires detailed notices for clinical trial participants and investigators and regulates transfers of personal data from the EEA to third countries that have not been found to provide adequate protection to such personal data, including the United States. In addition, the GDPR imposes substantial fines for breaches and violations (up to the greater of €20 million or 4% of our annual global revenue). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Further, from January 1, 2021, companies have to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU member states to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/extends that decision, and remains under review by the Commission during this period. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. These changes may lead to additional costs and increase our overall risk exposure.

If we or third-party contract manufacturing organizations, or CMOs, CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors’ ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.

86

Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.

Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management’s time and our resources and substantial monetary awards to trial participants or patients. We currently have insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition.

Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.

The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.

There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. However, one third-party payor’s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.

Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.

87

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations in the future may involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations in the future may also produce hazardous waste products. In the future, we may generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we will maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the potential use of hazardous materials in the future, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

The FDA or other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.

We may choose to conduct international clinical trials in the future. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the

88

foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary.  Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. If the FDA or any other comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.

Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.

Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from

89

the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory authority requirements may subject our company to administrative or judicially imposed sanctions, including:

• delays in or the rejection of product approvals;

• restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;

• restrictions on the products, manufacturers or manufacturing process;

• warning or untitled letters;

• civil and criminal penalties;

• injunctions;

• suspension or withdrawal of regulatory approvals;

• product seizures, detentions or import bans;

• voluntary or mandatory product recalls and publicity requirements;

• total or partial suspension of production; and

• imposition of restrictions on operations, including costly new manufacturing requirements.

The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.

The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.

We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We currently have a limited set of compliance policies and personnel, and intend to develop our compliance infrastructure in the future, as our clinical development programs progress. Developing a compliance infrastructure is costly and time-consuming, and even a well-designed and implemented compliance program cannot necessarily prevent all violations of relevant laws. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our product candidates, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In

90

particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, as a public company, future government shutdowns could impact our ability to further access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that  remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the pandemic related to COVID-19 and its variants. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

We may face difficulties from changes to current regulations and future legislation.

Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government

91

regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as the ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjected biologic products to potential competition by lower-cost biosimilars; increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain “branded prescription drugs” to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; required reporting of certain financial arrangements between manufacturers of biologics, physicians and teaching hospitals under the federal Physician Payments Sunshine Act; expanded the types of entities eligible for the 340B Drug Pricing Program; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare & Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court’s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace.  The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare

In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the coronavirus pandemic, unless additional congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.

Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. Further, it is possible that additional governmental action is taken in response to the pandemic related to COVID-19 and its variants.

92

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain patent and other intellectual property protection for our product candidates and technologies or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be impaired, and we may not be able to compete effectively in our market.

We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market. Our commercial success depends in part on our ability to obtain and maintain patent, trade secret or other intellectual property protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and, in some cases, abroad related to our product candidates, technology platforms and their uses that are important to our business.

As of March 3, 2022, we owned one issued patent and pending patent applications, in the United States only, related to our platform technologies, as well as pending patent applications related to our product candidates. We currently do not have any issued patents related to our product candidates. Further, patent prosecution with respect to our pending patent applications related to our product candidates is in the early stages and, as such, no patent examiner has yet scrutinized the merits of such pending patent applications. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology and such third parties practice the technology in countries where such patents have issued. With respect to our issued patent and patent applications related to our platform technology, we filed those applications only in the U.S., so it is possible that a competitor may practice outside the U.S. the aspects of our platform technology disclosed in those patent applications. We maintain other aspects of our platform technology as trade secrets, which were not disclosed in those patent applications. There can be no assurance that any of our current and future issued patents and patent applications, if any, owned by us or our future in-licensed patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around, invalidated or rendered unenforceable by third parties, or would effectively prevent others from commercializing competitive products or technologies. Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents may provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications related to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office, or USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the existence, issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.

Although we may obtain licenses to issued patents in the United States and foreign countries in the future, we cannot be certain that the claims in future in-licensed U.S. pending patent applications, if any, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in future in-licensed issued patents will not be found invalid or unenforceable if challenged.

93

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:

• the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;

• patent applications may not result in any patents being issued;

• patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise

may not provide any competitive advantage;

• our competitors, many of whom have substantially greater resources than we or our potential licensors do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates;

• there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and

• countries other than the United States may have patent laws less favorable to patentees than the patent law typically applied by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.

The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. In addition, we may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product or technology. For example, certain jurisdictions do not allow for patent protection with respect to method of treatment. Moreover, the scope of claims in a patent application can be significantly reduced before any claims in a patent are issued, and claim scope can be reinterpreted after issuance. Even if our current or future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner, which could materially adversely affect our business, financial condition, results of operations and prospects.

It is also possible that we may not identify patentable aspects of our research and development output before it is too late to obtain patent protection. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, the USPTO might require that the term of a patent issuing from a pending patent application to be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license, including those from our licensors, if any, and from third parties. We also may require the cooperation of our potential future licensors in order to enforce the licensed patent rights, and such

94

cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our potential future licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we may in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.

Even if our current or future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or potential future in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and any future in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity of our patents, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. There is also no assurance that there is no prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of patent rights, loss of exclusivity or our patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable or trade secret aspects of our technology platforms and research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, licensors, and other third parties, any of these parties may breach such agreements and disclose such aspects or output before a patent application is filed, thereby jeopardizing our ability to seek patent protection or maintain the trade secret status of our technology platforms or research and development output.

As referenced above, we have filed patent applications directed to our platform technologies that involve certain of our proprietary software modules. Moreover, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, rely on the above-referenced patent applications for protection of certain modules and trade secret protection for other of our software modules. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our software may be limited.

If we fail to comply with our obligations in future agreements under which we may license intellectual property rights from licensors and third parties or otherwise experience disruptions to our business relationships with future licensors, we could lose license rights that may in the future be important to our business.

In the future, we may enter into license agreements under which we are granted rights to intellectual property that may be important to our business. We expect that any future license agreements where we in-license intellectual property would impose on us various development, regulatory and/or commercial diligence obligations, payment of milestones and/or

95

royalties and other obligations. If we fail to comply with our obligations under these agreements (including as a result of COVID-19 and its variants impacting our operations), or we use the licensed intellectual property in an unauthorized manner or are subject to bankruptcy-related proceedings, the licensors may have the right to materially modify the terms of the licenses, such as by rendering currently exclusive licenses non-exclusive, or terminate the licenses, in which event we would not be able to market products covered by the licenses. We may also in the future enter into license agreements with third parties under which we are a sublicensee. If our sublicensor fails to comply with its obligations under its upstream license agreement with its licensor, the licensor may have the right to terminate the upstream license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize our product candidates incorporating the relevant intellectual property.

We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates or platform, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our product candidates or platform in the absence of such a license. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive for commercializing our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.

In addition, disputes may arise between us and any future licensors regarding intellectual property subject to a license agreement, including:

• the scope of rights granted and obligations imposed under the license agreement and other interpretation-related issues;

• whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;

• our right to sublicense patents and other rights to third parties;

• our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;

• the amounts, if any, we owe to a potential licensor in respect of sublicense fees or income or in respect of backup product;

• our right to transfer or assign the license; and

• the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and its affiliates and sublicensees and by us and our partners and sublicensees.

96

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our future licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.

In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor’s express consent in order for an assignment or transfer to take place.

The patent protection and patent prosecution for some of our product candidates may be dependent on our future licensors and third parties.

We or our future potential licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects as to form in the preparation or filing of our potential future in-licensed patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our future potential licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our future potential licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our future potential in-licensed patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.

As a future potential licensee of third parties, we would rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our future license agreements. We would not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Future potential licensors may have the right to control enforcement of our future potential licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our future licensors. We cannot be certain that our future licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may  need to operate our business. If any of our future potential licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents directed to any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.

In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties in the future, we may still be adversely affected or prejudiced by actions or inactions of our potential licensors and their counsel that took place prior to us assuming control over patent prosecution.

Technology we may acquire or license from various third parties in the future may be subject to retained rights. Our future licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for use in fields other than the fields licensed to us or for use in noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It may be difficult to monitor whether our future licensors may limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.

97

Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe or misappropriate their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.

Our commercial success depends in part on avoiding infringement or misappropriation of the patents and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Because the intellectual property landscape in the industry in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our ability to freely make, use, and sell our products without infringing third party rights. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates, as well as related to our platform.

As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates or platform may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that others have not filed patent applications for a product candidate or technology covered by our pending patent applications, or that we were the first to file a patent application related to a product candidate or technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents relating to such technologies. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe.

In addition, identification of third-party patent rights that may be relevant to our product candidates or platform is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.

Further, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time-consuming and could:

• result in costly litigation that may cause negative publicity;

• divert the time and attention of our technical personnel and management;

• cause development delays;

98

• prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or unenforceable or not infringed in a court of law;

• require us to develop non-infringing technology, which may not be possible on a cost-effective basis;

• subject us to significant liability to third parties; or

• require us to enter into royalty or licensing agreements, that may not be available on commercially reasonable terms, or at all, or that might be non-exclusive, which could result in our competitors gaining access to the same technology.

Although no third party has asserted a claim of patent infringement against us as of the date of this Annual Report on Form 10-K, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary.

Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and results of operations.

Parties making claims against us may be able to sustain the costs of complex patent or trade secret litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.

Moreover, if our product candidates or platform are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of such licensees and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.

We may be involved in lawsuits to protect or enforce our patents or the patents of our future licensors, which could be expensive, time-consuming and unsuccessful. Further, our future in-licensed issued patents could be found invalid or unenforceable if challenged in court.

Competitors may infringe or otherwise violate our, or our future licensors’, patents, trademarks or other intellectual property. To prevent infringement or other violations, we and/or our future licensors may be required to file claims, which can be expensive and time-consuming. Further, our future licensors may need to file such claims, but elect not to file them. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our future licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an

99

alleged failure to meet any of several statutory requirements, including lack of novelty or written description, non-patentable subject matter (laws of nature, natural phenomena, or abstract idea), obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO or the applicable foreign counterpart, or made a misleading statement, during prosecution. A litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have conducted our patent prosecution in accordance with the duty of candor to the USPTO and in good faith. The outcome following such a challenge is unpredictable. With respect to challenges to the validity of our patents, there might be invalidating prior art, of which we and the patent examiner were unaware during prosecution.

If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our future licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others.

Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights, particularly those in a foreign jurisdiction, may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us, which could be costly to defend, particularly in a foreign jurisdiction, and could require us to pay substantial damages, cease the sale of certain products or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all). We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.

Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.

During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our Class A common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.

Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.

Derivation or interference proceedings provoked by third parties or brought by us or our future licensors, or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our or our potential future licensors’ patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensors’ defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our

100

ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.

Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

In 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a “first inventor to file” system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This requires us to be cognizant of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1) file any patent application related to our product candidates or (2) invent any of the inventions claimed in our patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license.

The Leahy-Smith Act also includes a number of significant changes that (i) affect the way patent applications are prosecuted, (ii) redefine prior art, and (iii) provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.

Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would have been insufficient to invalidate the claim if presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation increase the uncertainties and costs surrounding the prosecution of our or our future licensors’ patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Further, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.

In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent

101

protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our future licensors’ ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors’ ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.

We or our future licensors may be subject to claims challenging the inventorship or ownership of our or our future in-licensed patents and other intellectual property.

We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we or our future licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we or our future licensors are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.

Our future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our future licensors are not the sole and exclusive owners of any patents we may in-license. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be

102

available in certain foreign countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.

We may not be able to protect our intellectual property rights throughout the world.

Although we have pending patent applications in the United States and we seek to file patent applications in certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our or our licensors’ patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our or our potential future licensors’ patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our potential future licensors’ patents at risk of being invalidated or interpreted narrowly and our or our potential future licensors’ patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our potential future licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our potential future licensors’ efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or

government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. While an inadvertent lapse,

103

including due to the effect of the pandemic related to COVID-19 and its variants, our patent maintenance vendors or law firms, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications relating to our product candidates, our competitive position would be adversely affected.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patent protection for some of our technology and product candidates, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position, especially with respect to our technology platform. Any disclosure, either intentional or unintentional, by our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into non-disclosure and confidentiality agreements with third parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Further, we cannot provide any assurances that all such agreements have been duly executed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. 

Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we or our licensors do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.

We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.

104

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers.

As is common in the pharmaceutical and biotechnology industries, we employ individuals and engage the services of consultants who previously worked for other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information, trade secrets or other proprietary information of their former employers, or that our consultants have used or disclosed trade secrets or other proprietary information of their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

We use and will continue to use registered and/or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.

Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.

We use third-party open source software, which could negatively affect our ability to offer our solutions and subject us to litigation or other actions.

We use open source software licensed to us by third-party authors under “open source” licenses in our platform and solutions and expect to continue to use such open source software in the future. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide support, warranties, indemnification or other contractual protections regarding infringement claims or the quality of the code. To the extent that our platform depends upon the successful operation of open source software, any undetected errors or defects in this open source software could prevent the deployment or impair the functionality of our platform, delay introductions of new solutions, result in a failure of our platform, and injure our reputation. For example, undetected errors or defects in open source software could render it vulnerable to breaches or security attacks, and, as a result, possibly

105

make our systems more vulnerable to data breaches. In addition, the public availability of such software may make it easier for others to compromise our platform.

Further, there are uncertainties regarding the proper interpretation of and compliance with open source licenses, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to use such open source software, and consequently to provide or distribute our platform and solutions. Some open source licenses contain express requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use, or grant other licenses to our intellectual property. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source licenses, be required to release the source code of our proprietary software to the public. This would allow our competitors to create similar offerings with lower development effort and time and ultimately could result in a loss of our competitive advantages. Alternatively, to avoid the public release of the affected portions of our source code, we could be required to expend substantial time and resources to re-engineer some or all of our software.

Despite our efforts to monitor our use of open source software to avoid subjecting our platform to conditions we do not intend, there is a risk that open source licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to provide or distribute our platform. Additionally, we may from time to time face claims from third parties claiming ownership of, or seeking to enforce the terms of, an open source license, including by demanding release of source code for the open source software, derivative works or our proprietary source code that was developed using, or that is distributed with, such open source software. These claims could also result in litigation and could require us to make our proprietary software source code freely available, devote additional research and development resources to re-engineer our platform, seek costly licenses from third parties, pay monetary damages to the owner of the copyright in the relevant open source software or otherwise incur additional costs and expenses, any of which could result in reputational harm and would have a negative effect on our business and results of operations. In addition, if the license terms for the open source software we utilize change, we may be forced to re-engineer our platform, incur additional costs to comply with the changed license terms or replace the affected open source software. Although we have implemented policies to regulate the use and incorporation of open source software into our platform and solutions, we cannot be certain that that such policies will be effective and that we have not incorporated open source software in our platform and solutions in a manner that is inconsistent with such policies.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

• others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we may own or license;

• we or our potential future licensors might not have been the first to make the inventions covered by the issued patents or patent application that we may own or license;

• we or our potential future licensors might not have been the first to file patent applications covering certain of our inventions;  

• others may independently develop similar or alternative technologies or duplicate any of our technologies without

infringing our intellectual property rights;

• it is possible that our or our future licensors’ pending patent applications will not lead to issued patents;

• future issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;

106

• our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

• we may not develop additional proprietary technologies that are patentable; and

• the patents of others may have an adverse effect on our business.

Should any of these events occur, it could significantly harm our business, results of operations and prospects.

Risks Related to Employee Matters and Managing our Growth

If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.

We currently do not have and have never had a marketing or sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks.

Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.

Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.

To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our results of operations. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary, including bioinformatics and computational biologist specialists, for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.

Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide a wide range of opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel,

107

the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.

In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.

As of December 31, 2021, we had 64 full-time employees, including 54 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, including operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:

• identifying, recruiting, integrating, maintaining and motivating additional employees;

• managing our internal development efforts effectively, including the clinical, FDA and other comparable foreign regulatory agencies’ review process of IMM-1-104, IMM-6-415, and any other product candidate we develop, while complying with any contractual obligations to contractors and other third parties we may have; and

• improving our operational, financial and management controls, reporting systems and procedures.

Our future financial performance and our ability to successfully develop and, if approved, commercialize IMM-1-104 and any other product candidate will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.

We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.

If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize IMM-1-104, IMM-6-415 and any other current or future product candidates and, accordingly, may not achieve our research, development and commercialization goals.

Risks Related to Ownership of Our Class A Common Stock

We may be unable to maintain an active, liquid and orderly trading market for our Class A common stock and, as a result, it may be difficult for you to sell your shares of our Class A common stock.

The market value of our Class A common stock may decrease from time to time, and you may not be able to resell your shares of our Class A common stock at or above the price you purchased them. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our Class A common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of Class A common stock as consideration.

108

The price of our stock may be volatile, and you could lose all or part of your investment.

The trading price of our Class A common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. The trading prices for common stock of other pharmaceutical and biotechnology companies have also been highly volatile as a result of the pandemic related to COVID-19 and its variants.

Broad market and industry factors may negatively affect the market price of our Class A common stock, regardless of our actual operating performance. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this Annual Report on Form 10-K, these factors include:

• the timing and results of preclinical studies and clinical trials of our product candidates or those of our competitors;

• the success of competitive products or announcements by potential competitors of their product development efforts;

• regulatory actions with respect to our products or our competitors’ products;

• actual or anticipated changes in our growth rate relative to our competitors;

• regulatory or legal developments in the United States and other countries;

• developments or disputes concerning patent applications, issued patents or other proprietary rights;

• the recruitment or departure of key personnel;

• announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;

• actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

• fluctuations in the valuation of companies perceived by investors to be comparable to us;

• market conditions in the pharmaceutical and biotechnology sector;

• changes in the structure of healthcare payment systems;

• share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;

• announcement or expectation of additional financing efforts;

• sales of our Class A common stock by us, our insiders or our other stockholders;

• expiration of market stand-off or lock-up agreements;

• the ongoing and future impact of the pandemic related to COVID-19 and its variants, or any future pandemics, and actions taken to slow their spread; and

109

• general economic, industry and market conditions, including the effects of recession or slow economic growth in the U.S. and abroad, interest rates, fuel prices, international currency fluctuations, corruption, political instability, acts of war, including the Russian Federation’s invasion of Ukraine in February 2022, acts of terrorism, and the ongoing COVID-19 pandemic or other public health crises.

The realization of any of the above risks or any of a broad range of other risks, including those described in this “Risk Factors” section, could have a dramatic and adverse impact on the market price of our Class A common stock.

If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.

The trading market for our Class A common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our results of operations fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of December 31, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 60.4% of our voting stock and these stockholders will be able to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our Class A common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their Class A common stock, and might affect the prevailing market price for our Class A common stock.

Sales of a substantial number of shares of our Class A common stock in the public market could cause our stock price to fall.

Sales of a substantial number of shares of our Class A and/or Class B common stock, or the perception that these sales might occur, could depress the market price of our Class A common stock and could impair our ability to raise capital through the sale of additional equity securities. The shares of Class A common stock that were sold in the initial public offering of our Class A common stock are freely transferable without restrictions or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for any shares acquired by our affiliates, as defined in Rule 144 under the Securities Act. The remaining shares of our Class A common stock that are outstanding are either unrestricted or restricted as a result of securities laws. In addition, there are shares of Class A common stock that are either subject to outstanding options or reserved for future issuance under our existing equity incentive plans and may become eligible for future sale subject to vesting, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of Class A common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our Class A common stock could decline.

As of December 31, 2021, the holders of approximately 11,939,281 shares, or approximately 45.4% of our outstanding shares of our common stock have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. Once we register the offer and sale of shares for the holders of registration rights, these shares will be able to be sold in the public market upon issuance, subject to the lock-up agreements described above.

110

In addition, in the future, we may issue additional shares of Class A common stock, or other equity or debt securities convertible into Class A common stock, in connection with a financing, acquisition, employee arrangement or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our Class A common stock to decline.

We do not currently intend to pay dividends on our Class A common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our Class A common stock.

We have never declared or paid any cash dividends on our equity securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our Class A common stock, which is not certain.

Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our Class A common stock.

Our certificate of incorporation and bylaws contain provisions that could depress the market price of our Class A common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:

• establish a classified board of directors so that not all members of our board are elected at one time;

• permit only the board of directors to establish the number of directors and fill vacancies on the board;

• provide that directors may only be removed “for cause” and only with the approval of two-thirds of our stockholders;

• authorize the issuance of “blank check” preferred stock that our board could use to implement a stockholder rights plan (also known as a “poison pill”);

• eliminate the ability of our stockholders to call special meetings of stockholders;

• prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;

• prohibit cumulative voting;

• authorize our board of directors to amend the bylaws;

• establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and

• require a super-majority vote of stockholders to amend some provisions described above.

In addition, Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.

111

Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our Class A common stock.

Our amended and restated certificate of incorporation and amended and restated bylaws provides for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America is the exclusive forum for the resolution of any complaint asserting a cause or causes of action against any defendant arising under the Securities Act. Such provision is intended to benefit and may be enforced by us, our officers and directors, employees and agents, including the underwriters and any other professional or entity who has prepared or certified any part of this Annual Report on Form 10-K. Nothing in our amended and restated certificate of incorporation or amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.

We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive-forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

112

General Risks

Our internal computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, collaborators or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.

Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants, collaborators and third-party service providers, are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to health-related or other personal information (violating certain privacy laws such), it could result in a material disruption of our drug discovery and development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws.

Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.

Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity, future pandemics and other events beyond our control, which could harm our business.

Our facilities are located in regions which experience severe weather from time to time. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity, future pandemics or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Class A common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:

• being permitted to provide only two years of audited financial statements, in addition to any required unaudited  financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in this Annual Report on Form 10-K;

113

• not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;

• not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on financial statements;

• reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and

• exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We cannot predict if investors will find our Class A common stock less attractive because we may rely on these exemptions. If some investors find our Class A common stock less attractive as a result, there may be a less active trading market for our Class A common stock and our stock price may be more volatile.

We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (2) the date we qualify as a “large accelerated filer,” with at least $700 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our initial public offering.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

The requirements of being a public company may strain our resources, result in more litigation and divert management’s attention.

As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and results of operations. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business and results of operations. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses.

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing

114

bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.

These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.

By disclosing information in this Annual Report on Form 10-K and in future filings required of a public company, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management’s resources and seriously harm our business.

If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our Class A common stock.

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.

We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.

We may be subject to securities litigation, which is expensive and could divert management attention.

The market price of our Class A common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

New tax legislation may impact our results of operations and financial condition.

The U.S. government may enact significant changes to the taxation of business entities including, among others, an increase in the corporate income tax rate, an increase in the tax rate applicable to the global intangible low-taxed income and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. The likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur. If such changes are enacted or implemented, we are currently unable to predict the ultimate impact on our business.

115

       

Item 1B. Unresolved Staff Comments

None

Item 2. Properties.

Our principal office is located at 245 Main Street, Second Floor Cambridge, Massachusetts 02142, where we lease approximately 586 square feet of office space under a service agreement that can be terminated by either party upon 30 days written notice.

We also lease the following properties in San Diego, California: (i) approximately 3,657 square feet of office space; under a lease that terminates on October 1, 2023 and is currently being subleased to a third-party through the remainder of the term of the lease; (ii) approximately 38,613 square feet of office and laboratory space under a lease that terminates on April 30, 2032; (iii) approximately 6,100 square feet of office and laboratory space under a lease that terminates on December 31, 2022 and currently being subleased to a third-party through the remainder of the term of the lease; and (iv) 4,760 square feet of office and laboratory space under a lease that terminates on March 31, 2024.  

Additionally, we lease approximately 190 square feet of office space in New York, New York under a service agreement that currently runs through March 31, 2022 and automatically renews unless we provide 30 days advance notice to terminate; and approximately 66 square feet of office space in San Francisco, California under an agreement that can be terminated by either party upon 60 days’ notice

We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.

Item 3. Legal Proceedings

From time to time we may be involved in claims and proceedings arising in the course of our business. The outcome of any such claims or proceedings, regardless of the merits, is inherently uncertain. We are not currently party to any material legal proceedings

Item 4. Mine Safety Disclosures

Not applicable

PART II — OTHER INFORMATION

Item 5.  Market For The Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information for Common Stock

Our common stock trades under the symbol “IMRX” on the Nasdaq Global Market.

Holders of Our Common Stock

As of March 3, 2022, there were approximately 83 registered holders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in “street name” by brokers or held by other “nominees”. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

116

Dividend Policy

We have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain all available funds and future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.

Securities Authorized for Issuance Under Equity Compensation Plans

See Item 12, Part III of this Form 10-K.

Unregistered Sales of Equity Securities

In December 2021, we acquired BioArkive, Inc. (“BioArkive”) and in exchange issued to BioArkive and its shareholders 379,635 shares of Immuneering’s Class A common stock, which was calculated using a value of $8.75 million divided by the average of the daily volume weighted average prices of the Class A common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the closing. These shares were offered and sold in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.

Issuer Purchases of Equity Securities

We did not purchase any of our registered equity securities during the quarterly period ended December 31, 2021.

Securities Authorized for Issuance Under Equity Compensation Plans

Information about our equity compensation plans will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 6. [Reserved]

Item 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing in Part II, Item 8 of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part I, Item IA. ‘‘Risk Factors’’ of this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.

Overview

We aim to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using our translational bioinformatics platform. We have more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, our disease-agnostic discovery platform enables us to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry. Our lead product candidate IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR to modulate the signaling dynamics of the MAPK pathway.  Specifically, it is designed to drive deep cyclic inhibition that deprives tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, moderate level of signaling sufficient to

117

spare healthy cells.  IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutations, and is translationally guided by our proprietary, human-aligned 3D tumor modeling platform combined with patient-aligned bioinformatics. In addition to IMM-1-104, we have six other oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway, as well as two discovery stage neuroscience programs.

We plan to submit an Investigational New Drug application, or IND, for IMM-1-104 to the U.S. Food and Drug Administration, or the FDA, in the third quarter of 2022. In addition, we plan to submit an IND for IMM-6-415 to the FDA in 2023.  We anticipate filing at least one additional IND for our other oncology programs in 2024.

For the period from inception through 2017, we devoted substantially all of our efforts to business planning, service revenue generation, developing tools to aid in drug discovery, and recruiting management and technical staff. Since 2018, we have also focused significant effort on our own internal research and development programs. We have financed our operations through service revenues, the issuance of convertible debt and the sale of convertible preferred stock and common stock.

On December 22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (“BioArkive”) for a market value of $8.75 million.

BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company's internal preclinical research activities for its oncology pipeline. In connection with the acquisition, the Company has assumed the obligations under BioArkive’s three lease agreements.

The purchase price was paid by Immuneering through the issuance of an aggregate of 379,635 shares of Immuneering’s Class A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the closing date. The sellers of BioArkive are restricted from selling these shares for a 6 month period from the date of the acquisition. As such, we estimated that there was an approximate 10% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $7.88 million.

Our operations have been financed primarily by service revenues and aggregate net proceeds of approximately $81.4 million from the issuance of convertible notes payable, convertible preferred stock (Series A and B) including gross proceeds of approximately $24.8 million from the issuance of shares in the second tranche of Series B Preferred in April and May 2021, common stock, exercise of stock options. On August 3, 2021, we completed our IPO pursuant to which we issued and sold 8,625,000 shares of Class A common stock, inclusive of 1,125,000 shares sold by us pursuant to the full exercise of the underwriters’ option to purchase additional shares. We received aggregate net proceeds of approximately $120.3 million from the IPO, after deducting underwriting discounts and commissions, but before deducting offering costs payable by us, which were $2.1 million.

Since inception, we have had significant annual operating losses. Our net loss was approximately $33.5 million, for the year ended December 31, 2021 and $17.0 million for the year ended December 31, 2020. As of December 31, 2021, we had an accumulated deficit of approximately $59.3 million and approximately $150.2 million in cash and cash equivalents and marketable securities.

Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our internally developed product candidates as well as add operational, financial and management informational systems and personnel to support our product development. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter

118

and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.

Based upon our current business plans, we believe that our existing cash and cash equivalents and marketable securities will be sufficient to fund our development activities and other operations into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured.

We have not had any internally developed products approved for sale. We do not expect to generate any product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our internally developed product candidates. If we obtain regulatory approval for any of our internally developed product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through service revenue, equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.

In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. In particular, the ongoing pandemic related to COVID-19 and its variants has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The effect of these orders, government imposed quarantines and measures we have taken, such as implementing work-at-home policies, may negatively impact productivity, disrupt our business and/or could adversely affect our development plans and results. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including personnel at third-party manufacturing facilities and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on us. While to date we have been able to continue to execute our overall business plan, some of our business activities have been slowed and taken longer to complete, particularly with respect to our process for recruiting new employees, and we continue to adjust to the challenges of operating in a largely remote setting with our employees. Overall, we recognize the challenges the pandemic may pose to our business, will continue to closely monitor events as they develop and plan for alternative and mitigating measures that we can implement if needed.

Components of Our Results of Operations

Revenue

Our revenue is generated by providing computational biology professional services to pharmaceutical and biotechnology companies. We charge an agreed upon rate per hour based on the aggregate level of personnel assigned to work on the project or a fixed fee for a defined scope of work. Our contracts specify the period of time over which these professional services will be provided. We recognize revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. We use input methods to measure the progress toward the complete satisfaction of performance obligations and evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

We expect revenue to continue to decrease as we have deprioritized new services work in order to focus on developing our wholly owned pipeline. We expect that, by the end of 2022, revenue associated with this computational biology professional services business will be eliminated.

119

We are in the process of discontinuing biosample storage, which was acquired through the BioArkive transaction, to external parties and expect it to complete in the second half of 2022. The revenue earned associated with this is immaterial to the financial statements and is expected to continue decrease until these external services are discontinued.

Cost of Revenue

Our cost of revenue expenses consists primarily of costs related to providing professional services to our customers. These costs include salaries, bonuses, benefits, and stock-based compensation expense, depreciation, facilities, and other outside services.

Operating Expenses

Our operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.

Research and Development

Research and development expenses account for a significant portion of our operating expenses. Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of our research platform, product candidates, discovery efforts and preclinical studies related to our program pipeline.

Our direct costs include:

expenses incurred under agreements with CROs and other vendors that conduct our preclinical activities on our behalf; including laboratory expenses related to the execution of preclinical studies on our behalf;
expenses associated with the manufacturing of our product candidates and preclinical material, including fees paid to contract manufacturers; and
consulting fees and expenses related to preparation of initiation of clinical trials

Our indirect costs include:

personnel-related expenses, consisting of employee salaries, bonuses, benefits and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities; and
facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, maintenance of facilities, insurance, and other supplies.

We expense research and development costs as incurred. Our direct research and development expenses are not currently tracked on a program-by-program basis, but we anticipate tracking costs on a program-by-program basis at the time IMM-1-104 enters clinical trials, which we expect to occur in the fourth quarter of 2022, assuming our IND application is accepted. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates.

Due to the inherently unpredictable nature and numerous risks and uncertainties associated with product development and the current stage of development of our product candidates and programs, we cannot reasonably estimate or know the nature, timing and estimated costs necessary to complete the remainder of the development of our product candidates or programs. We are also unable to predict if, when, or to what extent we will obtain approval and generate revenues from the commercialization and sale of any of our product candidates.

The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, such as:

successful completion of preclinical studies and initiation of clinical trials for future product candidates;
successful enrollment and completion of clinical trials for our current product candidates;

120

data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended patient populations;
acceptance by the FDA or other applicable regulatory agencies of IND applications, clinical trial applications and/or other regulatory filings for our product candidates;
expansion and maintenance of a workforce of experienced scientists and others to continue to develop our product candidates;
successful application for and receipt of marketing approvals from applicable regulatory authorities;
obtainment and maintenance of intellectual property protection and regulatory exclusivity for our product candidates;
making of arrangements with contract manufacturing organizations for, or establishment of, commercial manufacturing capabilities;
establishment of sales, marketing and distribution capabilities and successful launch of commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;
acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;
effective competition with other therapies;
obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;
maintenance, enforcement, defense and protection of our rights in our intellectual property portfolio;
avoidance of infringement, misappropriation or other violations with respect to others intellectual property or proprietary rights; and
maintenance of a continued acceptable safety profile of our products following receipt of any marketing approvals.

A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.

The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors.

We may never succeed in achieving regulatory approval for any of our product candidates. Further, a number of factors, including those outside of our control, could adversely impact the timing and duration of our product candidates’ development, which could increase our research and development expense. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development.

We expect that our research and development expenses will substantially increase for the foreseeable future as we continue to implement our business strategy, which includes advancing our product candidates through clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. As of the date of this Annual Report on Form 10-K, we cannot reasonably determine or accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.

121

General and Administrative

Our general and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses not otherwise included in research and development expenses.

We expect our general and administrative expenses will substantially increase for the foreseeable future as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercialization activities, as well as to support our operations generally. As we expand our operations, we also expect to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and rules and regulations of the SEC, Sarbanes-Oxley Act, director and officer insurance costs, and investor and public relations costs.

Other Income (Expense)

Interest income

Interest income consists of interest earned on our cash and cash equivalents balances and our marketable securities. The primary objective of our investment policy is capital preservation.

Other expense

Other expense consists of the amortization of premiums or accretion of discounts related to our marketable securities.

Income tax benefit

Income tax benefit is due to a release of a valuation reserve during 2021 as a result of the business combination.

122

Results of Operations

Comparison of the Years Ended December 31, 2021 and 2020

The following table summarizes our results of operations for the periods indicated:

    

Year Ended December 31, 

    

Change

    

2021

    

2020

    

$

    

%  

(in thousands, except percentages)

Revenue

$

2,080

$

2,311

$

(231)

(10.0)

%

Cost of revenue

 

1,153

 

1,280

 

(127)

(9.9)

%

Gross profit

 

927

 

1,031

 

(104)

(10.1)

%

Operating expenses

 

  

 

  

 

  

  

Research and development

 

26,541

 

15,004

 

11,537

76.9

%

General and administrative

 

8,272

 

3,110

 

5,162

166.0

%

Total operating expenses

 

34,813

 

18,114

 

16,699

92.2

%

Loss from operations

 

(33,886)

 

(17,083)

 

(16,803)

98.4

%

Other income (expense)

 

  

 

  

 

  

  

Interest income

 

170

 

43

 

127

295.3

%

Other expense

(127)

(127)

N/M

%

Loss before income taxes

(33,843)

(17,040)

(16,803)

98.6

Income tax benefit

307

307

N/M

%

Net loss

$

(33,536)

$

(17,040)

 

  

N/M – Not meaningful

Revenue

The following table summarizes the revenue recognized for the periods indicated:

    

Year Ended December 31, 

    

Change

 

    

2021

    

2020

    

$

    

%  

 

 

(in thousands, except percentages)

Revenue

$

2,080

$

2,311

$

(231)

(10.0)

%

Revenue decreased by approximately $0.2 million, or 10% to approximately $2.1 million for the year ended December 31, 2021 compared to approximately $2.3 million for the year ended December 31, 2020. The decrease in revenue was due to approximately $0.3 million related to customer agreements that were completed in 2020, offset by a $0.1 million increase in new customers in the year ended December 31, 2021.

123

Cost of Revenue

The following table summarizes the components of cost of revenue expenses for the periods indicated:

    

Year Ended December 31, 

    

Change

    

2021

    

2020

    

$

    

%  

 

(in thousands, except percentages)

Employee related costs

$

934

$

1,087

$

(153)

(14.1)

%

Stock-based compensation expense

 

103

 

108

 

(5)

(4.6)

%

Outside contract research services

6

(6)

(100.0)

%

Facilities and other allocated expenses

 

108

 

74

 

34

45.9

%

Depreciation

 

8

 

5

 

3

60.0

%

Total cost of revenue

$

1,153

$

1,280

$

(127)

(9.9)

%

Cost of revenue decreased by approximately $0.1 million, or 9.9%, to approximately $1.2 million for the year ended December 31, 2021 compared to approximately $1.3 million for the year ended December 31, 2020. The decrease was primarily due to decreased employee-related costs of approximately $0.2 million offset by an increase in facilities and other allocated expenses.

Research and Development

The following table summarizes the components of our research and development expenses for the periods indicated:

    

Year Ended December 31, 

    

Change

 

    

2021

    

2020

    

$

    

%

 

(in thousands, except percentages)

Employee related costs

$

8,001

$

5,505

$

2,496

45.3

%

Stock-based compensation expense

 

769

 

503

 

266

52.9

%

Outside contract research services

 

17,307

 

8,646

 

8,661

100.2

%

Facilities and other allocated expenses

 

434

 

330

 

104

31.5

%

Depreciation

 

30

 

20

 

10

50.0

%

Total research and development

$

26,541

$

15,004

$

11,537

76.9

%

Research and development expenses increased by approximately $11.5 million, or 76.9%, to approximately $26.5 million for the year ended December 31, 2021 compared to approximately $15.0 million for the year ended December 31, 2020. The increase of approximately $11.5 million was primarily due to approximately $8.7 million of outside contract research services for our preclinical candidates resulting from an increased number of discovery programs and increased spending on later stage preclinical efforts. The increase also includes approximately $2.5 million of additional employee-related costs, primarily due to an increase in headcount, approximately $0.3 million increase for stock-based compensation expense and $0.1 million increase for facilities and other allocated expenses.

124

General and Administrative

The following table summarizes the components of our general and administrative expenses for the periods indicated:

    

Year Ended December 31, 

    

Change

    

2021

    

2020

    

$

    

%  

(in thousands, except percentages)

Employee related costs

$

4,506

$

1,426

$

3,080

216.0

%

Stock-based compensation expense

 

931

 

476

 

455

95.6

%

Professional fees

 

1,803

 

836

 

967

115.7

%

Public relations

 

262

 

289

 

(27)

(9.3)

%

Outside consultants

 

75

 

18

 

57

316.7

%

Facilities and other allocated expenses

 

125

 

38

 

87

228.9

%

Other

 

570

 

27

 

543

2,011.1

%

Total general and administrative

$

8,272

$

3,110

$

5,162

166.0

%

General and administrative expenses increased by approximately $5.2 million, or 166.0%, to approximately $8.3 million for the year ended December 31, 2021 compared to approximately $3.1 million for the year ended December 31, 2020. The increase of approximately $5.2 million was primarily due to increased employee-related costs of approximately $3.1 million as a result of increased headcount, increased professional fees incurred for accounting, auditing, legal, public relations and tax services of approximately $1.0 million, increased facilities expenses of approximately $0.1 million, approximately $0.5 million increase in stock-based compensation expense and $0.5 million increase in other, which is primarily related to franchise tax expense.

Other Income (expense)

Interest income increased by approximately $0.1 million due to the interest earned on our cash and cash equivalents and marketable securities balances due to the higher balances as a result of the IPO proceeds.

Other expense increased by $0.1 million as a result of the amortization of premiums related to our marketable securities.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception, we have financed our operations through service revenues, the issuance of convertible notes payable, convertible preferred stock, common stock, and the exercise of stock options. As of December 31, 2021, we had an accumulated deficit of $59.3 million and $150.2 million in cash and cash equivalents and marketable securities. Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase.  Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, reflected in the change in our outstanding accounts payable and accrued expenses.

Since our inception, we have incurred significant operating losses. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for the next several years, if at all. To date, our operations have been financed primarily by service revenues and aggregate net proceeds of approximately $81.4 million from the issuance of convertible notes payable, convertible preferred stock including gross proceeds of approximately $24.8 million from the issuance of shares in the second tranche of Series B Preferred in April and May 2021, common stock, the exercise of stock options. In August 2021, we completed our IPO pursuant to which we issued and sold 8,625,000 shares of Class A common stock, inclusive of 1,150,000 shares sold by us pursuant to the full exercise of the underwriters’ option to purchase additional shares. We received aggregate net proceeds of approximately

125

$120.3 million from the IPO, after deducting underwriting discounts and commissions, but before deducting offering costs payable by us, which were $2.1 million.

As of December 31, 2021, we have contractual obligations related to various leases of $0.7 million for 2022, $0.9 million for 2023, $0.9 million for 2024, $0.9 million for 2025, $0.8 million for 2026 and $4.5 million for the periods thereafter.

We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Cash Flows

The following table summarizes our sources and uses of cash for the periods indicated:

Year Ended December 31, 

    

2021

    

2020

(in thousands)

Net cash (used in) provided by:

Operating activities

$

(30,851)

$

(14,621)

Investing activities

(75,616)

(53)

Financing activities

144,265

37,982

Net increase in cash and cash equivalents

$

37,798

$

23,308

Net Cash Used in Operating Activities

During the year ended December 31, 2021, operating activities used approximately $30.9 million of cash, primarily resulting from our net loss of approximately $33.5 million, deferred tax benefit of $0.3 million, and cash provided by changes in our operating assets and liabilities of approximately $0.9 million, partially offset by stock-based compensation expense of approximately $1.8 million, net amortization of premium (accretion of discount) on marketable securities of $0.1 million, and $0.2 million right of use amortization and depreciation.

During the year ended December 31, 2020, operating activities used approximately $14.6 million of cash, primarily resulting from our net loss of approximately $17.0 million, partially offset by stock-based compensation expense of approximately $1.1 million and cash provided by changes in our operating assets and liabilities of approximately $1.3 million.

Net Cash Used in Investing Activities

During the year ended December 31, 2021 and 2020, investing activities used approximately $75.6 million, and approximately $0.1 million respectively. For the year 2021, cash used from investing was primarily related to purchases of marketable securities of approximately $75.6 million, approximately $0.1 million for the purchases of property and equipment, and cash acquired in business combination of approximately $0.1 million.  For 2020 cash used in investing was a result of purchases of property and equipment of approximately $0.1 million.

Net Cash Provided by Financing Activities

During the year ended December 31, 2021, net cash provided by financing activities was approximately $144.3 million, consisting primarily of approximately $24.8 million in net proceeds received from the issuance of Series B preferred stock, approximately $118.2 million from the net proceeds from our initial public offering, approximately $0.9 million in net proceeds from the exercise of warrants and approximately $0.4 million from the exercise of stock options.

During the year ended December 31, 2020, net cash provided by financing activities was approximately $38.0 million, consisting primarily of approximately $37.0 million in net proceeds received from the issuance of Series B preferred stock and approximately $1.0 million in net proceeds from the issuance of Series A preferred stock.

126

Future Funding Requirements

We expect that our expenses will increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development. The timing and amount of our operating and capital expenditures will depend largely on:

the impacts of the pandemic related to COVID-19 and its variants and potential future pandemics;
the costs and results of our potential future clinical trials for our other product candidates;
the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our other product candidates;
the costs, timing and outcome of regulatory review of our product candidates;
our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical ingredient, or API, and manufacture of our product candidates and the terms of such arrangements;
the payment or receipt of milestones and receipt of other collaboration-based revenues, if any;
the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval;
the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property related claims;
the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights;
our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;
our ability to access the private and public capital markets or to obtain financing at commercially reasonable rate;
the ability to receive additional non-dilutive funding, including grants from organizations and foundations; and
the costs of operating as a public company.

We believe that our existing cash, cash equivalents and marketable securities, will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.

Critical Accounting Policies and Use of Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.

Research and Development Costs

We incur substantial expenses associated with manufacturing and clinical trials. Accounting for clinical trials relating to activities performed by contract research organizations, or CROs, and other external vendors requires management to

127

exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include the conduct of sponsored research, preclinical studies and contract manufacturing activities. The diverse nature of services being provided under CROs and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. Because payments of research and development activities do not always line up with the provision of such services, the balance sheet may reflect either an accrued or prepaid position. In estimating the duration of a clinical study, we evaluate the start-up, treatment and wrap up periods, compensation arrangements and services rendered attributable to each clinical trial and fluctuations are regularly tested against payment plans and trial completion assumptions.

We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.

Our expenses related to clinical trials will be based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that may be used to conduct and manage clinical trials on our behalf. We will accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we will modify our estimates of accrued expenses accordingly on a prospective basis.

Stock-Based Compensation

We measure stock-based awards granted to employees, non-employees and directors based on their fair value on the date of the grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of our common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the award for employees and directors and the period during which services are performed for non-employees. We use the straight-line method to record the expense of awards with service-based vesting conditions.

The Black-Scholes option-pricing model uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield.

Off-balance Sheet Arrangements

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

Recently Issued Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K.

Emerging Growth Company Status

As an emerging growth company, or EGC, under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two years of audited consolidated financial statements, an exemption from the requirement to provide an auditor’s report on internal

128

controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board, and less extensive disclosure about our executive compensation arrangements.

In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an EGC to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our  consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

We may remain classified as an EGC until the end of the fiscal year following the fifth anniversary of our IPO, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 of any year before that time, or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0 billion of non-convertible debt over a three-year period.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, we are not required to provide this information.

129

Report of Independent Registered Public Accounting Firm

 

 

To the Stockholders and the Board of Directors of Immuneering Corporation

 

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Immuneering Corporation and its subsidiaries (the Company) as of December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit) and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

 

/s/ RSM US LLP

 

We have served as the Company's auditor since 2020.

 

Boston, Massachusetts

March 10, 2022

131

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

IMMUNEERING CORPORATION

CONSOLIDATED BALANCE SHEETS

    

December 31, 2021

    

December 31, 2020

Assets

 

  

 

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

74,888,145

$

37,090,151

Marketable securities, current

74,311,203

Accounts receivable

 

246,040

 

500,110

Prepaids and other current assets

 

2,888,608

 

140,958

Total current assets

 

152,333,996

 

37,731,219

Marketable securities, non-current

996,560

Property and equipment, net

 

807,223

 

64,363

Goodwill

6,701,726

Intangible asset

439,000

Right-of-use assets, net

 

5,324,198

 

613,103

Other assets

 

102,129

 

14,333

Total assets

$

166,704,832

$

38,423,018

Liabilities, convertible preferred stock and stockholders' equity (deficit)

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

1,394,340

$

1,480,537

Accrued expenses

 

3,965,447

 

698,992

Lease liabilities, current

 

274,039

 

76,322

Total current liabilities

 

5,633,826

 

2,255,851

Long-term liabilities:

 

  

 

  

Lease liabilities, non-current

 

5,090,897

 

544,767

Total liabilities

 

10,724,723

 

2,800,618

Commitments and contingencies (Note 13)

 

  

 

  

Convertible preferred stock:

 

  

 

  

Series B preferred stock, $0.001 par value, 0 and 6,032,183 shares authorized at December 31, 2021 and December 31, 2020, 0 and 3,619,292 shares issued and outstanding at December 31, 2021 and December 31, 2020

 

 

36,983,910

Series A preferred stock, $0.001 par value, 0 and 2,495,933 shares authorized at December 31, 2021 and December 31, 2020, 0 and 2,495,933 shares issued and outstanding at December 31, 2021 and December 31, 2020

 

 

21,119,940

Total convertible preferred stock

 

 

58,103,850

Stockholders’ deficit:

 

  

 

  

Preferred stock, $0.001 par value; 10,000,000 and 0 shares authorized at December 31, 2021 and December 31, 2020, respectively; No shares issued or outstanding

 

Class A common stock, $0.001 par value, 200,000,000 and 22,026,200 shares authorized at December 31, 2021 and December 31, 2020 respectively; 26,320,199 and 4,950,129 shares issued and outstanding at December 31, 2021 and December 31, 2020

 

26,320

 

4,950

Class B common stock, $0.001 par value, 20,000,000 and 6,032,183 shares authorized at December 31, 2021 and December 31, 2020 respectively; 0 shares issued and outstanding at December 31, 2021 and December 31, 2020

 

 

Additional paid-in capital

 

215,276,186

 

3,251,240

Accumulated other comprehensive loss

(49,009)

Accumulated deficit

 

(59,273,388)

 

(25,737,640)

Total stockholders' equity (deficit)

 

155,980,109

 

(22,481,450)

Total liabilities, convertible preferred stock and stockholders' equity (deficit)

$

166,704,832

$

38,423,018

The accompanying notes are an integral part of these consolidated financial statements.

132

IMMUNEERING CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020

Year Ended December 31, 

    

2021

    

2020

    

Revenue

$

2,079,961

$

2,311,535

Cost of revenue

 

1,153,073

 

1,280,325

Gross profit

 

926,888

 

1,031,210

Operating expenses

 

  

 

  

Research and development

 

26,540,959

 

15,003,786

General and administrative

 

8,271,998

 

3,109,978

Total operating expenses

 

34,812,957

 

18,113,764

Loss from operations

 

(33,886,069)

 

(17,082,554)

Other income (expense)

 

  

 

  

Interest income

 

169,899

 

42,656

Other expense

(127,063)

Loss before income taxes

(33,843,233)

(17,039,898)

Income tax benefit

307,485

Net loss

$

(33,535,748)

$

(17,039,898)

Net loss per share attributable to common stockholders, basic and diluted

(2.46)

(3.44)

Weighted-average common shares outstanding, basic and diluted

13,612,677

4,950,129

Other comprehensive loss:

Unrealized losses from marketable securities

(49,009)

Comprehensive Loss

$

(33,584,757)

$

(17,039,898)

The accompanying notes are an integral part of these consolidated financial statements.

133

IMMUNEERING CORPORATION

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

Convertible Preferred Stock

Stockholders' Equity (Deficit)

Total

Additional

Accumulated other

Total

Series B

Series A

Convertible

Class A Common Stock

Class B Common Stock

Paid-In

comprehensive

Accumulated

Stockholders'

  

Shares

  

Amount

  

Shares

  

Amount

  

Preferred Stock

  

  

Shares

  

Par Value

  

Shares

  

Par Value

  

Capital

  

loss

Deficit

  

Equity (Deficit)

Balance at December 31, 2019

 

 

$

 

1,966,043

$

16,611,832

$

16,611,832

 

4,950,129

$

4,950

 

 

$

$

2,164,471

$

$

(8,697,742)

$

(6,528,321)

Issuance of Series A convertible preferred stock, net of issuance costs

 

 

 

529,890

 

4,508,108

 

4,508,108

 

 

 

 

 

 

 

Issuance of Series B convertible preferred stock, net of issuance costs

3,619,292

36,983,910

36,983,910

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

1,086,769

 

1,086,769

Net loss

 

 

 

 

 

 

 

 

 

 

(17,039,898)

(17,039,898)

Balance at December 31, 2020

 

3,619,292

 

$

36,983,910

2,495,933

$

21,119,940

$

58,103,850

4,950,129

$

4,950

 

 

$

$

3,251,240

$

$

(25,737,640)

$

(22,481,450)

Issuance of Series B convertible preferred stock, net of issuance costs

 

2,412,853

 

24,788,851

 

 

 

24,788,851

 

 

 

 

 

 

 

 

Issuance of common stock upon exercise of stock options

 

 

 

 

 

 

117,846

 

118

 

 

 

354,316

 

 

 

354,434

Issuance of common stock upon exercise of warrants

 

 

 

 

 

 

308,308

 

308

 

 

 

926,817

 

 

 

927,125

Conversion of Preferred Stock into common stock

 

(6,032,145)

 

(61,772,761)

 

(2,495,933)

 

(21,119,940)

 

(82,892,701)

 

11,939,281

 

11,939

 

 

 

82,880,762

 

 

 

82,892,701

Issuance of common stock upon initial public offering, net of issuance costs ($2,124,317)

 

 

 

 

 

 

8,625,000

 

8,625

 

 

 

118,185,808

 

 

 

118,194,433

Issuance of common stock for acquisition

 

 

 

 

379,635

380

7,874,620

7,875,000

Stock-based compensation expense

1,802,623

1,802,623

Net loss

(33,535,748)

(33,535,748)

Other comprehensive loss

(49,009)

(49,009)

Balance at December 31, 2021

 

 

$

$

$

26,320,199

$

26,320

 

 

$

$

215,276,186

$

(49,009)

$

(59,273,388)

$

155,980,109

The accompanying notes are an integral part of these consolidated financial statements.

134

IMMUNEERING CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 2021 and 2020

    

2021

    

2020

Cash flows from operating activities:

 

  

 

  

Net loss

$

(33,535,748)

$

(17,039,898)

Adjustment to reconcile to net loss to net cash used in operating activities:

 

 

  

Depreciation expense

 

45,467

 

24,328

Right-of-use asset amortization

 

113,605

 

54,977

Stock based compensation expense

 

1,802,623

 

1,086,769

Net amortization of premium (accretion of discount) on marketable securities

130,240

Deferred tax benefit

(307,485)

Change in assets and liabilities:

 

 

  

(Increase) decrease in:

 

 

  

Accounts receivable

 

279,713

 

(290,170)

Prepaid expenses and other current assets

 

(2,408,986)

 

(69,740)

Other assets

(14,333)

Increase (decrease) in:

 

 

  

Accounts payable

 

(130,398)

 

1,185,589

Accrued expenses

 

3,240,940

 

488,644

Lease liability

 

(80,853)

 

(46,991)

Net cash used in operating activities

 

(30,850,882)

 

(14,620,825)

Cash flows from investing activities:

 

  

 

  

Purchases of property and equipment

 

(60,786)

 

(53,415)

Purchases of marketable securities

(75,625,529)

Cash acquired in business combination

70,348

Net cash used in investing activities

 

(75,615,967)

 

(53,415)

Cash flows from financing activities:

 

  

 

  

Proceeds from the issuance of Series A preferred stock, net of issuance costs

 

 

998,306

Proceeds from the issuance of Series B preferred stock, net of issuance costs

 

24,788,851

 

36,983,910

Proceeds from initial public offering of common stock, net of commissions and underwriting

120,318,750

Payment of initial public offering costs

(2,124,317)

Proceeds from exercise of stock options

 

354,434

 

Proceeds from exercise of warrants

 

927,125

 

Net cash provided by financing activities

 

144,264,843

 

37,982,216

Net increase in cash and cash equivalents

 

37,797,994

 

23,307,976

Cash and cash equivalents at beginning of period

 

37,090,151

 

13,782,175

Cash and cash equivalents at end of period

$

74,888,145

$

37,090,151

Supplemental disclosures of noncash investing and financing information:

 

  

 

  

Conversion of convertible Series A and B preferred stock into common stock

$

82,892,701

$

Business combination non cash

7,804,652

Class A common stock issued for business combination

7,875,000

Reclassification of liability for Series A preferred stock

3,509,802

The accompanying notes are an integral part of these consolidated financial statements.

135

IMMUNEERING CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 – Organization and Nature of Business

Immuneering Corporation, a Delaware corporation, (“Immuneering” or the “Company”) was incorporated in 2008. The Company aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using the Company’s translational bioinformatics platform. The Company has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, the Company’s disease-agnostic discovery platform enables the Company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry.

On October 30, 2019, Immuneering formed a wholly owned subsidiary, Immuneering Securities Corporation (“ISC”), a Massachusetts securities corporation, for the sole purpose of buying, selling and holding securities on the Company’s behalf.

On December 22, 2021, the Company acquired all outstanding shares of capital stock of BioArkive, Inc. (“BioArkive”), a California corporation, which as a result became a wholly owned subsidiary.  

Immuneering, ISC and BioArkive are collectively referred to as “the Company” throughout these  consolidated financial statements.

The Company is subject to a number of inherent risks associated with any biotechnology company that has substantial expenditures for research and development. These risks include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. There can be no assurance that the Company’s research and development program will be successful. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, and consultants.

On August 3, 2021, the Company completed its initial public offering (“IPO”) pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional paid-in capital (see Note 8).

To date, the Company has funded its operations through service revenues, and with proceeds from the sale of its capital stock and convertible notes and, most recently, with proceeds from the IPO. The Company has incurred recurring losses over the past several years and as of December 31, 2021, the Company had an accumulated deficit of $59,273,388. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern and estimates that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the consolidated financial statements. The full extent to which coronavirus (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial

136

condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the pandemic related to COVID-19 and its variants and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgements or revise the carrying values of its assets or liabilities.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB sets generally accepted accounting principles (“GAAP”) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (“ASC”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Stock Split

On July 23, 2021, the Company approved a one-for-1.4 stock split which was consummated in connection with the Company’s IPO. All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.

Use of Estimates 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these  consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.

Segments

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.


137

Business Combination

Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition.

If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. Refer to Note 6, Business Combination for more information.

Cash and Cash Equivalents

Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (“FDIC”) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.

Marketable Securities

Our marketable securities are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the  consolidated balance sheets and statements of convertible preferred stock and stockholders’ equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021.  Realized gains and losses are included in other expense on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December 31, 2021.

Fair Value Measurements

We record cash equivalents and marketable securities at fair value. ASC 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2021. Fair value

138

information for these assets, including their classification in the fair value hierarchy is included in Note 4  Fair Value Measurements.

There have been no changes to the valuation methods during the year ended December 31, 2021. We evaluate transfers between levels at the end of each reporting period.

The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.

Accounts Receivable

Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management’s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December 31, 2021 and 2020 there was no allowance for doubtful accounts.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.

The following customers comprised 10% or more of the Company’s total accounts receivable or revenues as of or for the period ended December 31, 2021 (customers with an asterisk are less than 10%):

Year Ended December 31, 2021

As of December 31, 2021

 

    

Revenue

    

% of Total

    

Accounts Receivable

    

% of Total

 

Customer #1

$

745,030

 

35.8

%  

$

235,500

 

95.7%

%

Customer #2

380,000

 

18.3

*

*

Customer #5

353,050

 

17.0

*

 

*

Year Ended December 31, 2020

As of December 31, 2020

 

    

Revenue

    

% of Total

    

Accounts Receivable

    

% of Total

 

Customer #1

$

676,710

 

29.3

%  

$

214,345

 

42.9

%

Customer #2

570,000

 

24.7

71,250

 

14.2

Customer #3

306,900

 

13.3

*

 

*

Customer #4

250,880

 

10.9

63,000

 

12.6

Customer #5

 

*

 

*

91,975

 

18.4

Property and Equipment

Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service.

139

    

Estimated

Asset Class

Useful Lives

Computer equipment

 

3 years

Furniture and fixtures

 

5 years

Lab equipment

7 years

Leasehold improvements

1-10 years

Impairment of Long-lived Assets

Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.

Leases

In February 2016 the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASC 842”), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company’s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.

The Company adopted the leasing standard using the modified retrospective transition approach as of January 1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12 months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.

The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.

The Company has elected not to separate lease and non-lease components as a single lease component. The Company’s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.

Revenue Recognition

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in

140

an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:

• Identify the contract with a customer

• Identify the performance obligations in the contract

• Determine the transaction price

• Allocate the transaction price to the performance obligations in the contract

• Recognize revenue when or as performance obligations are satisfied

The Company’s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company’s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

The Company’s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.

Income Taxes

The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. As of December 31, 2021 and 2020, the Company had uncertain tax positions of $380,902 and $174,950.   The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.

Research and Development

Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.

141

Research and Manufacturing Contract Costs and Accruals

The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.

Patent Costs

 

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

Comprehensive Loss

 

Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders.

Deferred Offering Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder’s equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were no deferred offering costs as of December 31,2021 or December 31, 2020.

Net Income (Loss) per Share

 

Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.

142

The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December 31, 2021 and 2020.

Stock-based Compensation

The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation — Stock Compensation (“ASC 718”), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.

The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (“Black-Scholes”). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgement.

In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January 1, 2020.

As there had been no public market for the Company’s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company’s most recently available third-party valuations of common stock and its board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.

143

The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.

Goodwill

Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.

On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.

The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired.

The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were no impairments in 2021.

Intangible Assets

Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.

The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (“JOBS Act”). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

In 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) will become effective for the Company on January 1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.

144

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December 15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.

In January 2017, the FASB issued ASU No. ASU 2017-04,  Intangibles—Goodwill and Other (Topic 350), which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on today’s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements.  

Note 3 – Marketable Securities

Marketable securities as of December 31, 2021 consisted of the following:

December 31, 2021

    

Amortized Cost

    

Unrealized Gains

    

Unrealized Losses

    

Fair Value

Assets:

Current:

U.S. Treasuries

$

42,147,385

$

-

$

(28,575)

$

42,118,810

Government securities

19,218,057

-

(13,689)

19,204,368

Commercial Paper

12,992,165

57

(4,197)

12,988,025

Total Current

74,357,607

57

(46,461)

74,311,203

Non-current:

U.S. Treasuries

999,186

-

(2,626)

996,560

Government securities

-

-

-

-

Total Non-current

999,186

-

(2,626)

996,560

Total marketable securities

$

75,356,793

$

57

$

(49,087)

$

75,307,763

There were no marketable securities as of December 31, 2020.

There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021. Realized gains and losses are included in other expense on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December 31, 2021.

145

Note 4 – Fair Value Measurements

The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of December 31, 2021:

Level 1

Level 2

Level 3

Total

Assets:

Cash equivalents

Money market

$

33,961,344

$

-

$

-

$

33,961,344

Commercial paper

-

2,000,000

-

2,000,000

Total cash equivalents

33,961,344

2,000,000

-

35,961,344

Marketable securities:

U.S. Treasuries

$

43,115,370

$

-

$

-

$

43,115,370

Government securities

-

19,204,368

-

19,204,368

Commercial paper

-

12,988,025

-

12,988,025

Total marketable securities

43,115,370

32,192,393

-

75,307,763

Total cash equivalents and marketable securities

$

77,076,714

$

34,192,393

$

-

$

111,269,107

There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the year ended December 31, 2021. There were no marketable securities as of December 31, 2020.

Note 5 – Property and Equipment, net

Property and equipment, net consisted of the following:

    

December 31, 

    

December 31, 

2021

2020

Computer equipment

$

281,666

$

174,317

Furniture and fixtures

 

84,477

 

18,798

Lab equipment

463,182

-

Leasehold improvements

 

152,117

 

-

Total

 

981,442

 

193,115

Accumulated depreciation

 

(174,219)

 

(128,752)

Property and equipment, net

$

807,223

$

64,363

Depreciation expense totaled $45,467 and $24,328 for the year ended December 31, 2021 and 2020, respectively.

Note 6 – Business Combination

BioArkive Acquisition

On December 22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (“BioArkive”), for a market value of $8.75 million.

BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company's internal preclinical research activities for its oncology pipeline.

In connection with the acquisition, the Company has assumed the obligations under BioArkive’s three lease agreements.

146

The purchase price was paid by Immuneering through the issuance of an aggregate of 379,635 shares of Immuneering’s Class A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the closing date. The sellers of BioArkive are restricted from selling these shares for a 6 month period from the date of the acquisition. As such, we estimated that there was an approximate 10% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $7,875,000.

Prior to the acquistion, Brett Hall, Chief Scientific Officer of Immuneering and the Founder and Chairman of the board of directors of BioArkive, held the majority of the outstanding shares of BioArkive capital stock.  BioArkive provided contract services to the Company. Research and development expenses in the consolidated statement of operations include the cost of services provided by BioArkive to the Company which amounted to $4,548,780 in 2021 through date of the acquisition and $2,744,051 in 2020. As of December 31, 2020, $279,153 was owed to BioArkive and is included in accounts payable or accrued contract research expenses in the consolidated balance sheets.

Assets Acquired and Liabilities Assumed at Fair Value

The BioArkive Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. As of December 31, 2021, certain amounts relating to working capital have not been finalized. The finalization of these matters could result in changes to goodwill.

Intangible Assets

The estimated fair value of the intangible assets was determined using the relief from royalty approach.

Goodwill

Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected cost savings of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of BioArkive, is the planned investment in the internal preclinical research activities for our oncology pipeline. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.

Pro forma results are not presented for this acquisition as they are not material to the consolidated results of the Company’s operations.

    

Preliminary Valuation

    

Weighted Average Life

Cash

$

70,348

Other currents assets

225,790

Other long term assets

87,796

Property, plant and equipment, net

727,539

Right of use assets

4,824,700

Intangible asset

Technology

439,000

15 years

Goodwill

6,701,726

Total assets acquired

13,076,899

Accounts payable, accrued expenses and other liabilities

69,714

Deferred tax liabilities

307,485

Lease liabilities

4,824,700

Net assets acquired

$

7,875,000

147

Note 7 – Accrued Expenses

Accrued expenses consisted of the following:

    

December 31, 

    

December 31, 

2021

2020

Accrued professional services

$

250,977

$

269,302

Accrued employee expenses

 

2,917,282

 

163,668

Accrued contract research expenses

 

585,416

 

266,022

Accrued other

211,772

Total

$

3,965,447

$

698,992

Note 8 – Convertible Preferred Stock

Series A Preferred Stock

In September 2019, the Company authorized the sale and issuance of up to 1,987,979 shares of Series A Preferred Stock, $0.001 par value per share, at an original issuance price of $8.5514 per share. In January 2020, the number of shares authorized for the Series A Preferred Stock was increased to 2,495,933 shares. The Series A Preferred Stock financing was structured to be issued in rolling closes during 2019 and 2020.

On September 20, 2019, the Company issued an additional 1,122,458 shares of Series A Preferred Stock for gross cash proceeds of $9,598,847 and issued 785,706 shares of Series A Preferred Stock in conjunction with the conversion of the outstanding amount of the Convertible Notes. In 2019, the Company incurred issuance costs of $200,587 in connection with this offering.

The Company received funds for issuance of an additional 468,315 shares of Series A Preferred Stock for gross cash proceeds of $4,004,975 through December 31, 2019. Of these shares, 410,436 shares of Series A Preferred Stock for gross cash proceeds of $3,509,802 exceeded the authorized amount allowed by the articles of incorporation, resulting in a liability of $3,509,802 and a total of 1,966,043 shares of Series A Preferred Stock outstanding at December 31, 2019. In January 2020, the shares that were previously classified as a liability as of December 31, 2019 were reclassified to temporary equity upon the approved increase to authorized shares of Series A Preferred Stock.

In January 2020, the Company issued 119,454 additional shares of Series A Preferred Stock for gross cash proceeds of $1,021,413. The Company incurred issuance costs of $23,610 in connection with the financing in January 2020.

Series B Preferred Stock

In December 2020, the Company authorized the sale and issuance of up to 6,032,183 shares of Series B Preferred Stock, $0.001 par value per share, at an original issuance price of $10.2782 per share. The Series B Preferred Stock financing was structured to close in two tranches. The first tranche closed in December 2020 and the Company issued 3,619,292 shares of Series B Preferred Stock for gross cash proceeds of $37,199,929. The Company incurred issuance costs of $216,019 in connection with the financing in December 2020.

The Company determined the right of the investors to purchase 2,412,853 shares of Series B Preferred Stock in the second tranche does not meet the definition of a freestanding financial instrument as it is not separable from the Series B Preferred Stock issued in the first tranche. The issuance of the second tranche is subject to the Company meeting certain development milestones or at the election of the holders of at least a majority of the then outstanding shares of Series B Preferred Stock which must include one specific shareholder (the “Requisite Holders”). Each holder of Series B Preferred Stock may elect to purchase their requisite shares of the second tranche at any time. As of March 31, 2021, the Company had not met these development milestones nor did the Requisite Holders elect to purchase the second tranche prior to meeting these milestones and therefore no shares of the second tranche were issued.

148

In April and May 2021, all 2,412,853 shares of the second tranche of Series B Preferred Stock were issued based on the voluntary election of substantially all of the holders of Series B Preferred Stock. The Company received gross proceeds of $24,799,786. The Company incurred issuance costs of $10,935 in connection with the second tranche of Series B Preferred Stock.

The rights and preferences of the Series A Preferred Stock and Series B Preferred Stock (“Preferred Stock”) were as described below:

Conversion

Each share of Preferred Stock may be converted at any time, at the option of the holder, into shares of Class A common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The conversion price for the Series A Preferred Stock and Series B Preferred Stock (as may be adjusted for certain customary dilutive events) is $6.1081 and $7.3416, respectively. The Preferred Stock automatically convert into shares of Class A common stock at the then effective conversion rate upon the closing of a public offering of the Company’s securities with gross proceeds to the Company of at least $75,000,000 and a share price of at least $7.3416 or at the election of the holders of the Requisite Holders.

Holders of Series B Preferred Stock that would beneficially own at least 9.9% of any then outstanding class of equity securities may elect to receive a portion of their converted Series B Preferred Stock as Class B common stock upon conversion.

Upon the closing of the IPO on August 3, 2021, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock.

Dividends

Preferred Stockholders are entitled to receive per annum dividends of 7% of the original issue price share, payable only when, as and if declared by the Board of Directors. The right to receive these dividends is not cumulative, and therefore, if not declared in any year, the right to receive such dividends shall terminate and not carry forward into the next year. As of December 31, 2021 and December 31, 2020, no dividends had been declared.

Voting Rights

Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters are subject to the powers, preferences, and rights of the Preferred Stock. Preferred Stockholders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. As long as 2,132,029 shares of Preferred Stock are outstanding, certain actions such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events, must be approved by the holders of at least a majority of the then-outstanding shares of Preferred Stock.

Liquidation Preference

Upon liquidation, dissolution, or winding up of business, holders of Preferred Stock are entitled to receive a liquidation preference in priority to holders of common stock at the original respective Preferred Stock issue price for such series. If assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, assets available for distribution will be allocated among holders of Preferred Stock on a pari passu basis at an amount per share equal to the greater of the respective original Preferred Stock issue price for such series plus any declared but unpaid dividends or such amount had all shares been converted to common stock.

When holders of Preferred Stock are satisfied in full, any excess assets available for distribution will be allocated ratably among common stock holders based on their pro rata shareholdings. Upon a deemed liquidation event, as defined in the articles of incorporation, holders have the option to redeem their shares at the liquidation payment amounts summarized above.

149

Redemption

Other than described above, the shares of Preferred Stock are not redeemable.

Note 9 - Common Stock

The Company had 200,000,000 authorized shares of Class A common stock, $0.001 par value per share as of December 31, 2021 and 22,026,200 authorized shares of Class A common stock, $0.001 par value per share as of December 31, 2020, respectively, of which 26,320,199 and 4,950,129 were issued and outstanding, respectively. The holders of Class A common stock are entitled one vote for each share of common stock. Dividends may be paid when, and if declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Preferred Stockholders and on a proportionate basis with holders of Class B common stock.

As of December 31, 2021 and December 31, 2020, the following number of shares of Class A common stock have been reserved:

    

December 31, 

    

December 31, 

2021

2020

Conversion of Series A Preferred

 

 

3,494,306

Conversion of Series B Preferred

 

 

5,066,995

Exercise of common stock warrants

 

 

308,308

Exercise of common stock options

 

2,859,544

 

1,801,263

 

2,859,544

 

10,670,872

The Company had 20,000,000 authorized shares of Class B common stock, $0.001 par value per share as of December 31, 2021 and 6,032,183 authorized shares of Class B common stock, $0.001 par value per share as of December 31, 2020, of which no shares have been issued nor are outstanding. The holders of Class B common stock have no voting rights. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the preferred stockholders and on a proportionate basis with holders of Class A common stock.

Common Stock Warrants

During 2019, the Company issued warrants to purchase an aggregate of 308,308 shares of Class A common stock at an exercise price of $3.01 per share to several advisors, including 200,984 shares to entities related to members of the Board of Directors of the Company, in lieu of cash payments. These warrants vested immediately upon issuance, became exercisable on January 9, 2021 and have a 10-year term set to expire on January 9, 2030. The Company evaluated the terms of these warrants and determined that equity classification was appropriate. As of December 31, 2020, no warrants had been exercised. During June 2021, all warrant holders exercised their warrants to purchase an aggregate of 308,308 shares of common stock. As of December 31, 2021, there were no warrants outstanding.

Initial Public Offering

On August 3, 2021, the Company completed its initial public offering pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional paid-in capital.  

On August 3, 2021 in connection with the closing of the IPO, the Company filed a restated certificate of incorporation, which amended and restated the Company’s certificate of incorporation to, among other things: (i) increase the number of

150

authorized shares of common stock to 200,000,000 shares of Class A common stock, 20,000,000 shares of Class B common stock, par value $0.001 per share, and (ii) authorize 10,000,000 shares of Preferred Stock; and (iii) authorize the Board of Directors to establish the rights, preferences and restrictions on any unissued series of Preferred Stock.

Note 10 - Net Loss Per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders was calculated at December 31, 2021 and 2020 as follows:

    

Year Ended December 31, 

    

2021

    

2020

Numerator:

 

  

 

  

 

Net loss

$

(33,535,748)

$

(17,039,898)

Denominator - basic and diluted:

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

13,612,677

 

4,950,129

Net loss per share - basic and diluted

$

(2.46)

$

(3.44)

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at December 31, 2021 and 2020:

    

2021

    

2020

Series A Preferred

 

 

3,494,306

Series B Preferred

 

 

5,066,995

Warrants to purchase common stock

 

 

308,308

Options to purchase common stock

 

2,859,544

 

1,801,263

Total shares of common stock equivalents

 

2,859,544

 

10,670,872

Note 11 – Stock-Based Compensation

During 2015, the Company established the Long Term Incentive Plan (“Incentive Plan”), under which incentive stock options, nonqualified stock options, restricted stock or other awards may be awarded to employees, directors or consultants of the Company. The options typically vest over a four-year period. As of December 31, 2021, the maximum number of shares available for issuance under the Incentive Plan was 2,825,173 shares. Upon the effectiveness of the Company’s 2021 Incentive Award Plan, the Company ceased granting awards under the Incentive Plan. However, the Incentive Plan continues to goven awards outstanding thereunder.

On July 23, 2021, the Company’s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Incentive Award Plan (the “2021 Plan”), which became effective on July 29, 2021. The 2021 Plan provides for the grant of incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares reserved for issuance under the 2021 Plan was initially equal to 2,590,000 plus an annual increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 4% of the aggregate number of shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the Board of Directors. No more than 15,350,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. If an award under the 2021 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised/settled or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 Plan. In addition, shares subject to stock options issued under the Incentive Plan may become available for issuance under the 2021 Plan to the extent such stock options are canceled, forfeited, exchanged, settled in cash or

151

otherwise terminated. As of December 31, 2021, there were 2,298,432 shares available for future issuance under the 2021 Plan.

On July 23, 2021, the Company’s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective on July 29, 2021. A total of 250,000 shares of Class A common stock were initially reserved for issuance under this plan. The number of shares of Class A common stock that may be issued under the 2021 ESPP will automatically increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 1% of the shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the board of directors, provided that not more than 3,340,000 shares of Class A common stock may be issued under the 2021 ESPP. As of December 31, 2021, no shares had been issued under the 2021 ESPP.

During the year ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of $1,802,623 and $1,086,769, respectively. As of December 31, 2021, compensation expense remaining to be recognized for outstanding stock options was $8,403,600 and to be recognized over a weighted-average period of 2.93 years.

The fair value of options granted is calculated on the grant date using the Black-Scholes option valuation model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer public companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For the year ended December 31, 2021, the Company granted 1,452,462 shares of stock options at a weighted-average grant date fair value of $6.29. For the year ended December 31, 2020, the Company granted 343,169 shares at a weighted-average grant date fair value of $3.06.

The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants during the year ended December 31, 2021 and 2020:

Year Ended December 31, 

    

2021

    

2020

Weighted-average risk-free interest rate

0.89% - 1.71%

0.36% - 1.45%

Expected term (in years)

5.83 - 10 years

5.92 - 10 years

Expected dividend yield

0%

0%

Expected volatility

66.76% - 80.99%

67.30% - 80.85%

The following table summarizes the stock option activity during the year ended December 31, 2021 under the Plan:

    

    

Weighted

    

Weighted-

Average

Average

Remaining

Number of

Exercise Price

Contractual

Aggregate

Options

per Share

    

Term (in Years)

Intrinsic Value

 

  

 

  

 

  

 

  

Outstanding at of December 31, 2020

 

1,801,263

$

3.01

 

 

  

Granted

 

1,452,462

10.07

 

  

Exercised

 

(117,847)

3.01

 

  

Cancelled

 

(276,334)

3.58

 

  

Outstanding at December 31, 2021

 

2,859,544

$

6.55

8.30

$

27,615,466

 

Vested and exercisable at December 31, 2021

 

1,102,543

$

3.01

 

7.14

$

14,507,723

Vested and expected to vest at December 31, 2021

2,859,544

$

6.55

 

8.30

$

27,615,466

152

For the year  ended December 31, 2021 and 2020, the Company recognized share-based compensation expense recognized on the accompanying  consolidated statements of operations as follows:

Year Ended December 31, 

    

2021

    

2020

    

Cost of revenue

$

103,329

$

108,027

Research and development

 

768,679

 

503,111

General and administrative

 

930,615

 

475,631

Total

$

1,802,623

$

1,086,769

Note 12 – Income Taxes

A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate are as follows:

    

2021

    

2020

 

Statutory federal income tax rate

 

21.0

%  

21.0

%

State tax, net of federal benefit

 

5.5

%  

6.3

%

Permanent differences

 

(0.6)

%  

(1.5)

%

Federal research and development credits

 

5.6

%  

4.5

%

State research and development credits

 

0.4

%  

0.6

%

Uncertain tax positions

(0.6)

%  

(1.0)

%

Other differences

 

0.7

%  

(2.6)

%

Change in valuation allowance

 

(31.1)

%  

(27.3)

%

Effective income tax rate

 

0.9

%  

0.0

%

As of December 31, 2021 and 2020, the components and tax effects of each type of item that gave rise to the net deferred tax assets were as follows:

    

2021

    

2020

Deferred tax assets:

 

  

 

  

Stock-based compensation expense

$

373,602

$

73,984

Unrealized losses

12,990

R&D credit carryforward

 

3,346,097

 

1,574,596

NOL carryforward

 

14,699,524

 

5,525,123

Gross deferred tax assets

 

18,432,213

 

7,173,703

Valuation allowance

(17,677,899)

 

(7,127,448)

Net deferred tax assets

 

754,314

 

46,255

Net deferred tax liabilities:

 

  

 

  

Prepaid expenses deducted for tax

 

(425,755)

 

(28,671)

Tax depreciation in excess of book

 

(328,559)

 

(17,584)

Total deferred tax liabilities

 

(754,314)

 

(46,255)

Net deferred taxes

$

$

Federal net operating losses (“NOL”) generated in tax years ended after December 31, 2017 are limited to 80% of taxable income, only carried forward and carried forward indefinitely under the Internal Revenue Code (“IRC”). The Company recorded a deferred tax liability of $304,485 on the acquisition of BioArkive. It had pre-existing deferred tax assets for which there was a fuill valuation allowance. As a result of the taxable temporary differences recognized in the business combination, the Company released $304,485 of its valuation allowance and recognized the income tax benefit in the income statement at the acquisition date in accordance with ASC 740 There was no income tax expense or benefit in 2020. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December 31, 2021, the Company has federal and state NOLs of $56,544,731 and $51,310,112,

153

respectively all generated after the tax year ended December 31, 2017. At December 31, 2021, the Company has federal and state research and development credit carryforwards, $3,034,827 and $394,013, respectively, that start to expire beginning in 2025.

As the Company has not yet achieved profitable operations, management believes the tax benefits as of December 31, 2021 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2021 by $10,550,451 due to the increase in the deferred tax assets by the same amount, primarily due to NOL and research and development credit carryforwards.

Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, some amounts are being presented as an uncertain tax position.

As of December 31, 2021 and 2020, the Company had uncertain tax positions of $380,902 and $174,950 which have been classified as reductions of its tax carrforwards. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December 31, 2021 and 2020.

As of December 31, 2021 and 2020, unrecognized tax benefits were as follows:

2021

2020

Beginning balance

$

174,950

$

96,952

Increase due to current year tax position

205,952

77,998

Ending balance

$

380,902

$

174,950

The Company files tax returns in the United States including California, New York, Pennsylvania, Massachusetts and

Texas. All tax years from 2017 to 2021 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (“IRS”) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The enactment of the CARES Act resulted in increased federal and state research and development carryforwards from 2013 through 2018 of $93,437 and decreased federal NOL of $759,794 from 2018.

154

Note 13 – Commitments and Contingencies

Operating Leases

The Company leases office space in Cambridge, Massachusetts, New York, New York and as of July 2021, San Francisco, California, pursuant to short-term arrangements. The Cambridge and San Francisco leases are on a month-to-month basis, requiring one month’s notice before termination. The New York lease is renewable on a quarterly basis and the last renewal extended the lease term until March 31, 2022. These lease agreements include payments for lease and non-lease components and the Company has elected to not separate such components and these payments were recognized as rent expense.

As of December 31, 2021, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts, New York, New York and San Francisco, California was $30,840 due in 2022. The Company leases storage space for its electronic data equipment in Somerville, Massachusetts. This lease is renewable on an annual basis effective every March 1st. Prior to December 31, 2021, the Company renewed the lease through March 31, 2022. As of December 31, 2021, total future minimum lease payments for this lease were $3,569 due in 2022.

In October 2020, the Company entered into an office lease in San Diego, California with a lease term of 67 months. At the lease commencement date, a right-to-use asset and lease liability was recognized by the Company for $637,863.

As part of the BioArkive acquisition, the Company assumed the obligations of three leases in San Diego, California, one is for 38,613 square feet of office and laboratory space, under a lease that terminates on April 30, 2032, a second is a 6,100 square feet of office and laboratory space under a lease that terminates on December 31, 2022, and third is a lease for 4,760 square feet of office and laboratory space under a lease that terminates on March 31, 2024.  As a result, we recorded right-to-use assets and lease liabilities of $4,824,700 on the acquisition date of December 22, 2021.

Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at December 31, 2021 were as follows

    

Amount

2022

$

659,990

2023

 

880,121

2024

 

894,044

2025

 

906,839

2026

 

819,210

Thereafter

4,467,246

Total future lease payments

 

8,627,450

Less: Imputed interest

 

3,262,514

Total lease liabilities

$

5,364,936

Current portion lease liabilities

274,039

Lease liabilities, noncurrent

 

5,090,897

Total lease liabilities

$

5,364,936

155

Quantitative information regarding the Company’s leases for the year ended December 31, 2021 and 2020 is as follows:

    

December 31, 

    

December 31, 

2021

2020

Lease costs:

  

  

Operating lease cost

$

160,872

$

66,652

Short-term lease cost

 

258,357

 

252,796

Variable lease cost

 

 

14,700

Total lease costs

$

419,229

$

334,148

Cash paid for amounts included in the measurement of lease liabilities:

 

  

 

  

Operating cash flows from operating leases

$

111,527

$

58,666

Operating cash flows from short-term leases

 

236,700

 

252,796

$

348,227

$

311,462

Weighted-average remaining lease term - operating leases

 

9.62 years

 

5.33 years

Weighted-average discount rate - operating leases

 

9.7%

 

6.0%

As the Company’s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

Litigation

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its products and operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated the Company will accrue a liability for such matters. Significant judgement is required to determine both probability and estimated amount. The Company is not aware of any material legal matters.

Clinical Research Contracts

The Company may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination with a 30-day notice.

156

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. As permitted by related SEC staff interpretive guidance for newly acquired businesses, the internal control over financial reporting of BioArkive, Inc. was excluded from the evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2021. BioArkive, Inc., which we acquired in December 2021, represented less than 1% of our consolidated total assets, as of December 31, 2021.

Management’s Annual Report on Internal Control over Financial Reporting

This Annual Report on Form 10-K does not include a report of management’s assessment regarding our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) or an attestation report of our independent registered accounting firm due to a transition period established by rules of the SEC for newly public companies. Additionally, our independent registered accounting firm will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 for so long as we remain an “emerging growth company” as defined in the JOBS Act.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during fourth quarter of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As noted above, we acquired BioArkive, Inc. in December 2021, We are in the process of reviewing the internal control structure of BioArkive, Inc. and, if necessary, will make appropriate changes as we continue to integrate BioArkive, Inc. into our overall internal control over financial reporting process.

Item 9B. Other Information

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

157

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 11. Executive Compensation

The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item 12, including information regarding securities authorized for issuance under equity compensation plans pursuant to Item5(a), Part II of Form 10-K, will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 14. Principal Accountant Fees and Services

The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.

PART IV

Item 15. Exhibits and Financial Statement Schedules

(a) 1. Financial Statements

For a list of the financial statements included herein, see Index to Consolidated Financial Statements in this Annual Report on Form 10-K, incorporated into this Item by reference.

2. Financial Statement Schedules

Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.

3. Exhibits

See the Exhibit Index in Item 15(b) below.

158

(b) EXHIBIT INDEX

op

Incorporated by Reference

Filed/

Exhibit Number

Exhibit Description

Form

File No.

Exhibit

Filing

Date

Furnished

Herewith

2.1

Share Purchase Agreement by and among Immuneering Corporation, BioArkive, Inc. and BioArkive’s shareholders, dated as of December 22, 2021

8-K

001-40675

2.1

12/22/2021

3.1

Amended and Restated Certificate of Incorporation of Immuneering Corporation

10-Q

001-40675

3.1

09/09/2021

3.2

Amended and Restated Bylaws of Immuneering Corporation

10-Q

001-40675

3.2

09/09/2021

4.1

Form of Specimen Stock Certificate

S-1/A

333-257791

4.1

07/26/2021

4.2

Amended and Restated Investors’ Rights Agreement, dated December 21, 2020, by and among the Registrant and the other parties thereto.

S-1/A

333-257791

4.2

07/26/2021

4.3

Description of Securities

*

10.1†

Employment Agreement, dated July 23, 2021, by and between Biren Amin and Immuneering Corporation

S-1/A

333-257791

10.5

07/26/2021

10.2†

Employment Agreement, dated July 23, 2021, by and between Brett Hall, Ph.D. and Immuneering Corporation

S-1/A

333-257791

10.6

07/26/2021

10.3†

Employment Agreement, dated July 23, 2021, by and between Scott Barrett, M.D. and Immuneering Corporation

S-1/A

333-257791

10.7

07/26/2021

10.4†

Employment Agreement, dated July 23, 2021, by and between Benjamin J. Zeskind, Ph.D. and Immuneering Corporation

S-1/A

333-257791

10.8

07/26/2021

10.5†

Employment Agreement, dated July 23, 2021, by and between Michael D. Bookman and Immuneering Corporation

S-1/A

333-257791

10.9

07/26/2021

10.6†

Immuneering Corporation 2008 Stock Incentive Plan and form of option agreement thereunder.

S-1

333-257791

10.4

07/09/2021

10.7†

Immuneering Corporation Long Term Incentive Plan and form of option agreement thereunder.

S-1

333-257791

10.5

07/09/2021

10.8†

Immuneering Corporation 2021 Incentive Award Plan and forms of award agreements thereunder.

S-1/A

333-257791

10.10

07/26/2021

10.9†

Immuneering Corporation 2021 Employee Stock Purchase Plan.

S-1/A

333-257791

10.11

07/26/2021

10.10†

Form of Indemnification Agreement by and among the Registrant and its directors and officers.

S-1/A

333-257791

10.12

07/26/2021

10.11†

Immuneering Corporation Non-Employee Director Compensation Program.

S-1/A

333-257791

10.13

07/26/2021

10.12

Advisory Agreement, dated September 17, 2019, by and between PEF LLC and the Registrant.

S-1

333-257791

10.3

07/09/2021

10.13

Master Services Agreement, dated August 5, 2019, by and between Bioarkive LLC and the Registrant.

S-1

333-257791

10.2

07/09/2021

10.14

Lease Agreement, by and between BioArkive, Inc. and Thornmint 13, LLC, dated as of July 22, 2021

8-K

001-40675

10.1

12/22/2021

21.1

Subsidiaries of Immuneering Corporation

*

23.1

Consent of RSM US, LLP, Independent Registered Pubic Accounting Firm

*

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).

*

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).

*

32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

**

32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

**

159

op

Incorporated by Reference

Filed/

Exhibit Number

Exhibit Description

Form

File No.

Exhibit

Filing

Date

Furnished

Herewith

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

*

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

*

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

*

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

*

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

*

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

*

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*

*  Filed herewith.

**  Furnished herewith.

 Indicates a management contract or compensatory plan or arrangement.

Item 16. Form 10-K Summary

None.

160

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.

IMMUNEERING CORPORATION

Date: March 10, 2022

By:

/s/ Benjamin J. Zeskind

Name:

Benjamin J. Zeskind, Ph.D.

Title:

Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)

POWER OF ATTORNEY

Each person whose individual signature appears below hereby authorizes and appoints Benjamin J. Zeskind, and Biren Amin and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

161

Name

Title

Date

/s/ Benjamin J. Zeskind

President, Chief Executive Officer and Director (Principal Executive Officer)

March 10, 2022

Benjamin J. Zeskind, Ph.D.

/s/ Biren Amin

Chief Financial Officer (Principal Financial and Accounting Officer)

March 10, 2022

Biren Amin

/s/ Ann E. Berman

Director

March 10, 2022

Ann E. Berman

/s/ Robert J. Carpenter

Director

March 10, 2022

Robert J. Carpenter

/s/ Peter Feinberg

Director

March 10, 2022

Peter Feinberg

/s/ Diana F. Hausman, MD

Director

March 10, 2022

Diana F. Hausman, MD

/s/ Laurie B. Keating

Director

March 10, 2022

Laurie B. Keating

162

EX-4.3 2 imrx-20211231xex4d3.htm EX-4.3

Exhibit 4.3

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Immuneering Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). References herein to “we,” “us,” “our” and the “Company” refer to Immuneering Corporation and not to any of its subsidiaries.

The following description of our securities and certain provisions of our Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) and Amended and Restated Bylaws (“Bylaws”) are summaries and are qualified in their entirety by reference to the full text of our Certificate of Incorporation and our Bylaws, each of which has been publicly filed with the Securities and Exchange Commission (the “SEC”).  We encourage you to read our Certificate of Incorporation and our Bylaws and the applicable provisions of the Delaware General Corporation Law (the “DGCL”) for additional information.

Authorized Capital Stock

Our authorized capital stock consists of 200,000,000 shares of Class A common stock, $0.001 par value per share, 20,000,000 shares of Class B common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share.

Common Stock

Class A Common Stock

The holders of our Class A common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our Class A common stock do not have any cumulative voting rights. Holders of our Class A common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our Class A common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

In the event of our liquidation, dissolution or winding up, holders of our Class A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.

Upon our dissolution or liquidation, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our Class A common stock will be entitled to receive pro rata our remaining assets available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.

Class B Common Stock

The Class B common stock is identical to our Class A common stock in all respects, except that the holders of our Class B common stock are not be entitled to vote on shareholder matters except as required by law. In addition, holders of our Class B common stock do not have the right to convert each share of Class B common stock into one share of Class A common stock at the holder’s election, unless, as a result of such conversion, the holder and its affiliates would own more than 9.9% of the combined voting power of our outstanding share capital, and subject to certain additional restrictions as more particularly described in our Certificate of Incorporation. Shares of Class B common stock, once converted to shares of Class A common stock, may not be converted back into shares of Class B common stock.


Preferred Stock

Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. The issuance of our preferred stock could adversely affect the voting power of holders of Class A common stock and the likelihood that such holders will receive payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action.

Choice of Forum

Our Certificate of Incorporation and Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders; (iii) any action asserting a claim against us arising pursuant to the DGCL, our Certificate of Incorporation or our Bylaws (as either may be amended from time to time); and (iv) any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our Certificate of Incorporation and Bylaws will also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause or causes of action against us or any defendant arising under the Securities Act. Nothing in our Certificate of Incorporation and Bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.

If any action the subject matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our Certificate of Incorporation and Bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder’s counsel in the Foreign Action as agent for such stockholder. Although our Certificate of Incorporation and Bylaws will contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.

Dividends

Declaration and payment of any dividend will be subject to the discretion of our board of directors. The time and amount of dividends will be dependent upon our business prospects, results of operations, financial condition, cash requirements and availability, debt repayment obligations, capital expenditure needs, contractual restrictions, covenants in the agreements governing our current and future indebtedness, industry trends, the provisions of Delaware law affecting the payment of distributions to stockholders and any other factors our board of directors may consider relevant. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness, and therefore do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future.


Anti-Takeover Provisions

Our Certificate of Incorporation and Bylaws contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board of directors the power to discourage acquisitions that some stockholders may favor.

Authorized but Unissued Shares

The authorized but unissued shares of our common stock and our preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of the Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

Classified Board of Directors

Our Certificate of Incorporation provides that our board of directors is divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. In all other cases and at any other time, directors may only be removed from our board of directors for cause by the affirmative vote of a majority of the shares entitled to vote. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control of us or our management.

Stockholder Action; Special Meeting of Stockholders

Our Certificate of Incorporation provides that our stockholders are not able to take action by written consent for any matter and may only take action at annual or special meetings. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Bylaws, unless previously approved by our board of directors. Our Certificate of Incorporation further provides that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer, our president or another officer selected by a majority of our board of directors, thus limiting the ability of a stockholder to call a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.

Advance Notice Requirements for Stockholder Proposals and Director Nominations

In addition, our Bylaws establishes an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder has to comply with advance notice and duration of ownership requirements and provide us with certain information. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a qualified stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder’s intention to bring such business before the meeting. These provisions could have the effect of delaying stockholder actions that are favored by the holders of a majority of our outstanding voting securities until the next stockholder meeting.

Amendment of Certificate of Incorporation or Bylaws

The DGCL provides generally that the affirmative vote of the holders of a majority in voting power of the shares entitled to vote is required to amend a corporation’s certificate of incorporation, unless a corporation’s


certificate of incorporation requires a greater percentage. Our Bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders a majority of the votes which all our stockholders would be eligible to cast in an election of directors.

Section 203 of the DGCL

We are subject to Section 203 of the DGCL, which prohibits persons deemed “interested stockholders” from engaging in a “business combination” with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.

Limitations on Liability and Indemnification of Officers and Directors

Our Bylaws provide indemnification for our directors and officers to the fullest extent permitted by the DGCL, along with the right to have expenses incurred in defending proceedings paid in advance of their final disposition. We entered into indemnification agreements with each of our directors and executive officers that may, in some cases, be broader than the specific indemnification and advancement provisions contained under our Bylaws and provided under Delaware law. In addition, as permitted by Delaware law, our Certificate of Incorporation includes provisions that eliminate the personal liability of our directors for monetary damages resulting from breaches of certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders to recover monetary damages against a director for breach of fiduciary duties as a director.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.

Dissenters’ Rights of Appraisal and Payment

Under the DGCL, with certain exceptions, our stockholders have appraisal rights in connection with a merger or consolidation of Immuneering Corporation. Pursuant to the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such mergers or consolidations will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery, subject to certain limitations.

Stockholders’ Derivative Actions

Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, in certain circumstances. Among other things, either the stockholder bringing any such action must be a holder of our shares at the time of the transaction to which the action relates or such stockholder’s stock must have thereafter devolved by operation of law, and such stockholder must continuously hold shares through the resolution of such action.

Transfer Agent and Registrar

The transfer agent and registrar for our Class A common stock is American Stock Transfer and Trust Company, LLC.

Trading Symbol and Market

Our Class A common stock is listed on the Nasdaq Global Market under the symbol “IMRX.”


EX-21.1 3 imrx-20211231xex21d1.htm EX-21.1

Exhibit 21.1

Subsidiaries of Immuneering Corporation

Immuneering Securities Corporation

BioArkive, Inc.


EX-23.1 4 imrx-20211231xex23d1.htm EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (No. 333-258416) on Form S-8 of Immuneering Corporation of our report dated March 10, 2022, relating to the consolidated financial statements of Immuneering Corporation and subsidiaries, appearing in this Annual Report on Form 10-K of Immuneering Corporation for the year ended December 31, 2021.

/s/ RSM US LLP

Boston, Massachusetts

March 10, 2022


EX-31.1 5 imrx-20211231xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION

I, Benjamin J. Zeskind, certify that:

1.

I have reviewed this Annual Report on Form 10-K of Immuneering Corporation;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Omitted;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 10, 2022

By:

/s/ Benjamin J. Zeskind

Name:

Benjamin J. Zeskind, Ph.D

Title:

Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)


EX-31.2 6 imrx-20211231xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION

I, Biren Amin, certify that:

1.I have reviewed this Annual Report on Form 10-K of Immuneering Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Omitted;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 10, 2022

J.

By:

/s/ Biren Amin

Name:

Biren Amin

Title:

Chief Financial Officer and Treasurer

(Principal Financial Officer and Principal Accounting Officer)


EX-32.1 7 imrx-20211231xex32d1.htm EX-32.1

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K, for the fiscal period ended December 31, 2021 of Immuneering Corporation (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, the undersigned, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 10, 2022

By:

/s/ Benjamin J. Zeskind

Name:

Benjamin J. Zeskind, Ph.D.

Title:

Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)


EX-32.2 8 imrx-20211231xex32d2.htm EX-32.2

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K, for the fiscal period ended December 31, 2021 of Immuneering Corporation (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, the undersigned, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 10, 2022

J.

By:

/s/ Biren Amin

Name:

Biren Amin

Title:

Chief Financial Officer and Treasurer

(Principal Financial Officer and Principal Accounting Officer)


GRAPHIC 9 imrx-20211231x10k006.jpg GRAPHIC begin 644 imrx-20211231x10k006.jpg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end GRAPHIC 10 imrx-20211231x10k007.jpg GRAPHIC begin 644 imrx-20211231x10k007.jpg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end GRAPHIC 11 imrx-20211231x10k008.jpg GRAPHIC begin 644 imrx-20211231x10k008.jpg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end GRAPHIC 12 imrx-20211231x10k009.jpg GRAPHIC begin 644 imrx-20211231x10k009.jpg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˫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end GRAPHIC 13 imrx-20211231x10k010.jpg GRAPHIC begin 644 imrx-20211231x10k010.jpg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imrx-20211231x10k011.jpg GRAPHIC begin 644 imrx-20211231x10k011.jpg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end GRAPHIC 17 imrx-20211231x10k014.jpg GRAPHIC begin 644 imrx-20211231x10k014.jpg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imrx-20211231x10k015.jpg GRAPHIC begin 644 imrx-20211231x10k015.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH ADNK>**:62XB2.'_6NS@"/C/S'MP0>:2VO+6\M_M%K0+/;3QSPM]V2)PRGZ$5QMU')>WXU*UL+M+&!;19;=[5T9MDC,=J$9;8" M.@/MG%;WAZ-_^)G0.M &S17+ZIJ-U9^,= M+M(M1N#%=F026K0+Y:J(F(*OLSG=)_?/Y"CSI/[Y_(4=)_?/Y"D\V3_GH?R%',@Y&7**J><_]\_D*3S9,?ZP_D*.9!R,N454\ MY_[Y_(4GFR?WS^0HYD'(RY153SI/[Y_(4>;)_?/Y"CF0 M;)_?/Y"CF0<_]\_D*.=!R,MT54\Z3^^?R%'G2?WS^0HYD'(RW15/S M9,?ZP_D*7SG_ +Y_(4#T]*.=#5&;=DC;HK/MKY+RVCN+>X\R&095E P:E\Z3^^?R%'.A.G M):,MT53\V3_GH?R%+YTG]\_D*.9"Y&6Z*J>=)_?/Y"CSI/[Y_(4=)_?/Y"D M\V3'^L/Y"CF0=)_?/Y"D\Z3^^?R%',@Y&7**J>=)_?/Y"CSI/[Y_(4 M'"7B^S>=, FP[]WDOSNSC&.V/QK:K"\0+;?\)EX=82_Z5YDP,?FGA?)?G9G' M7OBMVLI[FU/84 GM1M/I2_\ +/\ &LK7-,YQGO]*(Q< MG9;C;LKLU-I]*-I]*SM%UF+7-/\ MD$*<7,&HQPS)I MTQ0S(T;.NTD@CW!/:H]2$EKIEMY<.O6PFU&&*1);QGE="&R$()M4U,Z5+_IG MEAX5E51A5[MC)R>2/85*G'N=;P&)5O=WVU7KW/7?-FOF/V>0PVX_Y:X!+GVS MV]ZS=>L9Y&TR5GO)8;>5S,UKQ+@J0",<]>..<&LSPS\08/$6KIIL>F/;$QLX M&_L"^9;7DB,RSRJ/E0R'"L M5Y\S9U/JS^RV:LL6XMAFRVA-C;M#>0WHCN[:4!VV",R'!!PI.ALWFCVE_+/).KEI[5K23#8 M!C8Y(^OO3I-*M)+JRNMKK-9J4B=6P=I&"K>HX'![BN;\,:W-JL&FRSZY+)<3 MQJ\EL+':N2,E=^WI[YHTSQ/=:S=QZ5:SQQW:RS-VUT4?A/F\ MY_WGY+]0HHHK4\H**** "BBB@ HHHH *I:C<7D"Q+96Z2R2.0S2N5CC4 DLQ M /IC\:NUEZWI,NKPP1)-X]Z2\8 89&0.N*3+I\O,N;8A&OD^&AJH MMP7+>6(P_P I6"&Q]W/.<=*I7'BJ6TW6MQ'9QWJ7 A8F9O) V;]V<9SCC M&,YK3FT^ZFTYK26]@"M%Y?%LH0MNX^4D\8^7;_*J%MX6-F4N+::VAO(YS,GE MV^(5!39MV9SC'?.;SMO\C9TV[-_IT%TRQJ9%R1'('7KC@CJ*M5 M3TRQ_LZP2V,GF,&9W?;MW,S%C@=AD]*N4TP)S6A7,7275UKCV\VFW:Z>MQ'(#;QIM MG<;2))&+9P"!P!_#^%)LUI0C)OF.@O+RWT^V:YNY5BB4@%F]2< ?7-0R:M91 MZC]@:4_:<@;!&Q )Y&2!@5B^(].U35[;SK58U1(R%M;A"7W[L;Q@XS@<9[$^ MM)/;WXU=GA@OH[R2YB9YHY?]%= &)7/' (P03G'-*[-(48.-V]=?T.HHHHJ MCF"BBB@ HHHH **** "BBB@ H'6B@=: +J?<7Z4ZFI]Q?I3JW.9G/^-_^1+U M3_KE_45OK]T?2L#QO_R)>J?]U;-8OB 7/\ PEOAPDP_9?-F MP,'?N\E^_3&*VJRGN;4]AW_+/\:P?%'AN/Q/IL=G)",?K6[D MXQ1FI:35F:TYRIR4XO5&-X9T!/#6D?V?'<-.OF-)O9=IY[8_"CQ#9W=['IRV M;%)(KZ.4R!0VQ0#DD=QV_&MG-&:%IL%22R-!M%%%(84444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !2CJ*2E'44 ?.'B#_ )&35?\ K\F_]#-9U:/B#_D9-5_Z M_)O_ $,UG5Q/<^[I?!'T1V7PP_Y'2/\ ZX2?RKVVO$OAA_R.D?\ UPD_E7MM M=%'X3YG.?]Y^2_4****U/*"BBB@ HHHH ***R_$.LIX?T6;4GA:98BHV*V"< MD#K^-#=BH1V9TVYA\Z)E$B7 M&"A[$$#UQ4.@_$73-&TZ*W@TZ[N=H_UTUSN8D]>NZCM6MQ%)Y95G#9XSFMZFG?5' M-.G*G)PDK-!1113)"BBB@ HHHH **** "@D $D@ TO[U M()[C'E(P)+22X=ILE8",1KC MEO\ :/\ 2K%%% PHHHH **** "BBB@ HHHH **** "@=:*!UH NI]Q?I3J:G MW%^E.KU1=\VAU*,'07,[:OIY(OZ[J,]H+*TLRBW=]<" M".1UW",;2S/CO@*<#/4BEMK35;34(\ZBU]9.I$HN519(V'0H8T4$'H01Z$'J M*?K6F2:C!;O;2K%>6DPN+=W&5W $%6 YVD$CCUSVQ4$5MK-WJEO%I6\'V^ER3)'J%KF2WN8B3Y4NXE2#C..<'CIFI?[!N]4U:._UIU3R M+810QV-U*FUV.9&W#:<'"@#T'-2E*UCIG.@YC>^([E_! M5GJ*77V.Y-Q%;W4F$_=-Y@27[P('?J*U]&GMKFX=K;Q.VJA%^:(26[!<]"?+ M0$=/7%9,GA*\B:\M[2>/[#-?6][&)YG=U96!DR2"3G:".>M=9/"MQ \+F0*X MP3'(R-^#*01^!IQ4KZF5:5)1M#JWVT3M^7J8FN:M=:=KFCPP13SQW/G"2"%% M+2$*NWEB ,9)SD"I;;Q-9W,UK#Y5Q%)<3R6Q610/*E1=Q1^>I'(QD'UZ57O= M$O(+_3;K26246AE+QWUU*Y?>%& YWD=,_P!.:R]:L9=-\-WNWG>[W7DK,V)?%EI'Y/EVE[.9[ MJ2TA$2*?,=,@D98#;D$9..AS@YBG^SR6813*LG7!^;:! MCYMV[;COGBL*^T^YTB7P?8V/DO<6\DB_O6(60^2QE6;KPYJE MS!<3M-%]IN[M9KFV2X>*)X@FP1>8J[NF"3CD\8Q2YI#=*A9/H_\ -K\OQZE\ M>*;417/FVEY#TDF-@!#%.<]=WUQ4LGB&."T,MQI]]#,9UMTMY M$4/([= K;MA'ONQP>_%8]CX8O;-=7(L=$\N]DA=;'83 %7AD/RC!Z$-M//.V MI+3PY>VNFW=N+;3G@EEC:/3+B62>W1!]X!F&5))R,)@8'!ZT[R!T\/T?;]+] M?7_,Z*PO6OH7=[2YM71RC1W"@-D8Y!!(8<]02/R-5KC5WL)G%]8W$=L#\MU" M/.3'^T%^9>AR2NT?WN:K^&]'N-'@N(Y2D<+N#!:1SO,ENH&,*SX/)R<8 %69 M=#LKJZ-Q>A[QMVY([AMT:K6QSM4HU&GJOZ\_\_F7UE62 M31$2HR[D*$'>,9&#TYK!\/:EJM[JNKP:I'#"8##Y<$3;A&&3=@M@;CTSV]*Z M&LNRTZ>UUO5[YFC,=X8C&H)R-B;3GCCGZT.]T*#CR33733[U^A!J=S=S:[8Z M1:73VHDAEN9YHU4N%4JH"[@1RS\\=JE\/WUQ>64\=VZR7%I& MP. 2""0.,YQ45[8:C)?:?JMLEJ+V".2&:W>9A&Z/@X#A,\,JD?+SSTJSH>G2 MZ=92"YD1[JXF>XG,?W [G)"YYP. ">3C/M25^8N7)[)+2_XWN_T-*BBBK.8* M*S?$%K/>^'=1MK9Y4GEMW6,Q'#;L<8Y'\ZYG1-'T6&^LYH_ VIZ]\)/^0!?_P#7U_[**]!KS[X2?\@"_P#^OK_V45Z# M773^%'QV8_[U/U"BBBK.(**** "BBB@ KF?%/C2V\+7%M#/9S7!G0N#&P&,' M'>NFKR?XO?\ (2TO_K@__H0J)MJ-T=F HPK5U">VOY%?Q#\1=,U>;26;3+I/ MLMX)LB18O%>0R0"5E8LPV\@ U,GWU^HK% MU961[D,IH<\N:.G35GTZK;T5AT8 TM,A_P!1%_N+_*GUTGRX4444 %%%% !1 M110 4444 %%%% !0.M% ZT 74^XOTIU-3[B_2G5N M7[H^E8/C?_D3-4_ZY?U%;R_='TJ5\3-I?P8^K_*(M%%%48A1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% &5X@>RL]*NM3O(#,MK;2_*&()5 M@-R_C@<]JY+3;2+2]126[T>QCE@OXK9GMIY3Y?F(I0C=][#-@]..:ZOQ)P4445)84444 %(S*BEG8*JC)8G I:, C# $' M@@]Z (+.]MM0M_/M)EFA+%0Z]"0<''XU1C\2:3(DKBZQ'%&TI=HV5613ABI( M^8 ^F:CTRTN+'3)+9K9@9;J;_5E?W:.S$-UZ8(X'-E- M(3=C=B GFDF;)4-L09XXZG\\_E4=]9R75WITJ,H6VG,C@]P49>/Q-6XH?)B2 M-5.U1@4ZDQQ?+JC$U:UU>^$<48A6VWOYJ)<-&TJ?PC<%)'?('YU4N?#$D_V> M:"?DOU"BBBM3R@ MHHHH **** "N5^(__(C7W^_%_P"ABNJKE?B/_P B-??[\7_H8J9?"SHPG^\0 M]5^9X51117&?;GKWPD_Y %__ -?7_LHKT&O/OA)_R +_ /Z^O_917H-==/X4 M?&YC_O4_4****LX@HHHH **** "O)_B]_P A+2_^N#_^A"O6*\G^+W_(2TO_ M *X/_P"A"LZOPGHY5_O4?G^1YQ2I]]?J*2E3[Z_45RGUQ]-P_P"HB_W%_E3Z M9#_J(O\ <7^5/KN/@&%%%% !1110 4444 %%%% !1110 4#K10.M %U/N+]* M=34^XOTIU;G,S \;_P#(F:I_UR_J*WE^Z/I6!XW_ .1,U3_KE_45OK]T?2I7 MQ,VE_!CZO\HBT4451B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 9?B.*XG\-ZC%:SK!.\#!)&?8%./[W;TSVKE(+.UN;W3HM&\)76D7=O M<1O+=/;)"J1*?G4NI_>;AE<UNKN?48Y$2"V1&?8 -S M?/\ +@;AU[D52\-65Q=6EG?Q>)=8GME)4VUW%"K94E2KX3=D$$'GMUH W-4" M[(&$CI<"4>243>2V"""/3&<]/K5&RNI[G5$6\D9Q&SK"\4'EQ.XX;DLQ) R. MPZXS5O6O-2TCF@@N)9HY 5^S[=RY!!.&ZC!Y%4=(VSW%NJ*RPVR'"&920YZL MZX#;CD]<=>E &^V=IVD XXS6-X:NKVZM;[[?.DTT-]-"&1-B[5; &3_ #-; M55ET^U1'1(0JO-Y[!21E\YW?F* .*U/6=3L=)BU:*^E:2[NYK8PL%*1+EU4J M,=5V G/7G-='I+W,&MZCILMS- /6@#' M\0_\C#X;_P"OB;_T0]:E<_KL8@\:Z',MK(#*\H> <@#^=;G MFC_GFOYFDZ;EJ6I\JL245'YH_P">:_F:#*H&2B@#W-+V+'[5%35-:TS1(8Y= M3O8;2.1BJ-*%)8F#QNH96'0@\@UBZSIDGB"T14NOL2(X>.00K M(S>X#<"M6#]S;Q1-B0H@4N1C=@=<#I1[)A[4L45'YH_YYK^9IDVR>%XGC&UP M5.">E'L6'M4-GN'\S[/; --_$3]V,>I_PJ>-"D:JSLY Y9NIJK9P0V,)BAC^ M4G/S,2?YU8\T?\\U_,T_9,7M22BH_-'_ #S7\S1YH_YYK^9I>Q8_:HDHJ/S1 M_P \U_,T>:/^>:_F:/8L/:HDHI@E&?\ 5K^9KR'5/$VM0ZM>11ZC,D:3NJJ" M, G K:C@Y56TF9U,2H;H]AHKQ/_ (2O7O\ H*3_ )C_ K8\+>(M7N_$EG! M#\IK:66U(INZ,UC8MVL6/BW<36[Z3Y4\D61+G8Y7/W?2O*[R_ MNBD>Z\G.) 1F4_XU]+3P6MUM^T6<$VW[OF)NQ],U =+TIOO:38GZP+7GO#2< MN:Y[=/-80PWL>37O\SYX.HWF#_IMQ_W^;_&OH[326TJR)))-O&23W^45#_9N ME_\ 0*LO^_(JV'55"K$H & !GBB&&E'J3CLSAB5%1A:Q+14?FC_GFOYFCS1_ MSS7\S6GL6>=[5$E%1^:/^>:_F:/-'_/-?S-'L6'M4245D^(+N2V\/W\T'[N5 M(2RNI.0:\I_X2O7O^@I/^8_PKHHX&=573,JF*C!V:/;*4=17B7_"5Z]_T%)_ MS'^%>@>!-3N]0T>XEO96N)%G*AG/(&T<<557 3IQYFT*&+C-V2/'?$!'_"2: MKS_R^3?^AFLW(]:^D6T_37=G?3+-F8Y+&($DTG]FZ7_T"K+_ +\BO.>$EW/I MH9_",4N3;S_X!Y%\,#_Q6D?_ %PD_E7MM4X;2QMI/,@L+:)\8W)&%/YBK'FC M_GFOYFM88=Q5KGE8W'K$U?:*-M"2BH_-'_/-?S-'FC_GFOYFJ]BSD]JB2BH_ M-'_/-?S-'FC_ )YK^9H]BP]JB2BN \>ZUJ&G:A:)973VZ/$2P0]3GWKDO^$K MU[_H*3_F/\*ZZ>73G%231A+&1B[-'ME??\)7KW_04 MG_,?X5[(XAN(!'/;Q2H0"5<9!_ UE7P4Z:LWN;X7&Q513MLTSYGR/6C(]:^D M/[-TO_H%67_?D4?V;I?_ $"K+_OR*X?J*=<6ZF5=3G #L 1P,U%_P )7KW_ $%)_P Q_A7;_9E3^9'-]>CV M/;*\G^+W_(2TO_K@_P#Z$*L^$/$&JWOB6W@N[V6:%E 9$W8_.N7$8.4/<;._ 9A&E557EO:_Y'S5D>M.0C>O/<5]'?V;I?\ MT"K+_OR*/[-TS_H%V7_?D5R_4Y=SW/\ 6&'_ #[?W_\ +L/^HB_W%_E3ZC$ M@ P(U_,T>:/^>:_F:W]BSYWVJ">>*UMY;B=PD42%W8]%4#)-K:OXY\.W MUU"TFB6\T^-.NX@'E:-3RS*W')!'X^V3H^,X8K_PE?VLNH0Z7'*JJUW)RJ#< M.O(Z]/QJSX9@@T_POI=G;S174,-LB)<1Y"R@#[PYZ'K3]DQ.H5-%\.ZUINI+ M:_F:Q_ M%5]-:>&KR>V;R9D"[74\CY@*J-&4I)=Q2JI*Y!K?A[6M2U#[18^++S3(=@7[ M/#;HZY'5LMSS0_A[6F\/Q:>OBN\2\28R-?BW3>Z\_(5Z8Y'/M7FW_"5Z]_T% M)_S'^%'_ E>O?\ 04G_ #'^%=?]F5/YD<_UV'9GI.C^']9T^2Y:]\5WFHK+ M"8XUEMT3RF/1QCJ1Z52M?"?B."ZAEE\=:C/'&ZL\36L0$@!R5)'3/2K/@?4K MF_T$S7DAGE\]EWN><8'%>9ZQXGUR+6KZ./5+E$2=U55?@ $\5P8B+H2M(]/! M4'B[\FENYZ7JOAK7;_4Y[FS\8WUA;R$%+:.VC98^ .">3Z_C4MYX>UJXTFPM M(/%=Y;7-ON\Z[2W0M<9Z;@>!CVKR+_A*M?\ ^@O=_P#?RNF\!:_JM]XJC@O+ M^>XA,,A*2/D9 XK"-52:1V5?F4#@]1U]*KZ=X9\0V.I6]S<>,[Z^MXVW26TEM&HE&#QD=.<5T_FC_ M )YK^9H\T?\ /-?S-=/LF>3[1%3PIXGM?%.FS7$$,MO+;SO;SV\V-\;J>_X8 M/_ZJW)'6*-I'.$4%F/H!7+>$]+TZQUWQ)>IR3 M75TR#B/$GB;2]:\/7>G:9+-=W=RH2..*WD.3D=]N!7;#@"E Z45*3O=FU2I M%Q48*R5^M][>2[!1115&(4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110!@ZUIFJ3ZWINIZ7)9A[6&>)TNMV&$AC.1M]/+_6H-#L/$FG$0W+Z M2]L]Q)-(8O,#C>Y8@9XX)K4U9]1BB66QGL88XU9IFNU8@ =P01COG-<[IWB\ M7>I6UO\ V]H-SYT@3RK19&D8^WS'ZY/ % '1ZS/<6^GF2UN(('W %YD+<'LH M');TX/T-9FCCSM6$MQYF:U[^*XD$#VT<,DD4 MN_;*Y0'@CJ >>?2JZPZC<:C:S7-O:11P;SF.=G8Y&,8*+_.@#4HHHH **** M.1\1B/\ X2_P\?M;&3S)?]&WC 'DO\VWKGMGI6O61XC9?^$O\/+]C2_RYSG/?&,5KUI'8ED+W=NEW':M,HGD!*QYY('4XJOJ%[9VAC%Y*X0@ MN8TC+;@,9)QT4=Z;M$XQ7PL*G@?@?J<>)^)!7IGPY_P"0%<_]?)_]!6O,Z],^'/\ R KG_KY/_H*U>,_A M$8?XSL****\D[PHHHH **** "BBB@#SCXD?\A.Q_ZXG_ -"KBJ[7XD?\A.Q_ MZXG_ -"KBJ]G#?PD>?6^-A7O:?<7Z"O!*][3[B_05S8[[/S-<+U%HHHKSSK" MBBB@ HHHH *4?>'UI*4?>'UH \'N?^/N?_KHW\ZBJ6Y_X^Y_^NC?SJ*OH%L> M4SHO W_(V6O^[)_Z":]:KR7P-_R-EK_NR?\ H)KUJO+QO\1>AW8;X HHHKC- MPHHHH Y;XBZ?>:KX$U&RL+=[BYD\O9%&,EL2*3^@-:'A*UGL?!^CVMU$T5Q# M9QI)&W56"\@UG?$B^NM.\!:E=65Q+;W">7LEB8JRYD4'!'L:T/"%Q-=^#=%N M;B5Y9Y;.-Y)'.69BHR2>YI=1]#:K"\9?\BG?_1?_ $,5NUA>,O\ D4[_ .B_ M^ABM:7\2/JB*GP,\@HHHKW#S#U+X>?\ (N-_U\O_ "6O*-;_ .0]J/\ U\R? M^A&O5_AY_P BXW_7R_\ ):\HUO\ Y#^H_P#7S)_Z$:^9S/X_F?7)/%=Y=6YCM[Z[CDMW+ [U"D$\=.?6NSKAO M ]_>7?BKQC;W%U-+#;7D2P1NY*Q H20H["NYK)[EA1112 **** "N8FU+6[S MQ;?:1I]SI]M!:6L,V^XLWF9S(7!'$J ;/?K73UR)'MI(!AD:0L"))%/\ &* +>G^)5CT_4FULPVMQI7'VHP)9@-B2<,8X!83F8JIP6,03>%R1 MR1CD<\UD:^FL^(]!N[-?#\MJ=UNR"YN(2[D3(S@!&9=H51R:I:?X9U&U\,6UI?Z+?2W,5Y=LLNG:H$N+<2,Q5XW9UW@YYWL#G!*GG M!V3^)](73[2^%RTD5V2MNL,$DDDA&=P$:J7R,'(QQ@YQBE;Q-I":8FH&Z)A> M;R%58G:4RYP8_* W[Q@Y7;D8.1P:Y.;0->G&C:CJ<=]?RVOVF*2WM[X6]R(I M&4QDO&T:,ZA & 8 YR,XYL1:%>6/]GZM8Z+<));W\L\MC+J'GSS))'Y7F%Y& M*B0 *=N\C /S9.* -KPUXB/B"\UI4"?9[*Z6"$^6R.1Y:LP<-R&#%AC QC!& M:Z"N9\*6>HPZAX@O=0L#9"^O5FAC:1'.P1(N3M) /R\C/7."1R>FH **** " MBBB@ HHHH QO%4E@/#E[#J-_#90SPL@EE8 X]/XOH.MR\8_"M&^6WDLY(KL_N9!L;DC@_ M2J5A)HTL\(LYHY)0A:+#EOEZ$C/Y9H UJ*** "BBB@#E?$'8S 1") MIB)MPP3Y+_+CK^-:=9GB.X!\4>';?RY'ZQ_P AN_\ ^OA__0C7=@?B9S8G9%*MWP=_R-EA_O-_Z":PJW?!W_(V M6'^\W_H)KOJ_PY>ARP^)'K]%%%>$>F%%%% !1110 4444 97B;_D6-2_ZX-7 MC%>S^)O^18U+_K@U>,5Z>!^!^IQXGXD%>F?#G_D!7/\ U\G_ -!6O,Z],^'/ M_("N?^OD_P#H*U>,_A$8?XSL****\D[PHHHH **** "BBB@#SCXD?\A.Q_ZX MG_T*N*KM?B1_R$['_KB?_0JXJO9PW\)'GUOC85[VGW%^@KP2O>T^XOT%4SHO W_(V6O^[)_P"@FO6J\E\#?\C9:_[LG_H)KUJO M+QO\1>AW8;X HHHKC-PHHHH Y[QSJ<>C^#[Z_EL+>^2+9FWN!E'RZCD>V<_A M5WPU>+J'AC2[Q+:*V6>UCD$$0PD8(^ZOL*K>,;+3-0\*WEKK%Z;*P?9YMP"! MLPP(Z^IP/QJYX?M[2U\.Z=;Z?,O\ D4[_ .B_^ABM:7\2/JB*GP,\@HHHKW#S#U'X>_\ (MM_ MU\/_ "6MYM$T:1V=])M&=B2S%.2?6L'X>_\ (M-_U\/_ "6NKKQ,3%.H[GJ4 M)RA!U4E6 90%X7G ."?RKI8+&PTV;^O(]/L9KJ4$K&N<#J3T 'XU#I]^]U+< %>V3ZU=TV] MDO$D,BPY0@;H9 ZG(Z9!ZCO34T]B949Q3;6Q%X4UTZIKGB.Q-G! -.N4B$D8 M^:;*DY;WKJLC.,\UY+KT>M:<^N7'@"2.ZO+B96U8!@\T#@$*$4C'(^I]*YWP MWJ'Q6.EE]'M8YX&E??+<>69F?/._V.U0]R3WRBO&O[0^-G_0.M?RA M_P#BJNZ1??%Y]:L%U.PMEL#<1BY8"'(BW#>>&STSTI >L445ROBB9KC5;#2K M=+^>[DCDG2WM[XV<14,BEY95._ W<*F" #JJAFN[>">W@EF1);ABD*$ M\N0I8@#O@ G\*\T\/ZM>:MIFA6%UJ5Q]CN=1O(7N(;QBTBQEC%&)QAR#_>R& M8+[D5I:CIMD?%'A6"+5+R\6'4;E"3?.S0D6[OY;,&R2#C[V6VG!)!Q0!W5O< M)8VV*JXSN?&U>O0 MD9YQT->=6>NW6C:+I?B2^OKF6Q6XO[6]625F&WSI3$V"<9!14!ZX<#H*25=3 M":;:ZG>WAEO=&U"[NHA<.H$C&-PO!& F[:,= ,=S0!Z3;W$5W;17,$BR0RH) M(W7HRD9!'X5)7ET>I3^#_#GA[4HI;J6TN]%%NL,D[NHN_+$D6-Q(&[YUP,?P M@< "N_T[39(/#MMIUY\DD&<+(T+QJ_NI8#7L%A8CO)8VFG4HN MP.&#!54EMBD#OCBK%I_-<9J<"V&H-I5EJ-]=65[HUQ/<)+?23,FS;Y^$;*6ZF>:53+$9)#EF"2,@)/N@H **** "BBB@#)\1'6AI4@ MT.WLY[EE8%;IRHQ@], @G/8X'O7.:3X7U*QUBWNET3P_9*KY>6"XEE=%[B-6 M0*I/3(Q@5VMQYWV:7[,(S/L/EB0D+NQQG'.,U#(;_P NU\L6V_>OVG<6P%P= MVSWSC&>V: )+H1M9SB5RD9C8.P_A&.36/IMQ+*/#LWVB0H9 MIE\G"[0?)?YNF<_CBM.M([$L****H04444 %%%% !1110 4444 %%%% "CJ* M\/UC_D-W_P#U\/\ ^A&O'ZQ_P AN_\ ^OA__0C7=@?B9S8G9%*MWP=_ MR-EA_O-_Z":PJW?!W_(V6'^\W_H)KOJ_PY>ARP^)'K]%%%>$>F%%%% !1110 M 4444 97B;_D6-2_ZX-7C%>S^)O^18U+_K@U>,5Z>!^!^IQXGXD%>F?#G_D! M7/\ U\G_ -!6O,Z],^'/_("N?^OD_P#H*U>,_A$8?XSL****\D[PHHHH *** M* "BBB@#SCXD?\A.Q_ZXG_T*N*KM?B1_R$['_KB?_0JXJO9PW\)'GUOC85[V MGW%^@KP2O>T^XOT%4SHO W_(V6O^[)_P"@FO6J M\E\#?\C9:_[LG_H)KUJO+QO\1>AW8;X HHHKC-PHHHH YGX@Z7>ZSX(U"PT^ M SW4OE[(P0"<.I/7V!J_X5L[C3_"6D6=U&8[B"TCCD0G[K!>165\2[NYL? & MIW-I<2V\Z>7MEB;# MD@@\Y!.<>E>E]=I=5DI3&6U6& M.*[O(@L43+$8HMN22#EATQ\HX'J:T+.QEM[J>XGDA::540B%"J +G'7G/)_2 MKM%)02=RI5YRCRO8Q?!VB7^F>(O%-]=Q!+?4+J.2V8.#N4*03@=.?6NO"*K, MRJ S?>(')^MY 4444@" MJ6H:1IFKHB:EIUI>K&24%S L@4GKC<#BKM% %&31M*ELI;.33;-[69_,D@:! M2COG.XKC!.0#FD_L3239067]EV7V6W<20P?9TV1.,G1ZFL3XBQ+-X M*N8GSM>YM%.#@X-S%WKF/%VJ75_\/YM*DF8WD-M=?;V!(+"W&S/_ -VC;W4 MGWH ]';3-/:Q:Q:QMC:,Q8P&)?+)+;B=N,9W?-]>:D>UMY+A+B2WB:=%9$D9 M 656QD ]0#@9'? KSZ\M;2Z^(-R+OPS_ &X%TFUVKY=N_E?/+S^^=>OMGI4_ MB01:5H6A2Z=X<>R8:U"ZZ="D*,[X8#_5L4&>.<].O2@#H;KPM;3-IMM;QV=I MI5E<"Z^QP6H7?*N2I!! 49.2-N21U'-;]<5X-2+6+V\UG55+^(K:9K::"51_ MH &<)$.?E*G.\??S^ 9\0[B21=-LK33FUBZCF-[+I>T%+B!%*MO)XP"RE1@Y M8#"GL =3/HFDW.GQ:?/I=E+91$&.VDMT:-,<#"D8'4_G4Z6%G&+4):0*+0;; M<",#R1MVX3CY1CCCMQ7/> -0T^Z\+VUK8ZBE\;1%61XT8+&6^81C=V4$+C.0 M <=*Q;JSLKKX@Z]]K\*_P!N[;>TVGRK9_)X?/\ KG7&?;/3GM0!WUS:V]Y M8+J"*>(D$QRH&4D$$'!]" 1[BH+#2M.TN!X-/T^ULX7;!ZDD_C4M%% !1110 4444 4=8U Z3HUY MJ @:4IP6P,XSVJG9S>)))X3=VFEQV[9,T9W8&U> >#ELG.1@=:XCPUIUN-3M'M+/21'%(4#6WB">4#JF1@]20:P-$O3 M$0,/SKH[L1M93B9BL1C8.1U QS63IUO.;Y)6$@BQO!: +D[ O7<< @ XQUH MW**** "BBB@#FO$G_(>\.?\ 7Q-_Z(>KU9GB..7_ (2GP[(9R83-,!#M& ?) M?YL]?PK3K2.Q+"BBBJ$%%%% !1110 4444 %%%% !1110 HZBO#]8_Y#=_\ M]?#_ /H1KW =17A^L?\ (;O_ /KX?_T(UW8'XFERD4$@ M8GE)E _4UZ%X/T>]T72YK>^C5)'F+@!@W& .WTJL35A.E[K)HTY1GJCH:*** M\T[ HHHH **** "BBB@#SCXD?\A.Q_ZXG_T*N&DGBA*B214+=,GK7=?$@$ZG M8_\ 7$_^A5YYJ"C?:9'_ "V Y%>M2DXT$U_6IPU$G5:9=KWM/N+]!7@N#Z&O M>D^XOT%8X[[/S+PO46BBBO/.L**** "BBB@ I1]X?6DHH \)N4;[7-\I_P!8 MW;WJE#-/+<21FU=40D>9G@FOH82M7.V/AJ:TU^^U1]7FE6[B# MYA]5_P *DCD25 \;!E/<&N>M5]K+FM8VIT^16'4445B6%%%% '/^-M7.@^$; M[4EM(+HP[/W,XRC9<#G\\U=\.7QU/PSIE^88X#<6R2F*(85,C.![54\9P:7< M>$[Z+69)X]/(4S- I+@!@1@ 'OBK?AQ;%/#.F+IDDDE@+9!;O(,,R8X)]\4N MH^AIT444Q"JQ4Y4D&FSW0MXI+B:0JB*69CV%+5'6+.:_TF>WMR/-;#*"W[VA4W31KY1D7**JXR3T.3VJM+ID^H0R"^L0TVPB+$X5 M8N00$P.#P.3GIZ5JH0OKL9.<[:+4UK>[CN6D5 ZO&0'212I&1D<5/6;IEC-; MW=[=3-,6N"@7SG5FPH/)V\#))X%:59R23T-(-M784445)1F>%/$$VK:YXCT^ M2WAC33;E(HWC!W2!E)RWO755RGA/^PSK?B-M+>=KTW*?VAYF=HDVG&WVQ75U MD]RPHHHI %%%% %#6-)@UO36L;EY$B:2*0F,@-E)%<=0>,J,^U9MYX-TN\DU MR1C.CZS"L-R4<#: NW* @@$\9ZYP*Z&B@#!N?#'F:P^IVFL:C8W#V\=LXMQ" MRLB%BO$D;<_,>E2OX?%Q#:)?:G?7CVMXMY'+*(E;"Z$)@F6(J$N$Z@2 @Y*GH00>W3BDU/08]0OK>_BO;NPOH$ M:-;BU*;FC;!*,'5E(R >1D$<$;S TO. MZ7D9#-WQQP, 4VX\-L^LW6IVFLZC8S721I,L"P,K! 0O^LC8C[Q[UNT4 8[> M'UG;3GO=1O;N:PN3@!]ZDFT*VE\0V^MI+-#=Q0M _ ME$!9XRA1HX8XWE>5E4 R. &<@=3@ 9/L /:GT4 %%%% !1110 4444 9GB*W M%WXM&[R;6+%;RVMXVD\L\'.,<'L>>M<_;Z0WAZ^L+Z^T/ M05C>=(0]FCB2!W8*I&[AADX/0\YH [>\_P"/*?#!/W;?,>@XZUEZ-;&+R2;& MYA_=_?>\,J=.PW'^5:UPS);2LL?F,J$A/[QQTK T8VZ7<"6UU9S90[XH(]IA MXSV)QZ8- '1T444 %%%% '->)/\ D/>'/^OB;_T0]7JH^)/^0]X<_P"OB;_T M0]7JTCL2PHHHJA!1110 4444 %%%% !1110 4444 *.HKP_6/^0W?_\ 7P__ M *$:]P'45X?K'_(;O_\ KX?_ -"-=V!^)G-B=D4JW?!W_(V6'^\W_H)K"K=\ M'?\ (V6'^\W_ *":[ZO\.7HFS6<&<,5V[3CY$Y-6L;4ES!#+%%)*BR2MMC0GEC@G@?@:A35+)[W[(LX,^2N M-IP2!D@'&"1Z9J*[M9+FYTRY%J5DBFWR;@-T:[&&"?J1TK/&FW1U&VC5;J*V MAO'N2'53'C#='')R6Z=LG/2JC&+6K)E.2>B.@HHHK(U"BBB@ HHHH /E/WHT M;_>4'^=U=/7/^)M)U+5+C2'L#:A;.\6YD\] MB"<< # ]S^E# U]LMO\ \L8KB/\ ZYJ''Z8-2Q7$<^=C?,.JD8(^HJO?7DEO M-;6]O"LT]PS!0[[0 !DDG!]OSIMK<1:E8QWOV9C(I8%$Y<,K$%0>,\@_6JY7 M:Y/,KV+U%9<.J7%UI$=_!:Q*#O,B3S;/+"DC.0I]*N6,\UU8PSSV_P!GDD7= MY6[=M';G [4.#6X*:>Q8HHHJ2@HHHH **** "@V]K'I.L(\\BQJSP* "QQD_-TYKT #H /PHVK_='Y M4M0.*U[XFZ9X?UJYTNXTW5)I8"H:2")60Y4-P2P]:GU'XAZ=IN@:9K$NGZB\ M.H[O+CCB4NFW^\,\5UVT'J!^5&!C&!^5/4#D=)^(>G:QI>JZA#I^HQQZ;$)9 M$EB4,XYX49Y/%5='^*6E:UK%KIL&EZK%+:Z[:O\ ='Y48!Z@?E1J!R-I\0].N_#%]KR:?J*V]G(L M;Q-$HD8L0,J,X(^;UIOA_P"(-IXHOVL+#3=3MY#&Q%Q<6X\M"!QNPU=A@8Q@ M8^E '0 ?04:@9W@3PP_AG1IA=W"W6I7L[W-W<*,!W)[>P_J:ZFH[?\ U*U) M6;*"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 4=9$K:+>B&".>0P/MAD0NLAQ]T@,@PQWWF/%; M-CMEBHQT![=J?XRN-,.OZ)8ZY?I:Z5-#-['&?Y5)X0 M\3:-+I\6G#Q!9W5TMQ-#"CW:/+(@D8)WRWR@<]Q0!T&KW=G96!FO;EH(MP 9 M9-A+=AGWK.T>:TN=0\R+5XY'VG%I'>";(_O-RHJLMOJ+.OG7L(0=?)@*LWXEC@?A^- $/B.:>W\-:E-;%EF2WN!WX'- '*Z^]U:W^MM%>7)#:;&P7< (09'#%< 8XR<\GBM'0 MDBM]=U6ULGW6$<5NR*)"X61M^\ DG^$1G'OGO6^8XV)+(I++M)(ZCT^E1VUI M;6<7E6MO%!'G.R) HSZX% '+^(KZW?Q5H%HKL9XYY2R[&X!@;OC!ZCI6KYB_ M[7_?)K.\1_:1XJ\.G=%]F\Z; P=^[R7[],8K5WMZUI'8ED?F+_M?]\FCS%_V MO^^34F]O6C>WK5"(]X_VO^^31YBX_B_[Y-2;V]:-[>M $?F+_M?]\FCS%_VO M^^34F]O6C>WK0!'YB_[7_?)HWK_M?]\FI-[>M'F-ZT 1[U_VO^^31YB_[7_? M)J3>WK1O;UH CWK_ +7_ 'R:-Z_[7_?)J3>WK1YC>M $8D7@_-_WR:\2U@YU MJ^/_ $\/_P"A&O<0[9'->':S_P AN_\ ^OA__0C7=@?B9S8G9%*MSP>0OBNP M)_O'_P!!-8=;O@TX\66!']YO_037?5_AR]#EA\2/7/,7_:_[Y-+YB_[7_?)J M3>WK1YC>M>$>F1>8O^U_WR:7S%_VO^^34F]O6CS&]: (_,7_ &O^^31YB_[7 M_?)J3>WK1O;UH C\Q?\ :_[Y-'F+_M?]\FI/,;UHWMZT 1^8O^U_WR:/,7_: M_P"^34F]O6CS&]: (_,7_:_[Y-'F+_M?]\FI/,;UH\QO6@"/S%_VO^^31YBX M_B_[Y-2>8WK1O;UH C\Q?]K_ +Y-'F+_ +7_ 'R:D\QO6C>WK0!'YB_[7_?) MH\Q?]K_ODU)YC>M&]O6@"/S%_P!K_ODT>8O^U_WR:D\QO6C>WK0!'YB_[7_? M)H\Q?]K_ +Y-2>8WK1O;UH S[VV:XFMKFWE$5Q;EBADB+*P88((&/8_A2Z?: MC3X8X5F+HH)8>206D9BS-UX&3TJ_O;UHWMZU7,[6%RJ_,9*Z7&ND+IQGM(9'YBXS\W_ 'R:-X_VO^^34F]O6C>WK0!'YB_[7_?)HWK_ M +7_ 'R:DWMZT>8WK0!'YB_[7_?)H\Q?]K_ODU)O;UHWMZT#(_,7_:_[Y-'F M+_M?]\FI-[>M'F-ZT"(_,7_:_P"^31YB_P"U_P!\FI-[>M'F-ZT 1[U_VO\ MODT>8O\ M?\ ?)J3>WK1O;UH CWC_:_[Y-'F+_M?]\FI/,;UH\QO6@"/>O\ MM?\ ?)H\Q?\ :_[Y-2;V]:-[>M $>]?]K_ODT>8O^U_WR:DWMZT;V]: (]X_ MVO\ ODT>8O\ M?\ ?)J3S&]:-[>M $>\?[7_ 'R:-Z_[7_?)J3>WK1O;UH C MWK_M?]\FC>O^U_WR:D\QO6C>WK0!?M75X0!GC/8BIJC@.85-25D]RPHHHI % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $H./SK#T2:WN-4U-"^FN([@&T%NT9<1;$R3MY'S[^M7]?M9;[P_J%K M!YAFE@=4$;!68XX )( STZCK7(W":DZZ:UIX GLY;6=)=T-Q:*44=54B09#= M#TX- '?T57LIYKFSCFN+22TE89:"1E9DY[E20?P-6* "BBB@ HHHH X_Q'%" M/&GAZ46;"8O*INL#!7RG^3.<^_2MFLSQ(;C_ (2GPZ"L7V?SIL-N._=Y+]L8 MQCWK3K2.Q+"BBBJ$%%%% !1110 4444 %%%% !1110 HZBO#]8_Y#=__ -?# M_P#H1KW =17A^L?\AN__ .OA_P#T(UW8'XF(Q<_\)5X=8O%]F\V8!-AW M[O)?G=G&,=L?C6I67XC>X_X2KPZAA06_FS$2^9\Q;R7XVXZ8[Y_"M2M([$L* M***H04444 %%%% !1110 4444 %%%% "CJ*\/UC_ )#=_P#]?#_^A&O M'ZQ_R&[_ /Z^'_\ 0C7=@?B9S8G9%*MWP=_R-EA_O-_Z":PJW?!W_(V6'^\W M_H)KOJ_PY>ARP^)'K]%%%>$>F%%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% &G;_ZE:DJ.W_U*U)63W+"B MBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% ',>)'7_A(?#B;AN\^8[<\X\EZT*S?$D$(\3>';@1)Y MQFF0R;1N*^2_&>N*TJTCL2PHHHJA!1110 4444 %%%% !1110 4444 *.HKP M_6/^0W?_ /7P_P#Z$:]O'45Y9J7A#7[C5+N:+396CDF=E8$<@GCO7;@Y1C)\ MSL<^(3:5CEJW?!W_ "-EA_O-_P"@FLZ'2=1GUB328[*=T>S &.O/2NH\ M->%M;L/$-I=76GR1PQL2SDC X(]:[*E6FX.TEL<\(24E='I%%%%>,>@%%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% &G;_ .I6I*CM_P#4K4E9/K+\1VT8\5>';K=)YAEF3'F-MQY+G[N<9]\9K4K2.Q+"BBBJ$ M%%%% !1110 4444 %%%% !1110 5D1:Q:4:K-H MV1L X*L 1P0>1WH M45F6WB'2KL2-'=!41#(7E1HU* XW*S !ESW&1T]:NVE MU!?6<%W;2"2WGC66)QT96&0?R- &!XD_Y#_AS_KXF_\ 1+U>JCXD_P"0_P"' M/^OB;_T2]7JTCL2PHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% &G;_P"I6I*CM_\ 4K4E9/Z0\5 MLH>9)8IE0G&_RY%?;D^NW'XU5L8+TSZAB,, M^XIVAVNS0;72KZU+%+5/-22/,?.?DYX)&.1]*?,PL*MQ9.("MY 1.,PXE3]Y M_N_-SU[596WW@E3D D'&#R/QK$TO0S'X;TM9(YX;F**.,PKPORMN7>,=%//& M/3VK1T6741<36]S!L@CR$/EE<$,0/FS\^1\Q(Q@FCF86)6,"Q32M<1B. D2L M77$9 !(8YXX/>D5K=GG1;B)FM\&90ZYCR,C=SQQSS62T5]LUW38]/F9[ZXD\ MN=@!$$>-5W$^V#P.>*271;Y;^811;K>[N?)N"6QF$)&=WO\ <=?^!T3/Y?DSQR>:A>/8ZG>HP"1SR.1S[TD1@GD\N&XCD?!.U'4G )4G&?4$?6L2[ M@^P:1IKWUA?2B!'4R:<)&N(G)& G)4@'/;@4075_H!&H:A9W]['CW,(AED=Y/+'50SD@'WP1GWS5RCF86*'V1_1OT_P :/LC^C?I_ MC5^BCF86*'V1O0_I_C4<*)<1>9!(LJ9(W(RL,@X(R#V((^HK3KF%T.[?PQ%I MTL8W_;S+(@? ,9N2YY]U/3\*.9A8U_LQ)P"2?P_QH^S'WZX[=?SKG5T;45U> M.:/3Q"B3SJS1F,*T;(RH<[BY_@R#@#L.!3'\)R+8N(K2(7(T^WC1MPR)T8EF MSZ_=^:CF86.DDA$2LTCA%12S,Q "@=2>>E"P;T#JVY2,A@01C\ZYFZ\.ZA=3 MW\<\+RM-/-(EQNC"-&R,$0G[Y !"[<8XSFIX/#UU+J%FUQ:J+.-X6:%G!"A8 M&0@J#@_,1QT[T+5B,C)'X?XURK^'-2%K M;1/:">&'RP8/. !5;DO@9..$Q_*NCT&TEM8;QI+8VL<]RTL-L6!\I=JC'RDJ M,L&; ./FHYF%B?[(_HWZ?XT?9']&_3_&K]%',PL4/LC^C?I_C1]D?T;]/\:O MT42I$B8,F2-G7[V1C'6IY8E@B:69Q'&HRSN0 ![DFL/ M2)9['1-/T(Z5<2WELR0N9H&\G"L,R^9C:>!N !SG'0YQD36-[-I30PVFHF[- MC,NI;E=?.E(& A;AB6W$%3@#TXHYF%CM#;%<;B1DX&<A([]:IRZ#=)I[O'%?-<+ID+J3- M(2;D$Y/7[W2CF86.M:W*(SN2JJ,DG 'YTB0B49C<., Y4@\'H>M6VG^'&SIC''-/M=*O)[C3K>2&]33U,&Z,LZ * M+9P0>$P?7%=)X=C>."](2XCM7NF:UCG#*RQ[5!X M;Y@"X<@'L:.9A8M?9']&_3_&C[(^>A_3_&K]%',PL4/LC^C?I_C1]D;T/Z?X MU?HHYF%C)1[>1('2YB9;@9@(=2)1C=\O//&3QV%3_9CD#G)Z#C_&N-L?#NKQ MZ/IEH+2ZAN+2T>*1Y[Q9(R3"R810QP=Q&&XP,^N*V(_#\ZW'VHP)]J_M&*82 ME\L(@BJP![#AN.]',PL;/V8\=>>G3_&C[.=N[/'KQ_C7,+X7O9=/*W,"O<"& MS1&:3)4I(3)@YX^4]>_2I;C0+Z*Y!AMM]@E[+*+2+RR"K1J%8*Y"\,'X_P!K M(HYF%CH/+3SS!YB^:%#E-R[@I. <9Z9S^5.^S'..<@9[?XUS?_".WT;*T=N3 M*;"&$2M*I="LV\H6X)^4]N/EQZ5-_P ([=) LD4"K=LU[YD@?YF60OY8)[CE M..V*.9A8W$B61F5) Q5MK!2#@\<'GKR*?]D?T;]/\:YFTT&]BG4-INVX-[!/ M]N$JG;&B1AP>=V3M=< $'.37:T]:=^/\:Y/3]+ MO[/S=L5Y]HDGA>65P09!]F(R<$C.[@X)YQ[4]=)U"RMK<6L=X))+&V\]C([, MTHE3=DD_>V[L^V:.9A8ZB.%9HQ)$XD0DC>*00^&]6N]#N DD4 M)-"L;QK.[UO3;>Z4@-#+=(CC(!&5)SR"#^-:E M;#')_ID ^90?^76*@#J%974,K!E(R"#D$4M><:5^MXW.[P)JA/.8!G\Q0!J6&N:1JKLFG:K8WC MJ,LMO<)(0/?:35^N6\5V]O;_ -C36L,::@-2@2W* *Q#-B0<=1Y>\D=.*R_[ M5U0^'O\ A*1J4IP:?M3R3'Y_E;.F[=CG.>O;'% '>T5Q":EJL&N*]_=W< M4$FH&"%XHHYK.2(N51"5^='Z D\!L]JJZ9KFNW]M9ZPJWV+FZ"M!((%MA"9- MFT$G?N YSU)&,@T5E:[JK:3:1S+-81;GVYO9S$IX[$ Y-0Z!K;:N\ZM< M:7+Y8!_T&Z,I&?[V5&* -EI$0J&=5+'"@G&3UP/R-1S7EK;R1QSW,,3R'"*[ MA2Q]@>M;<&0WK1^69F\L#R).0G3/'7K5*YM+6^A\:S:A%') M/$6C1GZQQ+ K)@_P\ECQWYH [.>\M;5D6XN88F+ MQ!)KT223K96T;&91^[0VRNV,]/G9SGU'M6XM_>VWPU6_$FV^CTL2AV&[YQ'G M)SUYH Z.21(HVDD=4C0%F9C@*!U)-117MK/9"\BN89+4IY@G20%"O][=TQ[U MQNIS:E937%E<:E+>17FB75PZR(BA)$"#Y-H& 0YX.>@YK/T_$.B)X/3(%U+# MY2CM:RKYDF/8;95_$4 >B6US;WEM'/>@#?HK%%_>6NH&RGDCF;$3B01[>&B_6SM6 MA0O=)!O="VT&)G)QD<_** -RBL)-1O4U;R[F1(H6G,<:M"2CKT&) 2 V?X3C MN/>I=3U"XCU&*QMV:,M"TS2" RG@@ 8!XZYS[4 ;%%9!&DUX#$ MH88$4@;&]N?N$8]\E1_%Q),[B!0!OT5 MA3:E?>1>:A')"MO:N1Y#)EG"@;LMG@G)QQZ>M(NI7T>H2+<.D:&218T: [64 M [=L@)&XX&5.#U':@#>HK&GU:>*QM956,RS6G3W5S:PS7$:Q%HQNCP..Y=[*+[1'Y,#R#S\_(#M!QP#G/9A0!U%%<[.C:M<1W\%O:W, M LU9(YY2#EB200 << <_6J&LZ];W%K;[9I;6!#;S$;6!?4X'8T M =C17(ZP9[6TO[OR)9+U9A);W*GY43*X&<\<<%<012T %8UWX3T2^OYKVXL0 M]Q.096$KJ'PH49 .#P .E;#,J*69@JJ,DDX %(DB2 E'5L$J=IS@CJ* *RZ7 M8H;,I:Q)]B!%L$&T1 KM. ..AQ5*Y\+:+=W4]S/8J\EPP>4%VV.PP Q7.W=P M.<9XK4BN(9R1%-')CKL8''^<'\JDH XK7/"-WJUY?(;;33;WI :Y\R1)$7 ! MS& 4=QCAB0>GI767EA;:A82V-W$);:5-CQL>&'IQ5AF5%+,0J@9))P *;YL? M[O\ >)^\^Y\P^;C/'KQS0!FZ?X:T?3+D7-I9*LX!59'9G90>N"Q.,^U(/#6D M"_\ MHM/WOG?:,>:_E^9_?V9V[N^<=>>M:U,EFBA&994C&"KA, M[0WN!GFM-Y$B3?(ZHO RQP.>*(Y$E0/&ZNAZ,IR#0 I /4 _6@*!T 'TI ZE MR@8;P 2N>0#G!_0_E2++&\7FI(K1XSN!R,?6@".>SM[F6WEFB5WMW\R(G^!L M%SL+6PL8[*UA6*VC7:D8Z >E58M%ME@MXY#(S6T9BBD65D81Y&%)4 MC/W5_*M!'23.QU;!*G!S@CJ*=0! ;.!K)K1U+P.I1E=RQ(/4$DY[TD]C:W+, MTT*2%X_*;<.JYSC\ZF1UD171@R, 593D$>HIU %%='LE@EB\MV$I!=WE=G)! MROSD[A@].>.U+!I-C;L&C@^<2>;O9BS%]I7<23DG:2,FK;R1Q#,CJ@YY8X[9 M_D"?PI&EC2+S6D01XSO+#&/7- %7^R;+[7]I\H[]_F;?,;9O_O;,[=WOC-27 M>GVUZ4:97WIG:\HW*0<' XJ=)$D7=3(9Y5D*AV 8!%4!P#A\;<\@]:UJ* *4N ME64UR;B2(ER0S .P5R,8+*#M8C Y(/04)I5DET;E8B'WF3'F,4#'.6"9V@G) MYQGDU=HH SXM$T^)]RP$G8T8WR,VU6ZJH)^4' X&!4MUIEK=F,RHX:,;5>.1 MHV [C*D'' XZ5;HH KPV<-O*KQ+L58A$J+PH4'CBI(X(H7E>- K2MO<_WC@# M/Y 4]F5%+,0J@9))P *:98UA\YI$$6-V\L,8]<^E %*30].DQF!D&"I$#QR:MR6T,D @>-3$-N$Z ;2"/R(%/1UD&48, 2,@YY!P1^8Q3 MJ *3Z59279N6B)D+!R/,;86&,,4SM)&!R1G@5);V@AN;FX)W2SL,GT4#"C^9 M^I-6::9$$BH74.P)52>2!U_F* '4444 %%-+H'5"RAV!(4GDXZ_S%.H **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH *IZI;WMUI[PZ=?BQN2RE;@PB7: P)&TD#D CVSFK ME% !5:YB>2XLV5V43C:H#DG<-WS?*>.#^%:M[Y]U8Q/#%. 75I(E?RY"OH#D M8/0]1P#6A10!SHYXS3#8ZNML$MEN MH@L87:]R"=WEN"1\QP,E,#VZ"NGHH P+G3M1C$OV*>XW>:0ADN"P\ORCV)Z[ M^_4?2J[L=@E@N5C";'4RAPS%Q@J 3M !.>GXXK=HH Q=0M+Q M]4::VCFRT42I(DP5%(=B=ZY^88/H>M58K#5O)9Y)+GSE:/8/M)QC^/(W8/'K M^%=)10!@6NFW[^4;J:[!\P+(!:)8[ MF.5YV=560,^TMD9;>.W7#9]S4$-KK(NX&D,RQ@KC:V[:H8Y# R\Y'7[_ %X/ M%='10!S*VFKQ:>EK''.&"1899E 3$04K][/WAGCCO4K:?JJ M!-.)04V&2X+ M*,I\Y().1NQQ@^U=#10!RHT[56BC9UNF>-B54RX*DQL,@^:Q(SM[CO@.-V/O?C72T4 8FF6EY;W@W1SQQ[I3(7E#(^YLKM4 M$X]^!WZU5>RUS[4R1RR"$L8U=INB!MP;KG./E]:Z6B@#G+2QU5C$EP]T$\Q3 M+^]*Y 5LD,)6/)*\<=!QUJUHUOJ4,\AOGE(*8.XY5FSU!WL1WX"J/:MFB@#G M4M=1'E^9%>LH(^T*MV,RG#,<<4L&GZF[(;F6Y_P!8@.VY('E[ M/FZ'KG'/7/(KH:* .=MM/U-]ANI+D8D12%N2/W83#=&ZYQSUJ%;/7=P+O/D( M%4JX( VXPV9 ,YYSM)Z C<[]V3SGMP?8KUJ MK/8:U-O0I.RM&R,&F!4_N\#^/'WO]G/N:ZNB@#GXXKJ+48;19F032RS2H'R5 M02LRD8/ ;< ?_P!=1/'J%W->BV:Y#K-*HD\_"!=APH7=P=Q!SC\>U=+10!A/ M;ZG=7SR@3V\?SF-7F&%;8H7(5B"-P)QS[]:@_LR]F=&*7L02&0+YEWE_,*KC MD'."1ZXXZ#OTE% ',O;:T]TSM]J565E8I(O=,# W@=?]D'_:[TCVFME$QYZH M P4(Y+J>,,B@##M;:]BU))YH;B1D64.YF4JQ9AMV*6^48'H. MG>MRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$! end GRAPHIC 19 imrx-20211231x10k016.jpg GRAPHIC begin 644 imrx-20211231x10k016.jpg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imrx-20211231x10k017.jpg GRAPHIC begin 644 imrx-20211231x10k017.jpg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end GRAPHIC 21 imrx-20211231x10k018.jpg GRAPHIC begin 644 imrx-20211231x10k018.jpg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imrx-20211231x10k019.jpg GRAPHIC begin 644 imrx-20211231x10k019.jpg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�!D7T5WKNA6DM MH$ADE5)2LLDB;01G&4(/>I- TZ\TZ&9;QXF9V!7RY9'X_P"!DX_"M?(HR/6M M?;2]G[/H.[M8PWMM1MK_ %F\M(HWDE6(P!SPY5<$>U0:!I]S!K.I7IMIK6WN M53]W/('=G&1ZT9'K5_6)6MN$1"W1L8P2#R.F1[4VQTW5[#6(HHG;["K[G;M/ZU-IIZWO^/8.9A1117,206?_ !Z1_2N%O=1M_$BLMS=7]JF^2VEA M@TAYU8)*RY$OEG&0!T/%=U9_\>D?TI\,$5M'Y<$21IN+;4&!DDDG\22?QH > M@ 10,X XS37BCD9&=%9D.Y21G:<8R/P)I]8VK:Q=Z?K.DVD5F'MKN1TFN&<# M9B-F 4=23M^@% %T:3IRQSQBPM@D_P#K5$2X?OSQS6)XU\,V'B#P9<:+-+'9 MVAV$,&$:IM8$#." ./2LP>,]4"62-;6GG:H(FLL!ML8>3:1)SSA<'C&3QQUK M6L?$!O\ 1 ]T#;W8FFMY/*MWG0/%*T;$8'0E M0W5[%&[ME7CXSQMQR/F^M=<8[>G:M2J4NC+4M+-7*EEJ=EJ*%K2YCEQ]X*>5^HZC\:MUFW^A6&HR+ M-)$8[E?NW$+&.1?^!#G\#Q51DU[3"#"\>JVXZI)B*91[,/E;\0*+)[,?+%_" M_O-VBN+UGQ/HT5W:"\GU"RG>95EA>26(A,'DA3C&<)-8ATR"VMYPH2]+P[VA:8 M(0A891>6''2J?A""S^T7]W;W$?9P2_:55)M\8/F*N2H;UQDX],U;KD; MSQC=6U_K%H-+VR6CV<-J)9<>>]Q(T:DXSM4$#WQGB@#<_P"$?T?;;K_9EKMM MCF$>4/D.<\?CS]:X/XI> [/Q3J6EWUQ>B%H<0!/,"E@SCD*5.X\^HK7_ .$V MO_WZC3;';41YYP LI3]W\O/ +M#Q'?6\K00)+'YB3QAE>U=B<\,/ZC\:TH-;@9A%=K)93DX\N M<8S]&Z'\#6E3)88IXS'-&DB-P5<9!K13BU:2^X=UU'YR,@T9/K64-(DL\G3+ MMX%ZB&3]Y'^ /(_ TBZM-:+C5+1H,=9HOWD1]\]1^(I^RYO@=_S^[_*X6[&M MD^M&3ZUSEOXAL;K65LX-2DD+'"JL8()SR,XZ8KHZ52E*FTI(&FMPR?6C)]:* M*S$&3ZT9/K110 9/K1D^M%% !D^M&3ZT44 &3ZT9/K110 9/K1D^M%% !D^M M&3ZT44 &3ZT9/K110 9/K1D^M%% !D^M&3ZT44 &3ZT9/K110 9/K1D^M%% M!D^M&3ZT44 &3ZT9/K110!8F9TL9'C^^L9*\9YQ7%:/INJ:E-IFI:KI4CLWE M7#L^LRLBO@'>(-H0$'G;T!KND^XOT%.H ***XB\UK6H=7U2Q>Z@C4W=G#;O' M'_J8Y68$\]6( Z\9/3U .WKB?B#XBM%5=K25S95W;EFKK^NIGVNLP7,+RL&A5/O,Y!7\&!(J]' M*DJ!XW#J>A4Y%4[C2XI$;[.S6LC-N+P@#7]?Y_(VOM$.[;YR9Z8W"I,GUKS"VU5I/ M&ZVZZD77SRH5G8!AZ8_SS7H:Z@BQ,]U');!2 3+C'/H1Q6F(PDJ/*M[JYS03 MG?EBU9VU+F3ZT9/K34D25 \;JRGH5.0:=7((,GUHR?6BB@ R?6C)]:** #)] M:,GUHHH ,GUHR?6BB@ R?6C)]:** #)]:,GUHHH ,GUHR?6BB@ R?6C)]:** M #)]:,GUHHH ,GUHR?6BB@ R?6C)]:** #)]:,GUHHH ,GUHR?6BB@"_1110 M!!9_\>D?TJ>H+/\ X](_I4] !5>YL8+N:VEF4L]M(9(^<88J5_'AC5BB@#!' M@_2!&Z>7-SL\LF9LP[6WJ(S_ X;GC^56TTZ#2M%^QV,=P(TR0(6!D9F;4RNCE'4D9Z,I'&>E $'AS/_".:?G=GR%^]UZ=ZU*R_#>/^$;T M[ 'D+P#D=/7O6I0 4444 8^M>&-*U^6WEU"WWO V58'!(_NGU'M31X8L8!B MQFN[$#H+:=U"4?' M^^AQG_@-/.LW]N,WFB7( ZM:L)Q^0PWZ5M443/F)\^FUL&M4,&&001[5%<6EM=ILN;>*9?21 W\ZRY/"^G@$V;7-@_9K29 MDQ_P'E?TH]UA[C\C:HKA/%UGK]CH$YM]4CO<#CSXU2=%[E"N 3CVSZ ,D@%P?TI*+$HMNQIT4@.0"01 M['M2TB0HHHH **** "BBB@ HHHH **9YL9./,7/IFGT %%%% !1110 4444 M7A]T?2EI!]T?2EH *R+WPWI]_->S3"427:P!V5\%3"Q:-E]"&;/Y5KUG:[J\ M.@Z-<:E<(SQPA?D4@%B6"@9. ,DCK0!G'P7I94+YEU\V[SSYO-QN?>1)QS\Q M/3'ITI_B=I!#:A/M6PSQ[O*";/OK]_//Y55/C6)8(96TZ.U*(KA9X]S?:"FWYU_@'#?C0!I4444 %%%% &+)X M8T]]6?4%5XI&3;B%BG.>6R.YJAHYJ M;WC]S_SN%UV,#4/&.DZ?.L32--N7<'@PZ_3(/6MY&WHK8*Y&<'J*R=1T"WOY MHG,%J%C?> 8N6X(P<$9'-/.@PA!Y%S=6K]S!,ZI!_K=+$HSUMY@<#Z-BL_97^%I_A^ M=B;&I164NOV?W9UN+5SP%N(64?GC'ZUE:5XQ34M6-D(E15!+2$@ ?C]/SJH MX:JTWRZ(?)(ZJBH?M=L?^7B+_OL4X3PMTE0_1A6/*^Q))12!E/0@_0TM( HH MK-N-?TNUO#:3WB)< @>60(-/! E::%CVE@=.&VDBMXHI+S*/&V7G>(JJGD,I1LYSD\>]:?B6[C? MRH$D0,DT8=7M'8G+K]U^ OZT :U%%% !1110!R4GP]TB77I-4=YR78N80P"A MCWZ9]ZTY-*O;6V2+3KT[5))6?YL^V?3VQ6U171+%UIVYW>WI0E-TX:V^8+^^^ M4$^QZ&K8((R#D5BS:'(EK';V5R41220_5LG\OS!J)XKR"_B01R0V\8 \Z,X! M4,"CV4)?"P=&G/X)=_P"OZN=!17GNL>,=2AU!4MVCCC0YP%!W#T/) M_2NK@\00O91W$T4B;F"X3#\XSV/2KJ8*K3BI-;G-&$Y3E32=XVO\^WNY=X*Y'XU86:-G*+(A8=0#S7,XR6Z!PDMT/HI"0 2>@]*K0ZC;3 MS&*-W+CJ/+88^N1Q246]4@46U=(M4444B0HHHH **** "BBB@ HHIKNL:%G8 M*HZDT .HJ**Y@F;$4J.1V4YJ6FTUN-IK1A1112$%%%% !129&<9Y]*6@"_11 M10!!9_\ 'I']*GJ"S_X](_I4] !0>1BBB@#DY?!;SS)![5JW]_;: M9:-=7<' /<'(( M/3!H S/#9!\-Z<1C'D+]T8'3TK4K$\.O=GP[8'R8S^Y'WY"#TXR-O7U]*T]] MY_SPA[?\MC^/\- %BBJ^^\_YX0=_^6Q_^)H#W>>8(<9'_+4]._\ #0!8HJOO MO-O^HASCIYQZYZ?=]*-]WG_40XR?^6IZ=OX: +%%5]]YC_409Q_SV/7_ +YH MWW>?]1#W_P"6I_#^'_/O0!8HJ#?=9'[F'M_RU/X_P]OU]J3?>8_U$&IZ?]\T;[S;_ *B# M..GG'KG_ '?2@"Q37CCD&'16'HPS41>ZR<0PD9./WIZ=OX?\^])OO/\ GA!V M_P"6Q_'^&@"M/H.D7)W3:9:,W][R5W?GC-_#:QN-=MK^VO+FUBBY:))&+ M CH48G*UUV^\_P">$'?_ );'\/X:-]YW@A[?\MC^/\-7&I..S-(5JD/A9FIH M5W FVWU_45_ZZ^7+_P"A+3A8:W&I":VDA]9K13_Z"16AOO,?ZB#./^>Q_P#B M:-]WG_40XS_SV/3_ +YI<[%[1_TD9WE^)(D.+C3)V_VXGC_D33/M?B6%29-) ML9SZ07A7_P!"2M/?>X_X]X,X_P">QZ_]\TN^[S_J(<9_Y['I_P!\T20*8[B *,#D_-SSCI7 M9;[S'^H@SC_GL>N?]VJ.I:=-J:K'-'$8D<.J%P1E3E3RA[]?ZU4)1O=HNG." MDG*.A7@\2(UK%(MAJDY90V1:$$Y^N!3U\0S/]W0-8/UB1?YO6C&;U$"M'$Y& M,L93D^O1:=OO/^>$/?\ Y;'\/X:5X]B>:/8RWUG53_J?#=XW_72>)/\ V8TB M:GX@?_F7$3_KI?)_0&M8/=9&88<9'_+4]._\-)OO-O\ J(<>N?\ =]*. M9=OS#G7\J_'_ #.$@N/%)\<3Q_V+8B 1 ["0$5><,),9SG/;\*ZDWOB%>NC6 MC?[M]_BE3K8.MQYPA^?.-QO9>0.1QC]*M[[S'_'O!G'_ #V/7_OFJE43Z%3J MQE;W5_7S,IM3\0+_ ,RZC?[M^G]0*9_;'B 'GPN_X7L1K9WW>?\ 4PXY_P"6 MI_#^'_\ 5[T;[O/^HA[?\M3^/\/_ .OVJ>9=OS_S)YX_RK\?\S)76=7_ (_# M5T/]VXB/_LU2#6KT??\ #VHC_=:$_P#L]:.^\Q_Q[P9Q_P ]CU_[YHWW>?\ M40XR/^6QZ=_X:7,NPN:/\OY_YG':YXXU'3M6TZUAT&[5)WPZS*-TG;";21GO MR:[@'(!P1GL:R;NPO[NXAG\T1F%O,C174A6VE>IC)Z,?QJ\K7BJ%,438XW&4 M@GCK]VG-Q:5D5.46ERJQKC[H^E+3(BYB4R*JOCD*V0/QP*?4&054U.SDO[![ M>*<02$JP;A>[80!(K.7(09^ M3J1WZ^M6O$T%O$;5T2R21YX\EX7(BDEP5&UB M "0H+$#"C) R<#)JAXI,PM[?RI)P/.CRB("C?.OWF()'X4 :%%1!Y\\Q)C(_ MC[=^U)ON,?ZE,XZ>9WS]* )J*AWSY_U*8S_ST[?E1ON,?ZE,X_YZ=_RH FHJ M+=/G_5)W_C_+M2;Y_P#GBG;_ ):?GVH FHJ'?'[=+^:[D2WD:;;Y@: 'H,<9Z5I;[C_GBG;_ ):?_6HWW&/]2G_?S_ZU M7&I*%^5[C3:V*YT;2VZZ;9GZP+_A3?[#TK_H&VH^D0%6]\^?]4F,_P!__P"M M2;[C'^I3./\ GIW_ "H]K/\ F8794.@Z4?\ EQA'T&/Y5$WAK26_Y=6'^[,X M_D:T-\^?]2F,_P#/3_ZU&^XQ_J4SC_GIW_*J5:JMI/[PYGW,T>&-+'W8[A?I M=2__ !559?!NES:C!=.LKB,'/GEW&P6%G:C$%K#%_N(!5BH=]Q_SQ3O\ \M/R[4NZ?/\ MJDZC^/\ /M6+;>K)):*AWW&/]2FG;\J0$U%0[[C' M^I3./^>G?\J4M/DXB3J?X_R[4 2T5#ON/^>*=O\ EI^?:C?).W\?Y]J3?<8_U*9Q_P ]/_K4 ,6PMEOS>K$HG,?E[@/X);?2K_P"R MR6T\@1(Y)Y8PNV%9'**3DY/(/0'@5%XJAFDMK=HTRB2IO?[2Z;?G7^ ##_CT MH T:*A$HK2,4N?^/EA_P$4GE3?\_3?]\K6/MN\5]QI]8[Q7W&\%^/^9G1ZZQ,JS:;>1O&I; 3.['7!Z5@3>/)$UI8$LA] MBW!69R1*/7CI77^5-_S]-_WRM4)/#]G+J:ZA)\UR"K;L#DCVK:C5PZ;]I#IW M,:\N9+V2MJK]=.J)O[:M-J$"5-_P _3?\ ?*UA>';\?^ :G)^+_KS.+\+>*KRYO&M9KB&7>0 MPWC!&3DXVC\>:Z:#7%G>;%U9[(P3GYLCG SFJVA>%(]!EE>VNE_> !L1 'CI MR2:W!"X'^O\ _'!6N*K4)5&Z<=/N_0SIOF&-=2LUD8#(*9W9Z8^:K,MBLZ;)75TSG:T2D?J*KRZ):S>6 M7V9C&$VQJNWG/&*P4Z?5?D:QJ4NJ_!,5;T-=.!J5L43):,+R .O.::MZI@DD M.JVY7(4.J !3^=2?V6!.TJW=P"Q)(#\<^W2A--ECC*#49SG'+!3C]*.:']6_ MR#GI=/+HO\CA= U)9?';(-3,FZ210V#B7 Z>G?\ 2O2Z\^TCPW?VGBTWSPB. M/S9&\X*,G<,=.U=WYZD)=B#]H<8!/ Z]A6O10!A7^BJ M/LOV=KO_ (^%\S%P_P!SG/>KG]B6G]^Y_P# E_\ &L;QMJ.H:=8_:-.OFCE@ MC:9[=!%ET!&7.\'*KW"X)R.:Z>)Q)$D@Y#*".,=: ,R'08$:4R3W3AGW(/M# M_*,#CKZY_.BYT"&6!DBGNHW.,-]HS2?9)YKR*"$>657R9 H M/"AER. MXPK.Q5>O92!^%;5% &#?Z*!+9?9VN]OV@>=BX?[FUNO/KBKO]B6G]^Y_\"7_ M ,:P;G4]0M]6\1PWNLQ6=G;VUK-!,L*_Z.KO*&ZYW,0@QG(SCCUUO"\][5560Q[CLWA0 &VXR !^= !;^'XHY;EI;FYD627=&OVAQY:[5 M&WKZ@G\:6[\/Q31*L%S=1,)8V+?:'.5#@LO7N 1^-;%% &=_8EI_?N?_ )? M_&J5OHJ_VI>B1KO[/MC\G-P^,X.['/TK8NQ.;.86KHD^P^6TB[E#=B1WK@I] M>UQ+/1KY[[_1DTV"YOA"T2RS.[*"0C(Q(Z\#;UX.: .IU#P]'>Y\MB,!L9['FK/]B6G]^Y_P# E_\ &M&B@#'&@1"]>4W%T83&%$?V MA^&!.3U]"/RJ9M$M=IP]UG'_ #\O_C6E6'K]UJ%I>:.;2>..VEO5BN%*;F<- MG ![#CGOTH 32M%0Z19&[:[%SY$?G;KA\[]HW9Y]P##_@5<]X4UW6+_Q+<17\KM93I.]KN\O#!)=ORA0&7 QD.22> MF.17B@#G[_ M $7%[I?V=KORC=-]IQZN MMEK2WD,,+@32P((HY]_W8PH!8*O!R3SCGJ*Z'PQ>7&H>$]&O;J3S+FXL8)97 MP!N=HU).!P.2>E &C#"L$2QH6*KT+,6/YFI*** "BBB@#EO$6AZA?WUP]FL+ M1WMFMG*TC[3" Y;,/GR0F$P>QWY/?"\4 :7_".VG_/SJ'_@;+_\ M54,?AJ,74S/>W[0L%\M!>2Y4\Y_B[\5IZ9=M?Z59WCQF-KB!)2A_A+*#C\,U M:H P[GPU"]M*L%Y?QS%2$&H4M84N+R_DF5%$CB]E 9L M)DO+\1C/F+]ME^;CC^+UK55/<@$ MBLWPCJ=_?P7L&IF7[7;2J&65$5@K(&'*$J>O;D=#ZD GF\-1,8O*O+] '!?- M[*=RX/'WOI4O_".VG_/SJ'_@;+_\56O10!A0>&HUFN3->W[HT@,*B\E&Q-BC M!YY^8,?QJ'5-!6*S#6L^I&7SH0=MW*QVF10W&?[I/TKHZY?Q?J^HZ8]BMFS1 M02B9IIXX1,ZLB[D79_=8YRW; Y&<@ T?^$=M/^?G4/\ P-E_^*J!/#*"]F=[ MV_-NR((X_MDN58%MQSGOE?RK0T6^?5-"T_4)$$;W5M',R#HI90Q'ZU>H P+[ MPRLNGW,=G?7\-TT3+#*UY*0CD':2,\X.*L?\([:?\_.H?^!LO_Q5:](?4XHM0^UW4*QV]L':YD25UCC13V^49)[#.1R:[.V,S6D)N%59RB MF0+T#8YQ[9H Q-/\,B'3;6*^O[Z>[2%%GE6\E =P!N8#/ )R:?)X:C-W Z7M M^L"AO,0WDN6)QCG/;FMVB@#(_P"$=M/^?G4/_ V7_P"*JAH^@^=8NU[/J8E% MS<* UW*IV"9PG&>FP+@]QS5WQ/=ZA8Z,UQISPHZ2)YC2J6PFX [1Z_6LAM8U M>'QOY%UOCT>2X%K;E/*O1OR'8YH TY_#4;26YAO;]$63,H-Y* M=Z[2,#YN.2I_"IO^$=M/^?G4/_ V7_XJM>B@#"@\-1K)<&:]OW1I,Q 7DHV) MM48/S<_,&/XU!JN@K%:1M:3ZD9#VLR QR(JR*C1J MPW;"4Y);&T],9YS754 8-]X9273[F.SOK^&Z:)EAE:\E(1R#M)&><'!J?_A' M;3_GYU#_ ,#9?_BJUZANV=+*=HI(XI!&Q620953C@GV'>@##&@)_:YC\_4OL MWD!L_;)<;]Q[Y].U6_\ A';3_GYU#_P-E_\ BJYO^V?$(\,:C?V]U%-##,OV M>\N(-C2Q8&YE0<8W$A2<<<\\9[H<@4 (BA$5!DA0 ,G)IU%% !1110!S^L^& M6U;4A<+>F""5(HKN(1;C*D_P#*G^'GO9/#6E/J0(OV MLXCE6CH6D%2/[+LN?^G= M/\*YHND?Q$MC:W5W,\DDD=W$[2?NQY65PIPGE@@8(YW-U/-=K0!E6GAK1K.R M@M4TVT9(8UC5G@0L0!C)..3Q2OX;T9[F*F>&M.M;,Q3Z;8LYFE?/D*>&D9E'3T(J;Q-)>1>&-3DL- MWVM;=S%LSN!QVQWK+\$96ROH@YEA2X CD#NR,"BD[=Y)ZYSR>=T"'!P!@<=.*K:MX9T^\M(X[?3K%'6Y@E)\A1\J2HS#IW52/QK=KB_ M'[3)':R)-A5BGVQ>=+%F7:-C HIRR\X4XSGCI0!TO]AZ1_T"K'_P'3_"HH_# M>C1SS2C3+0F4@D&!,# QQQQ5O3C.VF6INO\ CX,*&7/][ S^M6: ,J[\-:-> M6<]L^FVBI-&T;,D"!@",9!QP:F_L/2/^@58_^ Z?X5?IDJ-)"Z)(8W92 X ) M4^N#Q0!D1^&]-75KBY.FV/DO!%&J^0O#*TA)QCT9?RJTV@Z0R%3I=E@C'%NG M^%>=76Z'PW:V-W?ZDVH/>:A!;RRS.BI^_<"XE9<9*J!M'WMXH5TRS98T" M A) &.3CK3'\,Z,]]%=G3;4/%$\0 M40IM(8J22,=?D&/J?6M:B@"A_8>D?] NQ_\ =/\*J:;X;TVUT^&";3;%I$& M&/D*<\_2JWC*"ZDTRSDM;JXB,6H6C/'!C]ZIGC!#<9VX))QCISQ61I&^'Q]< MM]H-ZUS+/O'[Y#:*H&T%6.P@X ! YSD$B@#I9O#6C3RV\C:;: P2&10L" $[ M67!XY&&/X@5-_8>D?] JQ_\ =/\*OT4 9=OX;T:VC9%TRT8,[OEH$)RS%B. MG3GCVJ&_\-Z;<11+%IMBI6>.1OW"C*JP)'3T%;5D?] NQ_\!T_PJ"#PSHUO-N:Z>@#+N?# M>C7,#0OIEHJL0U2_P!AZ1_T"['_ ,!T_P *OUE>)9K:#PY?2WHZT 0Q^&M.76;FZ;3;$P26\,:+Y"\,K2%CC'<. MOY5<&B:2""-+L@1T(MT_PKAC!>R>$;*YM;^Y11K-M)]DAD,@2-KB(>4SG)(5 M22<'&3W KTB@ HHHH @L_P#CTC^E3U!9_P#'I']*GH **** "F2Q1S1/%*BR M1N"K(XR&!Z@CO3Z* (+2RM=/MEMK*VAMH$^[%"@11] .*GHHH **** *MYIM MAJ!B-[96UR86WQF:)7V-ZC(X-6J** "BBB@ JM%IUC!>RWL-E;QW];U<)KVC:Y+I>LIIT4JW%QJGGQ>7*$+1^0 MJYSD?Q#I[5DZ=X3UZUFAD(OM\7]E2*SWK-B0$B[)!;G*@9]>U 'J-5#JEB+6 MZN?M,9@M"ZSR Y"%!E@?IW_$5QO@+1/$&EWLS:O+F =%U#4/"C6:Z?>WT@!)$4$: MQKD]3@#%>9ZAH>N/K&J7E]K#ZJ:Z*@ ZUB MWBZ##>6T=W9V0:RC\R.62) MHF<##'[F2, #T]JVJYRYT6YO=6O#($^SR75M M*=XSNCC7.T>^\9Y]: -VUO+:^@$]I<13PMD"2)PRG\15676K&'47L7D831PM M.^4.U4&,G/3N*P9? \=XS2W-V1*TLLA"1JP^:1F_B&>A _"M"]TG4!/:&*.>.2)5W=M+I4$VX"[FC:-6W9XWL.^?6KUUJFGV44]DA>.V,8\I79P516QRWJY#8P,8[T[Q-9:C>ZP]O:6GF1W5JMN\TD9 M*QH7R^#TR1U!QT&,T!F>>,U,-1L6CWB\MRF M$^;S%Q\YPO?N>!ZU@-X>OX'@N;22T:Z6XN)W$P.PM)D(W R2BX&.,C/(K+D\ M(:E86\T=O-#/;(Z7 &#YTC1181 .@'F -U[T ;-H/"6FB[O-*M=)610%N6L8 MHM^UF_BV]L\\^E=!##%;01P01I%#&H2.-%"JJ@8 '0 =JXZ#PY?K:6]M/% M&>"*T8P9VQQ(0SLQ.,LQXP.F>IYKM*0(****!A1110 53U'2=.U>)(M1L;>[ MC1MRK/&' /3(S[5HHH **** &R1I-&T/H*MT4 %%%% !6-XE_P"$>734D\2K8FR60;3>*I0.01W[XR/SK9J*X4O; M2HHRS(0![XH H:3XAT;6@5TK4;:["@\0.&QC&>GIN7\Q6I7FEWH/B1X/"=I; MB\AMH+2TAOU@N-FW:R"0'!_NAAD?A4#Z#XOMM')LYK_[8\4Z2^; M 7'S& /C!!.>2#S0!ZBS*B%F8*JC))/ %01W]K-;VT\N1W[W,C-YCA&0HX@X+J TDC8QOQEL\X]*2_M=5FU@WEM8:A>2 M1W3W-M+'=J+9X?L["-5YP"6(&=N4-Q8?*<-W_NY M]L5S$ MD^] CMB0JEF( R2>U9G_"1:4UG]JCNUEA,IA1H@7\QP,D*!G=T/3T-4--T+ M4[;5FO+S48YXCN(B3SAR?]Z1EQ^%4I-(UBWL-.M;>VCD5#++<21RJD@=V)*H MQ!V@[CDCGZ4P.JM+N"_M(KJUD$D$J[D<="*;-:6ER^^>"&5A&T674-\C8W+S MV.!D=\"LBXDFL?"U_%:6+6_V:)H;1$RQ;Y0 <8S]XGZXSWKF4\$7:0Q&*TCM MH0D$,UI!(A\X1A_G8LI5B68=1T6@+GG:1 8-.L[>UB=MY6% H9L8R<= M3@#\!5S(]:Y?P[X9.F7OVF[BC=K>!(;5LAS&"79\8 QR^W@#@5R]IHTVOWLA M%F/.B6X\Z^8,KRM(X7:2P!&V/<-O..!]2P7/3]RY R,GWJ.X@@N[:6WN8TE@ ME0I)&XRKJ1@@CN"*Y&3PK*NHL;:RM(5BN%FMKH8S$BJ,1J,9&6SGL03ZUE2: M!JC7&E6]YID<\$44,7V;SLJZQAF_EB0.K=,8<_K5V+Q3H$\<\D6M:?(EN@DE9;E"$4]"3G@5@2 M>"KJ2]\/S-<6Y33([=9%(/SF/=DCCW&/I6;-\-[Q[6QCBN[>-[2"10%W*&%;V+P)?:<&CDO9+C[:$ M1V96=95D";FY.=@!)QG).!5"]\%:O?W*O;7-C%:&[N;Y&GA8S*T\#IL93P0K M/^( &..0#L;'7]&U0JMCJ=G=QZ'MVJ:\U^&+2KV]M();A[:(R&,H8LX]W %3/H-A(%5XW(#R28\P MCYI/O'BA=!T]+*XM$B=8;A=L@\UF)'U).*8M3*U+7M3LX[+R[>T\Z:%&,+N2 M\TA(W)&HY R2QX'%;>IZE#I5G]IF21P72-4B7Z)->V&FVDE[*PMI$DEF!VR.54X(]#NP: *5QX[TB MT3_2!-%,K.LD#[%=-IP2Y1U7:Y68@R_,6^8]2>U&@:E3_A+K4220_P!G:@LR&,+$80&??N*X&[T0GG&.]+_PE]BJ M+(]M=I&ZAHG9%Q+\ZI\OS?WG4X\X'S2^SY-@&X M@9P,]AUZ4G_"(::;=86>Z81[!"QF),(5@ZA?09 _(4:!J)=>+K&VN;F!;:[G M:V$C2F% 0JIMW')(X&['U!K0T_4?MUY>PX!6!D*,/XE9 PS[\G]*R(O!=I'> M3$S7'V5X]IC$QS+N=G?>>X);]*V=+L7LXIGG96N;B0RS%/N@G 'L /?&: MU+V****0PHHHH @L_P#CTC^E3U!9_P#'I']*GH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "D"JI8A0"QR2!U/2EHH :Z)(A1U5 ME(P589!IU%% "*BHNU%"KZ 8I:** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHH) ZF@ HHJ*>Y@M55KB:.)68(ID8*"QZ 9[GTH EHJI29O[9T_P H-M+_ &E-N>N,YZT M:E%017MI.(3%,=: M +%%,2:*222-)$:2/ =0P)7(R,CMQ437UHEZED]U MTZ[D@,@#L/4+U(X- % MBBBB@ HJ%+NVDN9+>.XB:>+_ %D:N"R< \CJ."/S%34 %%5UO[-[>*X2[@:" M5@D<@D!5V)P #T))XJ5I8TD2-I%#OG8I/+8ZX'>@!]%1I/%)+)&DJ-)$0)%5 M@2A(R,CMQS2QS13;_+D1]C%&VG.UAU!]Z 'T57O+^STZ$37MW!;1$[0\T@09 M],FH+C7-(M$A>YU2RA29=\323JH=?5G.B21LDBAD8896&0 M1Z&G572^M)+R2SCNH6NH@&DA60%T!Z$KU'4?G0!8HHHH **AANK>Y:18)XI3 M&=KA'#;3TP<=.A_*GRRQP1/+*ZQQHI9W<9^7UXYXI_FQ^;Y6]?,V[MF><>N/2@!U%,BFBG0M#(DBABA*," P."/ MJ""*2">*Y@2:"5)8G&4=&#*P]01UH DHJE<:QIEG=):W.HVD-P^-L4DRJ[9. M!@$YYI+K6M*L3B[U*SMSN*8EG5?F !(Y/7!!_$4 7J*9%+'/$DL,BR1N RNA MR&!Z$'O3Z "BBB@ HHHH **** "BBLK6/$-CH;1+>"Z)E!*^1:R3=/78IQ^- M &K17DGAKXZV&O:]-IT^BW5K'&K$31EYV.#C[BID?TKU.QO8=0LHKN#S/*E& M5\R-D;\58 C\: +%%<=HOB?4;[6+,7*0"RU&2\CMXT4AXC!(5!8YYW $]!@X M'-.O?B!;V+$C1G;!YP4J7#%MH8] .V:U;OQB[21I9Z==B'[>EH;V1$\EB)ECD MPVX'EL$@ [30!UE%:5XDFGCLHYU\N'[0C.4(D3.,C:Q([<, >1Q6%9!\A#Y^8@[SN+?6XE(6&$QO [1&4?Q$,N 1V[526'[450I)) M&A=E4!]V< X)4#(QF@#J:*R--UT:C]MC.G7EM=V>TR6L_E[R&7(-8U*"_P!.T[31##<75O<7+/7QI M%!H>E:@VFWEPU_9F\\JVV$QHJ!VR79>@;MR:B3Q];2R>1'HVJ/>8WBV AWF/ M8'\S/F;=N".,YR<8H ZVBO/[OXBK!J6EW(C8:5>QQ[(B@\YI7B,BH/FV@_-& M.N.O-=!;>*X;G5H;$:;?(DTLD"7+"/RS)&"67ARW&",XP2.#0!T%%<3J'C"[ MTU+^RN%C748;\11':=K6Y7S?-QGHL8D!_P!I/>H5^(\6HM8C2=/NII'O(X9; M?,)=HWBE=2I$FT',?.X@C!XH [RBN-L?'D%](QM;&^O&F*&&UBBC21!Y0=LE MI #C/J.3@9ZU4C^)EE:/)#J4$XF\^;Y4"*8HEE**6#."3P* .]HKAO M%_BC4])UE;:QE"Q+I[7>!8R7!D8-@*=A&T'U-0Q>*=9U>^MK6QN+*W^T31 2 M>7YRA6M1*<889^8]?2@#OZ*YBT\4/!X=U&^U* RSZ;.* .LHID M,T=Q!'/$P:.10Z,.X(R#3Z "BBB@ HHHH **** (+/\ X](_I4]06?\ QZ1_ M2IZ "C-5[Y;Q[.1;"6"*Z(^1YXS(@/NH92?SKYM^)7A_XC7?C>[FMX-2NXRD M>)=,AEC@/RCH-S<^O/6@#Z:J-YX4FCA>5%EDSL0L 6QUP.^*Q/"UOX@@TVV7 M6;JSD46T86.&V>.16P,[RSMD_@.:P?'-E?-XIT+5[.RN;DZ7;W,_[B,L2=\ M*#'\3)YF!WP: .SFU.PM@QGO;>(*^PEY57#8SCD]<N>: /2C/"ID#2H#&NY\L M/E'J?0<'\J%N(&,06:,F5=T>&'SCU'J.1^=>4VNC^(8]/?2Y+"9Y[ZTL+61I M WEI&IF:17D (X3"$\\L/6GKX>UV>\TFP2"6RNM%>\-E0)].1K&XAO;1M2 M.J73VK(MP))@8L2$ 29X88)P!VH ].HKS:6Q\1W%X[&]UJ-9IM1!$99515/^ MCXXX]O[WN.*QO^$@UV&[TU+F;6O[7GFN%GMV@86[*+5S&J$+MR"$) .X-NST M% 'KL%Q!=1^9;S1RIQ\T;!AR,]O8@_C3IIHK>)I9Y$BC7[SNP 'U)KRZ[MO$ M&@7FJ1VL5ZFF+$([1[->DBVT*LSY'(VJP0]-P(/)%=%X=%OX@L/$>G3/J-QI M[SFV5-01TD5&@3<,. P&6)&>>: .P,B!U0NH=@2%SR0.M EC:5HPZF10"R@\ M@'ID?@:\IN?^$E>*+4;BTOXCITD6F3&.-_,EB +2S)M1GV,_DJ2@)PK=.2'Z M)8>(9;NZU6YDU9+E;>U$),;(9E%Q+PZE1N(B*@Y /)) )X /4TDCE3?&ZNG/ MS*9YAV[1Q MUW$'&TKR:@\-77BR'7=.L[J&]A$^M+66&*XNH89)VVQ))(%,A]%!ZGZ4AO[,78M#=0"Y//D^8-_Y=:X#Q"+ M/3]9\02ZUX;OM9%ZL0L1;6+7!,?EA60, 1&0X9N2/O C-8RVD=QX/O;2YTB[ MU'7[RQMTLKV/3Y),RFUB57%P5VIB0$DLPQ@DT >P45P7BF[N[&XT:UN+W4Q( M;&8O_9T4CF6=0@4L$4G;N8GG SC/I5'0[_Q7)K-BFI)?KJAOBMY"('^Q+9^4 M2&5\;-VX+T;=N+ C'0 ]+ID4T1V"JJ@9))/0"O.!:^)K3,T=UJ M\\L::?(JR[BK.[XGR,=,=1T7KQ61IE_J6L:M8Z'=S:M.;RPB;5(KN)EC$GG* M9=AP 4*JR K\N&&#UH ]?1TD0.C*RGH5.0:22:*(H))$0NVQ-S8W-Z#U/!KR MJWE\0Z9#'#JBZK#9-U:Y&)6:*YD\L-TP<*%/3K0!W8D1I&C#J74 LH/(!SC(_ _E31/" M4D<2IMC)#G<,*1USZ5Y5JDNO+)_;$5KJMK%JGVB0K!!+Y\;+M2W5U2-F'RAV M"L-N6.34EKIOB&VLK^Y(U$W%W>7@F@$1\ME-JQ5@F".90,'N3B@#U-I8TCWL MZA./F)XYZ4ZO+%.LW:R6UXFNMJ N3O@%LWV06XD3RB&V[<[0#\IW9+;A@'&A MX)O?$MQKFW5UO$?R9?MTF2(Z+)!LC<2C>;HC$G##"CKD#M5B/3X8M(OK2^\.WMQJ<^F6L5FPTR1RD@@ M"_ZW9MC*MC.6&,4 >O45Y]XLO;RPO/#MC=7VK*9;"Z\[^RXGD>295A"MA%)^ M\QQD8R>>*AT:\\3-K-E'J*ZD-4-V!=1&!A9BU\GDAP-F[=SP=V[(Z4 >CT44 M4 %%%% #)ED:&18G$*M#\.Z3#JNJQ16L,;J^F&R7>F2V/WHC7&O:'9V-LLGF-?Q,'12?*(W$.<= #@YKK:* /$M0L=>U+4QXANM( MU&WN;FW@,B1VK2-!Y=U!\H7!R0%=P.XYKI9M1F.I:'>RVNNWT-I=RM,SZ-)& MRJ\#J,($&1GOCC->D44 >5&VU73]0_M/2]$NX(9'O7LK7R3^Y,B0JI90#L#2 M!WP>G.>]58?"6J6D,7A6_P!/<:?<36]RESI\DD@B=/ED9I-B[7)"2#CKN->O MT4 <'X3CU>WU_5/[;M[P7#W<427$41$5P$@QYC$1C3 M+F2YN-6LKNVO%B)CBBCCC#DR=%P%F7;U/F=.:[^B@#CM9L]7NM:N'@O=3@@6 MXM8XUM^$V-_K3T.>.I[>U<7K>L^(=-BU.*:]U5)+5(EL#"-QYN9$+3<9^9 @ M4GAL'&3FO9:I7.CZ;>7T%[NV>JVM MI=""X4W&IB*$B9@\S$*O'51Y>5^\57 JUX1UB^N_%UE;SW>HR>=I,UQDV'B;5=6MSJ%QJB6D M4DC12B*2)T)A(9=SJ&P6V]1UR 2*]8HH \HLIO$KW+/JJZ[#:R01%Y+*U(E: M;[/$1G"YQN\W/8, #@<50N4\;6\US]BCU*WAE>:2/_1RSM<,5P7V CICKA/O MOF6PU[3=9N=,NM0AM[2:-8[2 RM%.VWD*.?F 9V M+F^51#;GS)H;=[@E(AU^[&57 SC&!T%9UW/XG$5UY3:]L%JXTC9"=SS[W"_: M/ER!CRL;\#&XGFO3988IU42QJX5@P##."#D> 4A(PU"VCE6X\UH&+;%)A! MRN!G'E\X MQ7H5% '$W&FZO>:SN;4-7A@EOIHV6)MJ+"(B5(XX!8#YN_2N27Q%XC@%A+>2 MZJVI?;K>-H(HR8FB^SJ[(R@<2%MQ*_>Y'&,5['5+^R--_M3^T_L%M]OQM^T^ M6/,QC'WNO3CZ4 >9BT\0^&]2NY;>&X6P^R1AGC3'^D^22)')X,8;=N(Z,03Q MFNC\'W;:AJVN64TNI3VB6UL?*U)<,&<2[\ @'!P/;TXKM'19$9'4,C##*PR" M/0U6T_2]/TF%H=/LX+6-FW%84"@GUXH \OOM/\60VL<-C!<1PZ"RVD$NQB\T M3/\ ,Z8&6VQ+&N5!/S/CD5/;67BB6QN=1N)=26]M[&4VACC96E(E)17##+'' M8X)!&1FO5** /,],DUX74@U&/7(E-U,UHMG!M5C]JESYF5P 4,9!; (R0$XO&-E_8%G)'?6UO$MJGDM;R;1%@>:&XV@_>^\01Q@5['10!YAXTL[VXU_7 M((H-19+W3K>*(0Z<9XI75I?E9\83&1SD8SFHEBO-+\9Q:C>:/J,MM]HN=WV> MSDG W6]LH^Z#D$JPS[&O5** //W6\T3X?WDEO#CS0Q7$?ES M1K(F0VUAD9!R#^! -24 5M/-R=-M3>@"Z\I?. Z;\#/ZU9HHH **** "BBB@ M HHJ"YOK2SV_:KJ&#=]WS9 N?IFFDV[(<8N3LD4K'PWH6EWC7>GZ-I]I,](U/56T^"5Q("0KN %?'HBEF&3BF MS>%],G617CD(D%R&PYZ3_P"L_/MZ5DZCXTFTO5+BRNM+ 81220*EPK.P5U12 MX'"!RPV\D\'(&*T;?Q+%#I>IWFL(ME_9DA2Z*,954!5;<"!DC##M691AVWPZ M5=9$UUJ!DTV%VDM[2,.NTLP8YRY7'R\X49R?4YT-6\#V-Y#<26;M;7TKR2"8 MEF!9W#G(!!(W*",$$'D5+#X]\.SNZ"ZN(R@>.O#UC TTUY*T:^86:"UEE 6/&]_D4_("0"WW<\9H\1>+(]"33Y M([9KF.X822E6V^3;@J&EQCD+N4X],T /N/!>BW-K]FDAE\K[0]S@2'[[1&(_ M^.$T/X-TB2_2\9)RT=Q]ICC\T[(Y2P9F5>@)(Y^I]36?-X[C@O?$]L]F=VC( MCQ$2?\?.Y%; XX^9U7OU%,L_&>H:KI\=[IVDP/&EM#-<>?>"+#R1K)Y:$K@D M!AR=HY'X &[I7AVQT>1FM3<%?+\J..29F2),YVHIX _P [5F'X?Z'_:$%XHN ME:W??!$)V,<1.<[5.0!\S<=LG&*G\1>*!H>E6EVL,3R7,BH$EFVJF4+$EE#? MW<<9R2,5"_C#RKS287LMT%[;/5;"YN6D$"8QA 3A> !TS@5#%X*L'N;^6^>6Z6[GFE\EG(C3S%VG" MYZ[)/,S ^[!/ PPV\CGKP352'QA>BWL+^\TI M(-.U$?Z+(+C_0U-)XX\/PW%U#+=RQFV,BR.]K*J%H_OJKE=K ML/[JDD]A0!H3Z%I\\4$1A*QP6[VT2(!A?F.;2KP6-TH"-* MX=B4";, JZD<>^#^HWK'7;'4;"XO+8W!2V++-&]M(DJ, &(,;*'S@@@8R"KBP\2IJ$FJ--9P.\D$!#[M[KM8L2Y4GOD* M"2<\@VEW-;2 MS7AEB=T;R]/GD!9.6 94(; Y."<#F@#1N?#^FWFKC4[BW$ES]E:TRQX,;')& M/SY]SZU7M/"VGVDEO('NI7MY5DB::=GV[49%'/8*[?GS4'_"<>'_ +:EHMY( MSN2JNMM(8BPC\TKYFW9N"8JFQ&RVU>"3 M(% /WB,#- %J+P/H\$6VW^TP.#D2Q3E7'R;" ?0C^A[41>!]%MD5+5+BV09# M+#.R!U+[]C8ZKDGCW([FI+CQ;9GPOJVM6*2S#38Y3)#/"\#;T3<5(=01P1SC MO6*_Q&6'3_$=Q-IQ672G"01"7/VK)V+@XXRX(/7'6@#H-5\,66K7R7DMQ>P3 M+"8";6Y:+ M(;A].*RZ4$,<0E_X^-Z@C!QQ\QQWK9U'Q,UCX-&O1Z?+=/\ 9!<]ZBD\$:1*'+M M>&:7>L\_VEO,G5L!D<]UPJC'8 8Q5_4-7:QT)]1CM);J18@XMX2"Q)QW. , M\D]!61)XQE4P2)IX:W$%M-=.9L&/SCA0HQ\V._2@#J41(HUCC4*B@*JJ, = MA3JP=%\3Q:WKNKZ?! 1#8"+;<;N)BQD!VCT!C(SWYKG['XC-)%VC9G'OUH [ZBN,B\9Z@XO+QM)A_LJSG2&:9;G]X,HC%MA7! M \P=^QK9U/Q7H^CZDEA?7$L<[1K*=MO(Z1HS% SNJE47<",L0!0!M45DZ?XE MTO4[][*UFE:90Q!>WD1) IVL4=E"N >#M)K6H **** (+/\ X](_I4]06?\ MQZ1_2IZ "BH+R6XAM))+6V^TS@?+%O";OQ/2N$USQ1XRL]8TR"W\/+'',^"@ MF$OF^HW 83 YJX0<]C2G2=1Z?F>A45F:7>:I=22#4-)6R4 %6%RLNX^G &*Y M7QOJ=WI7B_P]=1WDT-E;P7-Q=Q*Y"21AX$)<=#M$C,/3%2U8AJSL=[17C2ZI MJMXQFN+J3;=ZLTJ07&J2V21Q-:JZ)O3)7 (.W&,YK:$FGOJ4$.JZS)86J:69 M5-OKLSHLGG-DB4LID(']X<=,8%(1Z717DMOXBUF32KB.>:\:^O[.P@A6(G># M(9MTBKT5S&I?MR/:E35_$$DNAP6$]VVH:2;R.XM+ER&O4C\HJ).3\[1N"&.? MF/UH ]9HKE/ VKG5]%CNOMI<3SW;I%-GS=HN' ZG("C"XQQQ63K=SJ5CJ7B8 M/JTYA-M:,I!$:VL;S2*Y7'0A.K=>,\8& #T&J46CZ;#J#ZA%86R7CY+3K& Y MS@'GKV%>8WFH2QWNJV4FM7D&EV,=[+8W O7W-*B0$ N6S(%9WPI)!Z$'%=5J MFN:W!9::ML;:&ZETV6\N//A9OFC5"5 ##&2Q'M0!UMQ;PW5O);W$22PR*5>- MURK ]00>M166GV>FPF&RM8;>,L6*Q(%!)[\=ZX>?Q;K-IJ-IIUW=Z=;BYQ(= M0E@9885,1?RR"_+$@X.X< \5SEQXOUV]AT?Q-:I+.Q6.$6%O*XCDD^SR2R,5 M'W@-T?')_=G')H ]DHKS=?'UY)K%M##>Z=)"^JV^GB'RR))HY(5D,Z_/PI+$ M 8/ ZYI^K^(;R'QFVHV\MV=*TVXCLKG9S;D,#YI8YQN5GBYQQM8=S0!Z+17B MFJ^(-7B\+Z_I":C>K>^=%;.0!)%MQQ@,!WK9N]8MHHK_4-1 MU/45U6"^D1[:WU$0_9D5SY0$+,JN'3:?NL6W&@#U*BO._%^H:AJKZ=%:W/\ M8\<;3S2Q7]U)9M=!$&-CQ')4;B3DCL<'%-N-1U5+.SU33[B\#7'A>YN;:PD) MD\N54A*9)^:1\OC+9/TR<@'H36\+7"7#1(9D4JDA'S*#C(!]\#\JDKA_#ETT M3:O#IFI7&I0QZ?;W*--<-.5N'23(!8DC(6-MN<#=P!FN=N-6M;:QTB;1_$E[ M=ZO>(QNXGNWD\Q&B=I&\LG;&49>-H&W&WO0!ZU17FO@^]A5O"OV'6;F]O+ZP M5]2MY;][@*/*#&0AF;8=Y XQG..U277CS4[2[U-U^QW*VM]C52L='TW2VD:PL+:V:3 ,J@\P$[2-QY /7HPJ/7KC[1;^'HI=2(L[R<">ZM)6A M64>4S+AU;*JS $8;T&30!T5[86FI6_D7MM%<0[@VR5 PR.AY[T^VMH+.VCM[ M:&.&",;4CC4*JCT %<=;ZSJJ^%O#8L[B&2YU"Y%M]IN5,F8]DC!^"-QP@/7G M-9-KXYULV]H;Q]/B-_!'(DPB8);9G\HELM\PY!ZC!./>@#TRBO*KCQ7JFJA) M8)_M/]EWJB7^SF*+=YNUBB49;!W*DN021R.<5:N/'VI+8BX%SI=O)':17#PS M*V9I'E=&B3D$%-N"<'+'H!0!Z717'^*M8NO#.JQ:@IDEM[VV>TCA+$HMT,M% MQVW?.I([A:XG4O%6N:7X:U726N9))+6VN[0W+-MF\R.%F\X/YF[);! VC 88 M/'(![-17F-]XOUG2M0DMKS[/<3V,32B2+?&C!K3VYX-,U'Q=JV MF:W/B^L]0:"V$0:U#",%Y8!N="VWV=HS]!4M>>:MK^H7_P --2O&D\FZANEM_-BE,&X"9%)+(S%,@D'! M..:P;36+^*^DLEU"4!-4@(2WU)[R)$:WERHF;#-EDR48#& 1G- 'L-%>:>'; MZ.*]\)KINL7-[=7T!.I6\E\]R%00EC(0S-Y9$FT<8SNQ5O6/&NI:7=ZK+']D MNH[*X>!-/C4^?)BW\T-NSZ\8V]* /0**Y;PQK]YJ6I7-E".T@NA<6:E M54R;OW9&X\@*"#GD'I74T (Y8(Q0 MC@$X!-<5XKF\6FSAFTZ#[(R2!'$,PD M+[B ."O8_P Z[:BMZ%949J7*GZE1ERN]C(TE]9CBM[?4+6,[4Q)@F[ MGA^L^(+K7=6DU2"[FBTZ^M+=889)WA14%U"K;BO*Y+2 L.0*VFMM+CNM%M+J M\MH;*>]E^T_9-5'CTVBH$ M>6PZ^VDZB)K:\N;W2;5[\61DE9S, D)";CRX$C.JDD\=ZIVESX@^PIX;O;G4 M=-UB2[MKN"XN61F?=_K" KL"@D7[I(^5P,5[!Y:8 V+@=!CI2E5+!BH)'0XH M X7PAK=_JNO:N;J1;26.ZAAGM9"QFLH[>*>V@"RP,['S>K9##IQ@8KF-2^(6M65OJ&Z73K M>73U4+Y\3?Z:QN)(CY8W<;0@)'/+=A7JFT9S@5CZIX9L=8NEEO'N&C 0/;B3 M]U)L;>NY?KUQC/ .0* .#_MW4M.\407D9;[+JY,MQ<3$R1VJ&79$=@(^\J1I MGH"V36YX9\67VK>(K.RGN]/E2YT^:[D@@0B2U=98U$;$L>0'(/ Y':NW$:!0 MH10H& ,<8K)TWPU9:9J37Z2W,]P8VA1[B4N8T9MQ4$\X) ZY/ YXH X;5=9O M]%MKK2+>*XN9=%EN-1*F0DO;H \2EMVXC=(J^XC:DT_Q/XBUS6;2%7MK=X'D MQ-F.17!AW$,D4KC((&,MT;IQ7J.U>Z629T5'PRC8#+(A50/3<1N'R^OKK00NNUXD8<'!4&E>&*3&^)&PQ?5]/B\074EGH_V.:=E%PT2O,I0[69""=J[B!G!YX.*XW1+ZSUC7 M((M9U:1M%@COAI]R=0>(SQI/&J,SJREB 749Z@ ]>:]CDBCF39+&CKZ,H(J* M*PLX=_E6D$?F.9'VQ@;F. 2?4\#GVH XRTUZ]L?AYI]\;U=SW@MX[S4%/S0& MX*1R/T))CVG)ZDY/6L^Y\=ZI"+\)=Z9_H-L]Q"YC;&I%9'79%\W!P@'!;EQQ MBO0;[3K?48(X;A28XY4E4#CYE.1^&14WV>'"#R8\1_<&T?+]/2@" 32O>6X\ MV*-'A9FMW'[PGY>0<]!D@\=Q7):Y]OMM3\2,NK%!+I*M 9B5BM>77(V@M[D\ MG\!7;X&O+X?\)QH\$5]J%N3LVX\1ZOJUI::Y;*+V>PE%ND%FQCCNG>X8<;C_ '(8^O\ ST/TKT[4 M]*AU.W2)Y;B QN)$>WDV,",\'L1R>""/TI=*TFTT?3HK&SC(BCYR[%F8DY+, M3R222<^] '!6_CN_N);9EU'3!OO+*W^S- RRS+,RAV4%N,;F7&#@QMGTIGQ MDU*77);.PO)X)'BL!'Y;D ,;B0?K@ ^U=I=>&;&\U5+^:6Z.R2.46_G'RMZ' M*MM[$'!P, D D&M@JI.2H)]<4 >,:IJ]_P"*-2FN;2_NK6TO=.2"#RW*['$] MNKN .X9W7_@)K6T_Q'K&H^)-,U26WNYA!;2V4NG6S*"]R@7SF&YE4X8@#)_A M/K7J'EH.B+Q[4H500Z7KNJVC:?-8O=WNJ7MG<'58=TDXM9_.C57,0)VA MM-KZY;X+ZC)]JNVN(FEC-Q<[HI&Q-C). 1QW'3GTKTE8HT9F1%5FY8@8)^M. M**5*E1M/48XH \@M[RZL[MK&&Z3R!J%DR"TU"6[B4,7#+YDGS9.,E>F,5=\* MRV<$'A&73-3N)]4O54ZC;_;9)@R>22[.C,0A#[<$ O4%BC486-0,YX%" MQ1HH^,]2L=2U$1/977V6[>W33HT/GLHA\S?G=Z\=.GO6OX7U M^ZU2]FMY[JSO4%K#<">T4JJ,^X&,_,>1MSVX/2MRTTRULI[F>*/][@PHXJS'%'$"(XU0$Y(48R: 'T444 %,DACEQYD:/CIN4'%/HHV&G;8 MR;/PUI%AJ+W]M9(EPY)+;B0,G)P"<#\*U5547:H 'H!6?:Z]I5]J,VGVM_!+ M=PY\R)6RRX.#^M:-:U75;_>WOYDQBHJT58Y2^\#QZG=-)>:K>2Q(TSVJ-@M; MM)U(<\L%_A!X'O@8LR^%5N= U73KJ]>274V9[BX"!>2 HPO8 *!4D_B_2K6X MGAN#<1&)9"&>!@LGED!PAQ\Q!8#CKVJ]9ZS9WEK//O:!;=S',+@>68V !^;/ M3@@_C60S"UCP3'?VU\8YRTT]Q-=(CG:OF/!Y0&0"0!@'.#]*S]-\#ZA>?VM= M>(;X276H0O %3#")61%)X51GY .G3NBV&FK?F^BGMV?8&MF$N3M9C]W_95C^% ')>(/A_J7ESV_ARYB MM[>ZMKBU9'?8L,#M.U"Z>;4E6\'V)+.*.1 5B M49W$>[9&?]T5JSZOIMK_ ,?&H6L.'\L^9,J_-C.WD]<S ME!>3+#$54L,L0 3CH,D<].10!ST?PZM1/#-+J-Q+(D@:0E0/. BC0*WJ-T2/ M]14@\!_9[&*SL=8GMH#;16]RA@CE6;RT"!P'!VOM&,\CIQQ6L_BS2(Y]:A>= ME?1E5KP%#\H9-XQZ\'M4 \:Z7);"XMX[RYA^S1W3M!;LXCC==R[O?;SCK0 ) MX1M;"SM8M&F;3I[8*HG5 QE55VXD'&[@_GS3XO"=G%#I$ ED:+3DE0!L?O?, M0JQ;TZD\5=OM;L[&TM;EO,E2[=4@6%"[2$J6&!] 343^)M,AU*TTZ:5HKRZA M:=870@H@!)+?W> >OH: *^A^%X](,AFO)+XFVCLXS,BC9 F[:AQU/S')[\5E M1^ I8KFR_P")[=2V-BNRWLYD#(B[64=QEE#D!NO3.<#&]I'B*PUK?]E,JE8D MG FC*%HWSM<9ZJ<'GVJM;>,-+N6@*K_ )'KCB@"'1 M/")(UA4@ G"C)8@ 9)Z9]:S?^$#EOS>+J>I2>0U[ M<7=K# J_N7=B5?<1R0">.F2>O&-[3/$]AJEQ;P1I#[1"4$J#&2I/7 M&1QUYJ\FJ:?)VS"\$VU%9948#)VG@-QP>V3P:T( M=0LKFR-[!=P2V@4MYZ2!DP.IW#C JMJNO:;HL5O)>W 3[3(L<*J"Q=B0. .W M/)Z"@#-L?!UOI^I030W,M'LI[B.XEEC2 R(TQB;RRZ+N9 W=@,\>Q]*O66MV5[;7 M,^YK<6K;)UN5\LQ':&^8'H,$'- '"CX>:J=4AM!?)%H<$S3@!PSNS0-$?EV M@G<2?F(Y..N!J:MX 226_P!0TNX:'4+E][#(59,!-@8X/*M&&4X/4CH3750: MOIES(L<&H6DKNK,JQS*Q(4X8@ ] >#Z52O\ Q9HMAI$NJ&^BN+6,X9K9A+SS M_=^A_(T 9FF>&=0G\*ZUIVMW0-SJ[2M*\1#>6'C"8Z 9 'I^)ZU'-\/+&>Y\ M][N8MYEQ)C P3*I R.^W)(]ZZ2;5]-MQ^_U"UB^?R_WDRK\^,[>3UQSBH-5\ M0Z?HT0DNY&V&"6X!12V4C +$8]B/K0!S[_#FQDG69KV?.9=P &'#QJH!'?:4 M##WS6N/"NGQ^';K2842(W5E]DFN$0!W&PIN/J>2<=/EZ>M68O%6DS/HR1SL7UA&DM%V'+*JACG^[C(Z]^* + T2Q M6.;9!&EQ-!Y$EPJ#>PV[>3WZ"LJ?P9#/Y,?VZ5;;R8(;F((/WXA.4Y_A]\=1 M6M+KFGPZY;Z,T_\ I\\;2I$ 3A1W)[=#CUP:2\UW3[#5;+3)Y\7EZQ6&-5)) MX)R?0?*>M %#0_!>D>'=7NK_ $V'R1/!' (@Q*H%+'C)[[A],>YK,B^'X!"7 M.K2S0Q+.+>,6Z)Y9E5E)+ 9; \$S+<-'%% USYLR%$>%20TBD M]5!'7W'K4DGB?3D\.P:Z#,UG.8Q%MB)=C(X11MZ\EA0!DQ^!W6:>)M:N#IEQ M.D\UDL* 2,JH,%\$[3L4D#%/UKPE<:WXBN9Y;WR=+N=/BM+B%%!:8+([,"2/ ME&& R#W/L:LS^-]'M8W:Y:XA='DC>.2%@ZLD1F.1_N#(]:O6.OVE]J!L/+N; M>Z\KSEBN(BA=,X)7/!P2,^F1ZT 5=*\,+IE_%.;V6:&V22.UA9 !$LC!FR1] M[H /;UZUOU3CU;3IGG2*_M7:W&Z8+,I,0]6YXZ'K4]M=6][;I<6L\4\#C*21 M.&5A[$<&@"6BBB@""S_X](_I4]06?_'I']*GH **** "H9[.VN3F>VAE.QH\ MR(&^5L;EY[' R.^!4U% %*ZT?2[U"EWIMG<*6#E98%<;@,9Y'7'&?2HAX>T0 M"$#1]/Q!GRA]F3]WSGY>..>>*TJ* (#96C72W36T)N%Z2F,;QP1UZ]"?S- L MK479NQ;0BY(P9O+&\CI][KV'Y5/10!!%9VL#!H;:&-ANP40 C<#=';7(= M5,4GFP.'ABW?NHV"[057MUS@<9YQGFM@V-FUO+;FU@,$Q9I8S&-KECEBPZ$D M\G/6K%% %9M.L71E:SMV5D9"#$I!5CEATZ$\D=Z273;&>\BO)K*WDNHAB.=X ME+H/9B,BK5% $%W8VE_$L5Y:P7,:L'59HPX##H0#W]ZD,4;2K*8U,BJ55R.0 M#C(!]#@?D*?10!!:V5K8QM':6T-NC,798HP@+'J2!W/K59]"TB2Y:Y?2K)IW M<2-*;=-S,,C).,D\GGWK0HH J6.EZ?IBNMA8VMHK\L((5C#?7 YJO8>'],TV M\N[RWM8_M5W*TLLS*"Y+8R W4+QTZ5IT4 5[6PL[*!H+2T@@A8EFCBC"*2>I M('K22Z?93V(L9;.WDM H40/$IC '0;<8P,59HH C-O"PB!AC(A.8\J/D.,9' MIP2/QJAJ&@:?J%@UFT(@0J$#0 (P7.[:./NYZ@\'N*TZ* ,S2_#^F:/9_9K6 MU3:7\QVY&"1P< MBM^B@!DL,4ZJLT22!6# .H.".0>>XJO)I6G33RSRV%J\TT9BDD:%2SH>JDXR M1[&K=% %6L"A=K') M&,8P3R15VB@"J=-L#I_]GFRMOL6-OV?RE\O&K=% %2RTO3]-W_ &"PM;7?R_D0JF[ZX'-16NB:=::E0L6,<+<"/)]., M;%0#=@$\+Z#K70?VQIGVBX@^WVWG6ZEID\T9C ZEAVJ6SOK74+<7%G<17$)) M >)@PS]16 '":MX VV^ISVB6\1EN;BY5;>'YRC6WE", 9^89QZ'UJCIWA;4 M?$$FMW<]E!ID%RDB6L0B>/\ >M"D?F%656X <9*C[QZ]3ZC5>]O[33K?S[VY MBMXYZ*,]3[4 <$W@'5I[V6ZN-0M=UXR"_"ACYJ+%$ !Z'S(C_P% MSWJ:W\':UIFBMIME/:2)-:VZ.YN)8&BGCB6,L&0993M4[?E[\\\=G_:EAOO$ M^V0;K+!N1Y@S#E=WS>G'//:JTWB31+<6YFU:SC%R@DA+3*/,4]&'/(.1S0!A M7/@Z&VG)SR&_K4L7A&<66@VLUTKKI\,T4S M@#)*^O'- '/Z#X:O;=I&U9[=B--ATQ!;,V&1-V7.0,%MW3G&.IK)_P"$ M7\3N-'TRYFTV71]-555HRRS2,J.B.07'E- MM?RI VT^AQ4$&O:1U &+I'A_5$O-&DU-K-(=( MM6BA6VD9S*[*$+,65<#:#QSR>O%RLXUU*\GBED5O,N [8" M.,#]V1U.3D!>.*[[3M=TG5V9=.U*UNRHW,(90Q ]>*T* .?T?1;BRM=7:YM[ M+S-0F,HLXV)@4>6J;22HSG;DG;WZ'O=UK3)-4T4V41CB;$R@,H W9([</=-Y B5RK*K8 :3MZ8SC->J57O;^TTVU>ZO;F*WMT^])*P51^)H M \Q\0>%]0TBQ>VMK,:JLT%Y;P*\+RE?.V,&74, V-)F1PORJ,L>>P M'6@#SR\^&5[/:3V\=_;E!)*MJ'#?NH'BF 3IV>8_\! K3B\!3KK;WK7^R)+E MC;"+*O! RR$JIQ@,7E)],*OI7576MZ79) ]UJ%K"LZ-)$9)0 ZJNXL/4 .>* ,^;0Y'O=*D6[D9+)9E>21LRMO7:#G M'44RXT"1AHZI>2S"QOOM+O=/N=U\N1<9 ]7'Y5L/=01W$5N\T:S2@F.,L SX MZX'?%)-=6]O+#'-/''),VR)68 NV"< =S@&@#A;/X?74BZ?:W]\(K/2K7[+: M&T(+S+YBL&D#H5'$:?+SR"<]JOW7A"\E\ 6^@?:DN+B&:&0O,Q17"3+(5RJY M&0N,XS736VJ6%[+/%;7D$TD!Q*L<@8H??'3I39M8TVWTP:G-?VZ6)QBX:0", MY.!\W3DD"@#A+KX=7]U#.LWMX+9VDR9"I=F9E7LB@ #UYJ\OB+1GM4NEU6S,#E@L@F7 M:2JEF&<]@"3["I=/UG3-6#G3[^VNMGWO)D#;?KB@#@(/!6IZII962"SL3%), MT:D-NN,W2RXE&T84A,'[V=V?:NR\-Z1/I4=_)<+;Q27MVUS]GMLF.'*JN 2! MDG;N)P,ECQ6W10 4444 06?_ !Z1_2IZ@L_^/2/Z5/0 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !56\MKBXV>1>R6V,YV(K;O^^@:M44TVG=%1DXN MZ.%T#P;K&E^*9]2N=5$D#%S\I):3)S\P(P/PKMH4>.(+)*TK#J[ G\N*DHK M:OB9UYX^S7C6TMK>F RW'R&.4*''RA2%V#."#P<@GJO$.@:OXEE@@3;!%96 M"O'-.A8M=,005PPPR;%Y_P!JN\9%3OH7B"\U'5;DZ9+$F MO&.*\4D#RU6"$Y]QE98_J15C3=-U?0]"-G)HES'+NYMP-36UG@NKG W1AHF"!B..K#..,UWM% '#^%=*OP\C264NEB/2 M+?3B& &Z9-^YUP>0-PP>^:QDM-6-MX>T1O#EQ:_V:H$M\@#*7$3H0N.JN2IS M[G(&.?4:* .#\.6E]=7_ (?D;2+K3DTJR:*XEN%53,S(JA% )) (W9/H*PY; M;7=0NM5?2/[8^T+?WB3RF[81/ &P(X@6PK_W2 ",'GFO6*0 #H,4 >^T'GKU]:Z*B@#R_7_#VLWE[JT6FVE\LMW+,UQY\J-;31>7A0 MIP"&8A!CL V3BM>2RU2Y\/>+KJRM+NRGU!2;.#_5RJPA5-PP?E)8'OV!KN:* M /++W0]=TF:]NK*[U1(X;N=(GGOI'1;8V1()W,1_KS]X\@X["LM8+KQ/I^M6 M6DP:C-IP@>5/M-T;C,PM]JHK%VZM)NQG^#W%>STU$2- B*JJ.@48% 'C_B.? M4M&LI(-;NM0:;RKQHI;:\,!EGQ&8I%&\?(H.W8,X(/!SD]1XETG4-3TVP$=M M)._]E7,4F>3O>- <]R0:[AD5RI902IR,CH:=0!XSJW@_P 03Z>EN]E).=-6 M>QLF!R6MS!-M/X[HD/NE;=MX8UJ+Q#9,D2QVNDW$EMIS.-ZI"Z.QUL=.A@6R-CIQ ML;V>9D4D*5.[!"$[N#^\/?-:5WHVKK\)[+3FM&%]!/;,8;- 61$N$;Y5 M;C(49P>.*]$HH \>U#PWKM]:W$J6%[()KBYD5KI(TF;=9/$"RH=H&[:HP![U MV>F176I^+;;55TBXTRUM;*2W=KE51[AW9"!M4GY5V$Y/=N.]==10!Y/;6NNW MUA=3:7_; =FF6[>6[8B9!\M[*]$Z7D=JUTS6 M45[*9)DBVKPQ8D\MO(!)(!'TKH0 !@#%% !1110!!9_\>D?TJ>H+/_CTC^E3 MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 4M7U :5I%W?F,R"WB:38#C=@9Q7/ZAXY@L/#%A MK#6E-"=S9G\5Q0:5J]ZULQ:PNVLTB# M9,TGRA0/3)<"K]EK,5_X=35XD.QH#*8\\J0#E3[@@C\*Y^3P;=W=W*ES=B*R M?4Y=0S;2%9U:5RSKO7Y@YQ_> MR>/6@-2/3_%=S<+I,UWIT<%MJ@4PNEP'*Y0N-PP,<#WJW/XPT6/3KN\AO([@ M6R!BD9RS9.U=OKEB #TYJOI7A.WTOP_;PPV]HFK160A^U!-X$NS:6&1G&>?> MN>C\#:MT$7F-=/,1*DBR*P!4 +E?NC&!1H&IU-KK.II=Q1ZKI/V M6&5&<3Q2^8D6T9Q(<#9QWZ9&*O:=K>FZN9!87D4YCP7"GD ]#CT.#@]*Q[BU M\4ZE&R22V5B$@D3;$QE$TA7"EMR\*#SCDUF:1X/OTU&:74'EC@FM4A9H]1D> M8,C$CYL# .>@P!CI0!K:EXK.G3W3'39WL;26.&>ZW*,,^/NJ>6 W+G'K6IJ. MJ+8W-A:K&9;B]F\N- <8 !9F)] ?QP*P9M U>;61-<):7MA;E!9P3W<@" M?.Z[#O?/.23CM5_6HI(O$.A:@$+P1R26\I SL\Q?E;Z;E _X%0!5L/&<>J&S M@LK1I;VX9S)"'X@C5RA=V[9QP.IJ.;QA=6]A=:D^EH;"WG>%F6Y'F$+)L)"D M>HSC-5=*\%7.BQV5Y8O;1ZK'-)]J(=O+N8GG23"*UCG6 MZE@$1+.7*GY54+RS'].M:D>AV&Z&:XMH9[I A:=T&YG7&&^N1G-33Z3I]T ) M[*"3#EQNC!PQZGZF@-3#L];U:[MQ?[+%(GGE@2RMV\*2:_;J9(%M&N@A."=JEMI]#QBI9+#3+!I=2^QPI+&I75G,NU^!&TH8@'&>F[!^E $]IXFG-S9QZC916L5W"TL MJ:>%[>ST* M6'3[:T@U)K,P+<;,@,5QU(Z9]OPK#LO!^J_:99+GR?+E2U!$MX\[9BF#G)*X MY&< 8 P/6C0-3J#XFT46'VTZC#]G\SR]V>=_7;CKG'.,=*5/$VB23")-4M6< MQ^;@2#A,$[CZ# /-8=SX9U*+Q0VNVIM9F6Y:1+>21E#*T*1DD[3A@4]^#51_ M!&H7=IKZ7,UC#+J=K;Q1FU5E5'C+%AC'"DD#CKSQ1H&ITZ>)=%DLI;Q-2@,$ M+!7;=]TGH,=>>WKVJE/XSTE+S3[>"=)_MOF['5L*A1GM7/OX/UEHI9X MF6*X:2$,K7\DKO&A8D"1E^0Y(Q@9'//-%GX*U>VN8)2UJ1'=74I!G=R5GB"_ M>89)4COUZ\=*- NSJ8O$^E;;)+B^MH[B[CC=8UDW#YQ\OS>A[$XS3]:UQ-"- MK-=1$6,LHBFN=W$!/W2W^R3P3VS7/Z7X8UC2;%;!$TVXCFBMEGEF+-L,:*K M+M^8?+E>1R3FMOQ%HT^OPP:] #+3Q39R: M8-2O=MC:S2LEJ9F^:=1T8+UYP2/;FK%QXGT.UCC>;5;54D02(?,!#(W! MYZ5S4_A/6O+T\&X2Y&G&6& I=R02/"V-I+*.&& #U!'O5BS\&SVNB7]G_HHF MN-+-G&0S$([-*S(-)AU!+"34+=;ER $+]ST&>@)[# MJ::/$>C-=M:KJ5L9U+ H'&">6[61A M)'L$>X!=O)S'P9 M6 &!W !R3FJ.J>$=5N+73[.VDA%O%IOV.14G:$!\ %CM7+IQ]W(IMCX1U>UL M;HLUF;AX=.6-!*V"UL?FR=O ...M&@:G1Z]K%UI.ER:C;6<=U;0PM-*3-L(4 M#/ P<\5)8:NTO[O4$@M;@P_:%B6;>?*&,L>!CDXIVNV$^K>&[_3XS&D]S;/$ MI8G:&9<,**M!A: M-9=5M4\Q5==T@ VL,J2>P(/!-./B?118_;/[1@,'F&+<#D[P,E<=<5:ET'4[7Q%/K-FMK.6G9U@DD M*?*T4:$YVG# I^1HT#4VQKVE-):QK?P,]T 8%5LF0'C(QVXJI)XC2+Q?E9YFD(7(^[\P'X=* MCUSP[J%[>7M]83V\5T5MFM&E)PLD9DSNP#P1)CC/>@-0T[QOI]Y>!G-&@:FU:>+-*FT^PN+JZAMI+R)94B=\D!NF3V'N:NV6IB\ M6_(CV?9)WA.6X;: <^W6N(;P%J:VR0%XI1+9Q6TVR\EB1"@(.54?.O/ XKK] M,TB:QMM3A9T;[3.\D9!)PI4 9R.O'O0"N,B\6:,3#%-J5I'^0UQ+N5(H$.&DF,F6.H6KW,0ST"KNP??J/J#4NG>,-%U"QBG^W01NR1L\;/]PO@ 9[ M\G&?6L:W\':A8"VMK>>"2TM6NDA\V1MXBF08S\O4-G\/RIVI>'$@T:V^WS6\ M=M:Z0UG*RYXD.S:R\H'\5Z1);W#V6H6=Q)#%YNWS@ 5XYSZ&,W;&>YO- M^=V^5 J@#'90!5:?P+J,FC:=9QS6:R6VG3VKG9QY6>Q6W&"=Z.'9@PXXQD$'/44!J3:5XAM=2EN825AG@GGC\LMDLL3["_P!,X_.J MVK^,M'TO3'NUO()I/L_GQ1+( 9%(^7Z9[>M8.F>$_$.E2B[$VGW-W(MW',6D M=5_?2*X4Z(%./E.1QD=,'- M&@79V:Z]I;:@NG_;H/MAX\G>,[L9V_7'..M4]3\2QZ9XFTS1Y+=F%\K'S@W$ M>" ,CW) _&N?@\$WT>L*TCK):B_^V^8;R7 YSCRA\N[/&QNHYPAPVT\K]15RN;\,:' !724AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110!!9_\>D?TJ>H+/_CTC^E3 MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M116=JCRAX$CD89W$HCA&; Z@GT]* -&BN>DURX%BTD(1@%"*SG#EC%OW;>F. M>GUJ2?6[FVMWE,,,FS*;0Y!+!-V>G2@#=HK$DUFXBNFB:&(A0RE@^!O5-W4] MN,5 VLW,L<@ 2.>-XE8%B%YD0<\>C>] '145EO>RS6+#*QR_:! SQMD=0"0? MH?P-4KO4[E)KR16E6$QRQQ';\H95R"#ZY#_D* .AHKE9M7O0MJLX#0>:!PY."!D8Z?>Z>U &Q16/##FU2.X#;&C9\X8!BW/IC;S_M?F M =!28 )( R>]9&G:S)?7,0,*)#-&'0AMQ^Z"0<<9YZ<=*&U:8*SA(-K.8XU, MAW B01Y;CISGVH V**Q/[8NWDF2."W)@*J[;SABS%?EX]N??(]Z!JU\UPT*V M\!,;I&S%R,EF89''0;<_C0!MT5@/K]PC#_14(0)YA+XR6)'&>W'X\BK*:E%1I 9#_&3@+QSC]30!K45RL_B"Y_L8R1IMW69(DW997\G?^/Y?X5HQ M:I.MT+4QAWEF81,3CY0[;\_10"/7- &S165<:I-#>31K'$8XGC4@N=[;\=![ M9IL>KR3F!88HRTJ0LBL)=4O+EK/RA;J9V#JGF$D*5;AAC MV'X\4W_A(9/-B @C*'".=^-KE"V,G\/SH WZ*YX^(+E0(_LL9FVL[9?:H50I MQD_[W7IQFK,>I3W%Y; "-(7E9-N[+\*3SVH V**** "@@$8(S110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 06?_'I']*G MJ"S_ ./2/Z5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %1_:(3)Y?FIOSC;N&:DK+NK>1;NYGAA^?R%V, MJC)8,Q./>@#4HKG[QM3N7N)+8W42)%*T(V@;G 39P1TSNXHE748IIXQ)=LB$ M_9F4 [FPI&XXZ9)Z\=: .@)P,GI3(Y8Y03&ZN!P2IS67]GNWT:X$QDEG=V)0 MD?=#G"CZJ*K;+F;4R+:&6WMY @>58_+. 3\N#]>N.] '04A( R2!7/R-JJ#S M(/M#RH298W VM\V %_X"2>/057DMM4N OVGSPZ*\"E.C$8PY^O)_"@#J"0H) M) ZDT$@#)( ]ZR;NWN6T?4;8>;*Q5A%N.6(*C^N:KW=K?RQ8\R=O,E^8:YV>"^W%9/M+1QSKM=0"^P,><]^#2&& M_D?>XN"JD>62OS$?O0-WX%>OK0!T@((R.E!( ))P!WKG3_:GDE4:Y6XVL& 4 M;%7;\NWC&F:A'(TCQI( C/R3'A2W/?JU &F+B%GV":,MZ!AFA) MXI%+)*C '!(8'FLJ]L6E>^:& ,'@BV[0!OPS%@#ZD''XU5FBEGO0;>R9(=T! M+>48\;9D.,=\#)SB@#HMR[=VX;?7/% (/0BLJWMQ=:/-$Q81&9VCV@$[1(6' M!ZCCIZ5'H\=Y:SFVFA/E>6#YA[8"A5SWXR/^ Y[T ;50R+;7(*2+%*$/(8 [ M3_2JT+:@;]A+&!;9.#\O3MWS5%[9;NQOD4%I5NF8*C$'(88S@\_C0!L?9H-^ M_P F/=C;NVC./2F-#9PD,\<"'&W)4#CTI\OGY'DF,#OO!_I5-E5M=Q.H8&V' ME C(SN.__P!DH LK%:3N9DCAD;H7 !/3U^E*;:TBA93#"L7<%0!532@\%G%: M>6(Y8[:-B",?,R@X_6@"(QVD]FT2F/R .?+( 7OGCI MZU,RP!0CB/:>BD#G/_Z_UK'LYOL%C:6DT,<8\B/S5<8)SD'\L<_6J=C%(YLY MY]ZQ@K!&'[ *Q4GW)8#ZJ* .B7[,\C*GE%P?UK5/VCSN#'Y7N#NH :!:Q7!P(4G?KC M 9J62.VRID2+,8W*6 ^7'<>E9IC"W,Z263RRO&2-D:1Y9-GW_G#*.>&Z#\*=IHN[(S13Q2)%M#"4#+=%P!V[L, M?PD]Z -@_9+W454N9M02\Q*UTEL\VV,Q %BN6W9XSG@8]NG- &ZUM SJ[0QEE& 2HR*5 MH(6=7:)"Z_=8J,CZ5@/)J@DML?:=JNAY7)9#*<[L#KLQU]>.:D5-1CAA\R2Z M9'2)IR "RGYMP7 X_A_#/>@#8^R6C'/V>$\;<[!TZ8_I1]FB%TLY^^JD*,\# M)Y./7WK!M4U..>%2URL7F[E!CR6!E8L6Z ';CK^'-7--2Y:_62?[06\AA+YB MX4.6'"^W'\J +J)8&YDN0T+2G#%R02N!C\*E@CM% :!(0&/!0#D\^GXUDS6+ MK)9(Q&@X'-Q\TA"OZAO89J%O[3ANUVI.L M8F1SM4D.#)\_3_9]?7@4 =+169?"_P#MJI;LX@D4,S*!E"N3@9_O?*/P-)I# MW*QM'<^>^6^5Y%([<]>G/U]J -2BN^ 3^)IT,^HH'1DN6#2)Y)*<[-YSN]#MQU_G0!NTFX;2& M&9+PSM]W#RC:22.1CM^!(YXIJV\]KHL\* *BFX)$A);:78C!^A[T :8N8&8* M)XR3T&X#5:&S-K!<6 M]S8O=7$NTAP.') S\W\.&W'VSD4 = CI("48, <'!SS2EE4$E@,=2WQ9)[A(O-1<(0!LVG=^ MN.:S=FL31>7/)<;VBV[0G!&SDD] <_C0!TX(.<$''6EZ5SD5MJ$$4DMNUQO= MR C8QCR.#@]]X%$WVYA*@:^-H4;RR%^D?TJ>@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH *.M%% !C P**** 8' HHH MH *0(JDD* 6ZD#K2T4 %& <<=*** "BBB@!" 1@@$'L:" 1@@&EHH **** " MD*JP(*@Y&#D=J6B@ P,"BBB@ HHHH *0@'&0#CD>U+10 4444 %%%% !111 M0 4444 %%%% !1110 @ &< #//%+110 4444 %!&1@]*** $50JA5 '0 4M M%% "*JH,*H SG@4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D! end GRAPHIC 23 imrx-20211231x10k020.jpg GRAPHIC begin 644 imrx-20211231x10k020.jpg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imrx-20211231x10k021.jpg GRAPHIC begin 644 imrx-20211231x10k021.jpg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end GRAPHIC 25 imrx-20211231x10k022.jpg GRAPHIC begin 644 imrx-20211231x10k022.jpg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imrx-20211231x10k023.jpg GRAPHIC begin 644 imrx-20211231x10k023.jpg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end GRAPHIC 27 imrx-20211231x10k024.jpg GRAPHIC begin 644 imrx-20211231x10k024.jpg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end GRAPHIC 30 imrx-20211231x10k027.jpg GRAPHIC begin 644 imrx-20211231x10k027.jpg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end GRAPHIC 31 imrx-20211231x10k028.jpg GRAPHIC begin 644 imrx-20211231x10k028.jpg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end GRAPHIC 32 imrx-20211231x10k029.jpg GRAPHIC begin 644 imrx-20211231x10k029.jpg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end GRAPHIC 33 imrx-20211231x10k030.jpg GRAPHIC begin 644 imrx-20211231x10k030.jpg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imrx-20211231x10k031.jpg GRAPHIC begin 644 imrx-20211231x10k031.jpg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end GRAPHIC 35 imrx-20211231x10k032.jpg GRAPHIC begin 644 imrx-20211231x10k032.jpg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end GRAPHIC 36 imrx-20211231x10k033.jpg GRAPHIC begin 644 imrx-20211231x10k033.jpg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end GRAPHIC 37 imrx-20211231x10k034.jpg GRAPHIC begin 644 imrx-20211231x10k034.jpg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end EX-101.SCH 38 imrx-20211231.xsd EX-101.SCH 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details) - Calc2 link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Income Taxes - Net loss and the effective income tax rate (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Income Taxes - Net deferred tax assets (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details) link:presentationLink link:calculationLink link:definitionLink 41303 - Disclosure - Commitments and Contingencies - Lease cost (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Business Combination - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Convertible Preferred Stock - Series A (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Convertible Preferred Stock - Series B (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Common Stock - Class A common stock (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Common Stock - Class B common stock (Details) link:presentationLink link:calculationLink link:definitionLink 40905 - Disclosure - Common Stock - IPO (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Stock-Based Compensation - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Stock-Based Compensation - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Commitments and Contingencies - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Business Combination (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Property and Equipment, net - Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Common Stock - Common stock warrant (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Stock-Based Compensation - stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - Income Taxes - Unrecognized tax benefits (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 39 imrx-20211231_cal.xml EX-101.CAL EX-101.DEF 40 imrx-20211231_def.xml EX-101.DEF EX-101.LAB 41 imrx-20211231_lab.xml EX-101.LAB EX-101.PRE 42 imrx-20211231_pre.xml EX-101.PRE XML 43 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 03, 2022
Jun. 30, 2021
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Entity File Number 001-40675    
Entity Registrant Name Immuneering Corp    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 26-1976972    
Entity Address, Address Line One 245 Main St    
Entity Address, Address Line Two Second Floor    
Entity Address, City or Town Cambridge    
Entity Address State Or Province MA    
Entity Address, Postal Zip Code 02142    
City Area Code 617    
Local Phone Number 500-8080    
Title of 12(b) Security Class A common Stock, par value $0.001 per share    
Trading Symbol IMRX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float   $ 136,900,000 $ 0
Documents Incorporated by Reference

Portions of the registrant’s Definitive Proxy Statement relating to the registrant’s 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the end of the registrant’s fiscal year ended December 31, 2021 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.

   
Auditor Name RSM US LLP    
Auditor Firm ID 49    
Auditor Location Boston, Massachusetts    
Entity Central Index Key 0001790340    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Amendment Flag false    
Class A Common Stock      
Entity Common Stock, Shares Outstanding   26,377,299  
Class B Common Stock      
Entity Common Stock, Shares Outstanding   0  

XML 44 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 74,888,145 $ 37,090,151
Marketable securities, current 74,311,203  
Accounts receivable 246,040 500,110
Prepaids and other current assets 2,888,608 140,958
Total current assets 152,333,996 37,731,219
Marketable securities, non-current 996,560  
Property and equipment, net 807,223 64,363
Goodwill 6,701,726  
Intangible asset 439,000  
Right-of-use assets, net 5,324,198 613,103
Other assets 102,129 14,333
Total assets 166,704,832 38,423,018
Current liabilities:    
Accounts payable 1,394,340 1,480,537
Accrued expenses 3,965,447 698,992
Lease liabilities, current 274,039 76,322
Total current liabilities 5,633,826 2,255,851
Long-term liabilities:    
Lease liabilities, non-current 5,090,897 544,767
Total liabilities 10,724,723 2,800,618
Commitments and contingencies (Note 13)
Convertible preferred stock:    
Convertible preferred stock   58,103,850
Stockholders' deficit:    
Preferred stock, $0.001 par value; 10,000,000 and 0 shares authorized at December 31, 2021 and December 31, 2020, respectively; No shares issued or outstanding
Additional paid-in capital 215,276,186 3,251,240
Accumulated other comprehensive loss (49,009)  
Accumulated deficit (59,273,388) (25,737,640)
Total stockholders' equity (deficit) 155,980,109 (22,481,450)
Total liabilities, convertible preferred stock and stockholders' equity (deficit) 166,704,832 38,423,018
Series B Preferred Stock    
Convertible preferred stock:    
Convertible preferred stock   36,983,910
Series A Preferred Stock    
Convertible preferred stock:    
Convertible preferred stock   21,119,940
Class A Common Stock    
Stockholders' deficit:    
Common stock 26,320 4,950
Class B Common Stock    
Stockholders' deficit:    
Common stock
XML 45 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock authorized (in shares) 10,000,000 0
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Series B Preferred Stock    
Convertible preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Convertible preferred stock, authorized (in shares) 0 6,032,183
Convertible preferred stock, issued (in shares) 0 3,619,292
Convertible preferred stock, outstanding (in shares) 0 3,619,292
Series A Preferred Stock    
Convertible preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Convertible preferred stock, authorized (in shares) 0 2,495,933
Convertible preferred stock, issued (in shares) 0 2,495,933
Convertible preferred stock, outstanding (in shares) 0 2,495,933
Class A Common Stock    
Common stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 200,000,000 22,026,200
Common stock, shares issued (in shares) 26,320,199 4,950,129
Common stock, shares outstanding (in shares) 26,320,199 4,950,129
Class B Common Stock    
Common stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 20,000,000 6,032,183
Common stock, shares issued (in shares) 0 0
Common stock, shares outstanding (in shares) 0 0
XML 46 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    
Revenue $ 2,079,961 $ 2,311,535
Cost of revenue 1,153,073 1,280,325
Gross profit 926,888 1,031,210
Operating expenses    
Research and development 26,540,959 15,003,786
General and administrative 8,271,998 3,109,978
Total operating expenses 34,812,957 18,113,764
Loss from operations (33,886,069) (17,082,554)
Other income (expense)    
Interest income 169,899 42,656
Other expense (127,063)  
Loss before income taxes (33,843,233) (17,039,898)
Income tax benefit 307,485  
Net loss $ (33,535,748) $ (17,039,898)
Net loss per share attributable to common stockholders, basic $ (2.46) $ (3.44)
Net loss per share attributable to common stockholders, diluted $ (2.46) $ (3.44)
Weighted-average common shares outstanding, basic 13,612,677 4,950,129
Weighted-average common shares outstanding, diluted 13,612,677 4,950,129
Other comprehensive loss:    
Unrealized losses from marketable securities $ (49,009)  
Comprehensive Loss $ (33,584,757) $ (17,039,898)
XML 47 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Preferred Stock
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Preferred Stock
Common Stock
Class A Common Stock
Additional Paid-In Capital
Accumulated other comprehensive loss
Accumulated Deficit
Series A Preferred Stock
Series B Preferred Stock
Total
Beginning Balance (in shares) at Dec. 31, 2019       4,950,129            
Beginning Balance at Dec. 31, 2019       $ 4,950 $ 2,164,471   $ (8,697,742)     $ (6,528,321)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense         1,086,769         1,086,769
Net loss             (17,039,898)     (17,039,898)
Ending Balance at Dec. 31, 2020       $ 4,950 3,251,240   (25,737,640)     (22,481,450)
Ending Balance (in shares) at Dec. 31, 2020       4,950,129            
Beginning Balance at Dec. 31, 2019 $ 16,611,832   $ 16,611,832              
Beginning Balance (in shares) at Dec. 31, 2019 1,966,043             1,966,043    
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Issuance of convertible preferred stock, net of issuance costs $ 4,508,108 $ 36,983,910 $ 36,983,910              
Issuance of convertible preferred stock, net of issuance costs (in shares) 529,890 3,619,292 4,508,108              
Ending Balance at Dec. 31, 2020 $ 21,119,940 $ 36,983,910 $ 58,103,850         $ 21,119,940 $ 36,983,910 58,103,850
Ending Balance (in shares) at Dec. 31, 2020 2,495,933 3,619,292           2,495,933 3,619,292  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock upon exercise of stock options       $ 118 354,316         $ 354,434
Issuance of common stock upon exercise of stock options (in shares)       117,846           117,847
Issuance of common stock upon exercise of warrants       $ 308 926,817         $ 927,125
Issuance of common stock upon exercise of warrants (in shares)       308,308            
Conversion of Preferred Stock into common stock $ (21,119,940) $ (61,772,761) (82,892,701) $ 11,939 82,880,762         82,892,701
Conversion of Preferred Stock into common stock (in shares) (2,495,933) (6,032,145)   11,939,281            
Issuance of common stock upon initial public offering, net of issuance costs       $ 8,625 118,185,808         118,194,433
Issuance of common stock upon initial public offering, net of issuance costs (in shares)       8,625,000            
Issuance of common stock for acquisition       $ 380 7,874,620         7,875,000
Issuance of common stock for acquisition, shares       379,635            
Stock-based compensation expense         1,802,623         1,802,623
Net loss             (33,535,748)     (33,535,748)
Other comprehensive loss           $ (49,009)       (49,009)
Ending Balance at Dec. 31, 2021       $ 26,320 $ 215,276,186 $ (49,009) $ (59,273,388)     $ 155,980,109
Ending Balance (in shares) at Dec. 31, 2021       26,320,199            
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Issuance of convertible preferred stock, net of issuance costs   $ 24,788,851 $ 24,788,851              
Issuance of convertible preferred stock, net of issuance costs (in shares)   2,412,853                
Ending Balance (in shares) at Dec. 31, 2021               0 0  
XML 48 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)
$ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)  
Issuance costs $ 2,124,317
XML 49 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2019
Jan. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:          
Net loss     $ (33,535,748) $ (17,039,898)  
Adjustment to reconcile to net loss to net cash used in operating activities:          
Depreciation expense     45,467 24,328  
Right-of-use asset amortization     113,605 54,977  
Stock based compensation expense     1,802,623 1,086,769  
Net amortization of premium (accretion of discount) on marketable securities     130,240    
Deferred tax benefit     (307,485)    
(Increase) decrease in:          
Accounts receivable     279,713 (290,170)  
Prepaid expenses and other current assets     (2,408,986) (69,740)  
Other assets       (14,333)  
Increase (decrease) in:          
Accounts payable     (130,398) 1,185,589  
Accrued expenses     3,240,940 488,644  
Lease liability     (80,853) (46,991)  
Net cash used in operating activities     (30,850,882) (14,620,825)  
Cash flows from investing activities:          
Purchases of property and equipment     (60,786) (53,415)  
Purchases of marketable securities     (75,625,529)    
Cash acquired in business combination     70,348    
Net cash used in investing activities     (75,615,967) (53,415)  
Cash flows from financing activities:          
Proceeds from initial public offering of common stock, net of commissions and underwriting     120,318,750    
Payment of initial public offering costs     (2,124,317)    
Proceeds from exercise of stock options     354,434    
Proceeds from exercise of warrants     927,125    
Net cash provided by financing activities     144,264,843 37,982,216  
Net increase in cash and cash equivalents     37,797,994 23,307,976  
Cash and cash equivalents at beginning of period   $ 13,782,175 37,090,151 13,782,175  
Cash and cash equivalents at end of period $ 13,782,175   74,888,145 37,090,151 $ 13,782,175
Supplemental disclosures of noncash investing and financing information :          
Conversion of convertible Series A and B preferred stock into common stock     82,892,701    
Business combination non cash     $ 7,804,652    
Class A common stock issued for business combination     7,875,000    
Reclassification of liability for Series A preferred stock       3,509,802  
Series A Preferred Stock          
Cash flows from financing activities:          
Proceeds from the issuance of preferred stock, net of issuance costs $ 4,004,975 1,021,413   998,306  
Payment of initial public offering costs   $ (23,610)     $ (200,587)
Series B Preferred Stock          
Cash flows from financing activities:          
Proceeds from the issuance of preferred stock, net of issuance costs     $ 24,788,851 $ 36,983,910  
XML 50 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Organization and Nature of Business
12 Months Ended
Dec. 31, 2021
Organization and Nature of Business  
Organization and Nature of Business

Note 1 – Organization and Nature of Business

Immuneering Corporation, a Delaware corporation, (“Immuneering” or the “Company”) was incorporated in 2008. The Company aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using the Company’s translational bioinformatics platform. The Company has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, the Company’s disease-agnostic discovery platform enables the Company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry.

On October 30, 2019, Immuneering formed a wholly owned subsidiary, Immuneering Securities Corporation (“ISC”), a Massachusetts securities corporation, for the sole purpose of buying, selling and holding securities on the Company’s behalf.

On December 22, 2021, the Company acquired all outstanding shares of capital stock of BioArkive, Inc. (“BioArkive”), a California corporation, which as a result became a wholly owned subsidiary.  

Immuneering, ISC and BioArkive are collectively referred to as “the Company” throughout these  consolidated financial statements.

The Company is subject to a number of inherent risks associated with any biotechnology company that has substantial expenditures for research and development. These risks include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. There can be no assurance that the Company’s research and development program will be successful. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, and consultants.

On August 3, 2021, the Company completed its initial public offering (“IPO”) pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional paid-in capital (see Note 8).

To date, the Company has funded its operations through service revenues, and with proceeds from the sale of its capital stock and convertible notes and, most recently, with proceeds from the IPO. The Company has incurred recurring losses over the past several years and as of December 31, 2021, the Company had an accumulated deficit of $59,273,388. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern and estimates that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the consolidated financial statements. The full extent to which coronavirus (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial

condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the pandemic related to COVID-19 and its variants and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgements or revise the carrying values of its assets or liabilities.

XML 51 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB sets generally accepted accounting principles (“GAAP”) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (“ASC”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Stock Split

On July 23, 2021, the Company approved a one-for-1.4 stock split which was consummated in connection with the Company’s IPO. All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.

Use of Estimates 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these  consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.

Segments

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.


Business Combination

Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition.

If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. Refer to Note 6, Business Combination for more information.

Cash and Cash Equivalents

Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (“FDIC”) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.

Marketable Securities

Our marketable securities are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the  consolidated balance sheets and statements of convertible preferred stock and stockholders’ equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021.  Realized gains and losses are included in other expense on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December 31, 2021.

Fair Value Measurements

We record cash equivalents and marketable securities at fair value. ASC 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2021. Fair value

information for these assets, including their classification in the fair value hierarchy is included in Note 4  Fair Value Measurements.

There have been no changes to the valuation methods during the year ended December 31, 2021. We evaluate transfers between levels at the end of each reporting period.

The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.

Accounts Receivable

Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management’s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December 31, 2021 and 2020 there was no allowance for doubtful accounts.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.

The following customers comprised 10% or more of the Company’s total accounts receivable or revenues as of or for the period ended December 31, 2021 (customers with an asterisk are less than 10%):

Year Ended December 31, 2021

As of December 31, 2021

 

    

Revenue

    

% of Total

    

Accounts Receivable

    

% of Total

 

Customer #1

$

745,030

 

35.8

%  

$

235,500

 

95.7%

%

Customer #2

380,000

 

18.3

*

*

Customer #5

353,050

 

17.0

*

 

*

Year Ended December 31, 2020

As of December 31, 2020

 

    

Revenue

    

% of Total

    

Accounts Receivable

    

% of Total

 

Customer #1

$

676,710

 

29.3

%  

$

214,345

 

42.9

%

Customer #2

570,000

 

24.7

71,250

 

14.2

Customer #3

306,900

 

13.3

*

 

*

Customer #4

250,880

 

10.9

63,000

 

12.6

Customer #5

 

*

 

*

91,975

 

18.4

Property and Equipment

Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service.

    

Estimated

Asset Class

Useful Lives

Computer equipment

 

3 years

Furniture and fixtures

 

5 years

Lab equipment

7 years

Leasehold improvements

1-10 years

Impairment of Long-lived Assets

Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.

Leases

In February 2016 the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASC 842”), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company’s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.

The Company adopted the leasing standard using the modified retrospective transition approach as of January 1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12 months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.

The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.

The Company has elected not to separate lease and non-lease components as a single lease component. The Company’s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.

Revenue Recognition

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in

an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:

• Identify the contract with a customer

• Identify the performance obligations in the contract

• Determine the transaction price

• Allocate the transaction price to the performance obligations in the contract

• Recognize revenue when or as performance obligations are satisfied

The Company’s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company’s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

The Company’s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.

Income Taxes

The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. As of December 31, 2021 and 2020, the Company had uncertain tax positions of $380,902 and $174,950.   The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.

Research and Development

Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.

Research and Manufacturing Contract Costs and Accruals

The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.

Patent Costs

 

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

Comprehensive Loss

 

Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders.

Deferred Offering Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder’s equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were no deferred offering costs as of December 31,2021 or December 31, 2020.

Net Income (Loss) per Share

 

Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.

The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December 31, 2021 and 2020.

Stock-based Compensation

The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation — Stock Compensation (“ASC 718”), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.

The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (“Black-Scholes”). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgement.

In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January 1, 2020.

As there had been no public market for the Company’s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company’s most recently available third-party valuations of common stock and its board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.

The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.

Goodwill

Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.

On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.

The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired.

The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were no impairments in 2021.

Intangible Assets

Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.

The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (“JOBS Act”). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

In 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) will become effective for the Company on January 1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December 15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.

In January 2017, the FASB issued ASU No. ASU 2017-04,  Intangibles—Goodwill and Other (Topic 350), which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on today’s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements.  

XML 52 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities
12 Months Ended
Dec. 31, 2021
Marketable Securities  
Marketable Securities

Note 3 – Marketable Securities

Marketable securities as of December 31, 2021 consisted of the following:

December 31, 2021

    

Amortized Cost

    

Unrealized Gains

    

Unrealized Losses

    

Fair Value

Assets:

Current:

U.S. Treasuries

$

42,147,385

$

-

$

(28,575)

$

42,118,810

Government securities

19,218,057

-

(13,689)

19,204,368

Commercial Paper

12,992,165

57

(4,197)

12,988,025

Total Current

74,357,607

57

(46,461)

74,311,203

Non-current:

U.S. Treasuries

999,186

-

(2,626)

996,560

Government securities

-

-

-

-

Total Non-current

999,186

-

(2,626)

996,560

Total marketable securities

$

75,356,793

$

57

$

(49,087)

$

75,307,763

There were no marketable securities as of December 31, 2020.

There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021. Realized gains and losses are included in other expense on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December 31, 2021.

XML 53 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2021
Fair Value Measurements  
Fair Value Measurements

Note 4 – Fair Value Measurements

The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of December 31, 2021:

Level 1

Level 2

Level 3

Total

Assets:

Cash equivalents

Money market

$

33,961,344

$

-

$

-

$

33,961,344

Commercial paper

-

2,000,000

-

2,000,000

Total cash equivalents

33,961,344

2,000,000

-

35,961,344

Marketable securities:

U.S. Treasuries

$

43,115,370

$

-

$

-

$

43,115,370

Government securities

-

19,204,368

-

19,204,368

Commercial paper

-

12,988,025

-

12,988,025

Total marketable securities

43,115,370

32,192,393

-

75,307,763

Total cash equivalents and marketable securities

$

77,076,714

$

34,192,393

$

-

$

111,269,107

There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the year ended December 31, 2021. There were no marketable securities as of December 31, 2020.

XML 54 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment, net
12 Months Ended
Dec. 31, 2021
Property and Equipment, net  
Property and Equipment, net

Note 5 – Property and Equipment, net

Property and equipment, net consisted of the following:

    

December 31, 

    

December 31, 

2021

2020

Computer equipment

$

281,666

$

174,317

Furniture and fixtures

 

84,477

 

18,798

Lab equipment

463,182

-

Leasehold improvements

 

152,117

 

-

Total

 

981,442

 

193,115

Accumulated depreciation

 

(174,219)

 

(128,752)

Property and equipment, net

$

807,223

$

64,363

Depreciation expense totaled $45,467 and $24,328 for the year ended December 31, 2021 and 2020, respectively.

XML 55 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Business Combination
12 Months Ended
Dec. 31, 2021
Business Combination  
Business Combination.

Note 6 – Business Combination

BioArkive Acquisition

On December 22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (“BioArkive”), for a market value of $8.75 million.

BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company's internal preclinical research activities for its oncology pipeline.

In connection with the acquisition, the Company has assumed the obligations under BioArkive’s three lease agreements.

The purchase price was paid by Immuneering through the issuance of an aggregate of 379,635 shares of Immuneering’s Class A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the closing date. The sellers of BioArkive are restricted from selling these shares for a 6 month period from the date of the acquisition. As such, we estimated that there was an approximate 10% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $7,875,000.

Prior to the acquistion, Brett Hall, Chief Scientific Officer of Immuneering and the Founder and Chairman of the board of directors of BioArkive, held the majority of the outstanding shares of BioArkive capital stock.  BioArkive provided contract services to the Company. Research and development expenses in the consolidated statement of operations include the cost of services provided by BioArkive to the Company which amounted to $4,548,780 in 2021 through date of the acquisition and $2,744,051 in 2020. As of December 31, 2020, $279,153 was owed to BioArkive and is included in accounts payable or accrued contract research expenses in the consolidated balance sheets.

Assets Acquired and Liabilities Assumed at Fair Value

The BioArkive Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. As of December 31, 2021, certain amounts relating to working capital have not been finalized. The finalization of these matters could result in changes to goodwill.

Intangible Assets

The estimated fair value of the intangible assets was determined using the relief from royalty approach.

Goodwill

Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected cost savings of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of BioArkive, is the planned investment in the internal preclinical research activities for our oncology pipeline. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.

Pro forma results are not presented for this acquisition as they are not material to the consolidated results of the Company’s operations.

    

Preliminary Valuation

    

Weighted Average Life

Cash

$

70,348

Other currents assets

225,790

Other long term assets

87,796

Property, plant and equipment, net

727,539

Right of use assets

4,824,700

Intangible asset

Technology

439,000

15 years

Goodwill

6,701,726

Total assets acquired

13,076,899

Accounts payable, accrued expenses and other liabilities

69,714

Deferred tax liabilities

307,485

Lease liabilities

4,824,700

Net assets acquired

$

7,875,000

XML 56 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Expenses
12 Months Ended
Dec. 31, 2021
Accrued Expenses  
Accrued Expenses

Note 7 – Accrued Expenses

Accrued expenses consisted of the following:

    

December 31, 

    

December 31, 

2021

2020

Accrued professional services

$

250,977

$

269,302

Accrued employee expenses

 

2,917,282

 

163,668

Accrued contract research expenses

 

585,416

 

266,022

Accrued other

211,772

Total

$

3,965,447

$

698,992

XML 57 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock
12 Months Ended
Dec. 31, 2021
Convertible Preferred Stock  
Convertible Preferred Stock

Note 8 – Convertible Preferred Stock

Series A Preferred Stock

In September 2019, the Company authorized the sale and issuance of up to 1,987,979 shares of Series A Preferred Stock, $0.001 par value per share, at an original issuance price of $8.5514 per share. In January 2020, the number of shares authorized for the Series A Preferred Stock was increased to 2,495,933 shares. The Series A Preferred Stock financing was structured to be issued in rolling closes during 2019 and 2020.

On September 20, 2019, the Company issued an additional 1,122,458 shares of Series A Preferred Stock for gross cash proceeds of $9,598,847 and issued 785,706 shares of Series A Preferred Stock in conjunction with the conversion of the outstanding amount of the Convertible Notes. In 2019, the Company incurred issuance costs of $200,587 in connection with this offering.

The Company received funds for issuance of an additional 468,315 shares of Series A Preferred Stock for gross cash proceeds of $4,004,975 through December 31, 2019. Of these shares, 410,436 shares of Series A Preferred Stock for gross cash proceeds of $3,509,802 exceeded the authorized amount allowed by the articles of incorporation, resulting in a liability of $3,509,802 and a total of 1,966,043 shares of Series A Preferred Stock outstanding at December 31, 2019. In January 2020, the shares that were previously classified as a liability as of December 31, 2019 were reclassified to temporary equity upon the approved increase to authorized shares of Series A Preferred Stock.

In January 2020, the Company issued 119,454 additional shares of Series A Preferred Stock for gross cash proceeds of $1,021,413. The Company incurred issuance costs of $23,610 in connection with the financing in January 2020.

Series B Preferred Stock

In December 2020, the Company authorized the sale and issuance of up to 6,032,183 shares of Series B Preferred Stock, $0.001 par value per share, at an original issuance price of $10.2782 per share. The Series B Preferred Stock financing was structured to close in two tranches. The first tranche closed in December 2020 and the Company issued 3,619,292 shares of Series B Preferred Stock for gross cash proceeds of $37,199,929. The Company incurred issuance costs of $216,019 in connection with the financing in December 2020.

The Company determined the right of the investors to purchase 2,412,853 shares of Series B Preferred Stock in the second tranche does not meet the definition of a freestanding financial instrument as it is not separable from the Series B Preferred Stock issued in the first tranche. The issuance of the second tranche is subject to the Company meeting certain development milestones or at the election of the holders of at least a majority of the then outstanding shares of Series B Preferred Stock which must include one specific shareholder (the “Requisite Holders”). Each holder of Series B Preferred Stock may elect to purchase their requisite shares of the second tranche at any time. As of March 31, 2021, the Company had not met these development milestones nor did the Requisite Holders elect to purchase the second tranche prior to meeting these milestones and therefore no shares of the second tranche were issued.

In April and May 2021, all 2,412,853 shares of the second tranche of Series B Preferred Stock were issued based on the voluntary election of substantially all of the holders of Series B Preferred Stock. The Company received gross proceeds of $24,799,786. The Company incurred issuance costs of $10,935 in connection with the second tranche of Series B Preferred Stock.

The rights and preferences of the Series A Preferred Stock and Series B Preferred Stock (“Preferred Stock”) were as described below:

Conversion

Each share of Preferred Stock may be converted at any time, at the option of the holder, into shares of Class A common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The conversion price for the Series A Preferred Stock and Series B Preferred Stock (as may be adjusted for certain customary dilutive events) is $6.1081 and $7.3416, respectively. The Preferred Stock automatically convert into shares of Class A common stock at the then effective conversion rate upon the closing of a public offering of the Company’s securities with gross proceeds to the Company of at least $75,000,000 and a share price of at least $7.3416 or at the election of the holders of the Requisite Holders.

Holders of Series B Preferred Stock that would beneficially own at least 9.9% of any then outstanding class of equity securities may elect to receive a portion of their converted Series B Preferred Stock as Class B common stock upon conversion.

Upon the closing of the IPO on August 3, 2021, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock.

Dividends

Preferred Stockholders are entitled to receive per annum dividends of 7% of the original issue price share, payable only when, as and if declared by the Board of Directors. The right to receive these dividends is not cumulative, and therefore, if not declared in any year, the right to receive such dividends shall terminate and not carry forward into the next year. As of December 31, 2021 and December 31, 2020, no dividends had been declared.

Voting Rights

Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters are subject to the powers, preferences, and rights of the Preferred Stock. Preferred Stockholders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. As long as 2,132,029 shares of Preferred Stock are outstanding, certain actions such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events, must be approved by the holders of at least a majority of the then-outstanding shares of Preferred Stock.

Liquidation Preference

Upon liquidation, dissolution, or winding up of business, holders of Preferred Stock are entitled to receive a liquidation preference in priority to holders of common stock at the original respective Preferred Stock issue price for such series. If assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, assets available for distribution will be allocated among holders of Preferred Stock on a pari passu basis at an amount per share equal to the greater of the respective original Preferred Stock issue price for such series plus any declared but unpaid dividends or such amount had all shares been converted to common stock.

When holders of Preferred Stock are satisfied in full, any excess assets available for distribution will be allocated ratably among common stock holders based on their pro rata shareholdings. Upon a deemed liquidation event, as defined in the articles of incorporation, holders have the option to redeem their shares at the liquidation payment amounts summarized above.

Redemption

Other than described above, the shares of Preferred Stock are not redeemable.

XML 58 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock
12 Months Ended
Dec. 31, 2021
Common Stock.  
Common Stock

Note 9 - Common Stock

The Company had 200,000,000 authorized shares of Class A common stock, $0.001 par value per share as of December 31, 2021 and 22,026,200 authorized shares of Class A common stock, $0.001 par value per share as of December 31, 2020, respectively, of which 26,320,199 and 4,950,129 were issued and outstanding, respectively. The holders of Class A common stock are entitled one vote for each share of common stock. Dividends may be paid when, and if declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Preferred Stockholders and on a proportionate basis with holders of Class B common stock.

As of December 31, 2021 and December 31, 2020, the following number of shares of Class A common stock have been reserved:

    

December 31, 

    

December 31, 

2021

2020

Conversion of Series A Preferred

 

 

3,494,306

Conversion of Series B Preferred

 

 

5,066,995

Exercise of common stock warrants

 

 

308,308

Exercise of common stock options

 

2,859,544

 

1,801,263

 

2,859,544

 

10,670,872

The Company had 20,000,000 authorized shares of Class B common stock, $0.001 par value per share as of December 31, 2021 and 6,032,183 authorized shares of Class B common stock, $0.001 par value per share as of December 31, 2020, of which no shares have been issued nor are outstanding. The holders of Class B common stock have no voting rights. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the preferred stockholders and on a proportionate basis with holders of Class A common stock.

Common Stock Warrants

During 2019, the Company issued warrants to purchase an aggregate of 308,308 shares of Class A common stock at an exercise price of $3.01 per share to several advisors, including 200,984 shares to entities related to members of the Board of Directors of the Company, in lieu of cash payments. These warrants vested immediately upon issuance, became exercisable on January 9, 2021 and have a 10-year term set to expire on January 9, 2030. The Company evaluated the terms of these warrants and determined that equity classification was appropriate. As of December 31, 2020, no warrants had been exercised. During June 2021, all warrant holders exercised their warrants to purchase an aggregate of 308,308 shares of common stock. As of December 31, 2021, there were no warrants outstanding.

Initial Public Offering

On August 3, 2021, the Company completed its initial public offering pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional paid-in capital.  

On August 3, 2021 in connection with the closing of the IPO, the Company filed a restated certificate of incorporation, which amended and restated the Company’s certificate of incorporation to, among other things: (i) increase the number of

authorized shares of common stock to 200,000,000 shares of Class A common stock, 20,000,000 shares of Class B common stock, par value $0.001 per share, and (ii) authorize 10,000,000 shares of Preferred Stock; and (iii) authorize the Board of Directors to establish the rights, preferences and restrictions on any unissued series of Preferred Stock.

XML 59 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Common Stockholders
12 Months Ended
Dec. 31, 2021
Net Loss Per Share Attributable to Common Stockholders  
Net Loss Per Share Attributable to Common Stockholders

Note 10 - Net Loss Per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders was calculated at December 31, 2021 and 2020 as follows:

    

Year Ended December 31, 

    

2021

    

2020

Numerator:

 

  

 

  

 

Net loss

$

(33,535,748)

$

(17,039,898)

Denominator - basic and diluted:

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

13,612,677

 

4,950,129

Net loss per share - basic and diluted

$

(2.46)

$

(3.44)

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at December 31, 2021 and 2020:

    

2021

    

2020

Series A Preferred

 

 

3,494,306

Series B Preferred

 

 

5,066,995

Warrants to purchase common stock

 

 

308,308

Options to purchase common stock

 

2,859,544

 

1,801,263

Total shares of common stock equivalents

 

2,859,544

 

10,670,872

XML 60 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation
12 Months Ended
Dec. 31, 2021
Stock-Based Compensation  
Stock-Based Compensation

Note 11 – Stock-Based Compensation

During 2015, the Company established the Long Term Incentive Plan (“Incentive Plan”), under which incentive stock options, nonqualified stock options, restricted stock or other awards may be awarded to employees, directors or consultants of the Company. The options typically vest over a four-year period. As of December 31, 2021, the maximum number of shares available for issuance under the Incentive Plan was 2,825,173 shares. Upon the effectiveness of the Company’s 2021 Incentive Award Plan, the Company ceased granting awards under the Incentive Plan. However, the Incentive Plan continues to goven awards outstanding thereunder.

On July 23, 2021, the Company’s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Incentive Award Plan (the “2021 Plan”), which became effective on July 29, 2021. The 2021 Plan provides for the grant of incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares reserved for issuance under the 2021 Plan was initially equal to 2,590,000 plus an annual increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 4% of the aggregate number of shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the Board of Directors. No more than 15,350,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. If an award under the 2021 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised/settled or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 Plan. In addition, shares subject to stock options issued under the Incentive Plan may become available for issuance under the 2021 Plan to the extent such stock options are canceled, forfeited, exchanged, settled in cash or

otherwise terminated. As of December 31, 2021, there were 2,298,432 shares available for future issuance under the 2021 Plan.

On July 23, 2021, the Company’s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective on July 29, 2021. A total of 250,000 shares of Class A common stock were initially reserved for issuance under this plan. The number of shares of Class A common stock that may be issued under the 2021 ESPP will automatically increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 1% of the shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the board of directors, provided that not more than 3,340,000 shares of Class A common stock may be issued under the 2021 ESPP. As of December 31, 2021, no shares had been issued under the 2021 ESPP.

During the year ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of $1,802,623 and $1,086,769, respectively. As of December 31, 2021, compensation expense remaining to be recognized for outstanding stock options was $8,403,600 and to be recognized over a weighted-average period of 2.93 years.

The fair value of options granted is calculated on the grant date using the Black-Scholes option valuation model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer public companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For the year ended December 31, 2021, the Company granted 1,452,462 shares of stock options at a weighted-average grant date fair value of $6.29. For the year ended December 31, 2020, the Company granted 343,169 shares at a weighted-average grant date fair value of $3.06.

The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants during the year ended December 31, 2021 and 2020:

Year Ended December 31, 

    

2021

    

2020

Weighted-average risk-free interest rate

0.89% - 1.71%

0.36% - 1.45%

Expected term (in years)

5.83 - 10 years

5.92 - 10 years

Expected dividend yield

0%

0%

Expected volatility

66.76% - 80.99%

67.30% - 80.85%

The following table summarizes the stock option activity during the year ended December 31, 2021 under the Plan:

    

    

Weighted

    

Weighted-

Average

Average

Remaining

Number of

Exercise Price

Contractual

Aggregate

Options

per Share

    

Term (in Years)

Intrinsic Value

 

  

 

  

 

  

 

  

Outstanding at of December 31, 2020

 

1,801,263

$

3.01

 

 

  

Granted

 

1,452,462

10.07

 

  

Exercised

 

(117,847)

3.01

 

  

Cancelled

 

(276,334)

3.58

 

  

Outstanding at December 31, 2021

 

2,859,544

$

6.55

8.30

$

27,615,466

 

Vested and exercisable at December 31, 2021

 

1,102,543

$

3.01

 

7.14

$

14,507,723

Vested and expected to vest at December 31, 2021

2,859,544

$

6.55

 

8.30

$

27,615,466

For the year  ended December 31, 2021 and 2020, the Company recognized share-based compensation expense recognized on the accompanying  consolidated statements of operations as follows:

Year Ended December 31, 

    

2021

    

2020

    

Cost of revenue

$

103,329

$

108,027

Research and development

 

768,679

 

503,111

General and administrative

 

930,615

 

475,631

Total

$

1,802,623

$

1,086,769

XML 61 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Taxes  
Income Taxes

Note 12 – Income Taxes

A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate are as follows:

    

2021

    

2020

 

Statutory federal income tax rate

 

21.0

%  

21.0

%

State tax, net of federal benefit

 

5.5

%  

6.3

%

Permanent differences

 

(0.6)

%  

(1.5)

%

Federal research and development credits

 

5.6

%  

4.5

%

State research and development credits

 

0.4

%  

0.6

%

Uncertain tax positions

(0.6)

%  

(1.0)

%

Other differences

 

0.7

%  

(2.6)

%

Change in valuation allowance

 

(31.1)

%  

(27.3)

%

Effective income tax rate

 

0.9

%  

0.0

%

As of December 31, 2021 and 2020, the components and tax effects of each type of item that gave rise to the net deferred tax assets were as follows:

    

2021

    

2020

Deferred tax assets:

 

  

 

  

Stock-based compensation expense

$

373,602

$

73,984

Unrealized losses

12,990

R&D credit carryforward

 

3,346,097

 

1,574,596

NOL carryforward

 

14,699,524

 

5,525,123

Gross deferred tax assets

 

18,432,213

 

7,173,703

Valuation allowance

(17,677,899)

 

(7,127,448)

Net deferred tax assets

 

754,314

 

46,255

Net deferred tax liabilities:

 

  

 

  

Prepaid expenses deducted for tax

 

(425,755)

 

(28,671)

Tax depreciation in excess of book

 

(328,559)

 

(17,584)

Total deferred tax liabilities

 

(754,314)

 

(46,255)

Net deferred taxes

$

$

Federal net operating losses (“NOL”) generated in tax years ended after December 31, 2017 are limited to 80% of taxable income, only carried forward and carried forward indefinitely under the Internal Revenue Code (“IRC”). The Company recorded a deferred tax liability of $304,485 on the acquisition of BioArkive. It had pre-existing deferred tax assets for which there was a fuill valuation allowance. As a result of the taxable temporary differences recognized in the business combination, the Company released $304,485 of its valuation allowance and recognized the income tax benefit in the income statement at the acquisition date in accordance with ASC 740 There was no income tax expense or benefit in 2020. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December 31, 2021, the Company has federal and state NOLs of $56,544,731 and $51,310,112,

respectively all generated after the tax year ended December 31, 2017. At December 31, 2021, the Company has federal and state research and development credit carryforwards, $3,034,827 and $394,013, respectively, that start to expire beginning in 2025.

As the Company has not yet achieved profitable operations, management believes the tax benefits as of December 31, 2021 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2021 by $10,550,451 due to the increase in the deferred tax assets by the same amount, primarily due to NOL and research and development credit carryforwards.

Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, some amounts are being presented as an uncertain tax position.

As of December 31, 2021 and 2020, the Company had uncertain tax positions of $380,902 and $174,950 which have been classified as reductions of its tax carrforwards. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December 31, 2021 and 2020.

As of December 31, 2021 and 2020, unrecognized tax benefits were as follows:

2021

2020

Beginning balance

$

174,950

$

96,952

Increase due to current year tax position

205,952

77,998

Ending balance

$

380,902

$

174,950

The Company files tax returns in the United States including California, New York, Pennsylvania, Massachusetts and

Texas. All tax years from 2017 to 2021 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (“IRS”) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The enactment of the CARES Act resulted in increased federal and state research and development carryforwards from 2013 through 2018 of $93,437 and decreased federal NOL of $759,794 from 2018.

XML 62 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies.  
Commitments and Contingencies

Note 13 – Commitments and Contingencies

Operating Leases

The Company leases office space in Cambridge, Massachusetts, New York, New York and as of July 2021, San Francisco, California, pursuant to short-term arrangements. The Cambridge and San Francisco leases are on a month-to-month basis, requiring one month’s notice before termination. The New York lease is renewable on a quarterly basis and the last renewal extended the lease term until March 31, 2022. These lease agreements include payments for lease and non-lease components and the Company has elected to not separate such components and these payments were recognized as rent expense.

As of December 31, 2021, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts, New York, New York and San Francisco, California was $30,840 due in 2022. The Company leases storage space for its electronic data equipment in Somerville, Massachusetts. This lease is renewable on an annual basis effective every March 1st. Prior to December 31, 2021, the Company renewed the lease through March 31, 2022. As of December 31, 2021, total future minimum lease payments for this lease were $3,569 due in 2022.

In October 2020, the Company entered into an office lease in San Diego, California with a lease term of 67 months. At the lease commencement date, a right-to-use asset and lease liability was recognized by the Company for $637,863.

As part of the BioArkive acquisition, the Company assumed the obligations of three leases in San Diego, California, one is for 38,613 square feet of office and laboratory space, under a lease that terminates on April 30, 2032, a second is a 6,100 square feet of office and laboratory space under a lease that terminates on December 31, 2022, and third is a lease for 4,760 square feet of office and laboratory space under a lease that terminates on March 31, 2024.  As a result, we recorded right-to-use assets and lease liabilities of $4,824,700 on the acquisition date of December 22, 2021.

Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at December 31, 2021 were as follows

    

Amount

2022

$

659,990

2023

 

880,121

2024

 

894,044

2025

 

906,839

2026

 

819,210

Thereafter

4,467,246

Total future lease payments

 

8,627,450

Less: Imputed interest

 

3,262,514

Total lease liabilities

$

5,364,936

Current portion lease liabilities

274,039

Lease liabilities, noncurrent

 

5,090,897

Total lease liabilities

$

5,364,936

Quantitative information regarding the Company’s leases for the year ended December 31, 2021 and 2020 is as follows:

    

December 31, 

    

December 31, 

2021

2020

Lease costs:

  

  

Operating lease cost

$

160,872

$

66,652

Short-term lease cost

 

258,357

 

252,796

Variable lease cost

 

 

14,700

Total lease costs

$

419,229

$

334,148

Cash paid for amounts included in the measurement of lease liabilities:

 

  

 

  

Operating cash flows from operating leases

$

111,527

$

58,666

Operating cash flows from short-term leases

 

236,700

 

252,796

$

348,227

$

311,462

Weighted-average remaining lease term - operating leases

 

9.62 years

 

5.33 years

Weighted-average discount rate - operating leases

 

9.7%

 

6.0%

As the Company’s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

Litigation

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its products and operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated the Company will accrue a liability for such matters. Significant judgement is required to determine both probability and estimated amount. The Company is not aware of any material legal matters.

Clinical Research Contracts

The Company may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination with a 30-day notice.

XML 63 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Summary of Significant Accounting Policies  
Basis of Presentation

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB sets generally accepted accounting principles (“GAAP”) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (“ASC”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Stock Split

Stock Split

On July 23, 2021, the Company approved a one-for-1.4 stock split which was consummated in connection with the Company’s IPO. All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.

Use of Estimates

Use of Estimates 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these  consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.

Segments

Segments

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.

Business Combination

Business Combination

Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition.

If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. Refer to Note 6, Business Combination for more information.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (“FDIC”) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.

Marketable Securities

Marketable Securities

Our marketable securities are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the  consolidated balance sheets and statements of convertible preferred stock and stockholders’ equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021.  Realized gains and losses are included in other expense on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December 31, 2021.

Fair Value of Financial Instruments

Fair Value Measurements

We record cash equivalents and marketable securities at fair value. ASC 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2021. Fair value

information for these assets, including their classification in the fair value hierarchy is included in Note 4  Fair Value Measurements.

There have been no changes to the valuation methods during the year ended December 31, 2021. We evaluate transfers between levels at the end of each reporting period.

The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.

Accounts Receivable

Accounts Receivable

Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management’s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December 31, 2021 and 2020 there was no allowance for doubtful accounts.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.

The following customers comprised 10% or more of the Company’s total accounts receivable or revenues as of or for the period ended December 31, 2021 (customers with an asterisk are less than 10%):

Year Ended December 31, 2021

As of December 31, 2021

 

    

Revenue

    

% of Total

    

Accounts Receivable

    

% of Total

 

Customer #1

$

745,030

 

35.8

%  

$

235,500

 

95.7%

%

Customer #2

380,000

 

18.3

*

*

Customer #5

353,050

 

17.0

*

 

*

Year Ended December 31, 2020

As of December 31, 2020

 

    

Revenue

    

% of Total

    

Accounts Receivable

    

% of Total

 

Customer #1

$

676,710

 

29.3

%  

$

214,345

 

42.9

%

Customer #2

570,000

 

24.7

71,250

 

14.2

Customer #3

306,900

 

13.3

*

 

*

Customer #4

250,880

 

10.9

63,000

 

12.6

Customer #5

 

*

 

*

91,975

 

18.4

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service.

    

Estimated

Asset Class

Useful Lives

Computer equipment

 

3 years

Furniture and fixtures

 

5 years

Lab equipment

7 years

Leasehold improvements

1-10 years

Impairment of Long-lived Assets

Impairment of Long-lived Assets

Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.

Leases

Leases

In February 2016 the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASC 842”), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company’s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.

The Company adopted the leasing standard using the modified retrospective transition approach as of January 1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12 months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.

The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.

The Company has elected not to separate lease and non-lease components as a single lease component. The Company’s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.

Revenue Recognition

Revenue Recognition

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in

an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:

• Identify the contract with a customer

• Identify the performance obligations in the contract

• Determine the transaction price

• Allocate the transaction price to the performance obligations in the contract

• Recognize revenue when or as performance obligations are satisfied

The Company’s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company’s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

The Company’s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.

Income Taxes

Income Taxes

The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. As of December 31, 2021 and 2020, the Company had uncertain tax positions of $380,902 and $174,950.   The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.

Research and Development

Research and Development

Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.

Research and Manufacturing Contract Costs and Accruals

Research and Manufacturing Contract Costs and Accruals

The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.

Patent Costs

Patent Costs

 

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

Comprehensive Loss

Comprehensive Loss

 

Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders.

Deferred Offering Costs

Deferred Offering Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder’s equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were no deferred offering costs as of December 31,2021 or December 31, 2020.

Net Income (Loss) per Share

Net Income (Loss) per Share

 

Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.

The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December 31, 2021 and 2020.

Stock-based Compensation

Stock-based Compensation

The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation — Stock Compensation (“ASC 718”), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.

The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (“Black-Scholes”). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgement.

In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January 1, 2020.

As there had been no public market for the Company’s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company’s most recently available third-party valuations of common stock and its board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.

The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.

Goodwill

Goodwill

Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.

On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.

The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired.

The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were no impairments in 2021.

Intangible Assets

Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.

The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (“JOBS Act”). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

In 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) will become effective for the Company on January 1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December 15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.

In January 2017, the FASB issued ASU No. ASU 2017-04,  Intangibles—Goodwill and Other (Topic 350), which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on today’s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements.  

XML 64 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Summary of Significant Accounting Policies  
Schedule of concentration of credit risk

Year Ended December 31, 2021

As of December 31, 2021

 

    

Revenue

    

% of Total

    

Accounts Receivable

    

% of Total

 

Customer #1

$

745,030

 

35.8

%  

$

235,500

 

95.7%

%

Customer #2

380,000

 

18.3

*

*

Customer #5

353,050

 

17.0

*

 

*

Year Ended December 31, 2020

As of December 31, 2020

 

    

Revenue

    

% of Total

    

Accounts Receivable

    

% of Total

 

Customer #1

$

676,710

 

29.3

%  

$

214,345

 

42.9

%

Customer #2

570,000

 

24.7

71,250

 

14.2

Customer #3

306,900

 

13.3

*

 

*

Customer #4

250,880

 

10.9

63,000

 

12.6

Customer #5

 

*

 

*

91,975

 

18.4

Schedule of property and equipment

    

Estimated

Asset Class

Useful Lives

Computer equipment

 

3 years

Furniture and fixtures

 

5 years

Lab equipment

7 years

Leasehold improvements

1-10 years

XML 65 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities (Tables)
12 Months Ended
Dec. 31, 2021
Marketable Securities  
Schedule of marketable securities

December 31, 2021

    

Amortized Cost

    

Unrealized Gains

    

Unrealized Losses

    

Fair Value

Assets:

Current:

U.S. Treasuries

$

42,147,385

$

-

$

(28,575)

$

42,118,810

Government securities

19,218,057

-

(13,689)

19,204,368

Commercial Paper

12,992,165

57

(4,197)

12,988,025

Total Current

74,357,607

57

(46,461)

74,311,203

Non-current:

U.S. Treasuries

999,186

-

(2,626)

996,560

Government securities

-

-

-

-

Total Non-current

999,186

-

(2,626)

996,560

Total marketable securities

$

75,356,793

$

57

$

(49,087)

$

75,307,763

XML 66 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2021
Fair Value Measurements  
Schedule of cash equivalents and marketable securities

Level 1

Level 2

Level 3

Total

Assets:

Cash equivalents

Money market

$

33,961,344

$

-

$

-

$

33,961,344

Commercial paper

-

2,000,000

-

2,000,000

Total cash equivalents

33,961,344

2,000,000

-

35,961,344

Marketable securities:

U.S. Treasuries

$

43,115,370

$

-

$

-

$

43,115,370

Government securities

-

19,204,368

-

19,204,368

Commercial paper

-

12,988,025

-

12,988,025

Total marketable securities

43,115,370

32,192,393

-

75,307,763

Total cash equivalents and marketable securities

$

77,076,714

$

34,192,393

$

-

$

111,269,107

XML 67 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment, net (Tables)
12 Months Ended
Dec. 31, 2021
Property and Equipment, net  
Schedule of property and equipment, net

    

December 31, 

    

December 31, 

2021

2020

Computer equipment

$

281,666

$

174,317

Furniture and fixtures

 

84,477

 

18,798

Lab equipment

463,182

-

Leasehold improvements

 

152,117

 

-

Total

 

981,442

 

193,115

Accumulated depreciation

 

(174,219)

 

(128,752)

Property and equipment, net

$

807,223

$

64,363

XML 68 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Business Combination (Tables)
12 Months Ended
Dec. 31, 2021
Business Combination  
Schedule of Assets Acquired and Liabilities Assumed at Fair Value

    

Preliminary Valuation

    

Weighted Average Life

Cash

$

70,348

Other currents assets

225,790

Other long term assets

87,796

Property, plant and equipment, net

727,539

Right of use assets

4,824,700

Intangible asset

Technology

439,000

15 years

Goodwill

6,701,726

Total assets acquired

13,076,899

Accounts payable, accrued expenses and other liabilities

69,714

Deferred tax liabilities

307,485

Lease liabilities

4,824,700

Net assets acquired

$

7,875,000

XML 69 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Expenses (Tables)
12 Months Ended
Dec. 31, 2021
Accrued Expenses  
Schedule of accrued expenses

    

December 31, 

    

December 31, 

2021

2020

Accrued professional services

$

250,977

$

269,302

Accrued employee expenses

 

2,917,282

 

163,668

Accrued contract research expenses

 

585,416

 

266,022

Accrued other

211,772

Total

$

3,965,447

$

698,992

XML 70 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock (Tables)
12 Months Ended
Dec. 31, 2021
Common Stock.  
Schedule of common stock for conversion of preferred stock, exercise of warrants and exercise of stock options

    

December 31, 

    

December 31, 

2021

2020

Conversion of Series A Preferred

 

 

3,494,306

Conversion of Series B Preferred

 

 

5,066,995

Exercise of common stock warrants

 

 

308,308

Exercise of common stock options

 

2,859,544

 

1,801,263

 

2,859,544

 

10,670,872

XML 71 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Common Stockholders (Tables)
12 Months Ended
Dec. 31, 2021
Net Loss Per Share Attributable to Common Stockholders  
Schedule of basic and diluted net loss per share attributable to common stockholders

    

Year Ended December 31, 

    

2021

    

2020

Numerator:

 

  

 

  

 

Net loss

$

(33,535,748)

$

(17,039,898)

Denominator - basic and diluted:

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

13,612,677

 

4,950,129

Net loss per share - basic and diluted

$

(2.46)

$

(3.44)

Schedule of potentially dilutive securities that have been excluded from the calculation of diluted net loss per share

    

2021

    

2020

Series A Preferred

 

 

3,494,306

Series B Preferred

 

 

5,066,995

Warrants to purchase common stock

 

 

308,308

Options to purchase common stock

 

2,859,544

 

1,801,263

Total shares of common stock equivalents

 

2,859,544

 

10,670,872

XML 72 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2021
Stock-Based Compensation  
Schedule of assumptions in its application of the Black-Scholes option pricing model for grants

Year Ended December 31, 

    

2021

    

2020

Weighted-average risk-free interest rate

0.89% - 1.71%

0.36% - 1.45%

Expected term (in years)

5.83 - 10 years

5.92 - 10 years

Expected dividend yield

0%

0%

Expected volatility

66.76% - 80.99%

67.30% - 80.85%

Summary of stock option activity

    

    

Weighted

    

Weighted-

Average

Average

Remaining

Number of

Exercise Price

Contractual

Aggregate

Options

per Share

    

Term (in Years)

Intrinsic Value

 

  

 

  

 

  

 

  

Outstanding at of December 31, 2020

 

1,801,263

$

3.01

 

 

  

Granted

 

1,452,462

10.07

 

  

Exercised

 

(117,847)

3.01

 

  

Cancelled

 

(276,334)

3.58

 

  

Outstanding at December 31, 2021

 

2,859,544

$

6.55

8.30

$

27,615,466

 

Vested and exercisable at December 31, 2021

 

1,102,543

$

3.01

 

7.14

$

14,507,723

Vested and expected to vest at December 31, 2021

2,859,544

$

6.55

 

8.30

$

27,615,466

Summary of recognized share-based compensation expense recognized

Year Ended December 31, 

    

2021

    

2020

    

Cost of revenue

$

103,329

$

108,027

Research and development

 

768,679

 

503,111

General and administrative

 

930,615

 

475,631

Total

$

1,802,623

$

1,086,769

XML 73 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Taxes  
Schedule of federal statutory rate to the net loss and the effective income tax rate

    

2021

    

2020

 

Statutory federal income tax rate

 

21.0

%  

21.0

%

State tax, net of federal benefit

 

5.5

%  

6.3

%

Permanent differences

 

(0.6)

%  

(1.5)

%

Federal research and development credits

 

5.6

%  

4.5

%

State research and development credits

 

0.4

%  

0.6

%

Uncertain tax positions

(0.6)

%  

(1.0)

%

Other differences

 

0.7

%  

(2.6)

%

Change in valuation allowance

 

(31.1)

%  

(27.3)

%

Effective income tax rate

 

0.9

%  

0.0

%

Schedule of net deferred tax assets

    

2021

    

2020

Deferred tax assets:

 

  

 

  

Stock-based compensation expense

$

373,602

$

73,984

Unrealized losses

12,990

R&D credit carryforward

 

3,346,097

 

1,574,596

NOL carryforward

 

14,699,524

 

5,525,123

Gross deferred tax assets

 

18,432,213

 

7,173,703

Valuation allowance

(17,677,899)

 

(7,127,448)

Net deferred tax assets

 

754,314

 

46,255

Net deferred tax liabilities:

 

  

 

  

Prepaid expenses deducted for tax

 

(425,755)

 

(28,671)

Tax depreciation in excess of book

 

(328,559)

 

(17,584)

Total deferred tax liabilities

 

(754,314)

 

(46,255)

Net deferred taxes

$

$

Schedule of unrecognized tax benefits

2021

2020

Beginning balance

$

174,950

$

96,952

Increase due to current year tax position

205,952

77,998

Ending balance

$

380,902

$

174,950

XML 74 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies.  
Schedule of Maturities of the lease liabilities due

    

Amount

2022

$

659,990

2023

 

880,121

2024

 

894,044

2025

 

906,839

2026

 

819,210

Thereafter

4,467,246

Total future lease payments

 

8,627,450

Less: Imputed interest

 

3,262,514

Total lease liabilities

$

5,364,936

Current portion lease liabilities

274,039

Lease liabilities, noncurrent

 

5,090,897

Total lease liabilities

$

5,364,936

Schedule of Quantitative information regarding the Company's leases

    

December 31, 

    

December 31, 

2021

2020

Lease costs:

  

  

Operating lease cost

$

160,872

$

66,652

Short-term lease cost

 

258,357

 

252,796

Variable lease cost

 

 

14,700

Total lease costs

$

419,229

$

334,148

Cash paid for amounts included in the measurement of lease liabilities:

 

  

 

  

Operating cash flows from operating leases

$

111,527

$

58,666

Operating cash flows from short-term leases

 

236,700

 

252,796

$

348,227

$

311,462

Weighted-average remaining lease term - operating leases

 

9.62 years

 

5.33 years

Weighted-average discount rate - operating leases

 

9.7%

 

6.0%

XML 75 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Organization and Nature of Business (Details) - USD ($)
12 Months Ended
Aug. 03, 2021
Dec. 31, 2021
Dec. 31, 2020
Organization and Nature of Business      
Aggregate net proceeds   $ 120,318,750  
Convertible preferred stock, outstanding (in shares) 8,528,078    
Shares issued upon conversion 11,939,281    
Accumulated deficit   $ 59,273,388 $ 25,737,640
Class A Common Stock      
Organization and Nature of Business      
Shares issued 1,125,000    
Convertible preferred stock, outstanding (in shares) 11,939,281    
IPO      
Organization and Nature of Business      
Aggregate net proceeds $ 120,318,750    
Offering costs $ 2,124,317    
Convertible preferred stock, outstanding (in shares) 8,528,078    
IPO | Class A Common Stock      
Organization and Nature of Business      
Shares issued 8,625,000    
XML 76 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Narrative (Details)
12 Months Ended
Jul. 23, 2021
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
Summary of Significant Accounting Policies      
Stock split, ratio 1    
Number of operating segments | segment   1  
Allowance for doubtful accounts   $ 0 $ 0
Impairment   $ 0  
Lease, practical expedients   true  
Uncertain tax positions   $ 380,902 174,950
Deferred offering costs   $ 0 $ 0
Expected dividend yield   0.00% 0.00%
Goodwill impairments   $ 0  
XML 77 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Concentration Risk [Line Items]    
Accounts receivable $ 246,040 $ 500,110
Revenue | Customer risk | Customer 1    
Concentration Risk [Line Items]    
Revenue $ 745,030 $ 676,710
Risk percentage 35.80% 29.30%
Revenue | Customer risk | Customer 2    
Concentration Risk [Line Items]    
Revenue $ 380,000 $ 570,000
Risk percentage 18.30% 24.70%
Revenue | Customer risk | Customer 3    
Concentration Risk [Line Items]    
Revenue   $ 306,900
Risk percentage   13.30%
Revenue | Customer risk | Customer 4    
Concentration Risk [Line Items]    
Revenue   $ 250,880
Risk percentage   10.90%
Revenue | Customer risk | Customer 5    
Concentration Risk [Line Items]    
Revenue $ 353,050  
Risk percentage 17.00%  
Accounts receivable | Customer risk | Customer 1    
Concentration Risk [Line Items]    
Accounts receivable $ 235,500 $ 214,345
Risk percentage 95.70% 42.90%
Accounts receivable | Customer risk | Customer 2    
Concentration Risk [Line Items]    
Accounts receivable   $ 71,250
Risk percentage   14.20%
Accounts receivable | Customer risk | Customer 4    
Concentration Risk [Line Items]    
Accounts receivable   $ 63,000
Risk percentage   12.60%
Accounts receivable | Customer risk | Customer 5    
Concentration Risk [Line Items]    
Accounts receivable   $ 91,975
Risk percentage   18.40%
XML 78 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Property and Equipment (Details)
12 Months Ended
Dec. 31, 2021
Computer equipment  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 3 years
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 5 years
Lab equipment  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 7 years
Leaseholds and Leasehold Improvements [Member] | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 1 year
Leaseholds and Leasehold Improvements [Member] | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 10 years
XML 79 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Marketable Securities    
Impairment on available-for-sale marketable securities $ 0  
Realized gains or losses on marketable securities 0  
Marketable securities, current    
Marketable securities at amortized cost, current 74,357,607  
Marketable securities unrealized gains, current 57  
Marketable securities unrealized losses, current (46,461)  
Marketable securities, current 74,311,203  
Marketable securities, non-current    
Marketable securities at amortized cost, non-current 999,186  
Marketable securities unrealized losses, non-current (2,626)  
Marketable securities, non-current 996,560  
Marketable securities    
Marketable securities at amortized cost 75,356,793  
Marketable securities unrealized gains 57  
Marketable securities unrealized losses (49,087)  
Marketable securities 75,307,763 $ 0
U.S. Treasuries    
Marketable securities, current    
Marketable securities at amortized cost, current 42,147,385  
Marketable securities unrealized losses, current (28,575)  
Marketable securities, current 42,118,810  
Marketable securities, non-current    
Marketable securities at amortized cost, non-current 999,186  
Marketable securities unrealized losses, non-current (2,626)  
Marketable securities, non-current 996,560  
Government securities    
Marketable securities, current    
Marketable securities at amortized cost, current 19,218,057  
Marketable securities unrealized losses, current (13,689)  
Marketable securities, current 19,204,368  
Commerical paper    
Marketable securities, current    
Marketable securities at amortized cost, current 12,992,165  
Marketable securities unrealized gains, current 57  
Marketable securities unrealized losses, current (4,197)  
Marketable securities, current $ 12,988,025  
XML 80 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Assets:    
Financial liabilities classified as Level 3 $ 0  
Marketable securities 75,307,763 $ 0
Recurring    
Assets:    
Total cash equivalents 35,961,344  
Total marketable securities 75,307,763  
Total cash equivalents and marketable securities 111,269,107  
Recurring | Money market    
Assets:    
Total cash equivalents 33,961,344  
Recurring | Commerical paper    
Assets:    
Total cash equivalents 2,000,000  
Total marketable securities 12,988,025  
Recurring | U.S. Treasuries    
Assets:    
Total marketable securities 43,115,370  
Recurring | Government securities    
Assets:    
Total marketable securities 19,204,368  
Recurring | Level 1    
Assets:    
Total cash equivalents 33,961,344  
Total marketable securities 43,115,370  
Total cash equivalents and marketable securities 77,076,714  
Recurring | Level 1 | Money market    
Assets:    
Total cash equivalents 33,961,344  
Recurring | Level 1 | U.S. Treasuries    
Assets:    
Total marketable securities 43,115,370  
Recurring | Level 2    
Assets:    
Total cash equivalents 2,000,000  
Total marketable securities 32,192,393  
Total cash equivalents and marketable securities 34,192,393  
Recurring | Level 2 | Commerical paper    
Assets:    
Total cash equivalents 2,000,000  
Total marketable securities 12,988,025  
Recurring | Level 2 | Government securities    
Assets:    
Total marketable securities $ 19,204,368  
XML 81 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment, net (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Property and Equipment, net    
Property and equipment, gross $ 981,442 $ 193,115
Accumulated depreciation (174,219) (128,752)
Property and equipment, net 807,223 64,363
Computer equipment    
Property and Equipment, net    
Property and equipment, gross 281,666 174,317
Furniture and fixtures    
Property and Equipment, net    
Property and equipment, gross 84,477 $ 18,798
Lab equipment    
Property and Equipment, net    
Property and equipment, gross 463,182  
Leasehold improvements    
Property and Equipment, net    
Property and equipment, gross $ 152,117  
XML 82 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment, net - Depreciation (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property and Equipment, net    
Depreciation expense $ 45,467 $ 24,328
XML 83 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Business Combination - Narrative (Details)
12 Months Ended
Dec. 22, 2021
USD ($)
agreement
D
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
BioArkive Inc | Accounts payable or accrued expenses      
Business Acquisition [Line Items]      
Amount owned to related party     $ 279,153
BioArkive Inc | Research and development      
Business Acquisition [Line Items]      
Amount of related party expenses   $ 4,548,780 $ 2,744,051
BioArkive Inc      
Business Acquisition [Line Items]      
Market value of acquisition $ 8,750,000    
Number of lease obligations acquired 3 3  
Shares issued | shares 379,635    
Trading days for share price | D 30    
Lock in period for shares issued 6 months    
Shares issued discount due to lack of marketability 10.00%    
Consideration transferred $ 7,875,000    
XML 84 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Business Combination - Assets Acquired and Liabilities Assumed (Details) - USD ($)
Dec. 22, 2021
Dec. 31, 2021
Intangible asset    
Goodwill   $ 6,701,726
BioArkive Inc    
Assets Acquired and Liabilities Assumed at Fair Value    
Cash $ 70,348  
Other currents assets 225,790  
Other long term assets 87,796  
Property, plant and equipment, net 727,539  
Right of use assets 4,824,700  
Intangible asset    
Technology 439,000  
Goodwill 6,701,726  
Total assets acquired 13,076,899  
Accounts payable, accrued expenses and other liabilities 69,714  
Deferred tax liabilities 307,485  
Lease liabilities 4,824,700  
Net assets acquired $ 7,875,000  
Weighted Average Life, technology 15 years  
XML 85 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Expenses (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Accrued Expenses    
Accrued professional services $ 250,977 $ 269,302
Accrued employee expenses 2,917,282 163,668
Accrued contract research expenses 585,416 266,022
Accrued other 211,772  
Total $ 3,965,447 $ 698,992
XML 86 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock - Series A (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 20, 2019
Jan. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Aug. 03, 2021
Sep. 30, 2019
Temporary Equity [Line Items]                
Issuance costs       $ 2,124,317        
Convertible preferred stock, outstanding (in shares)             8,528,078  
Series A Preferred Stock                
Temporary Equity [Line Items]                
Convertible preferred stock, authorized (in shares)     2,495,933 0 2,495,933     1,987,979
Convertible preferred stock, par value per share (in dollars per share)       $ 0.001 $ 0.001     $ 0.001
Convertible preferred stock, issuance price (in dollars per share)               $ 8.5514
Convertible preferred stock, issued (in shares) 468,315 1,122,458 119,454 0 2,495,933 468,315    
Gross proceeds from issuance of convertible stock $ 4,004,975 $ 9,598,847 $ 1,021,413   $ 998,306      
Number of shares issued upon conversion of debt   785,706            
Issuance costs     $ 23,610     $ 200,587    
Number of shares excess of authorized 410,436         410,436    
Proceeds from issuance of shares excess of amount authorized $ 3,509,802              
Convertible preferred stock liability $ 3,509,802         $ 3,509,802    
Convertible preferred stock, outstanding (in shares) 1,966,043     0 2,495,933 1,966,043    
Convertible preferred stock, conversion price       $ 6.1081        
Series A Preferred Stock | Minimum                
Temporary Equity [Line Items]                
Convertible preferred stock, issuance price (in dollars per share)       $ 7.3416        
Gross proceeds from issuance of convertible stock       $ 75,000,000        
XML 87 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock - Series B (Details)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
tranche
$ / shares
shares
May 31, 2021
USD ($)
shares
Mar. 31, 2021
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
tranche
$ / shares
shares
Aug. 03, 2021
shares
Temporary Equity [Line Items]            
Issuance costs | $       $ 2,124,317    
Dividend, Percentage       7.00%    
Dividend declared | $       $ 0 $ 0  
Preferred stock, outstanding 0     0 0  
Shares issued upon conversion           11,939,281
Minimum            
Temporary Equity [Line Items]            
Preferred stock, outstanding       2,132,029    
Series B Preferred Stock            
Temporary Equity [Line Items]            
Convertible preferred stock, authorized (in shares) 6,032,183     0 6,032,183  
Convertible preferred stock, par value per share (in dollars per share) | $ / shares $ 0.001     $ 0.001 $ 0.001  
Convertible preferred stock, issuance price (in dollars per share) | $ / shares $ 10.2782       $ 10.2782  
Number of tranches | tranche 2       2  
Convertible preferred stock, issued (in shares) 3,619,292     0 3,619,292  
Gross proceeds from issuance of convertible stock | $       $ 24,788,851 $ 36,983,910  
Number of shares not meet the definition of a freestanding financial instrument     2,412,853      
Convertible preferred stock, conversion price | $ / shares       $ 7.3416    
Percentage of equity securities to be own       9.90%    
Series B Preferred Stock Tranche One            
Temporary Equity [Line Items]            
Convertible preferred stock, issued (in shares) 3,619,292       3,619,292  
Gross proceeds from issuance of convertible stock | $ $ 37,199,929          
Issuance costs | $ $ 216,019          
Series B Preferred Stock Tranche Two            
Temporary Equity [Line Items]            
Convertible preferred stock, issued (in shares)   2,412,853 0      
Gross proceeds from issuance of convertible stock | $   $ 24,799,786        
Issuance costs | $   $ 10,935        
XML 88 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock - Class A common stock (Details) - Class A Common Stock
12 Months Ended
Dec. 31, 2021
Vote
$ / shares
shares
Dec. 31, 2020
Vote
$ / shares
shares
Class of Stock [Line Items]    
Common stock, shares authorized (in shares) 200,000,000 22,026,200
Common stock, par value per share (in dollars per share) | $ / shares $ 0.001 $ 0.001
Common stock, shares issued (in shares) 26,320,199 4,950,129
Common stock, shares outstanding (in shares) 26,320,199 4,950,129
Number of votes | Vote 1 1
XML 89 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock (Details) - shares
Dec. 31, 2021
Dec. 31, 2020
Class of Stock [Line Items]    
Shares reserved for future issuance 2,859,544 10,670,872
Series A Preferred Stock    
Class of Stock [Line Items]    
Shares reserved for future issuance   3,494,306
Series B Preferred Stock    
Class of Stock [Line Items]    
Shares reserved for future issuance   5,066,995
Common stock warrants    
Class of Stock [Line Items]    
Shares reserved for future issuance   308,308
Common stock options    
Class of Stock [Line Items]    
Shares reserved for future issuance 2,859,544 1,801,263
XML 90 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock - Class B common stock (Details) - Class B Common Stock
12 Months Ended
Dec. 31, 2021
Vote
$ / shares
shares
Dec. 31, 2020
Vote
$ / shares
shares
Class of Stock [Line Items]    
Common stock, shares authorized (in shares) 20,000,000 6,032,183
Common stock, par value per share (in dollars per share) | $ / shares $ 0.001 $ 0.001
Common stock, shares issued (in shares) 0 0
Common stock, shares outstanding (in shares) 0 0
Number of votes | Vote 0 0
XML 91 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock - Common stock warrant (Details) - USD ($)
1 Months Ended 12 Months Ended
Jun. 30, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2021
Common Stock.        
Warrants issued for common shares     308,308  
Warrant exercise price     $ 3.01  
Warrants in lieu of cash payment     200,984  
Term of warrant     10 years  
Warrant exercised 308,308 0    
Warrants outstanding       $ 0
XML 92 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock - IPO (Details) - USD ($)
Aug. 03, 2021
Dec. 31, 2021
Dec. 31, 2020
Class of Stock [Line Items]      
Convertible preferred stock, outstanding (in shares) 8,528,078    
Preferred stock authorized (in shares)   10,000,000 0
Class A Common Stock      
Class of Stock [Line Items]      
Shares issued 1,125,000    
Convertible preferred stock, outstanding (in shares) 11,939,281    
Common stock, shares authorized (in shares)   200,000,000 22,026,200
Common stock, par value per share (in dollars per share)   $ 0.001 $ 0.001
Class B Common Stock      
Class of Stock [Line Items]      
Common stock, shares authorized (in shares)   20,000,000 6,032,183
Common stock, par value per share (in dollars per share)   $ 0.001 $ 0.001
IPO      
Class of Stock [Line Items]      
Proceeds from Stock issued $ 120,318,750    
Offering costs $ 2,124,317    
Convertible preferred stock, outstanding (in shares) 8,528,078    
Preferred stock authorized (in shares) 10,000,000    
IPO | Class A Common Stock      
Class of Stock [Line Items]      
Shares issued 8,625,000    
Common stock, shares authorized (in shares) 200,000,000    
IPO | Class B Common Stock      
Class of Stock [Line Items]      
Common stock, shares authorized (in shares) 20,000,000    
Common stock, par value per share (in dollars per share) $ 0.001    
XML 93 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Numerator:    
Net loss $ (33,535,748) $ (17,039,898)
Denominator - basic and diluted:    
Weighted-average common shares outstanding, basic 13,612,677 4,950,129
Weighted-average common shares outstanding, diluted 13,612,677 4,950,129
Net loss per share, basic $ (2.46) $ (3.44)
Net loss per share, diluted $ (2.46) $ (3.44)
XML 94 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details) - shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total shares of common stock equivalents 2,859,544 10,670,872
Series A Preferred Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total shares of common stock equivalents   3,494,306
Series B Preferred Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total shares of common stock equivalents   5,066,995
Common stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total shares of common stock equivalents   308,308
Common stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total shares of common stock equivalents 2,859,544 1,801,263
XML 95 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation - Narratives (Details) - USD ($)
12 Months Ended
Jul. 23, 2021
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   $ 1,802,623 $ 1,086,769
Granted (in shares)   1,452,462 343,169
Grant date weighted average fair value   $ 6.29 $ 3.06
Shares reserved for future issuance   2,859,544 10,670,872
Incentive Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period   4 years  
Stock-based compensation expense   $ 1,802,623 $ 1,086,769
Compensation expense remaining to be recognized   $ 8,403,600  
Compensation expense recognized over a weighted-average period   2 years 11 months 4 days  
Incentive Plan | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares reserved for future issuance   2,825,173  
2021 ESPP      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Granted (in shares)   0  
2021 ESPP | Class A Common Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares reserved for future issuance 250,000    
Aggregate number of shares outstanding (as a percent) 1.00%    
2021 ESPP | Maximum | Class A Common Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Granted (in shares) 3,340,000    
2021 Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares reserved for future issuance   2,298,432  
2021 Plan | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares reserved for future issuance 2,590,000    
Aggregate number of shares outstanding (as a percent) 4.00%    
2021 Plan | Maximum | Class A Common Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Granted (in shares) 15,350,000    
XML 96 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation - Assumptions (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted-average risk-free interest rate, minimum   0.36%
Weighted-average risk-free interest rate, maximum   1.45%
Expected dividend yield 0.00% 0.00%
Expected volatility, minimum 66.76% 67.30%
Expected volatility, maximum 80.99% 80.85%
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted-average risk-free interest rate, minimum 0.89%  
Expected term (in years) 5 years 9 months 29 days 5 years 11 months 1 day
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term (in years) 10 years 10 years
XML 97 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation - stock option activity (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Number of options    
Outstanding at the beginning (in shares) 1,801,263  
Granted (in shares) 1,452,462 343,169
Exercised (in shares) (117,847)  
Repurchased (in shares) (276,334)  
Outstanding at the end (in shares) 2,859,544 1,801,263
Vested and exercisable (in shares) 1,102,543  
Vested and expected to vest (in shares) 2,859,544  
Weighted Average Exercise Price per Share    
Weighted Average Exercise Price per Share Outstanding at the beginning (in dollars per share) $ 3.01  
Weighted Average Exercise Price per Share Granted (in dollars per share) 10.07  
Weighted Average Exercise Price per Share Exercised (in dollars per share) 3.01  
Weighted Average Exercise Price per Share Repurchased (in dollars per share) 3.58  
Weighted Average Exercise Price per Share Outstanding at the end (in dollars per share) 6.55 $ 3.01
Weighted Average Exercise Price per Share Vested and Exercisable (in dollars per share) 3.01  
Weighted Average Exercise Price per Share Vested and Expected to Vest exercisable (in dollars per share) $ 6.55  
Weighted Average Remaining Contractual Contractual Term    
Weighted Average Remaining Contractual Term (in years) 8 years 3 months 18 days  
Weighted Average Remaining Contractual Term, Vested and exercisable (in Years) 7 years 1 month 20 days  
Weighted Average Remaining Contractual Term, Vested and expected to vest (in Years) 8 years 3 months 18 days  
Aggregate Intrinsic Value    
Aggregate Intrinsic Value Outstanding $ 27,615,466  
Aggregate Intrinsic Value Vested and exercisable 14,507,723  
Aggregate Intrinsic Value Vested and expected to vest $ 27,615,466  
XML 98 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 1,802,623 $ 1,086,769
Cost of service    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 103,329 108,027
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 768,679 503,111
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 930,615 $ 475,631
XML 99 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Net loss and the effective income tax rate (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate    
Statutory federal income tax rate 21.00% 21.00%
State tax, net of federal benefit 5.50% 6.30%
Permanent differences (0.60%) (1.50%)
Federal research and development credits 5.60% 4.50%
State research and development credits 0.40% 0.60%
Uncertain tax positions (0.60%) (1.00%)
Other differences 0.70% (2.60%)
Change in valuation allowance (31.10%) (27.30%)
Effective income tax rate 0.90% 0.00%
XML 100 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Net deferred tax assets (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Stock-based compensation expense $ 373,602 $ 73,984
Unrealized losses 12,990  
R&D credit carryforward 3,346,097 1,574,596
NOL carryforward 14,699,524 5,525,123
Gross deferred tax assets 18,432,213 7,173,703
Valuation allowance (17,677,899) (7,127,448)
Net deferred tax assets 754,314 46,255
Net deferred tax liabilities:    
Prepaid expenses deducted for tax (425,755) (28,671)
Tax depreciation in excess of book (328,559) (17,584)
Total deferred tax liabilities $ (754,314) $ (46,255)
XML 101 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Narrative (Details) - USD ($)
12 Months Ended
Mar. 27, 2020
Dec. 31, 2021
Dec. 31, 2017
Dec. 22, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Loss Carryforwards [Line Items]            
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount   $ 10,550,451        
Unrecognized Tax Benefits   380,902     $ 174,950 $ 96,952
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued   0     $ 0  
Domestic Tax Authority [Member]            
Operating Loss Carryforwards [Line Items]            
Operating Loss Carryforwards   56,544,731        
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]            
Operating Loss Carryforwards [Line Items]            
Tax Credit Carryforward, Amount   3,034,827        
Tax Credit Carryforward, Increase (Decrease), CARES Act $ 759,794          
State and Local Jurisdiction [Member]            
Operating Loss Carryforwards [Line Items]            
Operating Loss Carryforwards   51,310,112        
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]            
Operating Loss Carryforwards [Line Items]            
Tax Credit Carryforward, Amount   $ 394,013        
Tax Credit Carryforward, Increase (Decrease), CARES Act $ 93,437          
BioArkive Inc            
Operating Loss Carryforwards [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities       $ 307,485    
Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Income Tax Expense     $ 304,485      
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount     $ 304,485      
XML 102 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Unrecognized tax benefits (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
Beginning balance $ 174,950 $ 96,952
Increase due to current year tax provision 205,952 77,998
Ending balance $ 380,902 $ 174,950
XML 103 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Narratives (Details)
Dec. 31, 2021
USD ($)
ft²
Dec. 22, 2021
agreement
Dec. 31, 2020
USD ($)
Oct. 31, 2020
USD ($)
Lessee, Lease, Description [Line Items]        
Right of use asset $ 5,324,198   $ 613,103  
BioArkive Inc        
Lessee, Lease, Description [Line Items]        
Right of use asset 4,824,700      
Lease liability $ 4,824,700      
Number of Leases Obligations Assumed 3 3    
Lease Termination on April 30, 2032 [Member] | BioArkive Inc        
Lessee, Lease, Description [Line Items]        
Area of Property Under Lease | ft² 38,613      
Lease Termination on December 31, 2022 [Member] | BioArkive Inc        
Lessee, Lease, Description [Line Items]        
Area of Property Under Lease | ft² 6,100      
Lease Termination on March 31, 2024 [Member] | BioArkive Inc        
Lessee, Lease, Description [Line Items]        
Area of Property Under Lease | ft² 4,760      
Office Space In Cambridge, Massachusetts, New York [Member]        
Lessee, Lease, Description [Line Items]        
Minimum lease payment due 2022 $ 30,840      
Storage Space In Somerville, Massachusetts [Member]        
Lessee, Lease, Description [Line Items]        
Minimum lease payment due 2022 3,569      
2020 San Diego Lease        
Lessee, Lease, Description [Line Items]        
Minimum lease payment due 2022 659,990      
Lease term       67 months
Right of use asset       $ 637,863
Lease liability $ 5,364,936     $ 637,863
XML 104 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Maturities of the lease liabilities due (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Oct. 31, 2020
Lessee, Lease, Description [Line Items]      
Current portion lease liability $ 274,039 $ 76,322  
Lease liability, noncurrent 5,090,897 $ 544,767  
2020 San Diego Lease      
Lessee, Lease, Description [Line Items]      
2022 659,990    
2023 880,121    
2024 894,044    
2025 906,839    
2026 819,210    
Thereafter 4,467,246    
Total future lease payments 8,627,450    
Less: Imputed interest 3,262,514    
Total lease liabilities 5,364,936   $ 637,863
Current portion lease liability 274,039    
Lease liability, noncurrent $ 5,090,897    
XML 105 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Lease cost (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Lease costs:    
Operating lease cost $ 160,872 $ 66,652
Short-term lease cost 258,357 252,796
Variable lease cost   14,700
Total lease costs 419,229 334,148
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases 111,527 58,666
Operating cash flows from short-term leases 236,700 252,796
Total lease Payment $ 348,227 $ 311,462
Weighted-average remaining lease term - operating leases 9 years 7 months 13 days 5 years 3 months 29 days
Weighted-average discount rate - operating leases 9.70% 6.00%
XML 106 imrx-20211231x10k_htm.xml IDEA: XBRL DOCUMENT 0001790340 us-gaap:CommonClassAMember 2021-08-03 0001790340 imrx:SeriesBConvertiblePreferredStockTrancheTwoMember 2021-05-31 0001790340 imrx:SeriesBConvertiblePreferredStockTrancheTwoMember 2021-03-31 0001790340 imrx:SeriesBConvertiblePreferredStocksTrancheOneMember 2020-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2019-09-20 0001790340 imrx:SeriesConvertiblePreferredStockMember 2020-01-31 0001790340 imrx:SeriesConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001790340 us-gaap:PreferredStockMember 2020-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001790340 us-gaap:PreferredStockMember 2019-12-31 0001790340 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2021-12-31 0001790340 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2021-12-31 0001790340 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001790340 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-08-03 2021-08-03 0001790340 us-gaap:CommonClassAMember 2021-08-03 2021-08-03 0001790340 imrx:SeriesConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001790340 2021-07-23 2021-07-23 0001790340 us-gaap:RetainedEarningsMember 2021-12-31 0001790340 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001790340 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001790340 us-gaap:RetainedEarningsMember 2020-12-31 0001790340 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001790340 us-gaap:RetainedEarningsMember 2019-12-31 0001790340 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001790340 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001790340 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0001790340 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-12-31 0001790340 srt:MaximumMember imrx:TwoThousandTwentyOneIncentiveAwardPlanMember us-gaap:CommonClassAMember 2021-07-23 2021-07-23 0001790340 srt:MaximumMember imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember us-gaap:CommonClassAMember 2021-07-23 2021-07-23 0001790340 imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001790340 srt:MinimumMember 2021-01-01 2021-12-31 0001790340 srt:MaximumMember 2021-01-01 2021-12-31 0001790340 srt:MinimumMember 2020-01-01 2020-12-31 0001790340 srt:MaximumMember 2020-01-01 2020-12-31 0001790340 us-gaap:ResearchAndDevelopmentExpenseMember imrx:BioArkiveIncMember 2021-01-01 2021-12-31 0001790340 us-gaap:ResearchAndDevelopmentExpenseMember imrx:BioArkiveIncMember 2020-01-01 2020-12-31 0001790340 srt:MinimumMember us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-01-01 2021-12-31 0001790340 srt:MaximumMember us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-01-01 2021-12-31 0001790340 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001790340 us-gaap:ComputerEquipmentMember 2021-01-01 2021-12-31 0001790340 imrx:LabEquipmentMember 2021-01-01 2021-12-31 0001790340 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001790340 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001790340 us-gaap:ComputerEquipmentMember 2021-12-31 0001790340 imrx:LabEquipmentMember 2021-12-31 0001790340 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001790340 us-gaap:ComputerEquipmentMember 2020-12-31 0001790340 srt:MinimumMember imrx:SeriesConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001790340 us-gaap:IPOMember 2021-08-03 2021-08-03 0001790340 srt:MinimumMember 2021-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockTrancheTwoMember 2021-04-01 2021-05-31 0001790340 imrx:SeriesBConvertiblePreferredStocksTrancheOneMember 2020-12-01 2020-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2020-01-01 2020-01-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001790340 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001790340 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001790340 us-gaap:DomesticCountryMember 2021-12-31 0001790340 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001790340 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001790340 imrx:OfficeLeaseInSanDiegoCalifornia2020Member 2020-10-31 0001790340 imrx:StorageSpaceInSomervilleMassachusettsMember 2021-12-31 0001790340 imrx:OfficeSpaceInCambridgeMassachusettsNewYorkMember 2021-12-31 0001790340 imrx:OfficeLeaseInSanDiegoCalifornia2020Member 2021-12-31 0001790340 imrx:StockIncentivePlan2015Member 2021-12-31 0001790340 us-gaap:AccountsPayableAndAccruedLiabilitiesMember imrx:BioArkiveIncMember 2020-12-31 0001790340 imrx:BioArkiveIncMember 2017-01-01 2017-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2019-09-20 2019-09-20 0001790340 2021-08-03 0001790340 imrx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001790340 imrx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001790340 imrx:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001790340 imrx:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001790340 imrx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001790340 imrx:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001790340 imrx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001790340 imrx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001790340 imrx:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001790340 imrx:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001790340 imrx:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001790340 imrx:CustomerFiveMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001790340 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-08-03 0001790340 us-gaap:CommonClassBMember 2021-12-31 0001790340 us-gaap:CommonClassAMember 2021-12-31 0001790340 us-gaap:CommonClassBMember us-gaap:IPOMember 2021-08-03 0001790340 us-gaap:CommonClassBMember 2020-12-31 0001790340 us-gaap:CommonClassAMember 2020-12-31 0001790340 srt:MaximumMember imrx:StockIncentivePlan2015Member 2021-12-31 0001790340 us-gaap:EmployeeStockOptionMember 2021-12-31 0001790340 imrx:TwoThousandTwentyOneIncentiveAwardPlanMember 2021-12-31 0001790340 srt:MaximumMember imrx:TwoThousandTwentyOneIncentiveAwardPlanMember 2021-07-23 0001790340 imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember us-gaap:CommonClassAMember 2021-07-23 0001790340 us-gaap:WarrantMember 2020-12-31 0001790340 us-gaap:EmployeeStockOptionMember 2020-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2020-12-31 0001790340 2019-12-31 0001790340 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001790340 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001790340 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001790340 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001790340 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001790340 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001790340 imrx:StockIncentivePlan2015Member 2021-01-01 2021-12-31 0001790340 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001790340 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001790340 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001790340 imrx:StockIncentivePlan2015Member 2020-01-01 2020-12-31 0001790340 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001790340 imrx:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-12-31 0001790340 imrx:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-12-31 0001790340 imrx:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-12-31 0001790340 imrx:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-12-31 0001790340 imrx:CustomerFiveMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-12-31 0001790340 2019-01-01 2019-12-31 0001790340 2021-06-01 2021-06-30 0001790340 imrx:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001790340 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001790340 srt:MinimumMember imrx:SeriesConvertiblePreferredStockMember 2021-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2019-09-30 0001790340 imrx:SeriesConvertiblePreferredStockMember 2019-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2021-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001790340 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2020-03-27 2020-03-27 0001790340 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2020-03-27 2020-03-27 0001790340 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001790340 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001790340 imrx:SeriesConvertiblePreferredStockMember 2019-12-31 2019-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockMember 2021-12-31 0001790340 srt:MaximumMember imrx:TwoThousandTwentyOneIncentiveAwardPlanMember 2021-07-23 2021-07-23 0001790340 imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember us-gaap:CommonClassAMember 2021-07-23 2021-07-23 0001790340 us-gaap:IPOMember 2021-08-03 0001790340 us-gaap:CommonClassBMember 2021-01-01 2021-12-31 0001790340 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0001790340 us-gaap:CommonClassBMember 2020-01-01 2020-12-31 0001790340 us-gaap:CommonClassAMember 2020-01-01 2020-12-31 0001790340 imrx:SeriesBConvertiblePreferredStockMember 2020-12-31 0001790340 imrx:BioArkiveIncMember 2021-12-31 0001790340 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 imrx:GovernmentSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 imrx:GovernmentSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001790340 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001790340 imrx:GovernmentSecuritiesMember 2021-12-31 0001790340 us-gaap:CommercialPaperMember 2021-12-31 0001790340 2020-01-01 2020-12-31 0001790340 imrx:BioArkiveIncMember 2021-12-22 2021-12-22 0001790340 imrx:BioArkiveIncMember 2021-12-22 0001790340 imrx:BioArkiveIncMember imrx:LeaseTerminationOnMarch312024Member 2021-12-31 0001790340 imrx:BioArkiveIncMember imrx:LeaseTerminationOnDecember312022Member 2021-12-31 0001790340 imrx:BioArkiveIncMember imrx:LeaseTerminationOnApril302032Member 2021-12-31 0001790340 2021-12-31 0001790340 2020-12-31 0001790340 2022-03-03 0001790340 2021-06-30 0001790340 us-gaap:CommonClassBMember 2022-03-03 0001790340 us-gaap:CommonClassAMember 2022-03-03 0001790340 2021-01-01 2021-12-31 imrx:segment shares iso4217:USD utr:sqft pure imrx:D imrx:agreement imrx:tranche imrx:Vote iso4217:USD shares -2.46 -3.44 13612677 4950129 13612677 4950129 -2.46 -3.44 0001790340 --12-31 2021 FY false Immuneering Corp 3619292 0 0 4950129 26320199 0 0 0 637863 2495933 0 26320199 4950129 0 0 0 0 4824700 10-K true 2021-12-31 false 001-40675 DE 26-1976972 245 Main St Second Floor Cambridge MA 02142 617 500-8080 Class A common Stock, par value $0.001 per share IMRX NASDAQ No No Yes Yes Non-accelerated Filer true true false false false 0 136900000 26377299 0 <p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:3pt 0pt 0pt 0pt;">Portions of the registrant’s Definitive Proxy Statement relating to the registrant’s 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the end of the registrant’s fiscal year ended December 31, 2021 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p> 49 RSM US LLP Boston, Massachusetts 74888145 37090151 74311203 246040 500110 2888608 140958 152333996 37731219 996560 807223 64363 6701726 439000 5324198 613103 102129 14333 166704832 38423018 1394340 1480537 3965447 698992 274039 76322 5633826 2255851 5090897 544767 10724723 2800618 0.001 0.001 0 6032183 0 3619292 36983910 0.001 0.001 0 2495933 0 2495933 21119940 58103850 0.001 0.001 10000000 0 0 0 0.001 0.001 200000000 22026200 26320199 4950129 26320 4950 0.001 0.001 20000000 6032183 0 0 215276186 3251240 -49009 -59273388 -25737640 155980109 -22481450 166704832 38423018 2079961 2311535 1153073 1280325 926888 1031210 26540959 15003786 8271998 3109978 34812957 18113764 -33886069 -17082554 169899 42656 -127063 -33843233 -17039898 -307485 -33535748 -17039898 -2.46 -3.44 13612677 4950129 -49009 -33584757 -17039898 1966043 16611832 16611832 4950129 4950 2164471 -8697742 -6528321 529890 4508108 4508108 3619292 36983910 36983910 1086769 1086769 -17039898 -17039898 3619292 36983910 2495933 21119940 58103850 4950129 4950 3251240 -25737640 -22481450 2412853 24788851 24788851 117846 118 354316 354434 308308 308 926817 927125 -6032145 -61772761 -2495933 -21119940 -82892701 11939281 11939 82880762 82892701 2124317000 8625000 8625 118185808 118194433 379635 380 7874620 7875000 1802623 1802623 -33535748 -33535748 -49009 -49009 26320199 26320 215276186 -49009 -59273388 155980109 -33535748 -17039898 45467 24328 113605 54977 1802623 1086769 -130240 -307485 -279713 290170 2408986 69740 14333 -130398 1185589 3240940 488644 -80853 -46991 -30850882 -14620825 60786 53415 75625529 70348 -75615967 -53415 998306 24788851 36983910 120318750 2124317 354434 927125 144264843 37982216 37797994 23307976 37090151 13782175 74888145 37090151 82892701 7804652 7875000 3509802 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1 – Organization and Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immuneering Corporation, a Delaware corporation, (“Immuneering” or the “Company”) was incorporated in 2008. The Company aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using the Company’s translational bioinformatics platform. The Company has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, the Company’s disease-agnostic discovery platform enables the Company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 30, 2019, Immuneering formed a wholly owned subsidiary, Immuneering Securities Corporation (“ISC”), a Massachusetts securities corporation, for the sole purpose of buying, selling and holding securities on the Company’s behalf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 22, 2021, <span style="background:#ffffff;">the Company acquired all outstanding shares of capital stock of BioArkive, Inc. (“BioArkive”), a California corporation, which as a result became a wholly owned subsidiary.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immuneering, ISC and BioArkive are collectively referred to as “the Company” throughout these  consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of inherent risks associated with any biotechnology company that has substantial expenditures for research and development. These risks include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. There can be no assurance that the Company’s research and development program will be successful. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 3, 2021, the Company completed its initial public offering (“IPO”) pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional paid-in capital (see Note 8). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To date, the Company has funded its operations through service revenues, and with proceeds from the sale of its capital stock and convertible notes and, most recently, with proceeds from the IPO. The Company has incurred recurring losses over the past several years and as of December 31, 2021, the Company had an accumulated deficit of $59,273,388. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern and estimates that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the consolidated financial statements. The full extent to which coronavirus (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the pandemic related to COVID-19 and its variants and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgements or revise the carrying values of its assets or liabilities.</p> 8625000 1125000 120318750 2124317 8528078 11939281 -59273388 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2 - Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB sets generally accepted accounting principles (“GAAP”) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (“ASC”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On July 23, 2021, the Company approved a </span><span style="font-weight:normal;">one</span><span style="font-weight:normal;white-space:pre-wrap;">-for-1.4 stock split which was consummated in connection with the Company’s IPO. All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these  consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Segments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">​</span><br/><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">​</span><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;font-weight:bold;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. Refer to Note 6, Business Combination for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and Cash </b><b style="font-weight:bold;">Equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (“FDIC”) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our marketable securities are classified as available-for-sale pursuant to ASC 320,<span style="background:#ffffff;"> Investments – Debt and Equity Securities</span> and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the  consolidated balance sheets and statements of convertible preferred stock and stockholders’ equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021.  Realized gains and losses are included in other expense on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We record cash equivalents and marketable securities at fair value. ASC 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 1</i> – Unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 2</i> – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3</i> – Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2021. Fair value </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">information for these assets, including their classification in the fair value hierarchy is included in Note 4  Fair Value Measurements<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have been no changes to the valuation methods during the year ended December 31, 2021. We evaluate transfers between levels at the end of each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management’s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December 31, 2021 and 2020 there was no allowance for doubtful accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The following customers comprised 10% or more of the Company’s total accounts receivable or revenues as of or for the period ended December 31, 2021 (customers with an asterisk are less than 10%): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">95.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Property and Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1-10 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In February 2016 the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASC 842”), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company’s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company adopted the leasing standard using the modified retrospective transition approach as of January 1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12 months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company has elected not to separate lease and non-lease components as a single lease component. The Company’s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Identify the contract with a customer</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Identify the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Determine the transaction price</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Allocate the transaction price to the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Recognize revenue when or as performance obligations are satisfied</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company’s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company’s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company’s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. <span style="color:#222222;background:#ffffff;">As of December 31, 2021 and 2020, the Company had uncertain tax positions of </span><span style="color:#222222;background:#ffffff;">$380,902</span><span style="color:#222222;background:#ffffff;"> and </span><span style="color:#222222;background:#ffffff;">$174,950</span><span style="color:#222222;background:#ffffff;">.   The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Manufacturing Contract Costs and Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Patent </b><b style="font-weight:bold;">Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Com</b><b style="font-weight:bold;background:#ffffff;">prehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Deferred Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder’s equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> deferred offering costs as of December 31,2021 or December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Net Income (Loss) per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation — Stock Compensation (“ASC 718”), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (“Black-Scholes”). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January 1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As there had been no public market for the Company’s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company’s most recently available third-party valuations of common stock and its board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> impairments in 2021.</span><span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (“JOBS Act”). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) will become effective for the Company on January 1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December 15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2017, the FASB issued ASU No. ASU 2017-04,  Intangibles—Goodwill and Other (Topic 350<i style="font-style:italic;">)</i>, which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on today’s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB sets generally accepted accounting principles (“GAAP”) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (“ASC”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On July 23, 2021, the Company approved a </span><span style="font-weight:normal;">one</span><span style="font-weight:normal;white-space:pre-wrap;">-for-1.4 stock split which was consummated in connection with the Company’s IPO. All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.</span></p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these  consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Segments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.</p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;font-weight:bold;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. Refer to Note 6, Business Combination for more information.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and Cash </b><b style="font-weight:bold;">Equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (“FDIC”) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our marketable securities are classified as available-for-sale pursuant to ASC 320,<span style="background:#ffffff;"> Investments – Debt and Equity Securities</span> and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the  consolidated balance sheets and statements of convertible preferred stock and stockholders’ equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021.  Realized gains and losses are included in other expense on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December 31, 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We record cash equivalents and marketable securities at fair value. ASC 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 1</i> – Unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 2</i> – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3</i> – Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2021. Fair value </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">information for these assets, including their classification in the fair value hierarchy is included in Note 4  Fair Value Measurements<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have been no changes to the valuation methods during the year ended December 31, 2021. We evaluate transfers between levels at the end of each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management’s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December 31, 2021 and 2020 there was no allowance for doubtful accounts.</p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The following customers comprised 10% or more of the Company’s total accounts receivable or revenues as of or for the period ended December 31, 2021 (customers with an asterisk are less than 10%): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">95.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">95.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 745030 0.358 235500 0.957 380000 0.183 353050 0.170 676710 0.293 214345 0.429 570000 0.247 71250 0.142 306900 0.133 250880 0.109 63000 0.126 91975 0.184 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Property and Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1-10 years</p></td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1-10 years</p></td></tr></table> P3Y P5Y P7Y P1Y P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.</p> 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In February 2016 the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASC 842”), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company’s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company adopted the leasing standard using the modified retrospective transition approach as of January 1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12 months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company has elected not to separate lease and non-lease components as a single lease component. The Company’s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.</p> true <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Identify the contract with a customer</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Identify the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Determine the transaction price</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Allocate the transaction price to the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">• Recognize revenue when or as performance obligations are satisfied</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company’s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company’s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company’s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. <span style="color:#222222;background:#ffffff;">As of December 31, 2021 and 2020, the Company had uncertain tax positions of </span><span style="color:#222222;background:#ffffff;">$380,902</span><span style="color:#222222;background:#ffffff;"> and </span><span style="color:#222222;background:#ffffff;">$174,950</span><span style="color:#222222;background:#ffffff;">.   The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.</span></p> 380902 174950 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Manufacturing Contract Costs and Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Patent </b><b style="font-weight:bold;">Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Com</b><b style="font-weight:bold;background:#ffffff;">prehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Deferred Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder’s equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> deferred offering costs as of December 31,2021 or December 31, 2020.</span></p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Net Income (Loss) per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December 31, 2021 and 2020.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation — Stock Compensation (“ASC 718”), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (“Black-Scholes”). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January 1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As there had been no public market for the Company’s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company’s most recently available third-party valuations of common stock and its board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.</p> 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> impairments in 2021.</span><span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. </p> 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (“JOBS Act”). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) will become effective for the Company on January 1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December 15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2017, the FASB issued ASU No. ASU 2017-04,  Intangibles—Goodwill and Other (Topic 350<i style="font-style:italic;">)</i>, which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on today’s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3 – Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketable securities as of December 31, 2021 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Gains</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,147,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,118,810</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,218,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,992,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,197)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,357,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,461)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,311,203</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Non-current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 999,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 996,560</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Non-current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 999,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 996,560</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total marketable securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,356,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,087)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,307,763</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no marketable securities as of December 31, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021. Realized gains and losses are included in other expense on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December 31, 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Gains</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,147,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,118,810</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,218,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,992,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,197)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,357,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,461)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,311,203</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Non-current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 999,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 996,560</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Non-current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 999,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 996,560</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total marketable securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,356,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,087)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,307,763</p></td></tr></table> 42147385 28575 42118810 19218057 13689 19204368 12992165 57 4197 12988025 74357607 57 46461 74311203 999186 2626 996560 999186 2626 996560 75356793 57 49087 75307763 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4 – Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Money market</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Total cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,961,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> U.S. Treasuries</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Government securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Total marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,192,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,307,763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,076,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,192,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111,269,107</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no transfers between Level 1 and Level 2 and we had no financial assets or <span style="-sec-ix-hidden:Hidden_tlcK7EHhSU-TZzE4mXesaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities</span></span> that were classified as Level 3 at any point during the year ended December 31, 2021. There were no marketable securities as of December 31, 2020. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Money market</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Total cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,961,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> U.S. Treasuries</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Government securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Total marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,192,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,307,763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,076,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,192,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111,269,107</p></td></tr></table> 33961344 33961344 2000000 2000000 33961344 2000000 35961344 43115370 43115370 19204368 19204368 12988025 12988025 43115370 32192393 75307763 77076714 34192393 111269107 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5 – Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 281,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,317</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,798</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 981,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193,115</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (174,219)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (128,752)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 807,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,363</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation expense totaled $45,467 and $24,328 for the year ended December 31, 2021 and 2020, respectively. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 281,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,317</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,798</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 981,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193,115</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (174,219)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (128,752)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 807,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,363</p></td></tr></table> 281666 174317 84477 18798 463182 152117 981442 193115 174219 128752 807223 64363 45467 24328 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6 – Business Combination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">BioArkive Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On December 22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (“BioArkive”), for a market value of </span><span style="background:#ffffff;">$8.75</span><span style="background:#ffffff;"> million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company's internal preclinical research activities for its oncology pipeline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the acquisition, the Company has assumed the obligations under BioArkive’s </span><span style="background:#ffffff;">three</span><span style="background:#ffffff;"> lease agreements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The purchase price was paid by Immuneering through the issuance of an aggregate of </span><span style="background:#ffffff;">379,635</span><span style="background:#ffffff;"> shares of Immuneering’s Class A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the </span><span style="background:#ffffff;">30</span><span style="background:#ffffff;">-trading day period ending on and including the trading day immediately prior to the closing date.</span> The sellers of BioArkive are restricted from selling these shares for a 6 month period from the date of the acquisition. As such, we estimated that there was an approximate 10% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $7,875,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Prior to the acquistion, Brett Hall, Chief Scientific Officer of Immuneering and the Founder and Chairman of the board of directors of BioArkive, held the majority of the outstanding shares of BioArkive capital stock.</span>  BioArkive provided contract services to the Company. <span style="background:#ffffff;">Research and development expenses in the consolidated statement of operations include the cost of services provided by BioArkive to the Company which amounted to </span><span style="background:#ffffff;">$4,548,780</span><span style="background:#ffffff;"> in 2021 through date of the acquisition and </span><span style="background:#ffffff;">$2,744,051</span><span style="background:#ffffff;"> in 2020. As of December 31, 2020, </span><span style="background:#ffffff;">$279,153</span><span style="background:#ffffff;"> was owed to BioArkive and is included in accounts payable or accrued contract research expenses in the consolidated balance sheets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Assets Acquired and Liabilities Assumed at Fair Value</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BioArkive Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. As of December 31, 2021, certain amounts relating to working capital have not been finalized. The finalization of these matters could result in changes to goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the intangible assets was determined using the relief from royalty approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected cost savings of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of BioArkive, is the planned investment in the internal preclinical research activities for our oncology pipeline. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pro forma results are not presented for this acquisition as they are not material to the consolidated results of the Company’s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.4%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preliminary Valuation</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;width:19.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other currents assets</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long term assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 727,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,824,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible asset</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Technology</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 439,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15 years</p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,701,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,076,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable, accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,824,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,875,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 8750000 3 379635 30 P6M 0.10 7875000 4548780 2744051 279153 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.4%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preliminary Valuation</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;width:19.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other currents assets</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long term assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 727,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,824,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible asset</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> Technology</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 439,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15 years</p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,701,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,076,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable, accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,824,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,875,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 70348 225790 87796 727539 4824700 439000 P15Y 6701726 13076899 69714 307485 4824700 7875000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7 – Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 269,302</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,917,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 163,668</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued contract research expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266,022</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,965,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698,992</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 269,302</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,917,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 163,668</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued contract research expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266,022</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,965,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698,992</p></td></tr></table> 250977 269302 2917282 163668 585416 266022 211772 3965447 698992 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 8 – Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series A Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, the Company authorized the sale and issuance of up to 1,987,979 shares of Series A Preferred Stock, $0.001 par value per share, at an original issuance price of $8.5514 per share. In January 2020, the number of shares authorized for the Series A Preferred Stock was increased to 2,495,933 shares. The Series A Preferred Stock financing was structured to be issued in rolling closes during 2019 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 20, 2019, the Company issued an additional 1,122,458 shares of Series A Preferred Stock for gross cash proceeds of $9,598,847 and issued 785,706 shares of Series A Preferred Stock in conjunction with the conversion of the outstanding amount of the Convertible Notes. In 2019, the Company incurred issuance costs of $200,587 in connection with this offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company received funds for issuance of an additional 468,315 shares of Series A Preferred Stock for gross cash proceeds of $4,004,975 through December 31, 2019. Of these shares, 410,436 shares of Series A Preferred Stock for gross cash proceeds of $3,509,802 exceeded the authorized amount allowed by the articles of incorporation, resulting in a liability of $3,509,802 and a total of 1,966,043 shares of Series A Preferred Stock outstanding at December 31, 2019. In January 2020, the shares that were previously classified as a liability as of December 31, 2019 were reclassified to temporary equity upon the approved increase to authorized shares of Series A Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2020, the Company issued 119,454 additional shares of Series A Preferred Stock for gross cash proceeds of $1,021,413. The Company incurred issuance costs of $23,610 in connection with the financing in January 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series B Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2020, the Company authorized the sale and issuance of up to 6,032,183 shares of Series B Preferred Stock, $0.001 par value per share, at an original issuance price of $10.2782 per share. The Series B Preferred Stock financing was structured to close in two tranches. The first tranche closed in December 2020 and the Company issued 3,619,292 shares of Series B Preferred Stock for gross cash proceeds of $37,199,929. The Company incurred issuance costs of $216,019 in connection with the financing in December 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company determined the right of the investors to purchase 2,412,853 shares of Series B Preferred Stock in the second tranche does not meet the definition of a freestanding financial instrument as it is not separable from the Series B Preferred Stock issued in the first tranche. The issuance of the second tranche is subject to the Company meeting certain development milestones or at the election of the holders of at least a majority of the then outstanding shares of Series B Preferred Stock which must include one specific shareholder (the “Requisite Holders”). Each holder of Series B Preferred Stock may elect to purchase their requisite shares of the second tranche at any time. As of March 31, 2021, the Company had not met these development milestones nor did the Requisite Holders elect to purchase the second tranche prior to meeting these milestones and therefore no shares of the second tranche were issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April and May 2021, all 2,412,853 shares of the second tranche of Series B Preferred Stock were issued based on the voluntary election of substantially all of the holders of Series B Preferred Stock. The Company received gross proceeds of $24,799,786. The Company incurred issuance costs of $10,935 in connection with the second tranche of Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The rights and preferences of the Series A Preferred Stock and Series B Preferred Stock (“Preferred Stock”) were as described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Conversion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each share of Preferred Stock may be converted at any time, at the option of the holder, into shares of Class A common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The conversion price for the Series A Preferred Stock and Series B Preferred Stock (as may be adjusted for certain customary dilutive events) is $6.1081 and $7.3416, respectively. The Preferred Stock automatically convert into shares of Class A common stock at the then effective conversion rate upon the closing of a public offering of the Company’s securities with gross proceeds to the Company of at least $75,000,000 and a share price of at least $7.3416 or at the election of the holders of the Requisite Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders of Series B Preferred Stock that would beneficially own at least 9.9% of any then outstanding class of equity securities may elect to receive a portion of their converted Series B Preferred Stock as Class B common stock upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO on August 3, 2021, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stockholders are entitled to receive per annum dividends of 7% of the original issue price share, payable only when, as and if declared by the Board of Directors. The right to receive these dividends is not cumulative, and therefore, if not declared in any year, the right to receive such dividends shall terminate and not carry forward into the next year. As of December 31, 2021 and December 31, 2020, no dividends had been declared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Voting Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters are subject to the powers, preferences, and rights of the Preferred Stock. Preferred Stockholders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. As long as 2,132,029 shares of Preferred Stock are outstanding, certain actions such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events, must be approved by the holders of at least a majority of the then-outstanding shares of Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Liquidation Preference</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon liquidation, dissolution, or winding up of business, holders of Preferred Stock are entitled to receive a liquidation preference in priority to holders of common stock at the original respective Preferred Stock issue price for such series. If assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, assets available for distribution will be allocated among holders of Preferred Stock on a pari passu basis at an amount per share equal to the greater of the respective original Preferred Stock issue price for such series plus any declared but unpaid dividends or such amount had all shares been converted to common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When holders of Preferred Stock are satisfied in full, any excess assets available for distribution will be allocated ratably among common stock holders based on their pro rata shareholdings. Upon a deemed liquidation event, as defined in the articles of incorporation, holders have the option to redeem their shares at the liquidation payment amounts summarized above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other than described above, the shares of Preferred Stock are not redeemable.</p> 1987979 0.001 8.5514 2495933 1122458 9598847 785706 200587 468315 4004975 410436 3509802 3509802 1966043 119454 1021413 23610 6032183 0.001 10.2782 2 3619292 37199929 216019 2412853 0 2412853 24799786 10935 6.1081 7.3416 75000000 7.3416 0.099 8528078 11939281 0.07 0 0 2132029 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 9 - Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company had 200,000,000 authorized shares of Class A common stock, $0.001 par value per share as of December 31, 2021 and 22,026,200 authorized shares of Class A common stock, $0.001 par value per share as of December 31, 2020, respectively, of which 26,320,199 and 4,950,129 were <span style="-sec-ix-hidden:Hidden_hTzGFl4AukOhSIQvrJVGbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_lP6rYH5NMkSWKz0be_vdHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively. The holders of Class A common stock are entitled one vote for each share of common stock. Dividends may be paid when, and if declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Preferred Stockholders and on a proportionate basis with holders of Class B common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December 31, 2020, the following number of shares of Class A common stock have been reserved:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,494,306</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,066,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,308</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801,263</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,670,872</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company had 20,000,000 authorized shares of Class B common stock, $0.001 par value per share as of December 31, 2021 and 6,032,183 authorized shares of Class B common stock, $0.001 par value per share as of December 31, 2020, of which no shares have been issued nor are outstanding. The holders of Class B common stock have no voting rights. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the preferred stockholders and on a proportionate basis with holders of Class A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2019, the Company issued warrants to purchase an aggregate of 308,308 shares of Class A common stock at an exercise price of $3.01 per share to several advisors, including 200,984 shares to entities related to members of the Board of Directors of the Company, in lieu of cash payments. These warrants vested immediately upon issuance, became exercisable on January 9, 2021 and have a 10-year term set to expire on January 9, 2030. The Company evaluated the terms of these warrants and determined that equity classification was appropriate. As of December 31, 2020, no warrants had been exercised. During June 2021, all warrant holders exercised their warrants to purchase an aggregate of 308,308 shares of common stock. As of December 31, 2021, there were no warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 3, 2021, the Company completed its initial public offering pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company’s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional paid-in capital.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 3, 2021 in connection with the closing of the IPO, the Company filed a restated certificate of incorporation, which amended and restated the Company’s certificate of incorporation to, among other things: (i) increase the number of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">authorized shares of common stock to 200,000,000 shares of Class A common stock, 20,000,000 shares of Class B common stock, par value $0.001 per share, and (ii) authorize 10,000,000 shares of Preferred Stock; and (iii) authorize the Board of Directors to establish the rights, preferences and restrictions on any unissued series of Preferred Stock.</p> 200000000 0.001 22026200 0.001 26320199 4950129 1 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,494,306</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,066,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,308</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801,263</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,670,872</p></td></tr></table> 3494306 5066995 308308 2859544 1801263 2859544 10670872 20000000 0.001 6032183 0.001 0 0 0 0 308308 3.01 200984 P10Y 0 308308 0 8625000 1125000 120318750 2124317 8528078 11939281 200000000 20000000 0.001 10000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 10 - Net Loss Per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated at December 31, 2021 and 2020 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,535,748)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,039,898)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator - basic and diluted:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,612,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,950,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wHopsXwjskSWOmAaEI9k1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_--dUy7H6lkGzBYeWkeucsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.44)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at December 31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,494,306</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,066,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,308</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,801,263</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,670,872</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,535,748)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,039,898)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator - basic and diluted:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,612,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,950,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wHopsXwjskSWOmAaEI9k1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_--dUy7H6lkGzBYeWkeucsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.44)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> -33535748 -17039898 13612677 4950129 -2.46 -3.44 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,494,306</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,066,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,308</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,801,263</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,670,872</p></td></tr></table> 3494306 5066995 308308 2859544 1801263 2859544 10670872 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 11 – Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2015, the Company established the Long Term Incentive Plan (“Incentive Plan”), under which incentive stock options, nonqualified stock options, restricted stock or other awards may be awarded to employees, directors or consultants of the Company. The options typically vest over a four-year period. As of December 31, 2021, the maximum number of shares available for issuance under the Incentive Plan was 2,825,173 shares. Upon the effectiveness of the Company’s 2021 Incentive Award Plan, the Company ceased granting awards under the Incentive Plan. However, the Incentive Plan continues to goven awards outstanding thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 23, 2021, the Company’s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Incentive Award Plan (the “2021 Plan”), which became effective on July 29, 2021. The 2021 Plan provides for the grant of incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares reserved for issuance under the 2021 Plan was initially equal to 2,590,000 plus an annual increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 4% of the aggregate number of shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the Board of Directors. No more than 15,350,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. If an award under the 2021 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised/settled or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 Plan. In addition, shares subject to stock options issued under the Incentive Plan may become available for issuance under the 2021 Plan to the extent such stock options are canceled, forfeited, exchanged, settled in cash or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">otherwise terminated. As of December 31, 2021, there were 2,298,432 shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 23, 2021, the Company’s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective on July 29, 2021. A total of 250,000 shares of Class A common stock were initially reserved for issuance under this plan. The number of shares of Class A common stock that may be issued under the 2021 ESPP will automatically increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 1% of the shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the board of directors, provided that not more than 3,340,000 shares of Class A common stock may be issued under the 2021 ESPP. As of December 31, 2021, no shares had been issued under the 2021 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of $1,802,623 and $1,086,769, respectively. As of December 31, 2021, compensation expense remaining to be recognized for outstanding stock options was $8,403,600 and to be recognized over a weighted-average period of 2.93 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of options granted is calculated on the grant date using the Black-Scholes option valuation model. <span style="background:#ffffff;">The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer public companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price.</span> For the year ended December 31, 2021, the Company granted 1,452,462 shares of stock options at a weighted-average grant date fair value of $6.29. For the year ended December 31, 2020, the Company granted 343,169 shares at a weighted-average grant date fair value of $3.06.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants during the year ended December 31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.89% - 1.71%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.36% - 1.45%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.83 - 10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.92 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">66.76% - 80.99%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">67.30% - 80.85%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the stock option activity during the year ended December 31, 2021 under the Plan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (in Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,452,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (117,847)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (276,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,615,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,102,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,507,723</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,615,466</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year  ended December 31, 2021 and 2020, the Company recognized share-based compensation expense recognized on the accompanying  consolidated statements of operations as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 768,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 930,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,802,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,086,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> P4Y 2825173 2590000 0.04 15350000 2298432 250000 0.01 3340000 0 1802623 1086769 8403600 P2Y11M4D 1452462 6.29 343169 3.06 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.89% - 1.71%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.36% - 1.45%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.83 - 10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.92 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">66.76% - 80.99%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">67.30% - 80.85%</p></td></tr></table> 0.0089 0.0036 0.0145 P5Y9M29D P10Y P5Y11M1D P10Y 0 0 0.6676 0.8099 0.6730 0.8085 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (in Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,452,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (117,847)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (276,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,615,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,102,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,507,723</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,615,466</p></td></tr></table> 1801263 3.01 1452462 10.07 117847 3.01 276334 3.58 2859544 6.55 P8Y3M18D 27615466 1102543 3.01 P7Y1M20D 14507723 2859544 6.55 P8Y3M18D 27615466 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 768,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 930,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,802,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,086,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 103329 108027 768679 503111 930615 475631 1802623 1086769 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 12 – Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, the components and tax effects of each type of item that gave rise to the net deferred tax assets were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">R&amp;D credit carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,346,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,574,596</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">NOL carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,699,524</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,525,123</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,432,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,173,703</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,677,899)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,127,448)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 754,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,255</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses deducted for tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (425,755)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,671)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax depreciation in excess of book</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (328,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,584)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (754,314)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,255)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal net operating losses (“NOL”) generated in tax years ended after December 31, 2017 are limited to 80% of taxable income, only carried forward and carried forward indefinitely under the Internal Revenue Code (“IRC”). The Company recorded a deferred tax liability of $304,485 on the acquisition of BioArkive. It had pre-existing deferred tax assets for which there was a fuill valuation allowance. As a result of the taxable temporary differences recognized in the business combination, the Company released $304,485<span style="white-space:pre-wrap;"> of its valuation allowance and recognized the income tax benefit in the income statement at the acquisition date in accordance with ASC 740 There was no income tax expense or benefit in 2020. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December 31, 2021, the Company has federal and state NOLs of </span>$56,544,731 and $51,310,112, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">respectively all generated after the tax year ended December 31, 2017. At December 31, 2021, the Company has federal and state research and development credit carryforwards, $3,034,827 and $394,013, respectively, that start to expire beginning in 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;">As the Company has not yet achieved profitable operations, management believes the tax benefits as of December 31, 2021 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2021 by $10,550,451 due to the increase in the deferred tax assets by the same amount, primarily due to NOL and research and development credit carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, some amounts are being presented as an uncertain tax position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, the Company had uncertain tax positions of $380,902 and $174,950 which have been classified as reductions of its tax carrforwards. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, unrecognized tax benefits were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,952</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase due to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 205,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,998</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 380,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,950</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company files tax returns in the United States including California, New York, Pennsylvania, Massachusetts and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Texas. All tax years from 2017 to 2021 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (“IRS”) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The enactment of the CARES Act resulted in increased federal and state research and development carryforwards from 2013 through 2018 of $93,437 and decreased federal NOL of $759,794 from 2018.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> 0.210 0.210 0.055 0.063 -0.006 -0.015 0.056 0.045 0.004 0.006 -0.006 -0.010 0.007 -0.026 -0.311 -0.273 0.009 0.000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">R&amp;D credit carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,346,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,574,596</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">NOL carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,699,524</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,525,123</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,432,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,173,703</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,677,899)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,127,448)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 754,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,255</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses deducted for tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (425,755)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,671)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax depreciation in excess of book</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (328,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,584)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (754,314)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,255)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table> 373602 73984 12990 3346097 1574596 14699524 5525123 18432213 7173703 17677899 7127448 754314 46255 425755 28671 328559 17584 754314 46255 304485 304485 56544731 51310112 3034827 394013 10550451 380902 174950 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,952</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase due to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 205,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,998</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 380,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,950</p></td></tr></table> 174950 96952 205952 77998 380902 174950 93437 759794 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 13 – Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company leases office space in Cambridge, Massachusetts, New York, New York and as of July 2021, San Francisco, California, pursuant to short-term arrangements. The Cambridge and San Francisco leases are on a month-to-month basis, requiring one month’s notice before termination. The New York lease is renewable on a quarterly basis and the last renewal extended the lease term until March 31, 2022. These lease agreements include payments for lease and non-lease components and the Company has elected to not separate such components and these payments were recognized as rent expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts, New York, New York and San Francisco, California was $30,840 due in 2022. The Company leases storage space for its electronic data equipment in Somerville, Massachusetts. This lease is renewable on an annual basis effective every March 1st. Prior to December 31, 2021, the Company renewed the lease through March 31, 2022. As of December 31, 2021, total future minimum lease payments for this lease were $3,569 due in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into an office lease in San Diego, California with a lease term of 67 months. At the lease commencement date, a right-to-use asset and <span style="-sec-ix-hidden:Hidden_XdPatEybTkShRMLsu6QibA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease liability</span></span> was recognized by the Company for $637,863.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the BioArkive acquisition, the Company assumed the obligations of three leases in San Diego, California, one is for 38,613 square feet of office and laboratory space, under a lease that terminates on April 30, 2032, a second is a 6,100 square feet of office and laboratory space under a lease that terminates on December 31, 2022, and third is a lease for 4,760 square feet of office and laboratory space under a lease that terminates on March 31, 2024.  As a result, we recorded right-to-use assets and <span style="-sec-ix-hidden:Hidden_CeuFDcEWwUiE1feAvMT7Lw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease liabilities</span></span> of $4,824,700 on the acquisition date of December 22, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at December 31, 2021 were as follows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 659,990</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 880,121</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894,044</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 906,839</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 819,210</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,467,246</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,627,450</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262,514</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,364,936</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 274,039</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,090,897</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,364,936</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Quantitative information regarding the Company’s leases for the year ended December 31, 2021 and 2020 is as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,652</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,700</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 419,229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,148</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,666</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 348,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311,462</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.62 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.33 years</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the Company’s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its products and operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated the Company will accrue a liability for such matters. Significant judgement is required to determine both probability and estimated amount. The Company is not aware of any material legal matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Clinical Research Contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination with a 30-day notice.</p> 30840 30840 3569 P67M 637863 3 38613 6100 4760 4824700 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 659,990</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 880,121</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894,044</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 906,839</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 819,210</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,467,246</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,627,450</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262,514</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,364,936</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 274,039</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,090,897</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,364,936</p></td></tr></table> 659990 880121 894044 906839 819210 4467246 8627450 3262514 5364936 274039 5090897 5364936 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,652</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,700</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 419,229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,148</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,666</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 348,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311,462</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.62 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.33 years</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.0%</p></td></tr></table> 160872 66652 258357 252796 14700 419229 334148 111527 58666 236700 252796 348227 311462 P9Y7M13D P5Y3M29D 0.097 0.060 EXCEL 107 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

=PLJ@-RWM?!MMQ8^(3S#\.S=V'J55AF>_AH@2&(G#(?[ *+TM>[XWA?8!ITT&CG1<-CQ M1>Q&D9VF6/F=M2!Q8C]"7\0_O' >L(NBI:@M@<9Q^CC?K[;O^%Z :K\(8>+Z M75/\H1-YB9,$X2Y\VWDY6>G>O7UP<W_+_:HC_=!R__5@^6#9&CM) M;!79EW2#SBV[!#$W;PF)J;.L5'/AME3[7+EH;NE;]N:M\YF*.39@4L ,13TW MP=-8-.^'9J)X;>[L4Z[P!6!^%_CD J$9<'W&N6HG>@/[B)O\#5!+ P04 M" #2-&I4K[=@%',$ $# &0 'AL+W=O9ELXV$8GT2"I.]NMW MI&Q9CA4OV/9%$D]W#Y\[WAUOLI;J02\!#'FJ2J$O!TMC5N>CD7@V"P%=SQQ=)8P6@Z6;$%W(/YOKI5N!JU* 6O0&@N!5$POQR\#\ZO$JOO M%'YP6.O.-[&>S*1\L(M/Q>7 MX2@A-Q8!(:O1[B&LK1 2.//#>:@W=(:=K^W MZ!^=[^C+C&FXEN4?O##+R\%X0 J8L[HT=W+]&VS\B2U>+DOMGF2]T?4')*^U MD=7&&!E47#1O]K2)PUL,Z,: .M[-1H[E#3-L.E%R39351C3[X5QUUDB."WLH M]T;A7XYV9OI)Y+("\HT]@2:GW]BL!'TV&1F$M@JC? -SU<#05V "2CY+89:: M?! %%/L (^34$J-;8E?T*.(-Y$,2!AZA/@V.X(6MHZ'#2][@Z!&XJ(6+'%SX M"MP]5D=1ET#DG,RA ,5*H@TSM9'JF2AF@!A)S!*(P,HJI=:$B<()8#X'EXN$ M-YP,>W(6?6$_SN+=3V/JAQ?DW[YM;.W#)_$S0H4QL/MQ[0&H_M2[CCH?TVY MP]2[.:1U?J!^;V3^\(OMOP7!F.&=I)M PY/]AE;QA(1IZ"4^[4A0D(TC/'>\ MMDK^%T+8@@1]L$M O2SS>SD'](+GD1=G"?GR]?=^HR#RDBSS8AJUHAA7L1?0D/RJ;/?H.;R=^=B+0NK1 M(&Q%J1>@UZD?DA\].?G2P=,@]9(T]<99=K83(@9-O2@:GY$O_>FSVRZ.O##8 ML<<0T#@^-"LYF_$2ZPUZSOA6P8KQ8GNDUN>BS@V:8KR<>4LMPMBD<=PA2\?H M =89-GBTPP$EYXW7W.8(%JVV96#'@YU-B$9QW'49XQ"/(T21!AO1:]0[(6K\ M[B TGA]&K&-UTB;4@>1(U2=MU2=OKOH:,SZ7"^%RWCJQ:>^\A$#N$EW(L@RP;VSFFGTHX]KULK[ULR/6=W:@SF56@%F[^U-C!:F&: M(:V5MB/N^V:RVZDW\_%GIC ^FI0P1U.\@;!/JV;F;!9&KMR<-Y,&IT;WN<0Q M'915P/]S*T# !@"@ &0 M 'AL+W=O>I[."5TQ/9<-K^+*6JF(&2+7Q=*,XRYU257K$]ZE7,5%/ M%G/'>U"+N6Q-*6K^H)!NJXJIYSM>RNW-))CL&!_$IC"6X2WF#=OP1V[^:1X4 M4-Z DHN*UUK(&BF^OIG5J+N3?>WS,%*8^6<42*] G-^= M(>?E&V;88J[D%BDK#6CVQ87JM,$Y4=NB/!H%7P7HF<525I4PD&6C$:MSM)2U M$?6&UYG@&KU^8JN2Z]_FG@%;5L/+>MR[#I>H0J.W=<[S0P /G!P\ M)3M/[\A%Q#<\FZ(PP(CX)+B %PZ1APZ/_I_(IQ<,1(.!R!D(SQAXA '*VY(C MN4;WS+1*&)M3H$S!4\Y:?R?-G(+S_-B!_^CK[WO*UD6QN; M0S+P?D8T3G&:^I8=#NS9S,BHXW!9KP]61,Q&.:())1-&3-*Q$ZQ:RM$M-PYZ[X@R F)($1[&/WG.MK]&[ MJFD-SY&H 9MK,PB&F%""XR#J88]3O8\\QB&-U=B=) M(!<0]ON7DAC5LLYZO)UTC/W4Q[,T^1&O+K1A/+1A_-UM^'?+H,D-LSA-&HV'U\Z^Z-B&OD2V5$CZ8@3AA$.HAE: M,EW )(D<0:T1<\.OH?)9V>9N=%R]*T"%P;/C9KODJ#./T[=/5V8MK.'?KM%: MR0K)PT2.W0R" ,IO:EIY"+: ;9&9L-P9&( M$O3)_;-Y?L6^@ ,;#F-@]YA]%SC#5^=C2J> \LR9VK/B:1CVK"/X7.C,7;^ MQB_C)J\&@D[]5Z?N 6_TUZ^XVKC=1B-GH5L !NZP/MUV6\->O-N][IG:B-J. M^QI4_6D"TZVZ?:8CC&S<#K&2!C82]UK "LB5%8#O:RG-CK &AJ5R\0U02P,$ M% @ TC1J5% AJX&ULO59=;YLP%/TK%MI#*W4!\YTJB=0DFM:'K5&C;L\.W!"K@#/;)-VT M'S\;**0*0>G6[@5L\+GWW \?W=&>\4>Q 9#H*4MS,38V4FZO35-$&\B(&+ M MY.K/FO&,2+7EB2FV'$A<@K+4M"W+-S-"2"LAQQ6(^-&WP]QZ$& ME">^4=B+@S72H:P8>]2;VWAL6)H1I!!);8*HUPYFD*;:DN+QHS9J-#XU\'#] M;/U3&;P*9D4$S%CZG<9R,S9" \6P)D4J[]G^,]0!>=I>Q%)1/M&^.NOY!HH* M(5E6@Q6#C.;5FSS5B3@ 8/<$P*X!]KD IP8XYP+<&N"6F:E"*?,P)Y),1ISM M$=>GE36]*)-9HE7X--=U7TJN_E*%DY,[GI"<_B)5$?(8?26RX(#8&DT+H0X+ M@2[F( E-Q27ZB!Z6A*7F7'+>WHJ[Z;8-MR#V4IBQ? =$@.INC\N(=$ P].[2"L)N>U]#S>NDM M2X^("E$H6L5652,J&6M=ZN+A'?' >.@,[1!W$_$;(GY_J:*HR(I4U2K6LD,C M*KOJY!_5R1O:@>.$;1ZJ=CX^:'N!$_CNB7H&#<^@OYXI43?Z!LU8EJED+74A M>SHU;,R&[W@?AHV7X?G5[JKNL*.ZMF=9)Y*&K58EK?]R#6HWY_FY^ OA"SQ IC^DG&18Z6G8N/+0@!.+2BG?A0$0S_'A'GS MJ7VW%/,I+Q4E#)8"R3+/L7B\ LKW,R_TGE[_-.PD9O1=5" MMG@]65"3G;+XVL_&U*@Q-;*TP_\VU1$L;H+%-EC<%4SQY ')@A)UCDQY>%M- M*HZ!Y3"]8#?7WN]:PO:;L'UGV-LR7X,P*>H>9,+JK.HZ2/0+=9?DNO]:*8-& MRL IY9+J[H59 DCW093R,7?L3C8!)$SZHT?KF71OW)H,.[2:-SXM2Y M@ R$@%3O;CTP.SOALMVWR5\WDFO%B;HP^-.S Z>^#[J4B=+Z4K(C*; 4/1*@ M:6LS=3,%O2!XV]HW_QEWFLO1^1,ZF3YQGNX)I8@T_X]6HVL:EX_^T3%H+BW? ML-@0)A&%3&."WDCO$U'= ZJ)XH4]&==&PO=V]R:W-H965T M-[D;",/N6@V*=IE/_[0!-^F%O(>G_PS#9;43YP%K-=M*%+*K[MGG)YYS1: M5BRE6<%X!G*ZGEOWZ"YT82F@5OS!Z*$XN@9E*"^T83&HE01 MR8\W&M(D*35)/_ZIE5J-S5+P^/I=^Z\J>!G,2U30D"=_LI78SJV)!59T'>T3 M\

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end XML 108 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 109 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 110 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 171 429 1 false 61 0 false 10 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://immuneering.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://immuneering.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) Sheet http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) Statements 6 false false R7.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 10101 - Disclosure - Organization and Nature of Business Sheet http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness Organization and Nature of Business Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Marketable Securities Sheet http://immuneering.com/role/DisclosureMarketableSecurities Marketable Securities Notes 10 false false R11.htm 10401 - Disclosure - Fair Value Measurements Sheet http://immuneering.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 10501 - Disclosure - Property and Equipment, net Sheet http://immuneering.com/role/DisclosurePropertyAndEquipmentNet Property and Equipment, net Notes 12 false false R13.htm 10601 - Disclosure - Business Combination Sheet http://immuneering.com/role/DisclosureBusinessCombination Business Combination Notes 13 false false R14.htm 10701 - Disclosure - Accrued Expenses Sheet http://immuneering.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 14 false false R15.htm 10801 - Disclosure - Convertible Preferred Stock Sheet http://immuneering.com/role/DisclosureConvertiblePreferredStock Convertible Preferred Stock Notes 15 false false R16.htm 10901 - Disclosure - Common Stock Sheet http://immuneering.com/role/DisclosureCommonStock Common Stock Notes 16 false false R17.htm 11001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 17 false false R18.htm 11101 - Disclosure - Stock-Based Compensation Sheet http://immuneering.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 11201 - Disclosure - Income Taxes Sheet http://immuneering.com/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 11301 - Disclosure - Commitments and Contingencies Sheet http://immuneering.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 30303 - Disclosure - Marketable Securities (Tables) Sheet http://immuneering.com/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://immuneering.com/role/DisclosureMarketableSecurities 23 false false R24.htm 30403 - Disclosure - Fair Value Measurements (Tables) Sheet http://immuneering.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://immuneering.com/role/DisclosureFairValueMeasurements 24 false false R25.htm 30503 - Disclosure - Property and Equipment, net (Tables) Sheet http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://immuneering.com/role/DisclosurePropertyAndEquipmentNet 25 false false R26.htm 30603 - Disclosure - Business Combination (Tables) Sheet http://immuneering.com/role/DisclosureBusinessCombinationTables Business Combination (Tables) Tables http://immuneering.com/role/DisclosureBusinessCombination 26 false false R27.htm 30703 - Disclosure - Accrued Expenses (Tables) Sheet http://immuneering.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://immuneering.com/role/DisclosureAccruedExpenses 27 false false R28.htm 30903 - Disclosure - Common Stock (Tables) Sheet http://immuneering.com/role/DisclosureCommonStockTables Common Stock (Tables) Tables http://immuneering.com/role/DisclosureCommonStock 28 false false R29.htm 31003 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders 29 false false R30.htm 31103 - Disclosure - Stock-Based Compensation (Tables) Sheet http://immuneering.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://immuneering.com/role/DisclosureStockBasedCompensation 30 false false R31.htm 31203 - Disclosure - Income Taxes (Tables) Sheet http://immuneering.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://immuneering.com/role/DisclosureIncomeTaxes 31 false false R32.htm 31303 - Disclosure - Commitments and Contingencies (Tables) Sheet http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://immuneering.com/role/DisclosureCommitmentsAndContingencies 32 false false R33.htm 40101 - Disclosure - Organization and Nature of Business (Details) Sheet http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails Organization and Nature of Business (Details) Details http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness 33 false false R34.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 34 false false R35.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) Sheet http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) Details 35 false false R36.htm 40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 36 false false R37.htm 40301 - Disclosure - Marketable Securities (Details) Sheet http://immuneering.com/role/DisclosureMarketableSecuritiesDetails Marketable Securities (Details) Details http://immuneering.com/role/DisclosureMarketableSecuritiesTables 37 false false R38.htm 40401 - Disclosure - Fair Value Measurements (Details) Sheet http://immuneering.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://immuneering.com/role/DisclosureFairValueMeasurementsTables 38 false false R39.htm 40501 - Disclosure - Property and Equipment, net (Details) Sheet http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables 39 false false R40.htm 40502 - Disclosure - Property and Equipment, net - Depreciation (Details) Sheet http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails Property and Equipment, net - Depreciation (Details) Details 40 false false R41.htm 40601 - Disclosure - Business Combination - Narrative (Details) Sheet http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails Business Combination - Narrative (Details) Details 41 false false R42.htm 40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details) Sheet http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails Business Combination - Assets Acquired and Liabilities Assumed (Details) Details 42 false false R43.htm 40701 - Disclosure - Accrued Expenses (Details) Sheet http://immuneering.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://immuneering.com/role/DisclosureAccruedExpensesTables 43 false false R44.htm 40801 - Disclosure - Convertible Preferred Stock - Series A (Details) Sheet http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails Convertible Preferred Stock - Series A (Details) Details 44 false false R45.htm 40802 - Disclosure - Convertible Preferred Stock - Series B (Details) Sheet http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails Convertible Preferred Stock - Series B (Details) Details 45 false false R46.htm 40901 - Disclosure - Common Stock - Class A common stock (Details) Sheet http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails Common Stock - Class A common stock (Details) Details 46 false false R47.htm 40902 - Disclosure - Common Stock (Details) Sheet http://immuneering.com/role/DisclosureCommonStockDetails Common Stock (Details) Details http://immuneering.com/role/DisclosureCommonStockTables 47 false false R48.htm 40903 - Disclosure - Common Stock - Class B common stock (Details) Sheet http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails Common Stock - Class B common stock (Details) Details 48 false false R49.htm 40904 - Disclosure - Common Stock - Common stock warrant (Details) Sheet http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails Common Stock - Common stock warrant (Details) Details 49 false false R50.htm 40905 - Disclosure - Common Stock - IPO (Details) Sheet http://immuneering.com/role/DisclosureCommonStockIpoDetails Common Stock - IPO (Details) Details 50 false false R51.htm 41001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details) Sheet http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details) Details 51 false false R52.htm 41002 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details) Sheet http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details) Details 52 false false R53.htm 41101 - Disclosure - Stock-Based Compensation - Narratives (Details) Sheet http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails Stock-Based Compensation - Narratives (Details) Details 53 false false R54.htm 41102 - Disclosure - Stock-Based Compensation - Assumptions (Details) Sheet http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails Stock-Based Compensation - Assumptions (Details) Details 54 false false R55.htm 41103 - Disclosure - Stock-Based Compensation - stock option activity (Details) Sheet http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - stock option activity (Details) Details 55 false false R56.htm 41104 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details) Sheet http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails Stock-Based Compensation - Share-based compensation expense (Details) Details 56 false false R57.htm 41201 - Disclosure - Income Taxes - Net loss and the effective income tax rate (Details) Sheet http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails Income Taxes - Net loss and the effective income tax rate (Details) Details 57 false false R58.htm 41202 - Disclosure - Income Taxes - Net deferred tax assets (Details) Sheet http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails Income Taxes - Net deferred tax assets (Details) Details 58 false false R59.htm 41203 - Disclosure - Income Taxes - Narrative (Details) Sheet http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 59 false false R60.htm 41204 - Disclosure - Income Taxes - Unrecognized tax benefits (Details) Sheet http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized tax benefits (Details) Details 60 false false R61.htm 41301 - Disclosure - Commitments and Contingencies - Narratives (Details) Sheet http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails Commitments and Contingencies - Narratives (Details) Details 61 false false R62.htm 41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details) Sheet http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails Commitments and Contingencies - Maturities of the lease liabilities due (Details) Details 62 false false R63.htm 41303 - Disclosure - Commitments and Contingencies - Lease cost (Details) Sheet http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails Commitments and Contingencies - Lease cost (Details) Details 63 false false All Reports Book All Reports imrx-20211231x10k.htm imrx-20211231.xsd imrx-20211231_cal.xml imrx-20211231_def.xml imrx-20211231_lab.xml imrx-20211231_pre.xml imrx-20211231xex21d1.htm imrx-20211231xex23d1.htm imrx-20211231xex31d1.htm imrx-20211231xex31d2.htm imrx-20211231xex32d1.htm imrx-20211231xex32d2.htm imrx-20211231xex4d3.htm imrx-20211231x10k006.jpg imrx-20211231x10k007.jpg imrx-20211231x10k008.jpg imrx-20211231x10k009.jpg imrx-20211231x10k010.jpg imrx-20211231x10k011.jpg imrx-20211231x10k012.jpg imrx-20211231x10k013.jpg imrx-20211231x10k014.jpg imrx-20211231x10k015.jpg imrx-20211231x10k016.jpg imrx-20211231x10k017.jpg imrx-20211231x10k018.jpg imrx-20211231x10k019.jpg imrx-20211231x10k020.jpg imrx-20211231x10k021.jpg imrx-20211231x10k022.jpg imrx-20211231x10k023.jpg imrx-20211231x10k024.jpg imrx-20211231x10k025.jpg imrx-20211231x10k026.jpg imrx-20211231x10k027.jpg imrx-20211231x10k028.jpg imrx-20211231x10k029.jpg imrx-20211231x10k030.jpg imrx-20211231x10k031.jpg imrx-20211231x10k032.jpg imrx-20211231x10k033.jpg imrx-20211231x10k034.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 113 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "imrx-20211231x10k.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 171, "dts": { "calculationLink": { "local": [ "imrx-20211231_cal.xml" ] }, "definitionLink": { "local": [ "imrx-20211231_def.xml" ] }, "inline": { "local": [ "imrx-20211231x10k.htm" ] }, "labelLink": { "local": [ "imrx-20211231_lab.xml" ] }, "presentationLink": { "local": [ "imrx-20211231_pre.xml" ] }, "schema": { "local": [ "imrx-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 525, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 31, "http://xbrl.sec.gov/dei/2021q4": 7, "total": 38 }, "keyCustom": 48, "keyStandard": 381, "memberCustom": 21, "memberStandard": 32, "nsprefix": "imrx", "nsuri": "http://immuneering.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://immuneering.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Marketable Securities", "role": "http://immuneering.com/role/DisclosureMarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Fair Value Measurements", "role": "http://immuneering.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Property and Equipment, net", "role": "http://immuneering.com/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Business Combination", "role": "http://immuneering.com/role/DisclosureBusinessCombination", "shortName": "Business Combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "imrx:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Accrued Expenses", "role": "http://immuneering.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "imrx:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "imrx:TemporaryEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Convertible Preferred Stock", "role": "http://immuneering.com/role/DisclosureConvertiblePreferredStock", "shortName": "Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "imrx:TemporaryEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Common Stock", "role": "http://immuneering.com/role/DisclosureCommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "role": "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Stock-Based Compensation", "role": "http://immuneering.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Income Taxes", "role": "http://immuneering.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Commitments and Contingencies", "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Marketable Securities (Tables)", "role": "http://immuneering.com/role/DisclosureMarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Fair Value Measurements (Tables)", "role": "http://immuneering.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Property and Equipment, net (Tables)", "role": "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Business Combination (Tables)", "role": "http://immuneering.com/role/DisclosureBusinessCombinationTables", "shortName": "Business Combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "imrx:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Accrued Expenses (Tables)", "role": "http://immuneering.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "imrx:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Common Stock (Tables)", "role": "http://immuneering.com/role/DisclosureCommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "role": "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "role": "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://immuneering.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Income Taxes (Tables)", "role": "http://immuneering.com/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Organization and Nature of Business (Details)", "role": "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "shortName": "Organization and Nature of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_7_23_2021_To_7_23_2021_He5Glc1OZUuR4Os2aqbeew", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_7_23_2021_To_7_23_2021_He5Glc1OZUuR4Os2aqbeew", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)", "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails", "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oWqze6TNHUeol6NT43Q40A", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "imrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_twFlKCzRuEusunTslMr32A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "imrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_twFlKCzRuEusunTslMr32A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Marketable Securities (Details)", "role": "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails", "shortName": "Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Fair Value Measurements (Details)", "role": "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Property and Equipment, net (Details)", "role": "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Property and Equipment, net - Depreciation (Details)", "role": "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails", "shortName": "Property and Equipment, net - Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_Fdx8Pw88t0GYE-WWz9kZLQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Business Combination - Narrative (Details)", "role": "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "shortName": "Business Combination - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_Fdx8Pw88t0GYE-WWz9kZLQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details)", "role": "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "Business Combination - Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA", "decimals": "0", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "imrx:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Accrued Expenses (Details)", "role": "http://immuneering.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "imrx:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Convertible Preferred Stock - Series A (Details)", "role": "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "shortName": "Convertible Preferred Stock - Series A (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "imrx:TemporaryEquityDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_Tref9-4zckC3A4JsB3VTMA", "decimals": "INF", "lang": null, "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Convertible Preferred Stock - Series B (Details)", "role": "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "shortName": "Convertible Preferred Stock - Series B (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "2", "lang": null, "name": "us-gaap:PreferredStockDividendRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Common Stock - Class A common stock (Details)", "role": "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "shortName": "Common Stock - Class A common stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "imrx:NumberOfVotesPerShare", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Vps21bPl-0ucIcde4LcmUQ", "decimals": "INF", "lang": null, "name": "imrx:NumberOfVotesPerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Common Stock (Details)", "role": "http://immuneering.com/role/DisclosureCommonStockDetails", "shortName": "Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Common Stock - Class B common stock (Details)", "role": "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "shortName": "Common Stock - Class B common stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "imrx:NumberOfVotesPerShare", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_6Dv2gap2qUy2S6CUjLz70A", "decimals": "INF", "lang": null, "name": "imrx:NumberOfVotesPerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Common Stock - Common stock warrant (Details)", "role": "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails", "shortName": "Common Stock - Common stock warrant (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)", "role": "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_8_3_2021_atfZ3VjOmEGor-TZ8PR3vw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40905 - Disclosure - Common Stock - IPO (Details)", "role": "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "shortName": "Common Stock - IPO (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details)", "role": "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)", "role": "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Stock-Based Compensation - Narratives (Details)", "role": "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "shortName": "Stock-Based Compensation - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Stock-Based Compensation - Assumptions (Details)", "role": "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "shortName": "Stock-Based Compensation - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41103 - Disclosure - Stock-Based Compensation - stock option activity (Details)", "role": "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-Based Compensation - stock option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "INF", "lang": null, "name": "imrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41104 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)", "role": "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Share-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_dQH6PYSm8ke4t8B5Xp8bAw", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Income Taxes - Net loss and the effective income tax rate (Details)", "role": "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails", "shortName": "Income Taxes - Net loss and the effective income tax rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Income Taxes - Net deferred tax assets (Details)", "role": "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails", "shortName": "Income Taxes - Net deferred tax assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41203 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "-3", "first": true, "lang": null, "name": "imrx:StockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)", "role": "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals", "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "-3", "first": true, "lang": null, "name": "imrx:StockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41204 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)", "role": "http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized tax benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Commitments and Contingencies - Narratives (Details)", "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails", "shortName": "Commitments and Contingencies - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details)", "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "shortName": "Commitments and Contingencies - Maturities of the lease liabilities due (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg", "decimals": "0", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41303 - Disclosure - Commitments and Contingencies - Lease cost (Details)", "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails", "shortName": "Commitments and Contingencies - Lease cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and Nature of Business", "role": "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness", "shortName": "Organization and Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "imrx-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 61, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "imrx_AccruedContractResearchExpensesCurrent": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, related to contract research due within one year or within the normal operating cycle if longer.", "label": "Accrued Contract Research Expenses, Current", "terseLabel": "Accrued contract research expenses" } } }, "localname": "AccruedContractResearchExpensesCurrent", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_AccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accrued liabilities at the end of the reporting period.", "label": "Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "imrx_AreaOfPropertyUnderLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of property under lease.", "label": "Area of Property Under Lease" } } }, "localname": "AreaOfPropertyUnderLease", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "areaItemType" }, "imrx_BioArkiveIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Bio Arkive Inc.", "label": "BioArkive Inc" } } }, "localname": "BioArkiveIncMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails", "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails", "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "imrx_BusinessCombinationPurchasePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase price payable for the acquisition.", "label": "Business Combination, Purchase Price", "terseLabel": "Market value of acquisition" } } }, "localname": "BusinessCombinationPurchasePrice", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accounts payable, accrued expenses and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable, Accrued Expenses And Other Liabilities", "terseLabel": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets including goowill acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of right of use assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets", "terseLabel": "Right of use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of discount due to lack of marketability for shares issued in business acquisition.", "label": "Business Combination Shares Issued, Discount Due To Marketability, Percentage", "terseLabel": "Shares issued discount due to lack of marketability" } } }, "localname": "BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "percentItemType" }, "imrx_BusinessCombinationSharesIssuedLockInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lock in period for shares issued in acquisition.", "label": "Business Combination Shares Issued, Lock in Period", "terseLabel": "Lock in period for shares issued" } } }, "localname": "BusinessCombinationSharesIssuedLockInPeriod", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "durationItemType" }, "imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for valuation of shares issued in acquisition.", "label": "Business Combination Shares Issued, Share Price, Threshold Trading Days", "terseLabel": "Trading days for share price" } } }, "localname": "BusinessCombinationSharesIssuedSharePriceThresholdTradingDays", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "integerItemType" }, "imrx_CustomerFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to customer 5.", "label": "Customer 5" } } }, "localname": "CustomerFiveMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "imrx_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to customer 4.", "label": "Customer 4" } } }, "localname": "CustomerFourMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "imrx_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to customer 1.", "label": "Customer 1" } } }, "localname": "CustomerOneMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "imrx_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to customer 3.", "label": "Customer 3" } } }, "localname": "CustomerThreeMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "imrx_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to customer 2.", "label": "Customer 2" } } }, "localname": "CustomerTwoMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state research and development tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, State Research And Development , Percent", "terseLabel": "State research and development credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions.", "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Positions", "terseLabel": "Uncertain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositions", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "imrx_GovernmentSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to government securities.", "label": "Government securities" } } }, "localname": "GovernmentSecuritiesMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails", "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "imrx_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lab equipment.", "label": "Lab equipment", "terseLabel": "Lab equipment" } } }, "localname": "LabEquipmentMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "imrx_LeasePayments": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total cash paid towards operating lease payment including short term lease payment.", "label": "Lease Payments", "totalLabel": "Total lease Payment" } } }, "localname": "LeasePayments", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "imrx_LeaseTerminationOnApril302032Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to lease termination on April 30, 2032.", "label": "Lease Termination on April 30, 2032 [Member]" } } }, "localname": "LeaseTerminationOnApril302032Member", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_LeaseTerminationOnDecember312022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to lease termination on December 31, 2022.", "label": "Lease Termination on December 31, 2022 [Member]" } } }, "localname": "LeaseTerminationOnDecember312022Member", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_LeaseTerminationOnMarch312024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to lease termination on March 31, 2024.", "label": "Lease Termination on March 31, 2024 [Member]" } } }, "localname": "LeaseTerminationOnMarch312024Member", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_MarketableSecuritiesAccumulatedUnrealizedGains": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in marketable securities measured at fair value with change in fair value recognized in other comprehensive income .", "label": "Marketable Securities, Accumulated Unrealized Gains", "terseLabel": "Marketable securities unrealized gains" } } }, "localname": "MarketableSecuritiesAccumulatedUnrealizedGains", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income", "label": "Marketable Securities, Accumulated Unrealized Gains, Current", "terseLabel": "Marketable securities unrealized gains, current" } } }, "localname": "MarketableSecuritiesAccumulatedUnrealizedGainsCurrent", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesAccumulatedUnrealizedLosses": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in marketable securities measured at fair value with change in fair value recognized in other comprehensive income.", "label": "Marketable Securities, Accumulated Unrealized Losses", "negatedLabel": "Marketable securities unrealized losses" } } }, "localname": "MarketableSecuritiesAccumulatedUnrealizedLosses", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.", "label": "Marketable Securities, Accumulated Unrealized Losses, Current", "negatedLabel": "Marketable securities unrealized losses, current" } } }, "localname": "MarketableSecuritiesAccumulatedUnrealizedLossesCurrent", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in Non-current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.", "label": "Marketable Securities, Accumulated Unrealized Losses, Non-current", "negatedLabel": "Marketable securities unrealized losses, non-current" } } }, "localname": "MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in marketable securities measured at fair value with change in fair value recognized in other comprehensive income.", "label": "Marketable Securities, Amortized Cost Basis", "totalLabel": "Marketable securities at amortized cost" } } }, "localname": "MarketableSecuritiesAmortizedCostBasis", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesAmortizedCostBasisCurrent": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.", "label": "Marketable Securities, Amortized Cost Basis, Current", "totalLabel": "Marketable securities at amortized cost, current" } } }, "localname": "MarketableSecuritiesAmortizedCostBasisCurrent", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in Non-current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.", "label": "Marketable Securities, Amortized Cost Basis, Non-current", "totalLabel": "Marketable securities at amortized cost, non-current" } } }, "localname": "MarketableSecuritiesAmortizedCostBasisNonCurrent", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Marketable Securities, Current [Abstract]", "terseLabel": "Marketable securities, current" } } }, "localname": "MarketableSecuritiesCurrentAbstract", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "imrx_MarketableSecuritiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of marketable securities.", "label": "Marketable Securities, Fair Value Disclosure", "terseLabel": "Total marketable securities" } } }, "localname": "MarketableSecuritiesFairValueDisclosure", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "imrx_MarketableSecuritiesNonCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Marketable Securities, Non-current [Abstract]", "terseLabel": "Marketable securities, non-current" } } }, "localname": "MarketableSecuritiesNonCurrentAbstract", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "imrx_NumberOfLeasesObligationsAssumed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of lease obligations acquired in business combination.", "label": "Number of Leases Obligations Assumed", "terseLabel": "Number of lease obligations acquired" } } }, "localname": "NumberOfLeasesObligationsAssumed", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "integerItemType" }, "imrx_NumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of tranches.", "label": "Number of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "NumberOfTranches", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" ], "xbrltype": "integerItemType" }, "imrx_NumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of votes per share.", "label": "Number of Votes Per Share", "terseLabel": "Number of votes" } } }, "localname": "NumberOfVotesPerShare", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails" ], "xbrltype": "integerItemType" }, "imrx_OfferingCostPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of offering costs payable by the Company.", "label": "Offering Cost Payable", "terseLabel": "Offering costs" } } }, "localname": "OfferingCostPayable", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "imrx_OfficeLeaseInSanDiegoCalifornia2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to office lease in San Diego, California 2020.", "label": "2020 San Diego Lease" } } }, "localname": "OfficeLeaseInSanDiegoCalifornia2020Member", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to leases office space in Cambridge, Massachusetts, New York.", "label": "Office Space In Cambridge, Massachusetts, New York [Member]" } } }, "localname": "OfficeSpaceInCambridgeMassachusettsNewYorkMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_OperatingLeaseAdditionalInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating Lease, Additional Information [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "OperatingLeaseAdditionalInformationAbstract", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "imrx_PatentCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for patent costs.", "label": "Patent Costs Policy [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "PatentCostsPolicyPolicyTextBlock", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "imrx_PercentageOfAggregateNumberOfSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of aggregate number of shares outstanding.", "label": "Aggregate number of shares outstanding (as a percent)" } } }, "localname": "PercentageOfAggregateNumberOfSharesOutstanding", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "percentItemType" }, "imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity securities to be owned may elect to receive a portion of their converted shares upon conversion.", "label": "Percentage of Equity Securities Owned, To Get Converted Stock", "terseLabel": "Percentage of equity securities to be own" } } }, "localname": "PercentageOfEquitySecuritiesOwnedToGetConvertedStock", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" ], "xbrltype": "percentItemType" }, "imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock excess of amount authorized by the articles of incorporation.", "label": "Proceeds from Issuance of Convertible Preferred Stock Excess of Authorized Amount", "terseLabel": "Proceeds from issuance of shares excess of amount authorized" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_ReclassificationOfLiabilityOfPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The liability of preferred stock reclassified during the period.", "label": "Reclassification of Liability of Preferred Stock", "terseLabel": "Reclassification of liability for Series A preferred stock" } } }, "localname": "ReclassificationOfLiabilityOfPreferredStock", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for research and manufacturing contract costs and accruals.", "label": "Research and Manufacturing Contract Costs and Accruals [Policy Text Block]", "terseLabel": "Research and Manufacturing Contract Costs and Accruals" } } }, "localname": "ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "imrx_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Series B Preferred Stock" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "imrx_SeriesBConvertiblePreferredStockTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to series B preferred stock tranche two.", "label": "Series B Preferred Stock Tranche Two" } } }, "localname": "SeriesBConvertiblePreferredStockTrancheTwoMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" ], "xbrltype": "domainItemType" }, "imrx_SeriesBConvertiblePreferredStocksTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to series B preferred stock tranche one.", "label": "Series B Preferred Stock Tranche One" } } }, "localname": "SeriesBConvertiblePreferredStocksTrancheOneMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" ], "xbrltype": "domainItemType" }, "imrx_SeriesConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Series A Preferred Stock" } } }, "localname": "SeriesConvertiblePreferredStockMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares repurchased during the period under share based payment award.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Repurchased", "negatedLabel": "Repurchased (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of shares repurchased during the period under share based payment award.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options, Repurchased In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share Repurchased (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "imrx_StockIncentivePlan2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Stock incentive plan 2015.", "label": "Incentive Plan" } } }, "localname": "StockIncentivePlan2015Member", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_StockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of stock issuance costs.", "label": "Stock Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "StockIssuanceCosts", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals" ], "xbrltype": "monetaryItemType" }, "imrx_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share warrants exercised during the current period.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "imrx_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Issuance of common stock upon exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "imrx_StorageSpaceInSomervilleMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to leases storage space for its electronic data equipment in Somerville, Massachusetts.", "label": "Storage Space In Somerville, Massachusetts [Member]" } } }, "localname": "StorageSpaceInSomervilleMassachusettsMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in t tax credit carryforward from application of the Coronavirus Aid, Relief, and Economic Security (CARES) Act.", "label": "Tax Credit Carryforward, Increase (Decrease), CARES Act" } } }, "localname": "TaxCreditCarryforwardIncreaseDecreaseCaresAct", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "imrx_TemporaryEquityContingentlyIssuableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of convertible preferred shares does not meet the definition of a freestanding financial instrument and are issuable subject to the company meeting certain development milestones and other conditions as specified.", "label": "Temporary Equity, Contingently Issuable Shares", "terseLabel": "Number of shares not meet the definition of a freestanding financial instrument" } } }, "localname": "TemporaryEquityContingentlyIssuableShares", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" ], "xbrltype": "sharesItemType" }, "imrx_TemporaryEquityConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of conversion price of temporary equity.", "label": "Temporary Equity, Conversion Price", "terseLabel": "Convertible preferred stock, conversion price" } } }, "localname": "TemporaryEquityConversionPrice", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" ], "xbrltype": "perShareItemType" }, "imrx_TemporaryEquityDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Disclosure [Text Block]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "TemporaryEquityDisclosureTextBlock", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "imrx_TemporaryEquityDueToExcessAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of liability recognized due to shares issued in excess of amount authorized by the articles of incorporation.", "label": "Temporary Equity, Due to Excess Authorized Amount", "terseLabel": "Convertible preferred stock liability" } } }, "localname": "TemporaryEquityDueToExcessAuthorizedAmount", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" ], "xbrltype": "monetaryItemType" }, "imrx_TemporaryEquityIssuancePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance price of temporary equity.", "label": "Temporary Equity, Issuance Price", "terseLabel": "Convertible preferred stock, issuance price (in dollars per share)" } } }, "localname": "TemporaryEquityIssuancePrice", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" ], "xbrltype": "perShareItemType" }, "imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders excess of authorized by the articles of incorporation.", "label": "Temporary Equity, Number of Shares Excess of Authorized", "terseLabel": "Number of shares excess of authorized" } } }, "localname": "TemporaryEquityNumberOfSharesExcessOfAuthorized", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" ], "xbrltype": "sharesItemType" }, "imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of convertible preferred stock, net of issuance costs (in shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 2021 Employee Stock Purchase Plan.", "label": "2021 ESPP" } } }, "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_TwoThousandTwentyOneIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 2021 Incentive Award Plan.", "label": "2021 Plan" } } }, "localname": "TwoThousandTwentyOneIncentiveAwardPlanMember", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "imrx_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised.", "label": "Warrants Exercised", "terseLabel": "Warrant exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" ], "xbrltype": "sharesItemType" }, "imrx_WarrantsIssuedInLieuOfCashPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued to board of director's in lieu of cash payments.", "label": "Warrants Issued in Lieu of Cash Payment", "terseLabel": "Warrants in lieu of cash payment" } } }, "localname": "WarrantsIssuedInLieuOfCashPayment", "nsuri": "http://immuneering.com/20211231", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" ], "xbrltype": "sharesItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r169", "r280", "r281", "r525" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r232", "r245", "r294", "r296", "r449", "r450", "r451", "r452", "r453", "r454", "r473", "r524", "r526", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r232", "r245", "r294", "r296", "r449", "r450", "r451", "r452", "r453", "r454", "r473", "r524", "r526", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r169", "r280", "r281", "r525" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r232", "r245", "r283", "r294", "r296", "r449", "r450", "r451", "r452", "r453", "r454", "r473", "r524", "r526", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r232", "r245", "r283", "r294", "r296", "r449", "r450", "r451", "r452", "r453", "r454", "r473", "r524", "r526", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts payable or accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34", "r442" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r18", "r170", "r171" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": { "auth_ref": [ "r495", "r517" ], "calculation": { "http://immuneering.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.", "label": "Accrued Employee Benefits", "terseLabel": "Accrued employee expenses" } } }, "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://immuneering.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureAccruedExpensesDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r495", "r517" ], "calculation": { "http://immuneering.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued Professional Fees", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r31", "r207" ], "calculation": { "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r47", "r48", "r49", "r512", "r531", "r532" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r46", "r49", "r57", "r58", "r59", "r100", "r101", "r102", "r386", "r527", "r528", "r562" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted Average Life, technology" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r323", "r442" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r100", "r101", "r102", "r320", "r321", "r322", "r393" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r297", "r298", "r326", "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustment to reconcile to net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r298", "r316", "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.", "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total shares of common stock equivalents" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r93", "r150", "r159", "r165", "r183", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r384", "r387", "r410", "r440", "r442", "r492", "r511" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r45", "r93", "r183", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r384", "r387", "r410", "r440", "r442" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r396" ], "calculation": { "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total cash equivalents and marketable securities" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r293", "r295" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails", "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails", "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r293", "r295", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails", "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails", "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails", "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business combination non cash" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r379", "r380", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination." } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r377" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "terseLabel": "Lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r377" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r377" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other currents assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r377" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails", "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]", "terseLabel": "Intangible asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r376", "r377" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Technology" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r377" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other long term assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r376", "r377" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r377" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Assets Acquired and Liabilities Assumed at Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combination" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": { "auth_ref": [], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.", "label": "Cash Acquired in Excess of Payments to Acquire Business", "terseLabel": "Cash acquired in business combination" } } }, "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r27", "r83" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r78", "r83", "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r78", "r411" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r91", "r93", "r115", "r116", "r117", "r119", "r121", "r129", "r130", "r131", "r183", "r219", "r224", "r225", "r226", "r230", "r231", "r243", "r244", "r248", "r252", "r410", "r551" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DocumentDocumentAndEntityInformation", "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockIpoDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued for common shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commerical paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails", "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r39", "r216", "r496", "r516" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 13)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r213", "r214", "r215", "r217", "r536" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DocumentDocumentAndEntityInformation", "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Class B Common Stock" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DocumentDocumentAndEntityInformation", "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Shares reserved for future issuance", "terseLabel": "Shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r100", "r101", "r393" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value per share (in dollars per share)", "terseLabel": "Common stock, par value per share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r442" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]", "terseLabel": "Components and tax effects of each type of item that gave rise to the net deferred tax assets" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r52", "r54", "r55", "r65", "r501", "r520" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r139", "r140", "r169", "r407", "r408", "r535" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r139", "r140", "r169", "r407", "r408", "r533", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r139", "r140", "r169", "r407", "r408", "r533", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r134", "r509" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r139", "r140", "r169", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r137", "r139", "r140", "r141", "r407", "r409", "r535" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r139", "r140", "r169", "r407", "r408", "r535" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r85", "r86", "r87" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "verboseLabel": "Class A common stock issued for business combination" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r15", "r16", "r255", "r261", "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Shares issued upon conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r70", "r93", "r183", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r410" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of service" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r138", "r169" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r85", "r87" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Number of shares issued upon conversion of debt" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r81", "r94", "r356", "r363", "r364", "r365" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r12", "r13", "r346", "r493", "r510" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r44", "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r347" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r349" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred taxes" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r349" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r354", "r355" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "NOL carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r352", "r354", "r355" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "R&D credit carryforward" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r354", "r355" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": { "auth_ref": [ "r354", "r355" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.", "label": "Deferred Tax Assets, Unrealized Currency Losses", "terseLabel": "Unrealized losses" } } }, "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r348" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "terseLabel": "Net deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "negatedLabel": "Prepaid expenses deducted for tax" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r354", "r355" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Tax depreciation in excess of book" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense": { "auth_ref": [ "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the valuation allowance recorded in a business combination against deductible temporary differences for which related tax benefits will be recorded as a reduction of the acquired entity's income tax expense (after such benefits are first being applied to reduce goodwill and then other noncurrent intangible assets to zero).", "label": "Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Income Tax Expense" } } }, "localname": "DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r81", "r205" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r268", "r508" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "terseLabel": "Dividend declared" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r34", "r97", "r222", "r224", "r225", "r229", "r230", "r231", "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Amount owned to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r66", "r105", "r106", "r107", "r108", "r109", "r113", "r115", "r119", "r120", "r121", "r125", "r126", "r394", "r395", "r502", "r521" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic", "verboseLabel": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Denominator - basic and diluted:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r66", "r105", "r106", "r107", "r108", "r109", "r115", "r119", "r120", "r121", "r125", "r126", "r394", "r395", "r502", "r521" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted", "verboseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r122", "r123", "r124", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r337" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r95", "r337", "r366" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r337", "r366" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r337", "r366" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r337", "r366" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r337", "r366" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State tax, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r337", "r366" ], "calculation": { "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "terseLabel": "Federal research and development credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Compensation expense recognized over a weighted-average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Compensation expense remaining to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Common stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r57", "r58", "r59", "r100", "r101", "r102", "r104", "r110", "r112", "r128", "r184", "r260", "r268", "r320", "r321", "r322", "r359", "r360", "r393", "r412", "r413", "r414", "r415", "r416", "r418", "r527", "r528", "r529", "r562" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r396", "r397", "r398", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of cash equivalents and marketable securities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r396", "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r233", "r236", "r237", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r292", "r397", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r396", "r397", "r399", "r400", "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r233", "r284", "r285", "r290", "r292", "r397", "r446" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r233", "r236", "r237", "r284", "r285", "r290", "r292", "r397", "r447" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Financial liabilities classified as Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r233", "r236", "r237", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r292", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r402", "r404" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r177", "r178", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r235", "r258", "r392", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r551", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r202", "r476" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible asset" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r195", "r197", "r442", "r491" ], "calculation": { "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill", "weight": 1.0 }, "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r81", "r196", "r198", "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairments" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r69", "r93", "r150", "r158", "r161", "r164", "r166", "r183", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r410" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r81", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Impairment on available-for-sale marketable securities" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r204", "r210" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r32", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r62", "r150", "r158", "r161", "r164", "r166", "r489", "r498", "r503", "r522" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r209", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r95", "r338", "r344", "r351", "r361", "r367", "r369", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r111", "r112", "r149", "r336", "r362", "r368", "r523" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r56", "r334", "r335", "r344", "r345", "r350", "r357" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r80" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r80" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "(Increase) decrease in:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r80", "r431" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Liabilities [Abstract]", "terseLabel": "Increase (decrease) in:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r80" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r80" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r72", "r148" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r73" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedLabel": "Net amortization of premium (accretion of discount) on marketable securities" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperatingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Income, Nonoperating [Abstract]", "terseLabel": "Other income (expense)" } } }, "localname": "InvestmentIncomeNonoperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r179", "r490", "r506", "r534", "r558" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r434", "r436" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease costs:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Quantitative information regarding the Company's leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasePracticalExpedientsPackage": { "auth_ref": [ "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.", "label": "Lease, Practical Expedients, Package [true false]", "terseLabel": "Lease, practical expedients" } } }, "localname": "LeasePracticalExpedientsPackage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds and Leasehold Improvements [Member]" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of the lease liabilities due" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r435" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r435" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r435" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022", "verboseLabel": "Minimum lease payment due 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r435" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r435" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r435" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r435" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r435" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r93", "r160", "r183", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r385", "r387", "r388", "r410", "r440", "r441" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r93", "r183", "r410", "r442", "r494", "r514" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r38", "r93", "r183", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r385", "r387", "r388", "r410", "r440", "r441", "r442" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r497" ], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities.", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails", "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r5", "r36" ], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisCurrent", "weight": 1.0 }, "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "verboseLabel": "Marketable securities, current" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent", "weight": 1.0 }, "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Marketable securities, non-current", "verboseLabel": "Marketable securities, non-current" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Realized Gain (Loss)", "terseLabel": "Realized gains or losses on marketable securities" } } }, "localname": "MarketableSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Schedule of marketable securities" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r68" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized losses from marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money market" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r78", "r79", "r82" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r50", "r53", "r59", "r63", "r82", "r93", "r103", "r105", "r106", "r107", "r108", "r111", "r112", "r118", "r150", "r158", "r161", "r164", "r166", "r183", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r395", "r410", "r499", "r518" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r150", "r158", "r161", "r164", "r166" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r428", "r436" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r422" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r422" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liabilities, current", "verboseLabel": "Current portion lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r422" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, non-current", "verboseLabel": "Lease liability, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r423", "r431" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": { "order": 1.0, "parentTag": "imrx_LeasePayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r421" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets, net", "verboseLabel": "Right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r81" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Right-of-use asset amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r433", "r436" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r432", "r436" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r389" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r495", "r517" ], "calculation": { "http://immuneering.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r51", "r54", "r57", "r58", "r60", "r64", "r260", "r412", "r417", "r418", "r500", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r77" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of initial public offering costs", "terseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r175" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r75" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r299", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Dividend, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r243" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r243" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding", "verboseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r442" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 and 0 shares authorized at December 31, 2021 and December 31, 2020, respectively; No shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r25", "r26" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaids and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from Stock issued" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockIpoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Aggregate net proceeds", "verboseLabel": "Proceeds from initial public offering of common stock, net of commissions and underwriting" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r76" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from the issuance of preferred stock, net of issuance costs", "verboseLabel": "Gross proceeds from issuance of convertible stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r76", "r319" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r76" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r31", "r208" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails", "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r211", "r537", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r30", "r206" ], "calculation": { "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r208", "r442", "r507", "r515" ], "calculation": { "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r29", "r208", "r537", "r538" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r208" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r206" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails", "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails", "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r291", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r437", "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Amount of related party expenses" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r291", "r437", "r439", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r329", "r474", "r542" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r268", "r323", "r442", "r513", "r530", "r532" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r100", "r101", "r102", "r104", "r110", "r112", "r184", "r320", "r321", "r322", "r359", "r360", "r393", "r527", "r529" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r146", "r147", "r157", "r162", "r163", "r167", "r168", "r169", "r279", "r280", "r475" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r90", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r61", "r93", "r146", "r147", "r157", "r162", "r163", "r167", "r168", "r169", "r183", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r410", "r503" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r139", "r169" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities that have been excluded from the calculation of diluted net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails", "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of recognized share-based compensation expense recognized" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of net deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of federal statutory rate to the net loss and the effective income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r31", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed at Fair Value" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r299", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r302", "r306", "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions in its application of the Black-Scholes option pricing model for grants" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r40", "r91", "r129", "r130", "r238", "r240", "r242", "r243", "r244", "r245", "r246", "r248", "r252", "r258", "r261", "r262", "r263", "r265", "r266", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockIpoDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r15", "r16", "r17", "r239", "r240", "r242", "r261", "r262", "r263", "r265", "r266", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of common stock for conversion of preferred stock, exercise of warrants and exercise of stock options" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.", "label": "Schedule of Subsidiary or Equity Method Investee [Table]" } } }, "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r343", "r358" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of unrecognized tax benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r137", "r139", "r140", "r141", "r407", "r409" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of concentration of credit risk" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r151", "r152", "r153", "r154", "r155", "r156", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r80" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Weighted-average risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Weighted-average risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Shares issued", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date weighted average fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r304", "r318" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end (in shares)", "periodStartLabel": "Outstanding at the beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price per Share Outstanding at the end (in dollars per share)", "periodStartLabel": "Weighted Average Exercise Price per Share Outstanding at the beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested and exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share Vested and Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share Vested and Expected to Vest exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r299", "r301" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r312", "r324" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Vested and exercisable (in Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest (in Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r429", "r436" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeasePayments": { "auth_ref": [ "r424" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": { "order": 2.0, "parentTag": "imrx_LeasePayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability.", "label": "Short-term Lease Payments", "terseLabel": "Operating cash flows from short-term leases" } } }, "localname": "ShortTermLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r89", "r99" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r91", "r93", "r115", "r116", "r117", "r119", "r121", "r129", "r130", "r131", "r183", "r219", "r224", "r225", "r226", "r230", "r231", "r243", "r244", "r248", "r252", "r260", "r410", "r551" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://immuneering.com/role/DocumentDocumentAndEntityInformation", "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r43", "r57", "r58", "r59", "r100", "r101", "r102", "r104", "r110", "r112", "r128", "r184", "r260", "r268", "r320", "r321", "r322", "r359", "r360", "r393", "r412", "r413", "r414", "r415", "r416", "r418", "r527", "r528", "r529", "r562" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation", "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r100", "r101", "r102", "r128", "r475" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DocumentDocumentAndEntityInformation", "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r85", "r86", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Conversion of convertible Series A and B preferred stock into common stock" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r16", "r17", "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock for acquisition, shares", "verboseLabel": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r42", "r234", "r260", "r261", "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of Preferred Stock into common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r260", "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued", "verboseLabel": "Issuance of common stock upon initial public offering, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r260", "r268", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r43", "r260", "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock for acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r260", "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of Preferred Stock into common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r260", "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r43", "r260", "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r22", "r23", "r93", "r173", "r183", "r410", "r442" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock." } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r92", "r244", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r259", "r268", "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock split, ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Stock Split" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary or Equity Method Investee [Line Items]", "terseLabel": "Organization and Nature of Business" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of noncash investing and financing information :" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r331", "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "terseLabel": "Uncertain tax positions" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]", "terseLabel": "Convertible preferred stock:" } } }, "localname": "TemporaryEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r8", "r239" ], "lang": { "en-us": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r219", "r224", "r225", "r226", "r230", "r231" ], "calculation": { "http://immuneering.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Convertible preferred stock" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedBalanceSheets", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r8", "r239" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Convertible preferred stock, par value per share (in dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Convertible preferred stock, authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Convertible preferred stock, issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Convertible preferred stock, outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockIpoDetails", "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails", "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of convertible preferred stock, net of issuance costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.", "label": "Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r177", "r178", "r180", "r181", "r182", "r235", "r258", "r392", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r551", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r98", "r284", "r292", "r504" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U.S. Treasuries" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails", "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r333", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase due to current year tax provision" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r132", "r133", "r135", "r136", "r142", "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r430", "r436" ], "calculation": { "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Common stock warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockDetails", "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Term of warrant" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r114", "r121" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r113", "r121" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "310", "URI": "http://asc.fasb.org/topic&trid=2196771" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28511-109314" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28446-109314" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "740", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123403335&loc=d3e9901-128506" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r506": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r534": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r543": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r544": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r545": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r546": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r547": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r548": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r549": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r550": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r551": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r552": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r553": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r554": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r555": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r556": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r557": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r558": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r559": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r560": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r561": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" } }, "version": "2.1" } ZIP 114 0001558370-22-003208-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-003208-xbrl.zip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�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Ú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ϙ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end

++8)$5QN;T#T+F)>646)GJ:U>@'PT; M&DBBIWKA# '=!0M)78F]Y38M8B!##1$ V#BJ_)'EY'P@VQ M:*C:YNJ$D(E9$ GHE%0-:299I-AO1T"KR&2H(/KB%(M]4S6S# &8K8OO?48 M.;3?^U>"[ZWXAQ,CL\BFD2S?WOD:P$$(!AU7 I.E&8X!;>;JF,^*VA'W)6L5U?&^D=S?CP!@'0 M(MMP,S+9MV!]Q2O:+]?$SW;$.^L*V:,WM"Z*%D>-PPE+A(= IPOG>"C19BX> M S",Z-+-/'M&*J1H*I(>1\,/SZ_[L>D[YF- (Z0P9[B8W[6AA;:5/?6 M?\J!%3HJ:-LT$X?_WPY5NW8\_[*YFN"9[M(H>'?AL>_UB^6!0)\UID MO[+G#\F>/T(B,8JES[_)MRF^R%R^GPH_.9>?<8PF'C3/ +.+_J9>.5*]E/8A MI]/E<_7C=7V4D,)%0TK%O@G7X97T.N8&]X!+%LS.B-H(K0!#KIN^::Z!"]^V MD4Q/>?X:,I6HF*_I#W;4*PQ?)W'<[$\+9RT=?O ]O?WAGL//'/1\$6BM?[UN MIO/W>?+/J"#C-&]#=>2\")*.J0@O'[ZV^]L=L9^MH9\=$_T5T9[O7+2^IJ?? MI/@1K(W5E9$@@&Y#T#@3W+*^PJ2=IV@G$29.[&H[F%U1'"IYHGM?NS_5PDXL MF:V)@)Q&]HY+(-U>E-T%Z8;@ 77Y/+-\E!XT?A\\_;D+K(F&)Q'NGPBJSF; MG^W2$C*36D 9+R@4U>')>09=64)I30'H_G\.RIU":WQ_)I0XHW M+KIL:P%I0CW;BLR-]\==8QFP(UN3P->6]]2F-SRR(YFPI:--Z\AD&U MD_,<#4Y(O*8Z4DJ"JFM#=F+NL$3?L\(6M'JZ-U;?:&!9WQ@.7#)Z5/+\(-^X M_W/6P[/2.[$!>1@R-V %8W-7]RQYY[U-,S56T*7>T>KW/^Q7UX^_KMVUX:%= M"4LEEE[:L_\3+HJXAO8"A':JHP8:&GG/C8$U M)% N65^T/]G!P5.DT'1@1@-.O-+#7G4DY5=F5AIY47W2-I)1;O/\2@QA'E;L MFNZ97695_> 64V,02_+F<-OEN#RA5=%F[,)A@5AKPB65%)WZR';6&.KFAP&5 M":1LH]92^IQW!AW,+.H;TIAB)%(3J1ZHU!61RILO3]CRZC^1YV&,(GCDO"6/ M%:K_259QIX@X-N&]K=?16QX'*15:\ZJ)\2OEJZZ7->/\"X<#(N/AI>K554RC M9H_W[S><4GGL\H$;=Q,NEIWJ+O$/:(_VK02U)/._3(A36A5;JG]P69O30BMW MG]XW" D#"?\*!N:@!V#?9&AFNG5S2H_D,N'[!T NED6F+=; M\4+O3"-(H=6X6K?YZGG/ %\K!L#]\XP#YH*VW_UI[OB:/V2_50B4 MOJ/!1PR_L,!1SJN,)'^[!HG[L4D'N6WA=[OR7Y;#*1X@0[Z3I1.PO+/<<^O/^M%J)C\XY-B;8O_06L$W?[(7O9MU M2H0,D^";"(!-K.#ZXJ;>:I5.!LC,IG5OE79%]I Y%0E5G.&:2'[M$Y4#UF6W M?V?SG2\TNS&DPBIMT#CH;VR^,SZ0]\0W&Q#-;+[P-S;BWSFOQWVA>9OF*^U# M^CN;WQF/,LV((M5[YC.>B41 OSW42I4=KJ7=EX-"?QNW_U+X%P10L8\ 3O;/ M%:%%)B.PW.^*M*D9S1^*@9$#QR('-E]# 'MKWT>^J<#>".\:1H*\H7--_,7A M_@S?-<&1]@1-0$$PJ"S2<-%(B#V0_=UPB^R%._#$Y?3&YR"O]F6L\H.2J]DV M"P&<#-V'1>GW[KF56"_6,WF3X&I[FDH3Z^B5_]L4SG^5_O],Z(]G0K]&7^__ M#DK_6GV56!5=\V=[X'/G"O^OE%59?\,DO_B]X=_-@Y3%[1><4.P\*OX6)M$0 MD_\!4$L#!!0 ( -(T:E3T!M$+&30 (1$ 8 :6UR>"TR,#(Q,3(S M,7@Q,&LP,C@N:G!GY;L'5%1;UBZZR9(%R9(4E"09)%,@DD0D28Z*Q"+G()2" MB"!!0. DD4R*#F79)"<'AX^_B4" M(@IB(D)"(EKR*Z04#'1,C QT]/3,K#QLS-=OL=#3LXMPW.+C%Q(28F(3DQ(5 MD.01%!+X]B$8^/CX1(1$-,3$- +7Z*\)_,<7ZC- =@E# [,7"^,Z@$F&@46& M@6H!F-#SQ,'X]0)^OS PL;!QX5UWIA!X'I5^B>7.IT9*S8$]5L''+@'X!%34-+1T-VZR ML7-P"@G?%A$5$Y>[*Z^@J*1\3^NAMHZNGKZ!^1,+2RMK&UM7-W\C8V+_R4A,2/S?=:'[)S'1\#Y)8H[4>F?&O%9!#7W*!^[#!!0 ML0HMW(!]6]JO*_MK"POXKU;VQ\+^OJY)@ @+ VT\+#( !)PLRF!' PS*15I- MJ61":C0;NA7BUM7Z]KK.@M>?7U^[&D_D(N[>KJ&!4!L+#D9@Y7075OC&GM^2 MG-]QDF69YEF"Z[[V\FRMH7J]Z(@_8^,\(W?L)=V>6[:>5X(GQL/7+FIEWBNJ MG4;ZP3HC%&#_*U*D!^]B!*4VS9FA &V+8VC9Z8S/TUJ/\Z,>Y7E'*DB3U<) MOM_K+4B#=5VQ2/?7"-?GFU]E&+@I=$F74D,FU0(^5Q+P'@GH7I"(W7ZKU6O\ MT0/6;\[&$N8JP]!*V0//;AV @U5+8^V6ZQL:8LW*2L,#$HQK':3P&B1"K8+J M3":/CM.SYKY&V_@TI.CVE7G?3>,BRL>CP0OS-R\$W XUY &*OR!.#1SPPG0O M10-[3N201K2[_)LRLG0CQG?Q>(?YTF3PA#2OWF-#+M)R6;>0.GFWT _R.[K@ MR\[M#!"#14E%\*)*7WBE!MQ4O>(3E.XQ5=R"K!:C+LM;!]>(F3Q3$L5"&R9: M;C/8BSU;\?+CE"ZPJUVCIM#5\8!TZAP%VO:U<=HM-PUY3 +VC&?_5K@28'.O MH0L$>V<;T$?GEE9Z3XM%NC;P>SU2U>XIPOS[7D7!U;;$YFR.4\N]Z\41M;?/ MW7N^:4%/^A9,%1KD-I[MQ;BQL?K(T09\%1BZ-X.K)KOAZ[O'CN43NB8ILLBM MI5-;5SJ"$/'.G)[:-C-NZ>]X3UK+CJ%,NTRT=("5F889ROY/A8CI,OQ><\M8 MC7$K8DS"[6L=?#[\K2++$[\]6;;LQ^*)22VS5S_"+(-Y8G(2=/!I#9_>Q;M# M(HL=(%7C=K."/>W2K>V@Y/#ZG#CEN_P%_D_>4S\ELO@(=+9+$J2$L@,9_UZP MN@R1*DD7*#B$O<1\16#\I2MS5%8IW=HBI(^)R41(L5I>D' M'T!OUAZKP1.422SE7)W;/<-Y M MTR6 [>\V9.HKO#J_6\*D.W#NUO$TNH!7>6/?=H9UR<4G =CE8S"#;L=YLC M^YJM-E+8,&"K)Q;IR\:2S2F;IH@#P[H,+UY8F7[/7>89%K'EA"427PF*RBWC MG4-XPH0&^*S3AQ9#[Y!B=(0]/YH?<\ZW-K"LS:I(RIW(ZDEOWYECP79CCI ] MP1.F"EPH9&JF<@1GZF45/)A*Q2[E/[%D36V!R="5_0>!H97N56M@KX/R+GW.6ENCS\7%:XE6 M;/N?.\O/0BH(WT0!K$C0&3(2!VB\ 1QMB ML2[6DQKO'<I:(A052A/6"4H=J&=? M(3([R^@]ACR%^G\GBJPP^5L:M<\.^!\RS3)?03S/_1E\GA]-/SU'.DQIA-+% #E1E+X%8%V>E" OR&"'8/J;*0HO&1:P1*P$''M MW1U;<9 *OSQG,/T%)N=,'Q&,S67U$11)!$U^(I?Y]2-X'\Q>:6K[QFR%B:DU M9?:%,[+C)%-EX'#F.G)U?\*A;BHP?CK"E]1176W1+W>=6_6,D[2\_6("NML% M"6("1YZ70N;BT @H]]>FVP:]75H8-, MMRTGDT8$P_:[*?S?/QR)7R0]Q>&]\#.$K!\6WOL'?A%A$S=+%7M0KO 5VU% MPZ\>'UG_BUMD#9_PV92\+WTB<4E-;/-T MR-YMF[.7=B%0)+Q*1Z1E'1LI;S$QT^QV7(668;>5!Z"K8PN,B_V_52- MOA_\6>'Q" I(H68Z61_XXVXDD1VSD"VE_\ MPZ_;D@D/>ZS<4&;5L2"E!8+:O!'R!GG[D_B.A3N5;Q[IJE=MUC(MR%#])6KV MNW0/0Y8Y,E' 6#,*6(\O%/^Y_4-GSDMI')Z2+0&L!,!A&Z0MV=G=T88ZR552 MO?V=8U13V(7J0^3L /H];O/V"TDV>#]N$,7XLG*F_G5WMT>Q%F+8/H$/_ASE MT^J?%]E9/545U365(1O;KA-1_ 7[T<%9 7J:EV M;VW;GQFN<'RP]09\K,HOBI%J;;Y.,\_TN1]/15[6V]LQ>T+-VY.SV1&3EC6J MAO-Y-/B:I/E[X;(#P>FVO1(6PT[P]6Z5-3.]CNFIC\[/Q\_H@/(?G.]SPW"A MNR.)HK?5-:_$'9S3M_EUA-,J^693DVTM!-8.M5&IC&@ SD[ MTZNY>98Y_LM@N:]APJ=4]MMC+&,VC1?L6 Y_8VT]BL@[B:"+IR!DB,]0P0^M M'^R';:%+8X'M&]I1$@J"*Y6;SF2?58%>^$C9Z6C'(\)\BB]< T^E %N PHR( M5%;E/T=X##F#JI*R0R[8^ M#V)MS+U&!Z=%:U7J^4=9+@5H8O!4,8E&SE46>KBOFN#[V6YJ#A7M,L,$FSD% MZWM&#BTG]H-7^4EDV#)0 #[+X#,I+-U$%?OK&]8%=,B'86_+C2QUMNI@HU5Z MAQ<*5N5C#F7GI\)*PI<<'"F:KKC=$3,G:ZJ-T)8<]%Y>3LFF7#]4QZ.D#/JR M[JD;K^QL.^8S[&GCT(UQ5U ACX9$C+ JHC6_O !Z&=+! =GZ6;:B[()[HUD?(@"6D#C&=T\X8F?: M4,3):^0YQ7*3BO0LJ@[[E$R(H$(H&YQ'L2 M5%L;JU4)XAUC'%&1&UF 4;\J=B ?= ;;..)-S.YTM'1RT;X(4LEQK%T)C ) M)DD+IZQ.-7FZZ-S(C5D>1@CJHZ[/75)L56S&D_1@&5DYMO MK+HF+O*]8M9VK2QGDTM3ZGS4\8Q_5RVN)1KIKJDR(1N84,#=>IO1G]K]/]A! M7\=TGW\#>M1+NGR4_UWC$"/_OZ .V-11TUW67VV<*@[>V<5F'F >S+@(MC,H M&NSS$AO#F>1AQ,DM+'?),3?B/_KE4=V1U3JO)*I:P^-M T]PM6_=NF)*12=4 M4P1EC.'L9$Q@/7NJ3#_PUJQK%5._E/07#+-Z3Q>9-%*SC!@6)Y.U1 .@"X:' M"(A'-A1"#WUTLBS@@4A9M$>8ZLR=27%I_OO:\ILTPE(1H6,0M*?TMSKJD(:A M@&6=VK-LY$NN>Z"6R-QDTX6N_OU$]HSZTK9?^^>+(%[8@Z9C4(!%OK:!X^FE M24@U&[)+>4M(/R.4X]4W3^"JA[LC,]51@!\HJHB@=B[8=$.8]&3HE&ZM%8*? MM )C9@-92]F/@KX*5^06+6KRXH$LX'/NY2$RAIK5&JM8ND=C:O'OW2]Q(I* MJ0O]#/?V6P ;WSEX,/AXR+YHC<#9YM;V&@Z1M_Y#>V;Z^2N-QT6I;:96C)2U M(H)&3>D9_/4%CU8.[KY>"=)J)C]7(,43+7)LJB#?:&"U5]&$CD1DF9>OE->7 M1DQ?[KQ^]_,U%D!HZ:486VH-.U9_SG^42'-FO3P^78\6*1" M&G$>^@.F_B%HT_!S9Y64\+&P%AJ?[D2(YA\,>:D MU\D=GC=CQ$/0-'CJ>TI[]14SO17M[M?1N@HFTNY=HML&U&'IU:^OT2WID+-,M'$OQLFHW&*U>)#34/]STLK_)>S4H0N-Z3;J'F!W1S35)6RD^QWE8KH-?(4DGO&11D9;SW9H^?U?%L,Y M.=EOQ&G?-/1X$?C94BNU8[C\SJ\!L.O/ ,D9!LVI+8,#BDX6QL["Y2X.D0K5 M,-,F2[CI8F9E1BA7AY39SUL5R; P3UUQV;+(>S70\J0+R'C1"\'V\MBW'YQ3 M9/N8+US;00OV-[T0B@Q;=(XAA6FT!UDCY9+!IS08*[CV<+:P>9)Z!:X"V.U\ MZ9"%S<([LZS12A4 /;\VT4;6./LM;=E;3H+/P"R-TC>'$?+'H\/VURO)7KU_ MI1"1I:/:G7->4R5[E5ST8CZ-6(W^L;[AX0$>]5FM0DU[+2[ M<&T;Q,-K(^\KSPG+WXIH3*AZKF*46!$\M-_075-7RW>3'-DELU$KM(X95[S> M,EAFY4OTO'P$FF5A!'^\8V_@4JD>+K!XQG5JSOYT3H"O2MTU_'U;]EC.[F=L MKJ4.S;EM$?&G X9]=F,ZMUAU1"X5Y(=!",F_/E-3V."3O__4V/GX>3;D"=-V M#/_KK53KJ_PKITF(;K>I]OMKD3Y]*. %^8XO>\&.X\*^G3W=:&-FV Y0(UZ6 M(,KJK<0G?K#9&K,0;GJN!$ZU+4&.7Z&>^(2(Y.W:/SZ:25WL*Z; \&?0(3:# M^YP19?3="F-Q$>$@4Z*A][DL[R;(GP?DBK @HXZN1*:74S$4+GW! 4L!FM*V6L#M=X47F%XG%<:/ZE M^]IZ '(0G9$]>)=''/)DT>E&HN_D,5)5B5 ODZ),ZR-^*+^*/!56^1YPZMB0 M>P$N+^+Z#'(YWT@=K358S84)6F]1:,C+ROZ%!(,CI:M&5Y3$'5536TYN?C(: M_4N6T65_'09QL_,K)O;SM5,V1YNT\>HP^@##D$T:)E(2JIO-/F%OJ*>,J3$_%UJ%:)!J4TW%#CT#DZX>H?5 M>J;_6==)?(6";UCH@<8'@TABHZ_1&_Q3C6A2=94WZ6FA>(?]UO);I-U@S.;\=+ MLJ'J<""S4IM52)M_\HY1Z4NYIWM,D<*;]8%V_3OE?VJZB M#%P"G5(6(7-10'KH; $3+0KH*/0\4KL@TGD+"6'2$HO"&G(^UJ%_<.[ MLPAQ%*"1 VE([1C#,=YM+CZB"S[_B@AW782^Z-F#MBHZRE/HOO%I_,D&>-Q+ M2:)S2H:GO$>^KG:-Y%*W3[9FP1WKH?2';8MB4A@W2/#9IOR0F?W=<*5IK%9.UA3D+:*BK7#PY5GD^;T M%5O;2V-2^6P+^\:*V<:*H)?-W.:;1C&&!_XG4,G MY* 7K*6( HJ#4< KX'[S_]P^[7;ZNSWODL:#EHVAYPMQ_;I/I2F>,3=%,J> M=UE;";3,YHW<,NW,FWD8B+SCF;K3BDA\B5/S&U7XA:'XF?_*R0BHT*.\U0MO MQ]1/ZVP,;%0N?=.> 9W)<]C_2EW*U2O)G^65J@+#*;$=I%D0<94P4LYQ/'\$ M=L>ADJZ>(WM+NJ#^V3EQ5UAT=V5H155@\:IO+$+FGE] M*JP79YVF>J 4]<&Y>ASC;-1-//S-L,/XK.&S+D;21+'Y\_[/PQE1#$]DUAMC M7\KB,8<:?',:,X\&C//*N8?(\LDQRGFF:K\CM4WC0I=A>$*9!WH&:6E_X:0 M*+Z]YSV:I/_)7F>J-<.%IN_&-.PBQJ.M5\.'Z) A@JM_IY"Y+N1Q59C2Z^OW M,*1H:<13&]\R-=5!/FMZ>=?IVQRKDJI6#..T=)#/VMP?_721K$=-I"3*S:HZ MM-HF3@<%^T*15T2:4 E0SV:05N5YAEV#LFNU;1=$U?#U3@N6!YO'R]#X;] O_%^AGZ:9#X'!W_R%X_DD'&]G M[C>$TWWFO_T;['5I+5H.C*-=,N#GTN5/:?5)OYJKQ:W;8XXV@D7D7@-ZZ4?- MF*2+7#T(!M8UW8'!7=W1M6?7J&+4'E'PF7P,"2;G[5UR6+MZMMW'JINCFP07 MMC/4'.I.- WEWM&X^B7@&#\H.8E2HJZDF8 _UN@@,$(0G:KUPP*H^8($MB6P MWF'Z/CG3Q2,I+FQ()0Z?3<-9F:V_F7)R&Q:TGWEI]U6S%?W-_@<^:^C4& 5Z M>7BZ?;.RY=-II<*>,GV0B5A([XH4- Z?@1@P:\^9Z4R?GI@I&W.9V.2?N,@V MPQE6N\1F?K0OO^_RNPUE5:+'2E#$.2KG7TW4?5*Q\K MGEO:]/U2J\Y!RUH!T#:RX3$G9L];QA8)\U88VX;[4%T^G@PJT%EE/3TN*3#E M(/(DGGG0S1B;OW29-*CH1-]HMFB]4LZZ8,B\VZCLD?K5>;>971D&X]_CBC8Q$A$D!#F#0R[(C[+U M?VC]VH'1?DGME&8.67W#=:0?/H14$$$!1!JE7;D>@]?>0XJ\PK$=>;82UJ833S1;$W8-E;UZ&3LI$2YK8 M>H<6*#5R5+E3ALQ/A3]HVO 34".U/:YQJR2^45;IB<]>&=EEE"O115_UU/V\ MJ?;W*HBWA6F?P/3LK (=G%\-8O_D(( K**8]7IFE>#S]5"^R#EQ33)MT\12Z MF[IFH!7J&W5[8 32Y.N) J354<"<0B1,X/X[-TM?X!)VF%\L M& 2W5YJE'K)#=DN-J-#%-+-OZC=WO5-&JJ7(JMC=6XF\,@4]W0]&G@E]/W@U M'?MRY*._#_CHGPPX9YW"737BKE?(6AXJ[/1@Y;$:EO"H;H*7'%+!$')BB@)D MA;^6A]^-Z1_D6?\56[Z'<,.1[_GM8"2,9<-*%^YR*/DAE+W8#O8/./3=;LM\ M_O?[,$]U]Q(:J.$YV^L9H?ND>C\3LT6$J[FKK^\'TJUZ-8V/>MD'CSY6[^M; MW 1QATQ7 ][)9XE#>W[(0O?,1L<"&\^X>(_1O?+#45_(G!E^INLP-$Q_!CBT+O90:;C(KPY7AF=9>4UH1SV@?1,5 M#,!B^T2/WJ,57:ITSINZII8JTKDOW<.6#'78\O;U])M+RGX #H]O.AN9C7WT MV.Z^VONONW9%^SQ3V0?7+29E63&O+5?PZ?G0#8C[%Z++%U&8R/'#<\E]Z=8& MD(155"ED=BJY^8./Z[8, _V8D^GTNJY'2<%'52Y)AWH:&E/<"G#4H%#"8;XC M4;/;#EN$Q20 M.5C^.P/Z6R"9])@(BIR=0N9 O159PR%A[S-"Q[N_32T=K9L.QK5UZ-GE0JSA M4?\*TF/A/H9X%'"',NWS\N &AK(\Q>=O'6?V@A%AZ!#>@2(#P$/@[KIK*("% M&WI>C +2$@\GU_)A=')F&:%< DW_$Z[\'Y^#_6J\MN^-!_W?,5YZ=77$X*1* M2)*='\\M:-/<,[QN(=KNX4:A"T*[XH<@% !210'^ M4PAVM'N/W4$!J1]0 -0>26GR)7N_Q*] (AG'#/Y::>C]P)%$=LGS(ND^%N\L MW*T@43%TOR9P.J1O"#*'-@9!>B&\73Y>=IA%Y<.MT4&,\XK-LG.-K3P(%RF8 M9$W6ZKW-J$.IH;XL4:US_66L4*C1AM>0W"7H5]4AI'";H&LG(-E!C MK[Q\N%2?*G$'1PL,2KA*)KY7(,,*ZVBG$1X:8W43S+(6O)H="LY/UN3JO&]3 M3C9KW7:9_@T 6.6*26T6_N9G=9:.1_MH[(8D^PI[=<]MKJ" IRA ?#)>\Z:B M/(5.VZ-ONRYX T*G&*2$'Z5D$SI A2JX26!']CA6IR71F[J._8GE\ES,WTKD M;VGW:L-E-(6)GKL80],651][[_@7H&4+=%IQ1P&'5TR2C([\693LT(G54N]_ MA+E_+_\OLPU+KT"D_(4W'A5$=61ZO&IG)-I6WA*MM_-?/-(?)Y,7Y!(R\7X>9 M=V%FI^,'H2>!65\QA)1")^,B,"*_)7_*'K0TRG2V"OU2Q3_W9*?1G0T-3'T2 M3?^/(.@W,;CWVR<2SUV"='0Y(C?12'.S_G9=5Q/3OH A"JA!%\_XQ:I%/E"R M][?13E-ZB^O[O>OZ'R@P.M[(I3^X0X)YY;Y89X0>]]'\PX[*?WG8\L/B_]V) M,.GM[RK[]:90H_-^!$]MC!2>U%[NR(5 MMDEZX6JZ8D2S6^)I5A.#CI6UY(6?2@/<'ZW)]2,+??M;.(7U(!M,3_H.BBW_ ML+.AYL;=CO7OC?LW^?]B!OP_15\R!='JY=U@.MI! 5_J?.J#6T#?-^E)F_HD MKL*8T=JI6OHA(1Q/J<&/@I'5Q?O%Y,7V92@@4@^RF8@"..?;_6)J<893T%J2 MW/WAE=R<#9U$[>))1U8.6G?YR:R$A C,O&?*K,>8A6-2BU4\--8G_89=3C7^ M&97DK00[+BE&K^Y%P'E(Q.?IU;&.B!7&M/<./3TT3]^43Q.^HV1^_0+[LC?V M95F\J-#9(BW% =9AH:X)7O\)R\K$F#G%2_81H01;Q&.T[$R,V8ECR%;0(<4P M=!>.SKW <$8)"OBD=H$CS'N.!#5%;Jᧃ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imrx-20211231x10k025.jpg GRAPHIC begin 644 imrx-20211231x10k025.jpg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end GRAPHIC 29 imrx-20211231x10k026.jpg GRAPHIC begin 644 imrx-20211231x10k026.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W/5=2ATC3 M9;ZX61HHL;A& 6Y('&2/6N;_ .%D:/\ \^U]_P!^T_\ BJT/&_\ R)]__P!L M_P#T8M>/5Z>"PM.M3H_\ "R-'_P"?:^_[]I_\51_P MLC1_^?:^_P"_:?\ Q5>745U_V?1.+^T\1W7W'J/_ LC1_\ GVOO^_:?_%4? M\+(T?_GVOO\ OVG_ ,57EU%']GT0_M/$=U]QZC_PLC1_^?:^_P"_:?\ Q5'_ M LC1_\ GVOO^_:?_%5Y=11_9]$/[3Q'=?<>H_\ "R-'_P"?:^_[]I_\51_P MLC1_^?:^_P"_:?\ Q5>744?V?1#^T\1W7W'J/_"R-'_Y]K[_ +]I_P#%4?\ M"R-'_P"?:^_[]I_\57FME_Q_V_\ UU7^8KUTPP_V_P#VH"/- ^Q%<]]X.?KM MKFKX>A1:5F[^9U8;$XBNF^9*WD9G_"R-'_Y]K[_OVG_Q5'_"R-'_ .?:^_[] MI_\ %5ROB?\ Y!&D_P#76[_]'&CPY!<6!U282QJYTR9D:"X1V4@IS\I)4_7% M5]5HTY+]NG=7.J_X61H_P#S[7W_ '[3_P"*H_X61H__ #[7 MW_?M/_BJR;&T@UFWT635D:XF>&X+,[$.Z*?E)(Y..<5!I5I8:CH=NMQ!Y2W5 MX\$:I/($B?R_E(4L03NP.?7\*GV&'6\7IY^O^1HL1B7:TEKY>G^9N_\ "R-' M_P"?:^_[]I_\51_PLC1_^?:^_P"_:?\ Q58(T/2X9[V*2*,R:?91F42/)L:5 MOO,=F6P,C@4JZ/I$;ZG(MHTR17%NL:3>9&4$A^88^4]^"?;KW/8X;L_ZM_F+ MZQB^Z_X:_P#D;O\ PLC1_P#GVOO^_:?_ !5'_"R-'_Y]K[_OVG_Q5VM$Q<"Y#;E<#,8.UE#,3V[GWP#TCATJPNO#=M?SHO[N MVDD6&668Q+F3&< E@ /3\?6I=+#_ ,K_ *O_ )%JMBOYE_5O\S5_X61H_P#S M[7W_ '[3_P"*H_X61H__ #[7W_?M/_BJPET?2(WU.1;1IDBN+=8TF\R,H)#\ MPQ\I[\$^W7NS7K2UT[P[>6T%M& FJF-7)8MC9N'.>< D>F/?FFJ&'-(K^%"RQN#\JMVP21QW[^M:D&G0FV6PO8+>=WUHQ32IN0 MO\F[/!&.I&!P.>,\T3P]"$FFGIYA#$XB<5)26OE_7Y&E_P +(T?_ )]K[_OV MG_Q5'_"R-'_Y]K[_ +]I_P#%5@Z?I.G75[GVFER3LT,+_;$D88+GDMU7:>@X&,=32A1 MP\G9Q?W^=@GB,3%74D_EY)_J=1_PLC1_^?:^_P"_:?\ Q5'_ LC1_\ GVOO M^_:?_%5E2:/IMI6;YL'OA02.F.LPTNTU19VG5P MJZG<'R$E?;+L4G: 2<$XR2.>N,=E[+#;V=AJMBMN97+_ /PLC1_^?:^_[]I_ M\51_PLC1_P#GVOO^_:?_ !585OH^F2Z5_:;V"J[6$L_VH_\ M"R-'_P"?:^_[]I_\51_PLC1_^?:^_P"_:?\ Q5>744?V?1#^T\1W7W'KMSXV MTVUTVROG@NS%>>9Y85%W#8<'/S53_P"%D:/_ ,^U]_W[3_XJN.U?_D3_ Y_ MV\_^C!7/UG3P-&4;ON_P;-*N8UXRLK;+\4F?0-%%%>*>^8.M^+;#0;U+6ZAN M7=XQ(#$JD8)([D>AK-_X61H__/M??]^T_P#BJY[XD?\ (Q6__7HO_H;UQ]>Q M0P5*=-2>[/"Q./K4ZLH1V1ZC_P +(T?_ )]K[_OVG_Q5'_"R-'_Y]K[_ +]I M_P#%5Y=16W]GT3'^T\1W7W'J/_"R-'_Y]K[_ +]I_P#%4?\ "R-'_P"?:^_[ M]I_\57EU%']GT0_M/$=U]QZC_P +(T?_ )]K[_OVG_Q5'_"R-'_Y]K[_ +]I M_P#%5Y=11_9]$/[3Q'=?<>H_\+(T?_GVOO\ OVG_ ,51_P +(T?_ )]K[_OV MG_Q5>744?V?1#^T\1W7W'J/_ LC1_\ GVOO^_:?_%4?\+(T?_GVOO\ OVG_ M ,57EU=WX;L;74?#%O!>1>;$+N5]NXKR(\CD5E6PE"E'F:?WFM#&XBK+E37W M&M_PLC1_^?:^_P"_:?\ Q5'_ LC1_\ GVOO^_:?_%5AOI.E2Z>KKIZ122:5 M)>;UED.UUQ@ %CQUZYJ6YTC2+:UO'&FQNUO8PW +2R?,[9!SANG'0>_-9^QP MW9FWM\5_,OZU[&O_ ,+(T?\ Y]K[_OVG_P 51_PLC1_^?:^_[]I_\56#>:#I ML4^L1PVQW6\]J(AO8[5DQD=>D6MBT:C] M]'#!*LJ"5BY8X.\XV!3GC!!R/PIJCAGLF)XC%I:M&_\ \+(T?_GVOO\ OVG_ M ,51_P +(T?_ )]K[_OVG_Q585Q8V5OK>O65K;?9XK73Y&4QS2!G.$/S?-R. M3QT]]@B#K(Y+*X&5.XD9R>,8[?BO8X9;I_P!6_P Q M^WQ;O9KM^?\ D:/_ LC1_\ GVOO^_:?_%4?\+(T?_GVOO\ OVG_ ,57*Z[I MUC#H27=O8BVE-[) <.YRJY ^\3Z?G^5-M+NZL_ _F6=Q-#(=3VYB5)93QQ1R^8Y+ @$D@G& M>>P[BDMKR]MM)\*QVDTJ^;-*'C1CB3]Z.&'<1T'_ LC1_\ GVOO^_:?_%4?\+(T?_GVOO\ OVG_ ,566FF:9(9U MDCG>S76)E:.'S&4*(L_<7L#W SCOBJDV@V,-S=7/V>"2"/3_ +3#%%,[),'-&6ZN3Y9\G3 MI6:Z4RMEHC%O7\0WR\?CFFZ&&6Z?]6_S1,<1BI;-?U?_ "9J_P#"R-'_ .?: M^_[]I_\ %4?\+(T?_GVOO^_:?_%5SRZ+I(T."24 2W%I)<>;&)7=&!X !78 M.AW<\]12OIND+JVFZ8UE&@O+-&\_S7W+*RG!'S8QD#C'4_A1[##=GU_ /K.* MT]Y=/Q.@_P"%D:/_ ,^U]_W[3_XJC_A9&C_\^U]_W[3_ .*KA/$%G;Z=>064 M402:&!!OU'2LFMH8&A**DDS">8XB$G%M:>1ZC_PLC1_^?:^_P"_ M:?\ Q5'_ LC1_\ GVOO^_:?_%5Y=15?V?1)_M/$=U]QZC_PLC1_^?:^_P"_ M:?\ Q5'_ LC1_\ GVOO^_:?_%5Y=11_9]$/[3Q'=?<>H_\ "R-'_P"?:^_[ M]I_\51_PLC1_^?:^_P"_:?\ Q5>744?V?1#^T\1W7W'J/_"R-'_Y]K[_ +]I M_P#%5-:>/]*O+V"UCM[T/-(L:ED7 ).!GYO>O**T-!_Y&+3/^ON+_P!#%3/ M45%M%0S*NY).WW'H]WX_TJSO9[62WO2\,C1L51<$@X./F]JN:)XML->O7M;6 M&Y1TC,A,JJ!@$#L3ZBO+->_Y&+4_^ON7_P!#-=!\-_\ D8KC_KT;_P!#2L:N M#I1HN:WL;4<=6E75-[7/4:***\D]LQ_%-C39M7. M@->;?\(1XB_Z!W_D:/\ ^*KV&BNJABYT8\L4CCQ&"IUY_X0CQ M%_T#O_(T?_Q5'_"$>(O^@=_Y&C_^*KV&BC^TJO9?C_F']DT>[_#_ "/'O^$( M\1?] [_R-'_\51_PA'B+_H'?^1H__BJ]AHH_M*KV7X_YA_9-'N_P_P CQ]?! M7B-6#+8$,#D$3Q\?^/5:_P"$;\9;]^RYW>9YN?MBYWXQN^]UQQGTKU:BD\QJ M/=+^OF-9726TG]Z_R/*X] \;0Q^7$;Q$R3M6]4#).3QO]2:@MO"?BNSD,EK; MRP.1M+172*2/3(;V%>MT4?VA4_E7W?\ !'_9E/\ FE]__ /*&\->,6N?M+1W M)GV[?--XN[;Z9W9Q4:^$O%:1)$EM*L:/YB*+E %;^\!NX/O7K=%']H5/Y5]W M_!%_9E+^9_?_ , \FC\+>+HKIKF.&=+AL[I5NT#G/7)W9H'A7Q:/,Q!,/-<2 M2?Z4GSL#D$_-R<\YKUFBC^T:G\J_KYA_9=+^9_?_ , \C;PEXJ>Y^TM:RFXW M!O--RF[(Z'.[.:0>#_% N/M LW\[=O\ ,^T)NW9SG.[.<]Z]=HI_VC5[+^OF M']ETOYG]Z_R/*G\.^,Y)HYI!=/+%DQNUXI9,\'!W\4#P[XS$JR 70D7=M87B MY&XY;!W]SR?6O5:*G^T)_P J^[_@C_LVG_-+[_\ @'DP\*^+1YF()AYKB23_ M $I/G8'()^;DYYS2OX8\7RQRQR17#I,VZ56NU(<\36OA;Q;9%C:0SVY;[WE72)GZX:G1>&O&,"LL,=S&KO MO8)>*-S>IPW7CK7J]%#S"H_LK[O^""RRDMI/[_\ @'D\'AGQA;-*T$=Q$TIS M(8[M5+GWPW/4_G2IX;\8Q[]B7*^8_F/MO%&Y\YW'YN3D YKU>BC^T*G\J^[_ M ((_[,I_S2^__@'E \,^, Z.([@,F[81=KE=W+8^;C/?UIK>%_%SVHM7AG:V M7I";M"@_#=BO6:*/[0J?RK[O^"+^S*7\S^__ (!Y5-X=\9W&SSQ=2[&#KOO% M;:PZ$9?@\]:1_#GC*1P[KZXXS7JU%+^T*G\J^[_@C_LR MG_-+[_\ @'E#^&?&$LDDDD=P[R)Y;LUVI++_ '2=W(]JBG\(>*;EP\]I)*X M4-)(O\ H'?^1H__ (JC M_A"/$7_0._\ (T?_ ,57L-%/^TJO9?C_ )B_LFCW?X?Y'CW_ A'B+_H'?\ MD:/_ .*H_P"$(\1?] [_ ,C1_P#Q5>PT4?VE5[+\?\P_LFCW?X?Y'CW_ A' MB+_H'?\ D:/_ .*H_P"$(\1?] [_ ,C1_P#Q5>PT4?VE5[+\?\P_LFCW?X?Y M'CW_ A'B+_H'?\ D:/_ .*H_P"$(\1?] [_ ,C1_P#Q5>PT4?VE5[+\?\P_ MLFCW?X?Y'FVH^%M:G\-Z+:16>Z>V\_S5\U!MW.".[_#_(\>_X0CQ%_P! [_R-'_\ %4?\(1XB_P"@ M=_Y&C_\ BJ]AHH_M*KV7X_YA_9-'N_P_R/'O^$(\1?\ 0._\C1__ !5'_"$> M(O\ H'?^1H__ (JO8:*/[2J]E^/^8?V31[O\/\CQ[_A"/$7_ $#O_(T?_P 5 M5F'POXOMXQ'!%/$@)(5+M% )&"3?\(O MXNVA?)GVB,Q ?:TP$/5?O=/;I2MX8\7NKJ\5PP= C W:G4KX;\9)-),BW*RR !W%XH9@. "=W-(?#7C$OO* M7);S/-R;Q<[\8W?>ZXXS7J]%']H5/Y5]W_!'_9E/^:7W_P# /)SX8\7FW>W, M5QY,A+/']K7:Q)R21NP>:1O"WBY[9+9H9V@0Y2(W:%5/L-V!7K-%']H5/Y5] MW_!%_9E+^9_?_P \F/A7Q:TLLK03F29=DKFZ3+KZ$[N1P.#Z5+%X>\81W F M:"64F19'66Y1ED9>FX%N>E>J44?VA4?V5]W_ 1K+*:^T_O_ . >::OI/B[6 M8HXKC3(T1':3"3J*H)]N6^;D_6I1X;\9 M"W%N$N?("[?*^UKLQZ8W8Q[5ZM13_M"I_*ON_P""3_9E)?:?W_\ /.=3L/& M&JV36LNEPQQLRLWES+SM& "Y 'L *H0^'?&=M ((!=10C.(TO%51GKP'KU6 MBI6.G%645;^O,J670D^9RE?U7^1Y+%X5\66Z*D,$T:H_F*$ND #8QN&&ZXXS M3SX:\8FZ%T8[DW(&!-]L7>!Z9W9KU>BJ_M"I_*ON_P""3_9E+^9_?_P#RA/# M/C".Z>Z2.X6X<8>5;M0[#T)W9/0?E48\)>*U$P6VE F_UH%RG[SO\WS<_C7K M=%']H5/Y5]W_ 0_LNE_,_O_ . >3+X6\6I:-:K!.MLW)A%T@0_ANQ4MOX:\ M4PWT%W+IPNI(,>6)[E2%V_=Z.#@>G2O5**'F%1_97X_YC664E]I_A_D>277A M'Q/>7(O^@=_P"1H_\ XJO8:*:S*JM$E^/^ M9+RJBW=M_A_D>/?\(1XB_P"@=_Y&C_\ BJ/^$(\1?] [_P C1_\ Q5>PT4?V ME5[+\?\ ,/[)H]W^'^1X]_PA'B+_ *!W_D:/_P"*H_X0CQ%_T#O_ "-'_P#% M5[#11_:57LOQ_P P_LFCW?X?Y'CW_"$>(O\ H'?^1H__ (JC_A"/$7_0._\ M(T?_ ,57L-%']I5>R_'_ ##^R:/=_A_D>/?\(1XB_P"@=_Y&C_\ BJN:3X/U MZUUFQN)K#;%%<1N[>8U6K67]?,<6K9\$^'=5TC69KB^M?*B:W9 WF*W.Y3C@GT-= MY143QU24/9M*Q<,OI0J>T3=_Z\@HHHKC.\**** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRGXT:O MJ6E?V)_9VHW=GYGG[_L\S1[L>7C.TC.,G\Z]6KS_ ,>:-;Z]XS\'V%V-UNS7 M3R+_ 'PHC;;^.*:W \BM=1\=WML;FUO?$<\ ZR133,OY@TL-_P"/;BV:XAN_ M$DD"]9%EG*C\&+J[OD% MS>>?Y=N NU26!.#CH!@^]=$*%2<.=+0P]O#VRH7]YG#?#;Q)KE_\1-+M+S6- M1N(&\[?%-R7%U#.R(%$G[AF M5L#C(R1[X%>[5E5BX2Y6=#BXNS"BBBLQ!1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !152+4K.;4I].CG!N[=%>2/!RH;IST/X=,C.,C-+3/$^E:O+%':2 MW&9D+PM-:2PK*HYRC.H#\<\$\)--TR]:TN7N?.2)9G\FSFE6-& M+ ,S(I"C*-U(^Z:U$=)(UDC971@"K*<@@]P: '45#;74%Y$TMO()$61XB1V9 M&*,/P92/PJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHJMJ%]!IFG7-]< ML5@MXFED(&2%49/% %FBLK1->BUH7*BTNK.XMG59;>Z50Z[E#*?E9A@@CO\ M7%:O6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH *\K^+NK7&A:SX5U.T(\ZW>X< ]&'[L$'V(R*]4KF?%W@ M?3/&8LQJ,]W%]EW[/LSJN=VW.=RG^Z*:W \EG\5:-JMQ+J%SJSQS2G+I<1,7 M7_97:""!VZ5F:QJNCZK;V\-OJZ06D.799H)/-=SP3A01C S_.O1O\ A1OA MG_G^U?\ [_1__&Z/^%&^&?\ G^U?_O\ 1_\ QNNOZY4LE?1'-1PM.C5=:*]Y M]]3(^'=AIVJ:KHM_HU\VW2GG%W:7"A9&,D;*)ACL?E&.V.M>R5P_AWX6:)X8 MUN#5K&]U)IX0P"2RH48,I4@@(">N>O4"NXKEG)R=V=+;>K"BBBI **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH Y.Q\,ZG:ZM;ZPVI-)=R3R/=VS%3"$D # M*C",.2-D6-QP?+[=C0]$UJW@T.TU%+"*WT@95[:X>5IV$31#(:-0@P['J>0! M72W:W3VKK930PW!QLDFB,B#GG*AE)XSW%<[IGB&ZMM'M]0UZXMC%<[]CVUL8 MDAV*[$.6D8G(0X( Z8[B@"Q>V>N0^(;N_P!+@T^6.ZLH+?=+[5[OR9-/OX8U>..6>14"1.\:R*K8GW6VL.XH Y?5/A_J%UIQLK2WTN)!=7LJL'"X$T@:-] MK0NNY5^7@!@%&UP"17HENKI;1)*=TBH QSG)QSS6;I^I7ESKNIV-S;Q0Q6R1 M/"5.IYP-:@#EM+LIO$>GQ:O=:GJ$)N,+:P-SI^KR71)K66%@K9"G$BKD':W3TK5KG++_DHNL?]@RS_ /1E MQ0!T=%%% !1110!6U![J/3;I[&-)+Q87,".<*TF#M!]LXKEO"FK7E]H>IW.O M2/)IT>1YU[;I"Q 4B961>-JL& /?!ZXR>IU"XDL]-NKF&W:XEAA>1(4ZR, 2 M%'N>E>?^&/$FER:1>Z+K]Q:K;3-(RW!22&"<2[I)(PS@#%Y-"\.V$HU:9YC,SQO"MJKLWER2LPS]S8549) '0#(Z?P9X9N_#D5T+ MF6WQ,(E$5MOV912&D.XD[WSD_0=>37.>%O$%A8>%Y?L,\^I>(+R6;;"2TL\C M*2L1<'&U @CY.!CG.371>#!X@$5U_;?VO9B/RQ>&(R>9@^;CR^-F<;<\]>V* M .IHHHH **** "BBB@ HHHH **R]3\0Z?I4RVTCO/>N,QV=LADF<>H4=![G M]ZH?9=?UOF]G.C61_P"7:T<-<./]N7HGT3)_VJ '>(?$$=K<6NCV-[ FK7LR MQ*#AVA4Y)D*_0'&>"<5'>:'Q88DCA MMEBDE7NK.">#WVA: -?3;Q=1TNTOE0HMS"DP5NH#*#@_G5JFHBQHJ(H5%&%4 M# IU !1110 4444 %%%% !1110 456OX;FXLI(K.[^R3MC;-Y8DV\C/RG@Y M&1^-8O\ 8WB7_H:__*='_C0!T=%)?^AK_\IT?^-']C>)?^AK_\IT?^- '03316\+S3R)%$@RSN MP55'J2>E16=_9ZC!Y]C=P74.<>9!('7/ID5YO\1_"7BS5O"4D%OK#:F4E61[ M1;9(C(HST(/."0<=\>N*P?A-X+\7:8FH7,MS-HD4P11'-;J[2D9YV-]W&>O? M- 'MU%)?\ H:__ M "G1_P"-']C>)?\ H:__ "G1_P"- '1T5SG]C>)?^AK_ /*='_C4-G+K6G^+ M[/3;[5Q?V]S93S8^RK$59'B Y'7AS0!U-%%% !1110!XW\6=:U73?%5K#8ZG M>VL362,4@G9%)WN,X!Z\#\JY#2==U_4-3@MYO$NJ00,X$LQNY"(USU(W5UWQ M0T[^U?B'IUE]JM[7S;!1YUPVU%P\AY-<79V'VK5K73K6[M5B$Z[I&DX<@\NW M'3T]*]BCR^R7>QUPMR'=MJ6I_P!H-;1:U>O$LA7SO.<#:#][&?3FNE\)W<\G MB>[MO[5N+^V2W)1Y'8@G6WG1S>7;,/,B.5/S)TK2NH^R=NW;\3XS"RJ>WC?OW]=-ST*BBBO#/J HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M K%U/PY;W^DV^E1F.*QCGCDDC9"Y=%??L!+?+DC!//!([Y&U10!AQ>%[(:]> M:M<%YI9YEF2,NXC0K$L?*;MKGY202,C/'3-7--T6RTDM]C^TJC*%$M>O+I;T-C M^T]/_P"?ZV_[_+_C7*^._B'9>#]'CN(!%?7<[[(HEE&!@9)8CL/ZT :=IX;G MTF&=]+U$/J%S(K3WFI0?:&D15VJN$:/&,#'XY!)S4OV7Q5_T&=&_\%,O_P D MUQ7PZ^+,GB[5SI&I64-M=LC/"\!.Q\HT 8?V7Q5_T&=&_P#! M3+_\DT?9?%7_ $&=&_\ !3+_ /)-;E% &']E\5?]!G1O_!3+_P#)-'V7Q5_T M&=&_\%,O_P DUN44 8?V7Q5_T&=&_P#!3+_\DT?9?%7_ $&=&_\ !3+_ /)- M6]4US3M'""\N,32<16\:EY93Z(BY9OP%9N/$.N=:2:3_=07&<>_0=R*KI9>/=;LI%NM5T_149 MAL\BR9IV7T?]\0G_ %B?<5TVEZ'I^CJ_P!CMPLLG,L[DO+*?5W.6;\36A0! MRNF>'-:T>)H['4-$BWG=)(=*F9Y#ZNYN2S'W)-7OLOBK_H,Z-_X*9?\ Y)K< MHH RK.WU]+I&O=3TR:W&=\<.GR1.>.,,9F YQV/]:U:IZGJ4&DV375P'8;@B M1QKN>1V.%51W))K*EU_5+&)KO4M":"Q49DDBN5EDB7NS( .!WVEJ .AHIJ.L MB*Z,&1AE6!R"*=0 4444 %%%% !1110 4444 %%%% !1110 5B>(?$/]@-8, MUJ\\-Q,R3,CI<%E%M*PS"C2YB5$8R':#M7Y^I]*MW'B/2K5&>>Z"*LKQ-\C' M#(F\\8Z;<$'OD8ZBLR'P)IUHEQ'97=[:QW/F+*L;H'D/7\*X6S@>35[;2;,J9'N%C M>1F $C!NF>RC'X]?2O=?$W@#2O%6IQW]]<7L4L<(A @=5& 2>ZGGYC6,/@UX M=!!%[JF1_P!-8_\ XBO2I8F$8*+?3L=$:L5&QS-XALKB>V!!E#%97!]^@]OY MUT'P]_Y#\_\ UZM_Z$E;W_"O=)_Y^+W_ +[3_P")K0T;PM8Z'>/2QF1(]IY49[] >&P.^T^AJK;^)M,N;B.%9)U\V5H8Y)+:1(W M=205#E=N1PLYF5=AC 7)V@G<>,^M '0:GJMEH]N MD]]-Y4;R"-3M)^8_3M@$D]@"3TJV74,%+ $]!GK6%KOAZ;7K^$37KV]C%!(N MV$(SR/(-K;@Z,,!,@$<_.W3OF1>$KV1/.OVLY[]/L:QW)R6Q#+N9LE<@LN,X M[Y'3F@#K8KB.5 P)7)( <%3P2.AY[4_S$RHWKEON\]?I7$CP-)+YK7*64KM< MP2*S9;$:7#R.O*_Q(V,=#T/%5CX(U1;TE&L! E\MQ 5(4Q1BY:;;_JBWW3@! M64#)X/4@'=6=Y!J%JMS;/OB8L V".02IZ^X-3UG:%I\NEZ1%:3LC2(\C$H21 M\SLPZ@=B*P_'FLZA866GZ7H\JPZIK%VMG!.1GR%P6>3'<9>0Y )/0=:X M_P 0>%--\$JNL7?A[3=HH O>%_%$?B2"[1[.:PU"QF\B\LYR"T3XR.1 MPRD'((ZUO5Y;I=]=^$_%_P!OOHV>P\5WJHWFE/M%G<GQW,/AS1K!KQ M/.@G>%'O(-Z6US&=@B1@NU=S?=+Y(&, G&/5*P=5\):;JERUT/,L[MR#)/;; M09,$$!PRLK8*J1D$C QB@#BGO=1OE\11WEE#I]M'J"FZDN\3H[^3&$1$4;GR MP4@C:>1CGBM_1%N+KQP+J2:9_)TD"6"10JVQE=2L:C ;I&Q.[D_)5IO =EEV MBU+4XI)9!-<.LJ,T\HZ2'&_^A>TG_P"C_PK8HH Q_\ MA$O#?_0O:3_X!1_X4?\ ")>&_P#H7M)_\ H_\*V** ,?_A$O#?\ T+VD_P#@ M%'_A7.>,_A?I'B31UM].M[32[N-]\7'=V[<[]MDN;6>.>"0922)@RL/8CK4M8%SX7BCN7O=$N7TF]<[G, M*AH9C_TTBZ'ZC#>]1KXDGTMA#XEM!9#.!?0DO:O]6ZQGV?C_ &C0!T=%-1TD MC62-E=&&593D$>HIU &/XBL;F[M;6>S027-C=)=1PLVT2X!4KGL2K'&>,XJE M>:YJTCL$1G8X51DT >?V?BZ^ MN4CMC-9J\D10V:[_ +5$HMS()RY(-.G56\UXE:(S*T\3QJR 9)!8 ' Y^ ME-;6]/FCDC>.X8%-S1/:299#P3M*\KV/U&>M5R2[#LSF;'QI=R6UY=R7FE7U MI91VTUQ-91L B2%Q(.7;YD"JQ]@>,G Z_29[NZTFUN+Z)(KF6,2/&H("9YV\ MD\@$ ^X-9&EZ'H-UI+QVMO>-:3^6S&XGG+2*HRB[G;<4Q_#G;R>.371U+5MQ M!1110 5RNL7UII_C_1IKVZ@MHCIUVH>:0(I/F0<9/?@UU507%E:7FW[3:PS[ M?N^;&&Q],T 4?^$GT#_H.:9_X%Q_XT?\)/H'_0,_BAH_A;3HIK22WU6ZFX/&"/:@"EX-^)^C^*=,DGNY+?2[F% M]CPW%RH!ST92<9'X<5TG_"3Z!_T'-,_\"X_\:R?"OP]T+PKIK6D-NMV\C[Y) M[I%=F.,8'' ]JW?[%TK_ *!EG_WX7_"@"#_A)] _Z#FF?^!(/[/\ $VF:2UMNBO4I'K6W63JWAZ MUUB4RS37$4GD&%'A8*4^='#C(/S!D4@]/:@#,L/'-C<-J/VF.2$6EPZ*8T>7 M?"J1OYQVK\JD2#KVJY=^*;*#5;2QB#2&6Y-O++M81QD1-(?GQM) 4<9[GT-0 M/X+L1-=26MU=V@NU\N982F&C\J.,(,J2 %B&".02W//$Q\)V)N$83W*VJ3-. M+0,OE;VC:,_P[L$,>-V,\T !\5V,JP&SWS&2>",AT:/Y)20KC<.1P?RK>KG+ M'P9IUA'$L5)"Z';&I_=DE0=J#/7DG)..M='0 5X1K#6T'C+5[_Q!KO\ M8WB6RU+SM'GO$=[9[/;A4 '!!!.['(->[TQXHY<>9&KXZ;AF@#QN[U;7/B1I M-[X:M?$G@R8W4>'6W,XEP"#E0W7IZ&I)_@R\MI87*6'AR+4K:1Q- J3_ &6Y MC90!N^;<&!R>..:]#U[PI:ZU=YD84R;ESG!WD#@?ZI^N146AZWK,\& MAW>I2V$L&L#:D=O;O$\+F)I1DM(P<81AT7L:W4T:PCMK2W6 B.TD$L'[QBRO MS\V[.23N;.2B-%-]JE MP$^:(;F*;P I<.1CC<%VYXW9!Q:NO#&E7E_+>3Q7#23,K2H+N58I2H &^(-L M;@ 8(.<)85N)8K33]0OUA00<@@]*YK1-:L/#VDPZ1J\_P!DO+7=&1*I M'VCDG>F!\^[KQSDD&C2++Q"PO;RTN[*QMKVZ>XCMKS3WDD12 ,DB9,;MN[&, M@L M:21$:=WH,;/RW\ZV-N&,?F'? MSOP&Z+QTSU'I5<[-IGASPO-)KLL;P,&8 ^9+*JM*XW>7$"0&9L?<7)_.@#F= M7\>ZGH\.CB6>PFN[N*&YF@6U*#RY' ^5FGSD#=]U7^[DA0:BM/$FJP:Y)#/. MFHSIJU[&+:(R1NJ);NR+M#D$-L& RD=2,GD>AZ=J-KJUA%?64OFV\N=K%2IX M)!!! ((((P1VJU0!YG%\0-6DTTRP2:5>.PLC]HMXG\J%YY-C0N-Y)=1SU'7E M178>%]6N]6LKS[=Y)N+.^GM'>!"B/L; 8*68C(QQDUN44 %%%% !1110 4C* MKJ58!E(P01D$4M% '.OX9DTZ1I_#=W_9[$[FLW7?:R'_ '/X#[H1[@TZ#Q.M MO.EIKUJVE73G:CNVZWE/^Q+P,_[+;6]JZ"HYX(;J!X+B))87&UXY%#*P]"#U MH 66:*"%YII$CB0%F=V "CU)[5DV_BO1+FXCACO<&0A8WDB>-)">@5V 5L^Q M-8.N>'X]'M[66WN+G^PHKJ.2\TYOWL21@_>7/S*H;:2H)7 /%:_B'4]&F\-7 M*S3P745S$4ABB<.TS$?*$ ZG.,8Z=>U '0454TJ.ZBTBRCO7WW:01K.WJX4; MC^>:MT %%%% !1110 4444 %%%% !1110 4444 %,F0R02(,992!GZ4^B@#E MG\/ZCJ&EV5A>FUMTLX2J202M*7?RC&"057 ^8G'.>*V(EU2?S!=K:0QF(H%A MD9]SGN25& /3GK[5HT5;FV4Y7*NFVSV>E6=K(5+PP)&Q7H2% ./RJU114-WU M)"BBB@ HHHH **** "BBB@#G-;\0W.CZ_9Q&&-]--O)->28.^)0R*''^R"WS M>V3VY@TWQBL]LSSVLKB*S:.*';MB6>38=KEUW+NPV&)(R#C\!0!6N M?&VFVL:-)%/N.0Z?*#&XE\H*Q+ E@_.<81CGIF;2O$8U?588H$"VTEK)*0V M"P=) F,@D$=3QUX-6Y?#NE2O=NUKMDNY$EF=)&5BZ?=8$'*D=>,1G8JS;CDDG))YR>: +U%%% !1110!SFB?\C?XH_ZZVW_H MD5T=2( MNU&N(%/ MY5TVCZ[I^NZ1;:G8SJUM<+N0L<$=B".Q!!!^E>>>,?@K8:[?Q7>BSV^DX0)+ M EN/+;G[P Q@_P ^.E=-HWPU\+Z5I%M8RZ18WTD2X>YN+9&>1B_ [# MH ZOSHO^>J?]]"CSHO\ GJG_ 'T*P_\ A!O"?_0MZ3_X")_A1_P@WA/_ *%O M2?\ P$3_ H WP00"#D'O14=O;PVEM';V\2101*$CC1<*JC@ =!4E !1110 M 4444 %%%% !1110 4444 07=G:ZA:O:WMM#&]1\1W'B2Z@U59$MP)?W;0R!4(<;-C^0J8VYR/-J6 MJ1O/:P-(BR@E21ZX(./QH V*Y_QEH=SXAT,:? 8GC:='N()96B6XC!R4+JK% M><'(!^[CO5#3_$^I0V^JW>J6IEL;18FBN1:-IYD+$AEV7,@QMX.XL ;3-*N+JUU""ZFSOB# P\%1\^,[N^2.F,\X -#P3H^KZ#H?\ 9NK7 M%M.(7Q;&# "1;1A#A$R00?FQELY..@Z2N$L_B?IJV>C_ -JP26UW?VT5PZAX MML:R-M5L%]S G)PH9@.6 K2F\;N"*6';+)#)%,%WQNC%6!VDCJ.Q(K1H **** "BBB@ H MHHH **J?VE9C5?[+\]?MIA\_RL'/EYVYSTZBJ5IXHTJ]NUMH9;@.\C1(\MI+ M'&[J2"JR,H5C\K< GH?2@#8JE;Z/IEI=-=6VG6D-P_WI8X%5S]2!FH=1U^PT MNZCM;C[4\\B&18[:SFG.T'!)\M6P,D=:O6MS!>VD5U;2++!,@>-UZ,I&0: ) M:*K6]_;73!8':0$RKN5&VAHWV."V, ALC!.3@XS@XLT %%0I=027T_E4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %)T;3Y-0.EWZ62*S>>QAPP!QP M!)NZ^HK5-[:*N3

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imrx-20211231x10k012.jpg GRAPHIC begin 644 imrx-20211231x10k012.jpg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end GRAPHIC 16 imrx-20211231x10k013.jpg GRAPHIC begin 644 imrx-20211231x10k013.jpg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